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SUMMARIES
SECTION 1
Renal transplantation is undoubtedly the best treatment for patients with irreversible renal failure. As a prelude to establishing the nature of malignancies in renal transplant patients we sought to determine factors 
influencing the outcome of renal transplantation. The survival of renal allografts and 
of recipients is influenced by a number of demographic, clinical and therapeutic 
factors. Some of these factors have been better studied than others, and we sought 
to establish the influence of particular factors on our own patients and allografts. 
The total number and nature of malignancies developing in these patients 
subsequent to transplantation was also established.
All patients transplanted in our unit between April 1, 1976 and March 31, 1999 were 
included in the study. In the study period, 542 patients received 623 renal allografts. 
Demographic details were analysed. Patient and graft outcomes were assessed 
using Kaplan-Meier survival analysis. The survival curves were compared using 
univariate analysis; results that were significant were subjected to multivariate 
analysis. The influence of a number of factors on graft and patient survival were 
assessed and compared. The impact of a variety of variables on the number and 
behaviour of malignancies was also established.
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Patient and graft survival were superior in recipients who were aged less than 40 
years; cyclosporine improved graft survival but not patient survival. Early graft loss 
was associated with a high patient mortality rate. Contrary to the experience 
elsewhere, black and white patients had similar outcomes after renal transplantation.
Of the 542 recipients 41(8.1%) developed malignancies with Kaposi's sarcoma 
occurring, in 21 patients and skin cancers in 13 patients. The relative risk for the 
Kaposi's sarcoma development was 235. Kaposi's sarcoma was the most common 
tumour in non-white patients (accounting for 79% of malignancies in this group) and 
occurred less than 2 years after transplantation. Kaposi's sarcoma was equally 
common in male and female recipients. Under cyclosporine the latent period to 
malignancies was reduced but the frequency remained unaffected. Kaposi's 
sarcoma skin lesions were present in all the affected patients, with the lower limbs 
the most common site of involvement. Kaposi's sarcoma responded to reduction of 
immunosuppression without the need for complete discontinuation, and with 
preservation of renal function. Extracutaneous involvement occurred in over one 
quarter of the patients and invariably proved fatal in all patients with visceral organ 
involvement. The histopathology of posttransplant Kaposi's sarcoma was the same 
as that described in the other epidemiological forms of the disease.
White male recipients were at the greatest risk of developing skin cancers after renal 
transplantation. Squamous cell carcinomas were relatively more common and were 
found in sun-exposed areas. The lesions were treated only by local excision and 
none metastasized. Malignant lymphoma, breast cancer and lung cancer occurred 
in individual patients but the relative risk of all these lesions were close to unity. 
Patients with preexisting cancers did not develop recurrences following 
transplantation.
SECTION 2
Both immunosuppression and immunostimulation are thought to play a role in the 
development of Kaposi's sarcoma after renal transplantation. We investigated the 
quantitative and qualitative aspects of the immune system of patients who had 
developed Kaposi's sarcoma.
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The lymphocyte phenotypes were established using flow cytometry while 
transformation studies were performed using mitogens. Pokeweed was used as the 
B-cell mitogen, and concanavalin A and phytahaemagglutinin were the T-cell 
mitogens. Cell mediated immunity was also tested using delayed type 
hypersensitivity skin tests and the serum immunoglobulin levels were estimated.
Firstly, with regard to humoral immunity, 2/3 of the patients had normal serum 
immunoglobulin levels, although the B-cell count was reduced in all the patients on 
immunosuppression. B-cell transformation tests with pokeweed mitogen revealed 
that B-cell function was not impaired in patients with Kaposi's sarcoma. The patients 
with decreased immunoglobulin levels also appeared to be malnourished as 
evidenced by low albumin levels. Secondly, CD3 and CD4, but not CD8, cell counts 
were reduced in patients with Kaposi's sarcoma. The transformation analyses 
revealed significant differences compared to controls, with reduced responses in 
patients with Kaposi's sarcoma. Thirdly, natural killer (NK) cell numbers were also 
reduced in patients with Kaposi's sarcoma. There were no significant differences in 
delayed type hypersensitivity skin reactions that could not be accounted for by racial 
differences.
Cellular immunity is impaired in patients with Kaposi's sarcoma with a reduction in 
the number of NK cells. Both of these components of the immune system are 
important in protection against malignant transformation.
SECTION 3
Kaposi's sarcoma is an important complication of renal transplantation. If the human 
herpesvirus 8 (HHV-8) causes Kaposi's sarcoma, the virus should be present in all 
Kaposi's sarcoma lesions and be drastically reduced or cleared from involved tissue 
on remission of the Kaposi's sarcoma.
Fourteen renal transplant patients with cutaneous Kaposi's sarcoma, including 
autopsy material from two cases, were investigated for the presence of HHV-8. A 
second skin biopsy was taken from 11 survivors, after remission of Kaposi's 
sarcoma, from normal skin in the same anatomical region as the first biopsy.
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Remission was induced by reduction or cessation of immunosuppression. A 
peripheral blood sample was collected simultaneously with the repeat biopsy. A 
nested polymerase chain reaction assay was used to detect HHV-8 DNA in the 
biopsy tissue and peripheral blood mononuclear cells followed by direct sequencing 
of polymerase chain reaction product to detect any nucleotide changes.
HHV-8 DNA was detected in all the cutaneous Kaposi's sarcoma and all the visceral 
Kaposi's sarcoma samples, as well as a number of Kaposi's sarcoma-free organs 
including the thyroid, salivary gland, and myocardium that have not been described 
before. Mutations in the viral DNA could be demonstrated in all patients. The 
mutations found were related more to that seen in AIDS-Kaposi's sarcoma cases 
than that found in African endemic Kaposi's sarcoma cases. HHV-8 sequences 
could be detected in follow-up frozen skin biopsies of five patients but were negative 
in the equivalent formalin-fixed specimens. Viral DNA was also detected in 2 of 11 
peripheral blood mononuclear cell samples collected at the time of the follow-up skin 
biopsies.
Reduction or withdrawal of immunosuppression allows the immune system to 
recover sufficiently to reduce viral replication with subsequent viral persistence and 
low-grade viral replication that coincides with clinical remission of the Kaposi's 
sarcoma lesions. This provides further evidence for the important etiological role 
played by HHV-8 in the pathogenesis of posttransplant Kaposi's sarcoma.
SECTION 4
The recently discovered HHV-8 is an important factor in the aetiopathogenesis of 
Kaposi’s sarcoma. The reason for the exceptionally high prevalence of Kaposi's 
sarcoma in our area, as well as that of other developing countries, remains 
unexplained. We investigated the seroprevalence of the virus in the different healthy 
subjects as well as organ donor-recipient pairs.
All recipients were tested at the time of transplantation, as were the paired donors. 
Control subjects tested were healthy blood donors, Renal Unit staff, and household 
contacts of patients with Kaposi's sarcoma. An enzyme-linked immunoassay
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(ELISA) to the whole virus was used for screening and all positives were confirmed 
using ELISA to the latent ORF 73 antigen.
The prevalence of HHV-8 was similar in all groups and averaged less than 6%. After 
transplantation the seroprevalence increased to almost 20% but neither the 
transplanted kidney nor blood transfused perioperatively could account for the 
increase. Kaposi's sarcoma developed in 3 of the 116 patients transplanted. All 
patients with Kaposi's sarcoma were proven to be HHV-8 seropositive before the 
development of the disease. Two of the patients who developed Kaposi's sarcoma 
were seropositive before transplantation. No patient who received a graft from a 
seropositive donor developed Kaposi's sarcoma.
We refute the notion that a high prevalence of HHV-8 in the general population is 
responsible for the high prevalence of Kaposi's sarcoma in our population or that the 
donor organ is a major source of infection in renal transplant recipients. 
Reactivation, rather than primary infection appears to be the source of the virus after 
renal transplantation.
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OPSOMMINGS
AFDELING 1
Nieroorplanting is ongetwyfeld die beste behandeling vir pasiente met onomkeerbare nierversaking. As ‘n aanloop om die aard van maligniteite in nierooorplantingspas'fente vas te stel het ons gepoog om die faktore wat 
die uitkoms van nieroorplantings bemvloed te bepaal. Die oorlewing van 
oorgeplante niere en van nierontvangers word deur ‘n aantal demografiese, kliniese 
en terapeutiese faktore bemvloed. Sommige van hierdie faktore is beter ondersoek 
as ander and ons het gepoog om die invloed van sekere faktore op ons eie pasiente 
en oorgeplante niere te bepaal. Die getal en aard van maligniteite wat ontwikkel het 
in hierdie pasiente na nieroorplanting is ook gedokumenteer.
Alle pasiente in ons eenheid in wie ‘n nier tussen 1 April 1976 en 31 Maart 1999 
oorgeplant was, is in die studie ingesluit. Tydens die studieperiode het 542 pasiente 
623 niere ontvang. Demografiese detail is ontleed. Pasient- en nieroorplantings 
uitkomste is beraam deur gebruik te maak van Kaplan-Meier oorlewing analiese. 
Die oorlewingskurwes is vergelyk deur gebruik te maak van enkelveranderlike 
ontledings; noemenswardige resultate is onderwerp aan meerveranderlike 
ontledings. Die invloed van ‘n aantal faktore op oorgeplante nier- en 
pasientoorlewing is ondersoek en vergelyk. Die impak van ‘n verskeidenheid 
veranderlikes op die getal en gedrag van maligniteite is ook ondersoek.
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Pasient oorlewing asook oorlewing van oorgeplante niere was beter in ontvangers 
onder die ouderdom van veertig jaar. Vroee verlies van ‘n oorgeplante nier het 
verband gehou met ‘n hoe pasientmortaliteit. Siklosporien het die oorlewing van 
oorgeplante niere verbeter, maar nie die van pasiente nie. In teenstelling met die 
ervaring elders, het swart en wit pasiente soortgelyke uitkomste uitkoms gehad na 
‘n nieroorplanting.
Van die 542 ontvangers, het 41 (8.1%) maligniteite ontwikkel; Kaposi se sarkoom het 
in 21 pasiente voorgekom en velkanker in 13 pasiente. Die relatiewe risiko (“relative 
risk") vir die ontwikkeling van Kaposi se sarkoom was 235. Kaposi se sarkoom was 
die algemeenste tumor in swart en gekleurde pasiente (verantwoordelik vir 79% van 
maligniteite in die groep) en het binne twee jaar voorgekom. Kaposi se sarkoom 
was ewe algemeen in manlike en vroulike ontvangers. Met behandeling deur middel 
van siklosporien het die latente periode totdat maligniteite ontwikkel het verkort, 
maar die insidensie daarvan het onveranderd gebly. Velletsels geassosieer met 
Kaposi se sarkoom was teenwoordig in alle pasiente met die vel van die onderste 
ledemate die mees algemeen betrokke ligging. Die sarkoom het gereageer op 
vermindering van immuunonderdrukking, sonder die nodigheid vir volkome 
onttrekking, en met die bewaring van nierfunksie. Ekstrakutane betrokkenheid het 
in meer as ‘n kwart van die pasiente voorgekom en was altyd noodlottig in pasiente 
met viserale aantasting. Die histopatologie van postoorplanting Kaposi se sarkoom 
was dieselfde as die wat beskryf is vir die ander epidemiologiese vorms van die 
siekte.
Wit mans het die hoogste risiko vir die ontwikkeling van velkankers na 
nieroorplanting gehad. Plaveiselsel karsinoom was betreklik meer algemeen en het 
in son-blootgestelde areas voorgekom. Die letsels was uitsluitlik met lokale eksisie 
behandel en geen pasiente het metastases ontwikkel nie. Maligne limfoom, 
borskanker, en longkanker het in enkele pasiente voorgekom maar die relatiewe 
risiko van al die letsels was om en by een gewees. Nie een van die pasiente met 
vorige maligniteite het herhaling van die tumore na oorplanting ontwikkel nie.
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XAFDELING 2
Die vermoede is dat beide immuunonderdrukking en immuunstimulasie ‘n rol speel 
in die ontwikkeling van Kaposi se sarkoom na ‘n nieroorplanting. Ons het die 
kwantitiewe en kwalitatiewe aspekte van die immuunsisteem van pasiente wat 
Kaposi se sarkoom ontwikkel het na ‘n nieroorplanting, ondersoek .
Limfosiet fenotipes is met behulp van vloeisitometrie bepaal, terwyl 
transformasiestudies uitgevoer is deur gebruik te maak van mitogene. “Pokeweed” 
is gebruik as die B-sel mitogeen, en konkanavalien A en fitaheemagglutinien was die 
T-sel mitogene. Sel-gemedieerde immuniteit was ook getoets deur die gebruik van 
vertraagde tipe hipersensitiwiteit veltoetse. Die serum immunoglobulien vlakke was 
ook bepaal.
Eerstens, met betrekking tot humorale immuniteit, het 2/3 van die pasiente normale 
serum immunoglobulienvlakke gehad, alhoewel die B-seltelling verminder was in al 
die pasiente op immuunonderdrukking. B-seltransformasie-toetse met “pokeweed” 
mitogeen het getoon dat B-sel funksie nie ingekort was in pasiente met Kaposi se 
sarkoom nie. Die pasiente met verminderde serum immunoglobulinvlakke het ook 
wangevoed voorgekom soos die verlaagde serum albumienvlakke uitgewys het. 
Tweedens was CD3 en CD4 seltellings, maar nie CD8 nie, verlaag in pasiente met 
Kaposi se sarkoom. Betekenisvolle verskille is ook aangetoon met T-sel 
transformasietoetse in vergelyking met kontroles, met verminderde response in 
Kaposi se sarkoom pasiente. Derdens was natuurlike dodersel (NK) getalle ook 
minder in pasiente met Kaposi se sarkoom. Daar was geen noemenswaardige 
verskille in vetraagde tipe hipersensitiwiteit velreaksies wat nie deur rasseverskille 
kon verklaar word nie.
Sellulere immuniteit is ingekort in pasiente met Kaposi se sarkoom met ‘n verlaging 
in die aantal NK selle. Beide die komponente van die immuunstelsel is belangrik vir 
beskerming teen maligne transformasie.
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AFDELING 3
Kaposi se sarkoom is ‘n belangrike komplikasie van nieroorplanting. As die menslike 
herpesvirus-8 (HHV-8) Kaposi se sarkoom veroorsaak, behoort die virus 
teenwoordig te wees in alle letsels en as Kaposi se sarkoom remissie ondergaan 
behoort dit drasties te verminder of te verdwyn in weefsel waarin dit voorkom.
Veertien nieroorplantingspasiente met Kaposi se sarkoom van die vel, insluitend 
outopsiemateriaal van twee gevalle, is ondersoek vir die teenwoordigheid van HHV-
8. ‘n Tweede velbiopsie van dieselfde anatomiese area as die eerste is uitgevoer op 
11 oorlewende pasiente na remissie van die sarkoom. Remissie was deur die 
vermindering of onttrekking van immuunonderdrukking bewerkstellig. ‘n Perifere 
bloedmonster is by dieselfde geleentheid as die tweede biopsie geneem. ‘n Geneste 
polimerase kettingreaksietoets (“nested polymerase chain reaction”) is gebruik om 
die teenwoordigheid van HHV-8 DNA in die biopsieweefsel en perifere bloed 
mononukluere selle te bepaal, gevolg deur direkte volgordebepaling (“sequencing”) 
van die polimerase kettingreaksieproduk om enige nukleotiedveranderings te 
dokumenteer.
HHV-8 DNA is waargeneem in al die kutane Kaposi se sarkoom en al die viserale 
Kaposi se sarkoom monsters, sowel as in weefsel waar die Kaposi se sarkoom nie 
voorgekom het nie en waar die teenwoordigheid van die virus nie tevore beskryf is 
nie, soos die skilklier, speekselklier, en hartspier. Mutasies in die virale DNA kon in 
alle pasiente aangetoon word. Die mutasies wat gevind is, was nader verwant aan 
die wat in VIGS-Kaposi se sarkoom beskryf is as die wat in endemiese Kaposi se 
sarkoom in Afrika gevind word. HHV-8 volgordes kon waargeneem word in bevrore 
opvolg-velbiopsies van vyf pasiente, maar was afwesig in die ekwivalente formalien- 
gefikseerde monsters. Virus DNA is ook waargeneem in 2 van 11 perifere bloed 
mononukluere selmonsters wat versamel is tydens die opvolg velbiopsies.
Vermindering of onttrekking van immuunonderdrukking laat die immuunsisteem toe 
om genoegsaam te herstel om virale replikasie te verminder met daaropvolgende 
teenwoordigheid en laegraadse virale replikasie wat ooreenstem met kliniese 
remissie van letsels van Kaposi se sarkoom. Dit verskaf verdere bewyse van die
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belangrike oorsaaklike rol wat deur HHV-8 gespeel word in die patogenese van 
postoorplanting Kaposi se sarkoom.
AFDELING 4
Die onlangs-ontdekte HHV-8 is ‘n belangrike faktor in die etiopatogenese van Kaposi 
se sarkoom. Die rede vir die buitengewone hoe prevalensie in ons gebied, sowel as 
die van ander ontwikkelende lande, is nie voor die hand liggend nie. Ons het die 
seroprevalensie van die virus in verskillende gesonde persone, sowel as orgaan 
donor-ontvanger pare ondersoek.
Alle nierontvangers en hul gepaarde donors is getoets ten tye van die 
nieroorplanting. Getoetste kontrole persone was gesonde bloedskenkers, 
niereenheid personeel en huishoudlike kontakte van pasiente met vorige Kaposi se 
sarkoom. ‘n Ensiemgekoppelde immuuntoets (enzyme-linked immnoassay; ELISA) 
vir die volledige virus was gebruik vir sifting en bevestiging is verkry vir alle positiewe 
toetse deur gebruik te maak van van ‘n ELISA vir die latente ORF 73 antigeen.
Die prevalensie van HHV-8 was vergelykbaar in alle groepe en was gemiddeld 
minder as 6%. Na oorplanting het die prevalensie gestyg tot byna 20%, maar nog 
die oorgeplante nier nog perioperatiewe bloedoortappings kom die styging verklaar. 
Kaposi se sarkoom het in 3 van 116 van die pasiente wat ‘n oorplanting ondergaan 
het, ontwikkel. Al die pasiente met Kaposi se sarkoom was HHV-8 seropositief voor 
die ontwikkeling van die Kaposi se sarkoom. Twee van die pasiente wat Kaposi se 
sarkoom ontwikkel het was seropositief voor die oorplanting. Geen pasient wat ‘n 
nier van ‘n seropositiewe donor ontvang het, het Kaposi se sarkoom ontwikkel nie.
Ons weerle die stelling dat ‘n hoe prevalensie van HHV-8 in die algemene bevolking 
verantwoordelik is vir die hoe prevalensie van Kaposi se sarkoom onder ons 
nieroorplantingspasiente of dat die donornier ’n belangrike bron van infeksie is. Dit 
wil voorkom of heraktivering, eerder as primere infeksie, ‘n bron van die virus is na 
nieroorplanting.
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Chapter 1
INTRODUCTION
O rgan transplantation is arguably one of the most impressive medical therapeutic advances of the last century. It has prolonged the survival of countless patients around the world suffering from endstage organ failure. 
Perhaps, as important, is the often-dramatic improvement in the quality of life that 
these patients experience following organ transplantation. No other form of 
treatment has raised as much hope and expectation. The success of organ 
transplantation has resulted in an increase in the demand for this form of treatment 
by a public that has become increasingly aware of its benefits, but is often ignorant 
of its many problems, of which development of malignancies is an uncommon, but 
serious one.
A successful kidney transplant is undoubtedly the best treatment for the patient with 
endstage renal failure. For the individual patient, not only is it the most cost-effective 
option, but it also holds the promise of improved quality of life (Hathaway et a/., 1998) 
and longevity compared to dialysis therapy (Basadonna et a/., 1992;Denton et
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a/.,1999;Grenfell et a/.,1992;Khauli et a/.,1986;Krakauer et a/.,1983;Port et 
a/.,1993;US Renal Data System,1999;Vollmer et al., 1983). The success of renal 
transplantation is dependent on adequate immunosuppression to prevent and treat 
acute rejection. Adequate immunosuppression, however, represents a fine balance 
between minimising the toxicity of the drugs and maximising the efficacy (Fig.1-1). 
The price that patients pay for long-term immunosuppression can be quite 
considerable. The commonest causes of morbidity in recipients of renal allografts 
are infections and cardiovascular disease (Arend et a/.,1997;Mazzuchi et 
al., 1999;Ojo et a/.,2000;Washer et al., 1983) with malignancies accounting for 
significant mortality in long-term survivors (Sheil et al., 1980). It is well recognised 
that the longer patients survive the greater the likelihood of them developing 
malignancies (Disney et a/.,1998;Disney et a/., 1997;Sheil, 1994b).
Adequate
Immunosuppression
Fia • 1 i t  a  delicate balance exists between under-immunosuppression that may 
result in acute rejection and over-immunosuppression that may produce adverse 
events.
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MOTIVATION FOR THIS STUDY
The idea for this study arose as a result of observations made while collecting data 
on our renal allograft recipients for the Cincinnati Transplant Tumor Registry (CTTR) 
(now known as the Israel Penn International Transplant Tumor Registry) at the 
request of the late Dr Israel Penn, the founder of the Registry. It became clear to us 
that the pattern of malignancies that we were observing in our transplant patients 
differed entirely from that reported by other countries that were submitting data to the 
same registry. While countries such as Australia (Sheil,1994a;Sheil,1996) and the 
United States of America (USA) (Penn,1994), and even European countries were 
reporting very high incidences of skin cancers following renal transplantation 
(Blohme et a/.,1990;Coebergh et a/.,1991), we were observing a very high incidence 
of Kaposi's sarcoma. Our suspicion of an alternative pattern of cancers was 
supported by the experience of other developing countries with the first reports 
originating in Saudi Arabia (Qunibi et al., 1988).
Our first approach was to study our renal transplant recipients as a group as this had 
never been done previously. This involved studying the demography of this 
population and the outcome of renal transplantation in these patients. We made 
some interesting observations in this preliminary phase of the study especially with 
regard to the impact of the immunosuppressive agents. Although we found that 
infections and cardiovascular disease were the major causes of mortality we did 
proceed to study the nature of the malignancies that occurred in these patients. 
These aspects of the study are contained in Section 1 of this dissertation and form 
the core this study. The various chapters of this section explore the outcome of 
renal transplantation in our cohort in comparison with local, national and international 
groups. Our study spans a period of 23 years, which is one of the longest reported 
but more importantly allows comparisons in different treatment eras. These chapters 
are also unique because we look at factors influencing graft survival that have never 
been addressed in this country. The remaining chapters in this section specifically 
address the problems of transplant malignancies. We recount in detail our 
experience with Kaposi's sarcoma and compare it with experience elsewhere. Our 
treatment of the disease confirms what has been suggested by the literature but 
never proven until this study. The unique pattern of malignancies in the black
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compared to the white patients epitomises the experience of cancers in developing 
and developed countries respectively.
In Section 2, Chapter 14 of this dissertation we expand on our published study 
(Moosa et a i, 1998). An important aetiological factor of Kaposi's sarcoma is 
postulated to be the human herpesvirus type 8 (HHV-8). In this chapter we describe 
the presence of the HHV-8 in the Kaposi's sarcoma tissue of all our patients with the 
posttransplant form of the disease, as have some other authors. Unique to this 
study is our observation that when the disease remits, the virus can no longer be 
detected locally.
In Section 3, Chapter 15, we investigate the role of the immune system in the 
development Kaposi's sarcoma. Since some degree of immunosuppression is 
present in most if not all the forms of Kaposi's sarcoma, we attempt to establish the 
immune status of posttransplant patients who had developed Kaposi's sarcoma. 
Although, immunosuppression has been recognised to contribute to the development 
of the disease, the exact nature of the immune defect that allows Kaposi's sarcoma 
to occur remains unknown. We also discuss the known mechanisms of action of the 
immunosuppressive agents that we used and explore the influence of these agents 
on the development of malignancies in Chapter 16.
Finally, with growing acceptance of an important aetiological role for HHV-8 in the 
development of Kaposi's sarcoma, the question of the epidemiology of the virus 
becomes an issue. The virus belongs to the herpesvirus group and the question that 
remains to be answered is whether HHV-8 behaves like other viruses in the group. 
We attempt to answer the question by investigating the presence of antibodies to the 
virus in different groupings including transplant recipients, Renal Unit staff, healthy 
blood donors, relatives and contacts of Kaposi's sarcoma patients. Also unique to 
this project is the study of organ donor-recipient pairs and the assessment of the risk 
for the development of Kaposi’s sarcoma.
An important thread that runs through this dissertation is the fact that we are 
reporting our experience from a developing country. Most of the data that exist 
today has been reported from countries with developed economies. We show that
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the experience from these first world countries cannot and should not be 
extrapolated to countries with emerging market economies. Differences between the 
two economic extremes have a profound impact on the disease patterns in these 
countries including malignancies (Jones, 1999), and this theme is exploited 
throughout.
For the sake of convenience, the references have been included at the end of each 
chapter. An extensive review of the literature has been undertaken with the citations 
included mainly in the Introductory and Discussion portions of the chapters, where it 
was easier to place our own experience in perspective. Extensive use has also been 
made of Tables and Figures to aid in the illustration of important points.
Most of the surgical and other principles applied in organ transplantation today 
evolved over time, and the successes we enjoy today and the techniques we take for 
granted is a tribute to the hard work and astute observations of our predecessors. In 
honour of their illustrious achievements, a brief review of the History of Renal 
Transplantation has been undertaken in Chapter 2. In honour of the amazing 
contributions to medicine generally and dermatology specifically, a brief biography of 
Moritz Kaposi is presented in Chapter 7.
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Chapter 2
AN HISTORICAL 
PERSPECTIVE OF RENAL 
TRANSPLANTATION
It is often enough to know that a thing is possible
M a riu s  B arnard
T he replacement of a diseased, malfunctioning organ with a healthy one removed from a living or dead donor is an attractive solution to the problem of end-stage organ failure. Man's fascination with transplantation dates 
back several millennia and began as the medicine of mythology (Kahan,1991). 
Greek and Egyptian mythologies are rich in examples of metamorphoses and other 
fantastic events portraying man's earliest thoughts and imaginings about 
transplantation and grafting. In Ovid's Metamorphosis Diana transforms Actaeon 
into a stag as punishment for his voyeurism. He is then set upon and ripped to 
pieces by his own dogs who fail to recognise him. Nagy (1999) suggests that (sic) 
this could be considered the first literary evidence of transplantation and rejection . . 
.!" This rich mythological world has served to foster the imaginations of many
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painters including Picasso. In Picasso's Guernica the Minotaur's head is replaced 
with that of a bull's. However, the ancient civilisations of India and China have 
legends specifically relating to transplantation, which pre-date the Greek mythology. 
Some of these myths date back at least 3 millennia in the medicine of mythology 
(Bhandari et al., 1997;Kahan, 1991). Although it is impossible to test the rationality or 
authenticity of these myths, they emerged from deep-seated religious beliefs. These 
fantastic stories in no way undermine the achievements of modern researchers in 
the last 100 years but by the same token, there can be little doubt of the conceptual 
contributions made by these seemingly impossible legendary feats (Bhandari et 
al., 1997).
INDIAN MYTHOLOGY
The legend of Lord Ganesha
The Hindu scriptures contain accounts of transplantation that are reputedly 5000 
years old. The Vedas are the main religious scriptures of Hinduism but it is the 
Pur'a'nas, a collection of verses composed by Vedavyasa that vividly describes the 
nefarious activities of the gods Brahma the creator, Vishnu the preserver and Siva 
the destroyer. The disputes between the gods result in the mythical xenogeneic 
transplantation on the sage Daksha and the Indian god Ganesha that are performed
Fig.2-1 Upper left: Depiction of 
the legendary tale of Judge Lu 
performing a heart transplant. 
Lower right: The Lord Ganesha 
after his reincarnation. From 
Bhandari et al. (1997).
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by Siva. The legend of Daksha has it that the latter had 60 daughters, one of who, 
Sita, was married to Siva the destroyer. Daksha had a great dislike of his son-in-law 
and deliberately failed to invite him and Sita to a large religious ceremony. Sita 
attended the function uninvited, which resulted in her father humiliating her and 
insulting her husband in front of the invited guests. Disgraced, Sita killed herself by 
jumping into the fire. Upon hearing of the fate of his wife, Siva became furious and 
ordered two monsters under his control to disrupt the festivities, which they promptly 
did killing all the guests and beheading the hapless Daksha. The head was thrown 
into the same fire that had consumed his ill-fated daughter. At the request of all the 
gods, Siva however later called off his monsters and was ordered to bring Daksha 
back to life. However, the head was nowhere to be found and it was replaced with 
that of a ram with the help of Brahma the creator (Moore et a/.,1984;Wilson,1961).
The legend of Ganesha (Fig. 2-1)
This legend is even more popular and well documented in Indian mythology. 
Parvati, another wife of Siva, created Ganesha to act as her sentry to forewarn of the 
god’s untimely visits. On the fateful day, Siva decided to pay Parvati, who was 
taking a bath, a visit, but was confronted by the trustworthy and reliable Ganesha, 
who making no exceptions refused him entry. He severely assaulted Siva and his 
companions and a heated battle ensued. Realising that her pride was at stake, 
Parvati endowed Ganesha with supreme powers and weapons, which made him 
invincible. Realising this, Siva stealthily crept up on Ganesha and in the heat of the 
battle decapitated him with his trident. Parvati was furious when she learnt of her 
loyal servant’s fate and threatened to destroy the universe. She only relented when 
Siva agreed to reincarnate Ganesha and to endow him with divine powers. 
However, Ganesha's head could not be found and Siva sent his allies to bring back 
the head of the first living creature found to be committing an error against nature. 
This happened to be an elephant that was found to be sleeping facing the north. 
They removed the head of the elephant and attached it to the headless body of 
Ganesha who was thus restored to life (Kahan,1989b; Mackenzie,1978).
Xenotransplantation: acts of repentance
It would appear that most instances of xenotransplantation in Hindu mythology are 
related to the god Siva who decapitates human beings in a fit of rage. He then uses
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animals as donors when he performs the transplants as penitence for his brash 
actions. These accounts are reputedly 5000 years old and probably represent the 
oldest accounts of transplantation in history (Bhandari et a/., 1997).
CHINESE MYTHOLOGY
Judge Lu (Figs. 2-1 and 2-2)
The Chinese legends are less gruesome and are acts of kindness rather than acts of 
retribution and include two popular stories. The story of Judge Lu tells of a brave but 
simple man, Zhu Ertan, who was encouraged by his mischievous companions, in the 
middle of the night, to bring the Infernal Judge back to them. To their surprise he 
returned with a full-length effigy of the Judge. Zhu proceeded to invoke the image 
and invited it to drink with him whenever he felt the fancy to do so. He then returned 
the image to its rightful place. The following evening the judge walked into Zhu's 
humble abode and the poor man pleaded for his life. But the good Judge did not 
intend to punish the imbecile and instead accepted the offer of the drink. The judge 
became a regular visitor thereafter stopping by 2 to 3 days a week. One evening 
Zhu awoke with a throbbing pain in his chest to find the judge at his bedside. The 
judge had cut open his chest and was about to remove his heart. Zhu pleaded for
FiQ. 2-2 Another depiction ol 
Judge Lu at work. From Lerut 
(2000).
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f i g- 2-3 Various depictions of the 
miracle of the saints Cosmas and 
Damian transplanting the leg of a Moor 
to a sexton.
his life but the judge reassured him and informed Zhu that he was replacing his heart 
with a smarter one. He completed his operation and not only was Zhu fine after the 
procedure but he became a famous writer with a faultless memory. He was most 
grateful to the Judge for his wonderful gift but pleaded for one more favour. He 
argued that if the Judge could exchange his heart he surely could perform his craft 
on Zhu's ugly wife. The Judge was delighted to comply and a few days later he 
returned with the head of a beautiful young woman that he successfully transplanted 
to Zhu's wife (Zhuangzi,1991).
Doctor Pien Ch‘ iao The other classical Chinese legend describes the story of the 
Chinese doctor Pien Ch' iao. Kung He and Ch'i Ying were two men from the 
province of Po-Hai in China who sent for Pien Ch' iao when they both took ill. The 
doctor diagnosed a domination of "yin" in one and a domination of "yang" in the other 
patient. Pien Ch' iao recommended an exchange of hearts to restore equilibrium of 
the two men's energy. Not only did the two men accept the diagnosis but also they 
agreed to the treatment. Pien Ch' iao cut open their chests and exchanged their
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hearts. More importantly he used a strong narcotic to render the patients 
unconscious and postoperatively applied potent drugs. Both patients made a full 
recovery (Wong et a/., 1973).
CHRISTIAN ERA (FIG. 2 -3 )
Miracles
The arrival of the Christian era saw the emergence of miracles based on acts of 
faith. The most famous miracle was recorded in the 13th century in the Leggenda 
Aurea of Jacopo da Varagine who recounts the "miracle of the black leg" performed 
by twin brothers Saint Cosmas and Saint Damian in 348 A.D. In this account the 
holy men grafted the leg of a deceased Ethiopian Moor gladiator to replace the 
gangrenous limb of Deacon Justinian, the sacristan of the Roman basilica. 
(Kahan,1983;Nagy,1999)
These myths and miracles were the product of mans' fertile imagination. However, 
for several centuries, transplantation remained the domain of eccentric painters and 
imaginative writers until the early part of the last century (Nagy,1999). Renal 
transplantation has now become routine treatment for end-stage renal failure but its 
path to clinical acceptance was a rocky one fraught with difficulties that often 
appeared to be insurmountable. However, developments along three major areas 
set the stage for the success of the procedure. These developments occurred in the 
surgical technical aspects of the procedure that were mastered relatively early, the 
appreciation of the immunological nature of rejection and lastly the development of 
immunosuppressive drugs.
1. P e r f e c t in g  t h e  s u r g ic a l  t e c h n iq u e s  o f  r e n a l  
TRANSPLANTATION 
THE EARLY PIONEERS
In the second century BC the Indian surgeon Sushruta performed the first skin 
autotransplants for rhinoplasty (Susruta,1907). This skill was rediscovered by 
famous Bolognese surgeon and anatomist Gaspare Tagliacozzi in 1596, to 
reconstruct noses destroyed by syphilis and other diseases (Gnudi et al., 1950).
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Tagliacozzi was also the first physician to appreciate the relevance of biological 
individuality when he stated: "The singular character of the individual entirely 
dissuades us from attempting work (tissue transplantation) on another person” 
suggesting that he had a notion of the barriers to allotransplantation (Converse et 
a/.,1968). Hunter (1935) was however successful at engrafting a human tooth to the 
comb of a cock in the 18th century which led him to conclude that " . . .  transplantation 
is founded on a predisposition in all living substances to unite when brought into 
contact with each other".
Early animal experiments
In 1804 Baronio successfully grafted skin both allogeneically and xenogeneically 
(Baronio,1804). Paul Pert (1863), successor to Claude Bernard disputed this claim 
in 1863 in his doctoral dissertation De la Greffe Animale. In his thesis he outlined 
animal experiments using skin and tissue, alio- xeno- and rat parabiont "Siamese" 
grafts. He concluded that autografts would be successful but that allografts and 
xenografts would predictably fail.
Surgical advances
In the last quarter of the 19th century advances in suturing techniques were made by 
Murphy (1897), Payr (1900) and Jaboulay (1906). Animal experiments were 
performed intermittently in the early years of the 20th century to address the issues of 
transplantation. The kidney emerged as the best experimental model. The reason 
for this was that the kidney was paired, had a relatively simple blood supply, and the 
flow of urine through the ureter served as an instant marker of function.
Uliman's contribution
In 1902 Emerich Ullman made a major breakthrough when he reported the first 
successful experimental renal transplant (Fig. 2-4) (Ullman, 1902). He removed a 
kidney from a dog and transplanted it into the neck of another dog. The graft 
functioned for 5 days. He proceeded to experiment with auto-, alio- and 
xenotransplants and even attempted to transplant the kidney of a pig into a uraemic 
woman in 1902 (Nagy, 1999;Ullman, 1914). However, although he failed to report his 
attempts at human transplant until 1914, he is credited with the initiating the 
transplant era (Hamilton, 1994;Nagy, 1999)
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Fig. 2-4 Publication of Ullman's first series o f experimental transplants in 1902. The 
obituary o f M. Kaposi who described Kaposi's sarcoma also appeared in this issue of 
the journal.
Mathieu Jaboulay
Jaboulay performed the first recorded human kidney transplant in 1906. He 
performed two xenotransplants using grafts obtained from a pig and a goat. The 
grafts were anastomosed to vessels in the patients' antecubital fossa. The kidneys
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EiSi 2-5 Nobel laureate Alexis Carrel 
pioneered a number o f surgical 
techniques many of which are still in 
use today. The Carrel patch was a 
major advance in vascular surgery and 
is still used today
produced urine for one hour before they failed. The failure of the grafts was 
attributed to vascular thrombosis. Although the grafts failed this is considered the 
first technically successful xenotransplant in humans (Jaboulay,1906).
Alexis Carrel (Fig. 2-5)
Working with Jaboulay was his protege Carrel, who in 1902, under Jaboulay's 
guidance started developing the suturing techniques that are still in use a century 
later. With fine silk suture material he used his newly developed triangulation 
technique to perform renal autotransplants in animals and noted that they produced 
urine. Infection ultimately destroyed all the grafts. Carrell (1902) also performed 
experimental transplants of blood vessels, thyroid, parathyroids, heart and other 
organs. In 1906 Carrel, in collaboration with Guthrie described his famous "patching 
method" for anastomosing small blood vessels (Carrel et al., 1906). This was one of 
the most useful techniques to be developed in surgery and contributed immensely to 
the technical success of organ transplantation surgery. He also developed the 
internal vascular shunt and reported aortic patching using inert foreign materials.
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For his invaluable contributions Carrel received the Nobel Award in Physiology and 
Medicine in 1912 (Kahan.1991).
Ernst Unger
The second attempt at human transplantation was better documented than the first 
one. In 1909 Ernst Unger attempted to transplant a kidney from a pig ape to the 
thigh vessels of a young girl dying from renal failure. The kidney failed to produce 
urine and together with his extensive experience in animal studies he concluded with 
some foresight that there had to be a “biochemical” barrier to transplantation 
(Unger,1909). These early experiments established that renal transplantation was 
technically possible (Table 2-1) but lack of simple tests to monitor renal function as 
well as uncertainty of mechanisms underlying graft rejection led to a decline in 
interest in transplantation until well after the Second World War (Hamilton,1994).
Table 2-1 Early experimental renal transplantation
Year Event Reference
1902 Kidney allograft and xenografts in dogs and goats Ullman,1902
1902 Kidney autografts in dogs Carrel, 1902
1905 Kidney allografts to groin, neck , renal fossa in dogs Floresco*
1906 First human kidney transplant (xenograft) Jaboulay, 1906
1906 Improved technique for vascular access Carrel et al., 1906
1909 Second human kidney transplant (xenograft) Unger, 1909
1910 Kidney allografts in dogs Villard*
1924 En bloc kidney xenografts: cats to dogs in cold preservation Avromovici*
1923 Kidney autografts in dogs and goats Williamson,1923
1926 Kidney autografts in dogs and goats Williamson,1926
1926 Kidney allografts in dogs Holloway*
1934 Kidney auto/allografts in dogs Win and Mann*
1948 Kidney allografts could clear urea Oudet*
1950 Biology of renal transplantation (neck) in dogs Dempster, 1950
1953 Biology of renal transplantation (abdomen) in dogs Simonsen,1953
These references were cited by Lerut (2000).
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Fig. 2- 6 Voronoy's article describing the first human allotransplantation appeared 
in the Spanish journal El Siglio in 1936.
The intermediate period (Table 2-2)
The highlight of this period was a dramatic but little known event that took place in 
the Ukraine province: Soviet surgeon Yu. Yu. Voronoy performed the first human 
renal allograft in 1936. He published his report in an obscure Spanish medical 
journal under the title, which translated into English, read "On the blockage of the 
reticulo-endothelial system in some kinds of corrosive sublimate poisoning and the 
transplantation of the kidney from the cadaver as method of treatment of that anuria" 
(Fig. 2-6). Not only does the title convey the fact that he performed a renal 
transplant from a cadaver, but also clearly shows his insight into the immunological 
characteristics of graft rejection (Voronoy, 1936). Voronoy was an experienced 
investigator who worked under Shamov, a respected surgeon. Their main area of 
interest was blood transfusion and testicular transplantation, then in vogue for its 
potentially rejuvenating ability (Hamilton et al., 1984). Voronoy turned his attention to 
kidney transplantation in dogs using Carrel’s vascular suture methods (Fig. 2-7). He 
was technically successful but took the experiments further by measuring the level of 
complement fixing antibodies using the Bordet-Gengou reaction in the dogs on which 
he had performed autotransplantation (vide infra) (Voronoy, 1929;Woronoy, 1930).
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Table 2-2 Early clinical renal transplantation
Year Comments No. of Site of kidney Reference
patients placement
1936 First human cadaveric transplant. No 
function.
6 Groin Voronoy, 1936
1946 No function 1 Renal fossa Hume1
1951 Functioned 19 days 1 Pelvis Servelle et al., 1951
1951 No function 2 Pelvis Dubost et al., 1951
1953 Questionable function 6 Pelvis Kuss et al., 1951
1953 First living related transplant 1 ? Michon et al., 1953
1954 Successful transplant between 
identical twins
- Iliac Merrill et al., 1956
1955 4 functioned 35- 188 days 9 Groin Hume et a/.,1955
1962 First use of tissue typing to select 
recipient
Iliac Hamburger et 
al., 1962
1963 First renal transplant in UK - Iliac Woodruff ef al., 1963
1966 First renal transplant in RSA - Iliac Myburgh et al., 1983
Cited by (Moore,1964)
Fig- 2-7 The surgical method used by Voronoy for renal grafting in the dog. 
From Woronoy (1929).
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The first human-to-human kidney transplant
The first human renal allograft transplant took place on April 3, 1933 and was 
described in detail in a recent Soviet review (Mirskili,1973). The patient was a 26 
year-old female who had developed acute renal failure following a suicide attempt 
using mercuric chloride. When the patient failed to improve on conservative 
measures and remained anuric, Voronoy decided to proceed to perform a cadaveric 
transplant. The donor was a man who had sustained a base of skull fracture and 
had died in the emergency room. The donor nephrectomy was performed 6 hours 
later. The blood groups of the patients were also incompatible: The patient was 
blood group O while that of the cadaver was B. Voronoy decided to proceed with the 
transplant despite the difference in blood groups because he felt that the blood of the 
recipient would dilute the blood in the graft. Perhaps more importantly, there was no 
other potential donor kidney available. The surgery was performed under local 
anaesthesia and the graft was implanted in the right upper thigh and anastomosed to 
the femoral vessels, while the ureter was brought out onto the skin. In spite of a 
modest exchange transfusion the graft never worked. The patient died 2 days later. 
At autopsy the blood vessels were patent.
Success and failure
The operation was technically a success and reasons the graft failed to work are 
obvious now: the prolonged warm ischaemia time and the blood group 
incompatibility. From his experience in dogs the non-functioning of the graft did not 
perturb Voronoy. He was not discouraged by the poor outcome and proceeded to 
perform a further 5 transplants none of which functioned (Voronoy, 1950).
The second group to attempt renal allotransplantation
In 1946 Hufnagel, Hume and Landsteiner undertook the second documented human 
renal allograft transplant in Boston. The operation was also performed under local 
anaesthesia and the kidney was grafted onto the brachial artery and cephalic vein of 
a young woman with acute renal failure. The graft functioned transiently but 
fortunately the patient's own kidneys started recovering a few hours after the 
transplant and the graft was removed after 2 days (Moore, 1964).
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Haemodialysis
In 1944 a remarkable development took place in Holland that was to have a 
profound impact on the transplantation of kidneys. Kolff (1944) had invented the 
artificial kidney that was to provide patients with end-stage renal failure with support 
while awaiting transplantation and a refuge for those whose grafts failed. The first 
patients were placed on a chronic haemodialysis program at the Peter Bent Brigham 
Hospital in Boston in 1949 under the supervision of Thorn and Merrill (Merrill et 
al.,1950). It soon became apparent that this form of treatment was capable of 
sustaining the life of a patient with end-stage renal failure for almost indefinite 
periods. The success of chronic haemodialysis was crucial to the development of 
clinical renal transplantation. This life support system allowed the development of a 
pool of transplant recipients and prevented the diagnosis of chronic renal failure 
being equated with death. Chronic dialysis provided patients (and still does so) with 
a dimension of safety not enjoyed by patients with other vital organ failure 
(Banowsky,1983).
European developments o f the 1950s
In 1951, 3 teams under Servelle et al. (1951), Dubost et al.{ 1951) and Kuss et 
al.( 1951) respectively, all working independently in Paris reported their experience 
with renal allografts in small number of patients. None of the grafts functioned for 
any length of time. The Parisian teams all placed the grafts in the pelvis, 
anastomosed the kidneys to the iliac vessels and made cutaneous ureterostomies. 
The patients were all transplanted without immunosuppression. The Boston group 
under Hume embarked on a kidney transplant trial in 1952. They placed the renal 
allografts in the upper thigh, which had many anatomical disadvantages but gave 
them an opportunity to observe the behaviour of the graft. Many of the grafts worked 
for varying periods of time and one graft functioned for a remarkable 175 days 
without immunosuppression (Hume et a/.,1952;Hume et al., 1955). All allografts used 
up to this point were from unrelated donors but in 1953 Michon and his group 
reported the first kidney transplant from a healthy living-related donor. The patient 
was 16-year-old male who lost his solitary kidney, which had been damaged in a 
scaffolding accident. The mother was the donor. The graft functioned immediately 
but abruptly rejected on the 22nd day. The young man died shortly thereafter 
(Michon et al., 1953).
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Fig. 2-8 Oil painting The first successful kidney transplantation - December 23, 1954 
- depicting that pioneering event by Murray, Merrill and Hamilton.
The insurmountable barrier
Up to this point the surgical techniques were standardised and the short-term results 
acceptable but the problem of the immunological barrier that resulted in acute 
rejection remained to be broached. Interest in clinical and experimental 
transplantation again waned, although knowledge of basic immunological 
mechanisms in the laboratory was steadily increasing (Hamilton, 1994;Toledo- 
Pereyra et a/., 1999).
The late period: the barrier overcome?
The barrier breached
With the pioneering work of Medawar and others (Billingham et al., 1954) involved in 
the successful transplant of skin graft in human identical twins and syngeneic
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animals to encourage them, the team of Murray, Merrill and Harrison performed the 
first long-term successful renal transplant (Fig. 2-8). They overcame the problem of 
the immunological barrier by applying the concept of genetic similarity (Brower et 
a/., 1977; Toledo-Pereyra et a/., 1999). The operation was performed in Boston on 
December 23,1954 when a kidney was transplanted into a patient from an identical 
twin (Merrill et a/., 1956; Murray et al.,1958). Harrison removed the left kidney of the 
healthy twin brother while Murray was performing the dissection in the patient. The 
graft was placed retroperitoneally and anastomosed to the iliac vessels with the 
ureter implanted into the bladder. The graft started functioning immediately and the 
donor made a full recovery (Merrill et al., 1956). The patient returned to work and 
raised a family, after marrying one of the nurses who cared for him in hospital. The 
patient developed proteinuria two years later and biopsy confirmed that he had a 
recurrence of glomerulonephritis in his graft. However, he died of an acute 
myocardial infarct 8 years later, with the graft still functioning (Merrill et al., 1956). 
From then on a number of similar transplants were performed with great success 
with many patients achieving long-term survival. The successes were however 
tempered by failures caused by the recurrence of glomerulonephritis in the 
transplanted kidney (Hamilton,1994).
2. H is t o r y  o f  t h e  im m u n o l o g ic a l  a s p e c t s  o f  r e n a l  
T r a n s p l a n t a t io n
The early pioneers
The greatest barrier to renal allotransplantation once the technical aspects of the 
surgery were mastered was overcoming the problem of acute rejection. All 
transplants done up this point had been undertaken without the benefit of 
immunosuppression. Over the years many observers had a notion that that there 
were biological reasons for the failure of grafts to function. As mentioned above, 
Tagliacozzi (Gnudi et al., 1950) and Pert (1863) made pertinent observations that 
suggested that they appreciated the barrier to allotransplantation (Converse et 
al., 1968).
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Landmarks in renal transplant immunology
The most important immunological landmarks in the early part of the 20th century 
were the discovery of the ABO blood groups by Landsteiner (1900). The other major 
event of this era was the discovery by Gorer (1937) of the genetic system controlling 
histocompatibility that provided the basis for further genetic studies in animals and 
man on histocompatibility. In 1944 Medawar demonstrated the actual immunologic 
basis of allograft rejection using skin grafts in rabbits and thus established the basis 
of transplantation research (Medawar, 1944; 1945; 1946). Sir Peter Brian Medawar 
was therefore the first to recognise that rejection was an immune reaction and all 
subsequent contributions to the field of organ transplantation sprang forth from this 
sentinel observation. Sir Medawar received the 1960 Nobel Prize in Medicine for his 
remarkable work. In 1952 Dausset and Nenna described the presence of antibodies 
to leucocyte antigens in patients who had received multiple blood transfusions. They 
further showed that these antibodies recognised cell surface antigens on leucocytes 
that were distributed in a group fashion in man. Dausset named the first group MAC, 
subsequently renamed HL-A2, and that later was found to be part of the major 
histocompatibility complex in man (Dausset, 1958). Parenthetically, Voronoy had 
also shown the presence of antibodies in his dogs that had undergone renal 
transplantation (Fig. 2-9).
Recognition of acute rejection
As early as 1910 Da Fano had observed the presence of lymphocytes in rejected 
allografts (DeFano,1910). Many others later described histological changes that 
would subsequently be recognised as those of acute rejection (Toledo-Pereyra et 
a/., 1999). This included Carrell, and his observations prompted him to state th a t,". . 
. the technical aspects of the organ grafting are solved but from a biological 
standpoint no conclusions has thus far been reached, because the interaction of the 
host and the new organ are practically unknown" (Converse et a/., 1968). Carell may 
have failed to recognise the immunological basis of acute rejection but Guthrie, a 
one-time associate of Carrell suggested that "The outlook is by no means hopeless 
and the principles of immunity, which yield such brilliant results in many other fields 
would seem to be worthy of being tested in this case" (Converse et a/., 1968). In 
1923 and 1926 Williamson was able to confirm Carrel's finding that in dogs and 
goats renal autografts lasted much longer than allografts
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Fig. 2-9 Voronoy observed that antibodies to kidney antigens measured by the 
Bordet-Gengou reaction resulting from autotransplantation o f the kidney to the neck 
o f dogs. The antibodies were most marked in the animals (marked with crosses) 
that died because o f infection or infarction of their grafts. In one successful graft no 
immune response occurred (Voronoy, 1930).
(Williamson,1923; 1926). He described the histological changes following renal 
allotransplantation as acute atypical glomerulonephritis with lymphocytic infiltration. 
He concluded that the failure of the renal allografts was due to biological 
incompatibility between the donor and the recipient (Williamson,1926). His 
suspicions were proved correct following the work of Simonsen (1953) in Denmark 
and Dempster (1950) in London. Both of them working independently showed that
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immunological mechanisms were involved in the destruction of the renal allograft. 
Both considered that a humoral mechanism was involved in rejection. Together with 
the pioneering of Medawar (1944), it became self-evident that successful 
transplantation would depend on weakening or otherwise altering the immune 
response of the host. Dempster (1950) found that radiation, but not cortisone 
delayed rejection.
Tolerance demonstrated
The difficulties encountered in the attempts at transplantation appeared to support 
Loeb's concept of the biological uniqueness of individual characteristics as a 
prohibitive barrier to transplantation (Loeb,1945). The possibility of inducing 
tolerance to alloantigens seemed impossible until the brilliant contributions of 
Billingham, Brent and Medawar (Billingham et a/.,1953;Billingham et a/.,1956). They 
elegantly demonstrated that tolerance could be induced in mice by the injection of 
viable cells from the prospective graft donor strain in-utero into embryos of a different 
strain. After birth the inoculated recipients were fully tolerant to skin grafts from the 
donor strain. It was this observation among others (Bauer,1927;Little et a/.,1916) 
which encouraged Murray to successfully undertake the first renal allograft 
transplantation between identical twins (Merrill et a/., 1956). However, allograft 
transplantation remained a problem.
3. H is t o r y  o f  Im m u n o s u p p r e s s iv e  T r e a t m e n t  in R e n a l  
T r a n s p l a n t a t io n  (T a b l e  2 -3 )
Irradiation
Irradiation was the first form of immunosuppression to be employed in an attempt to 
control the immunological response to allografts. The immunosuppressive capacity 
of radiation was discovered in 1908 by Benjamin and Sluka who noticed that total 
body irradiation (TBI) impaired the ability of rabbits to produce precipitating 
antibodies to bovine serum (Benjamin et a/.,1908). The first attempts at 
immunosuppression for renal allografts were with TBI between 1959 and 1962 
(Hamburger et a/.,1959;Kuss et a/.,1960;Murray et a/.,1960). However, results were
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Table 2-3 Summary of immunology landmarks in that contributed to renal 
transplantation
Year Event Reference
1900 Discovery of ABO blood groups Landsteiner,1900
1937 Discovery of histocompatibility genes Gorer,1937
1944 Immunological basis of allograft rejection Medawar, 1944
1948 Congenic line of mice produced Snell,1957
1952 Describe leucocyte antibodies Dausset, 1958
1953 Induce immunological tolerance in mouse experimental model Billingham et al., 1953;
1954 Identical twin donors - first successful long-term survival Merrill et al., 1956
1955 Apply irradiation to induce tolerance in mouse model Main et al., 1955
1959 Immunosuppressive properties of 6-mercaptopurine 
discovered
Schwartz et al., 1959
1961 First clinical use of azathioprine Caine et al., 1962
1963 First large series of successful renal allografts; use of high 
doses of steroids to reverse acute rejection
Starzl et al., 1970
1964 Description of mixed lymphocyte reaction (MLC) Bach et al., 1964
1966 Describe humoral basis for hyperacute allograft rejection Kissmeyer-Nielsen et 
al., 1966
1967 Describe class II HLA antigens Bach et al., 1967
1969 Describes microchimerism Starzl et al.,1992
1973 Blood transfusion effect described Opelz et al., 1973
1974 Demonstrate MHC restriction of immunological reactivity Doherty et al., 1974
1976 Discovery of cyclosporine Borel et al., 1976
1977 Clinical use of cyclosporine Caine et al., 1978
1987 Discovery of tacrolimus Kino et al., 1987
1989 Clinical use of tacrolimus Starzl et al., 1989
1993 Attempts at humanising the pig Cozzi et
a/.,1995;Galili,1993
generally poor and mortality high. Strober (Levin et al.,1985) applied the method of 
radiation as refined by Kaplan (Kaplan,1980) who used total lymphoid irradiation to 
renal transplantation while Myburgh used the wide-field method (Myburgh et 
al., 1986; 1987). However, despite these refinements the propensity toward 
unpredictable side-effects and high mortality from infection remained a major 
problem (Kahan,1991).
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Pharmacotherapy: the early days
The pharmacological era of immunosuppression began in the early part of the last 
century when Murphy (1914) and Hektoen (1916) observed the effects of the simple 
organic compounds toluene and benzene on tissue grafts and antibody production 
respectively. Baker (1952) was the first to prolong the survival of experimental renal 
allografts by the use of nitrogen mustards. Schwartz and Dameshak (1959) initiated 
the modern era of pharmacological immununosuppression when they reported the 
prolonged survival of rabbit skin allograft using 6-mercatopurine.
Azathioprine
Hitchings and Elion (1954) developed the anti-proliferative agent 6-mercatopurine as 
a competitive inhibitor of purine salvage pathways. In 1960 Hitchings and Elion 
provided Caine with new derivatives of 6-mercatopurine of which BW57-322 proved 
to be the most successful at prolonging survival of dog renal allografts and was less 
toxic than 6-mercatopurine (Caine et al., 1962). Azathioprine, as the compound 
came to be known, became available for clinical use in 1961 with Murray (1963) 
reporting the first successes with extended renal allograft survival. Although initial 
results with azathioprine alone were disappointing, Starzl (1963) and Goodwin
(1962) working independently were able to prolong graft survival by combining it with 
prednisilone and the combined use of the two agents became conventional 
immunosuppressive treatment. Using the combined conventional therapy and with 
live-related donors, remarkably good results were reported by Starzl (1963) and 
Hume (1963) which did much to encourage renal transplantation.
Therapeutic antibodies
Another development that had an impact on therapeutic options was the rediscovery 
of antilymphocyte globulin. This agent was initially produced by Metchnikoff (1899) 
and rediscovered by, among others, Medawar (Levey et al., 1966a; 1966b). Starzl 
and Machioro adopted this powerful immunosuppressive agent into the clinical 
transplant setting (Starzl et al., 1967) while Najarian and Simmons refined its use 
(Najarian et al., 1970). Its potent non-specific attack on T-cells was associated with 
many serious adverse events and required great care in its use. Monoclonal 
antibody development saw the birth of more selective agents capable of neutralising 
cells bearing specific antigens. OKT3 was one of the first of this generation of
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agents to become available for clinical use. However, the non-specific effect of the 
antibody as well as the high incidence of serious adverse events has seen OKT3 
falling into disuse (Cosimi et a/.,1981). A number of other monoclonal agents with 
much better safety profiles have now become available for clinical use (Kahan,1991).
Cyclosporine
The next major development in transplantation after the implementation of 
conventional treatment was the discovery of cyclosporine. Cyclosporine was 
isolated in 1969 from a fungus Tolypocladium inflatum Gams, present in the soil from 
the plains of southern Norway. Jean-Francois Borel (1976) discovered the potent 
immunosuppressive properties of cyclosporine in transplantation and autoimmune 
diseases. The first use of the drug in animals was by White et al. (1981) who 
showed that the short-term administration markedly prolonged allograft survival in 
animals. Caine (1978) was involved in the initial clinical trials of cyclosporine 
reviving his earlier triumph with azathioprine. Graft survival improved by up to 15- 
30% under cyclosporine compared to conventional treatment (Banowsky,1983). 
Despite its potency it posed an amazingly low immunosuppressive hazard. 
However, its nephrotoxic side effects limited its use in doses that exploit its full 
immunosuppressive potential (Kahan,1989a). However, the success of 
cyclosporine in renal allotransplantation resuscitated interest in all other forms of 
transplantation that had been waning because of the poor results obtained with 
conventional treatment. The result was an ever-increasing demand for 
transplantable organs. The success of cyclosporine also stimulated the search for 
alternative agents that were to make their appearances later.
Tacrolimus
In 1987 the highly potent tacrolimus was discovered by Kino (Kino et al., 1987) 
expanding the available armamentarium of immunosuppressive agents available. 
The drug was introduced into the clinical arena by Ochiai et al. (1987) and Starzl et 
al. (1989) who confirmed its efficacy. Since that time several other drugs have 
entered the transplant pharmacopoeia including mycophenolate mofetil and 
rapamycin (Rapaport,1999).
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Other important developments in transplantation
Blood Transfusion effect
Opelz et al. (1973) demonstrated that blood transfusions, which had been avoided 
during regular dialysis up to this time, were in fact beneficial to the outcome of renal 
transplantation. This may explain the initial failure of cadaveric renal transplantation 
survival to improve in the 1970s, as immunosuppressive regimens were perfected 
and patient survival increased. Following these observations by Opelz, many 
centres liberalised their transfusion policies with consequent improvement in graft 
outcomes (Belzer,1988). Salvatierra et al. (1980) deliberately applied donor-specific 
blood transfusions to mismatched siblings and other living-related donors and was 
able to show results comparable to that of HLA - identical siblings.
Discovery o f HLA antigens
Rapaport did extensive work on skin allografts and was able to demonstrate the 
existence of tissue groups in man (Rapaport et al., 1962). Rapaport et al. (1968) 
working with Dausset et al. (1965) was able to show that the histocompatibility 
groups detected by skin graft experiments were the same as the leucocyte groups 
that had been identified serologically by Dausset. They also showed that these 
were part of a major human histocompatibility complex first named Hu-1, later 
renamed HLA. Bach and Hirschhorn (1964) described the mixed lymphocyte culture 
(MLC) test while the class II HLA antigens were identified by Bach and Amos (1967). 
Ting and Morris (1978) reported the first successful application of HLA-DR typing in 
1978. Another important development was the description of the lymphocyte 
microcytotoxicity test that was to form the basis of HLA typing (Terasaki et al., 1964). 
Tissue typing was introduced into routine use in 1962 (Hamburger et al., 1962; 
Dausset, 1980) and allowed the selection of a recipient and donor to be made. 
Kissmeyer-Nielsen et al (1966) documented the humoral basis of hyperacute renal 
allograft rejection that was greatly reduced by the direct cross-match between donor 
cells and recipient serum.
Xenotransplantation
Man's preoccupation with xenotransplantation has enjoyed a revival with the 
prospect of transplantologists having an unlimited supply of organs available for 
treatment. The current interest focuses on xenotransplantation with intense efforts to
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humanise the pig by selective genetic engineering techniques. One approach has 
been to breed animals that do not express the -GAL epitope (Galili, 1993). Another 
approach has been to insert into the porcine genome genes that code for the 
inhibitors of the human complement cascade (Cozzi et al.,1995). The challenges 
facing the transplant community with respect to xenotransplantation are large and no 
doubt many of the frustrations that we experience in this regard probably reflect the 
same frustration that our predecessors experienced a century ago with regard to 
allotransplantation.
Chimerism
Starzl reported the persistence of numbers of donor cells (which he termed 
microchimerism) in the tissues of long surviving liver transplant recipients. He 
believed that these cells of graft donor origin, present in the graft and lymph nodes of 
the host constituted the basis for long-term allograft acceptance by the host and 
suggested that this may be the ultimate form of inducing tolerance (Starzl et 
a/.,1989;Starzl et al., 1992), although others felt that chimerism was not a feasible 
clinical strategy to employ in renal transplantation (Kahan,1991). However, the 
search is on for the most effective method of inducing tolerance, which is thought to 
be the ultimate way of ensuring graft survival.
T h e  S o u th  A fr ic a n  t r a n s p l a n t  S c e n e
The pioneering years
South Africa stole world centre-stage in 1967 when the late Christiaan Barnard 
performed the world's first human heart transplant at the Groote Schuur hospital in 
Cape Town. Although there was remarkable interest shown in this historic event in 
the lay press, the response from the more objective scientific community was 
somewhat muted (Barnard, 1968). Tom Starzl and Bert Myburgh performed the first 
renal transplant in South Africa in Johannesburg in June 1966. The same team 
undertook a second transplant a month later. Both were living-related donor 
transplants with siblings being the donors in both cases. Both patients were treated 
with conventional therapy. The first patient died of sepsis after 2 months. The 
second died after 10 months of metastatic calcification and other complications
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arising from severe hyperparathyroidism (Meyers, A.M., personal communication). 
By 1982 the Johannesburg group had performed 525 renal transplants, both 
cadaveric and living-related donor, over the 17-year period and was achieving 
results that were comparable to centres elsewhere in the world (Myburgh et 
al., 1983). The group used azathioprine and steroids between 1966 and 1968. They 
then introduced equine anti-lymphocyte globulin, which in true pioneering spirit they 
produced themselves from 1968 to 1973. From 1973 the group used irradiation, 
pioneering the technique of wide field low-dose total lymphoid irradiation (Myburgh et 
a/.,1986;Myburgh etal., 1987).
Cape Town
A little known fact is that Christiaan Barnard also performed the first kidney 
transplant in Cape Town in 1967, several months before his historic heart transplant 
(Uys et al., 1970). This patient (and all subsequent patients) received conventional 
immunosuppressive treatment consisting of steroids and azathioprine. This patient 
survived for over 2 decades with a well-functioning graft and died of ischaemic heart 
disease (Pascoe, M.D., personal communication). In 1983 the group converted to 
cyclosporine but pioneered the discontinuation of the drug at 3-12 months after the 
transplant (Jacobson et al., 1988), a practice continued successfully to this day. As 
elsewhere in the world, the liberalisation of blood transfusion protocols and the 
introduction of cyclosporine markedly benefited graft survival (Jacobson et 
a/.,1988;Myburgh et al., 1983).
National Registry
Furman undertook a national annual audit of renal transplantation and dialysis in 
South Africa starting in 1974. This effort culminated in the formation of the South 
African Dialysis and Transplant Registry (SADTR) in 1984 (Furman,1974; 
Furman,1977; Furman,1978). The registry, the only one of its kind on the African 
continent, continues to document the details of all patients who enter any of the renal 
replacement programs in South Africa and their outcomes. It surveys all the units in 
the country involved in renal replacement treatment and documents their number 
and various activities. The registry reports on its results annually. Since 1984, the 
number of transplants has steadily grown and currently 5 state centres and a
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Fig. 2-10 Donor Source of Kidneys Transplanted in 
South Africa (1984-1994
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Drawn from data obtained from Du Toit et al. (1994)
growing number of private hospitals offer renal transplantation as a therapeutic 
option. Since the establishment of the SADTR in 1984, almost 5000 renal 
transplants have been done. The source of the kidneys is largely cadaveric although 
more living (both related and unrelated) are being done (Fig. 2-10). In 1994, the 
one- year graft survival was 70% and patient survival 97% (Du Toit et al., 1994).
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Chapter 3
AIMS AND METHODS
PART 1
C ancer remains one of the major scourges to afflict humankind. There is evidence that cancers are not new diseases. The earliest drawings and writings from ancient civilisations in all parts of the world have provided 
descriptions of cancer. Bone and urinary bladder cancers have been identified in 
Egyptian mummies, while the writings of Hippocrates contained descriptions of, and 
even recommended treatment for, cancers. The writings of the ancient physicians 
make it obvious that they appreciated that cancers exhibited spatial and temporal 
characteristics that ultimately proved fatal (Bryan et a/., 1999). However, the cause 
of cancers was never really fully understood nor investigated, and it was generally 
assumed that cancers were an inevitable accompaniment of the aging process. This 
led to the belief that there was little that could be done except to diagnose the 
disease early when it was amenable to surgery or radiotherapy. However, a change 
in attitude occurred following the Second World War and it was increasingly realised 
that certain environmental factors, genetic factors, and viruses all contributed to the 
development of malignancies. Many iatrogenic factors were also implicated in 
cancer development. Among these was the use of immunosuppressive agents. It 
therefore came as no surprise when the first cases of lymphomas following a renal
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Table 3-1 Variation in the incidence of cancers in different geographical areas.
Type of Cancer High incidence area Low incidence area
Skin Australia India
Oesophagus Iran Nigeria
Bronchus England Nigeria
Stomach Japan Uganda
Uterine cervix Colombia Israel
Liver Mozambique Norway
Prostate USA Japan
Breast USA Uganda
Colon USA Nigeria
Buccal mucosa India Denmark
Rectum Denmark Nigeria
Bladder USA Japan
Ovary Denmark Japan
Uterus USA Japan
Nasopharynx Singapore England
Pancreas New Zealand Uganda
Penis Uganda Israel
Modified from Doll (1977).
transplant were described soon after transplantation became accepted treatment for 
end-stage renal failure (Penn et a/.,1969;Siegel et al., 1969).
What has been interesting in looking at the epidemiology of cancer is that the 
incidence of cancers varies widely not only in different geographical regions but that 
the incidence of certain cancers differ between different ethnic groups residing in the 
same geographical locality. These observations have contributed much to the 
understanding the process of carcinogenesis (Doll,1977). A generalisation is that 
the poor and the rich in this world are at high risk for different kinds of cancer (Table 
3-1). Cancers of the upper gastrointestinal tract such as oesophageal cancers are 
digestive cancers of the poorest populations, as seen in our black patients. When 
caloric intake increases because of greater starch intake, stomach cancer becomes
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the dominant cancer, as is the case in the Western Cape. The most affluent groups 
replace carbohydrates with animal fat and protein and by doing so substitute colonic 
cancer for stomach cancer. Affluence also increases the risk of cancer of the breast, 
prostate, and endometrium suggesting that dietary factors may contribute to the 
enhanced risk of these cancers (Willett,2000; Lee et a/.,2000; Larking,1999). By 
contrast, cervical cancer is mainly a cancer of poverty and poor hygiene (Berg, 1977).
Malignancies are the second only to cardiovascular disease as the most common 
cause of death in industrialised countries, especially with the increasing age of the 
population in these countries (Balducci et a/.,2001). In developing countries cancers 
become important causes of mortality as infectious disease are increasingly brought 
under control. It is estimated that by 2020, new cancer cases will double to 20 
million a year (Sikora,1999); over 50% of all new cancers arise in people from 
developing countries but by 2020 the proportion will reach a staggering 70% (Murray 
et a/., 1996).
The causes of cancer vary worldwide. In developed countries tobacco is a major 
culprit, causing 1 cancer death in 3 (Jones,1999). The effect of the widespread use 
of tobacco over decades in developed countries is starting to wane because of public 
resistance to its use resulting in the reduction of tobacco-related cancer deaths 
(Levi,1999;Smith et a/.,2000). Sadly, however, the epidemic is now being 
propagated globally with devastating effects in developing countries (Pandey et 
a/., 1999). In developing countries chronic infection plays a major role in the 
development of cancer and is responsible for 1 in 4 cancer deaths (Jones, 1999). 
The human papillomavirus causes uterine cervical cancer; Helicobacter pylori, has 
been implicated in stomach cancer; and hepatitis B and C viruses are major causes 
of hepatocellular cancer. Together these agents account for over 90% of infection- 
related cancers (Pisani et al., 1997). Variations in cause are reflected in the 
differences in cancers that predominate in different parts of the world (Fig. 3-1) 
(Parkin et a/., 1999).
The theme of this dissertation revolves around the ideas developed in this 
introduction: with this brief perspective of the global situation with regard to cancers, 
the question arises as to the nature of cancers following organ transplantation. The
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experience with malignancies following renal transplantation is still rather limited but 
preliminary evidence suggests that geographic and ethnic differences may exist 
(Penn,2000;Qunibi et al., 1988). The role of chronic infections remains uncertain. 
The objective of this study was to formally investigate whether there were indeed any 
differences in the pattern of posttransplant malignancies and if these in anyway 
followed the patterns seen in cancers in general.
The study was designed to answer the following questions in relation to the patients 
who had undergone renal transplantation in the Renal Unit, Tygerberg Hospital:
1. What was the incidence of malignancies in renal allograft recipients with a 
minimum of 2-year follow-up?
2. What was the pattern of malignancies?
3. Were there any racial differences in the malignancies?
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4. What was the influence of the introduction of cyclosporine on the incidence and 
pattern malignancies?
5. What happened to patients with pre-existing malignancies in remission who 
received renal allografts?
Our experience was then compared with that of both developed and developing 
countries.
We found that the experience of posttransplant malignancies in developing countries 
differs remarkably from industrialised countries and in many ways reflects the global 
cancer experience.
However, in order to be able to address these questions, a full review of the 
transplant program of the Tygerberg Hospital first had to be undertaken.
PART 2
Kidney transplants have been performed in South Africa since the pioneering days of 
this form of treatment (see Chapter 2, History of Transplantation). Since the initiation 
of the transplant program in South Africa there have been few single centre reports 
of the outcome and successes of this form of treatment. One of the most 
comprehensive reviews of the subject appeared in 1983, before the introduction of 
cyclosporine (Myburgh et al., 1983). This study reviewed the Johannesburg 
experience of 525 renal transplants over a 17-year period and found graft survival 
rates of 52% in cadaveric donor renal transplants. Myburgh et al. (1983) report a 
steady attrition over 10 to 15 years in both graft and patient survival with infection 
and myocardial infarction as the main causes of mortality. There have been 
subsequent reports from Myburgh’s unit and other South African units (Bauling et 
a/.,1989;Botha et a/.,1988;Modiba et al., 1989); others have looked at a particular 
aspect of renal transplantation (Meyers et al., 1988) but none as comprehensively as 
the earlier report of Myburgh and his colleagues. However, the transplant centres in 
this country have been submitting their data to the South African Dialysis and 
Transplant Registry (SADTR) since the inception of this body. The SADTR uses this 
data to generate a report that includes details of patient and graft survival, as well as
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other important information, for the country as a whole. Individual unit data are not 
generally available for evaluation. Limitations of registry data are discussed below.
A vast body of experience with regard to renal transplantation now exists which 
reflects the world experience of this treatment modality, but in many developing 
countries renal transplantation is still in its infancy and the experience is different 
from that in developed countries, as are the results (Moosa et a/.,2001).
The Renal Unit attached to the Department of Medicine of the Faculty of Medicine of 
the University of Stellenbosch commenced its renal transplant program in 1976. 
Detailed records of all transplants have been maintained on a computerised 
database. An initial report was generated from this Unit looking specifically at racial 
differences in transplant outcome (Moosa et a/.,1992). A very large database of 
renal transplant patients has been built up since the inception of the transplant 
program and the large number of patients has allowed us to study various aspects of 
renal transplantation, including the factors that influence patient and graft survival. 
Our experience in renal transplantation is documented here. It is hoped that it will 
add to the South African and developing countries experience and give a perspective 
of the population from which our cohort of patients, who developed posttransplant 
malignancies, are derived.
METHOD
DATA COLLECTION
This was a single centre retrospective cohort study. All patients transplanted 
between April 1st 1976 and 31st March 1999 were included. Data were obtained from 
several sources to establish a complete database including:
1. Computerised patient records: The details of all patients transplanted have been 
computerised and date back to the inception of the renal transplantation program.
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2. Registry Data: All details of patients who received renal transplants have been 
recorded by the SADTR based in Cape Town. The SADTR has been collecting 
information since 1984.
3. Anatomical pathology reports: The names of patients obtained from the previous 
sources were reconciled with histology reports. All pathology reports generated 
on transplant patients were also reviewed.
4. Postmortem reports: All reports on postmortem examinations on transplanted 
patients were reviewed.
All malignancies recorded in the pathological records were reviewed and confirmed. 
In the absence of pathological confirmation, clinical diagnoses of malignancies were 
accepted only if there was sufficient evidence from the available clinical data to 
support the diagnosis. The details of patients with confirmed malignancies were 
recorded. Data included demography, nature of the transplant (cadaveric or living- 
related), primary renal disease, type of immunosuppression, number of transplants, 
duration of graft survival, and reason for graft failure or death. The relevant 
information of all the renal transplants that were performed in our unit over the 23 
years between 1976 and 1999 were also collected to provide an epidemiological 
basis for this study. All data were recorded on Microsoft Excel Office 97 
spreadsheet.
DATA ANALYSIS
Statistical analysis was performed using software package Statistica for Windows, 
(Release 5.5, 2000; Stat Soft Inc, Tulsa, OK).
For the first part of the study, the date of study entry was the date of the first kidney 
transplantation. The closing date was March 31, 1999 or the date of graft loss, 
whichever occurred first. Patient death was considered graft failure. The variables 
considered were the patients' age at transplantation, race, sex, primary renal disease 
and immunosuppressive therapy.
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Continuous data
Continuous data were compared by Student's t-test that has been designed to deal 
with the problem of working with small samples of 30 or less (provided that the 
population from which it is derived has a normal distribution) (Mould,1998d). The 
conditions to be fulfilled before the Student's t-test can be used are listed in 
Appendix Table 3-2. When faced with small numbers many authors use the more 
robust non-parametric Mann-Whitney U test which does not require the data to be 
analysed to follow any sort of distribution (Mould,1998d). In most cases the 
Student's t-test was used but where there was uncertainty about the distribution of 
data the Mann-Whitney U test was also applied.
Categorical data
Categorical data were analysed using the x2 - test. The test was applied with Yate's 
correction if the population was less than 20 or if any value entered was less than 5. 
Alternatively, if the value entered was less than 5, or the sample size less than 20 
the 2x2 table was not used and Fisher's exact test was applied. In all cases the null 
hypothesis was assumed unless otherwise stated. All tests performed were two- 
tailed.
Multivariate vs. univariate analysis
Multivariate as well as univariate analyses of graft survival were performed using the 
following variables: sex, race, age less than and equal to 40 years, and greater than 
40 years, immunosuppressive therapy and primary renal disease. Multivariate 
analyses were also used to compare the influence of variables on the incidence of 
malignancies, skin carcinoma and Kaposi's sarcoma. Univariate analyses such as 
the use of contingency tables ignore the fact that variables may influence each other, 
and were therefore avoided. The main advantage of multivariate analyses is that 
several variables can be studied simultaneously with attention to the analysis of the 
correlations that reflect the extent of the relationship among three or more variables. 
Analysis of variance (ANOVA) is used very extensively in the current literature to 
compare several variables but in this study multiple regression analyses was used 
because it provided a mathematical model of the linear relationship between a
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dependent and two or more independent variables (Weintraub et al., 1985). The 
superiority of multivariate analyses is discussed below.
Survival analysis.
The Kaplan-Meier method of calculating the survival of allografts in this cohort was 
used mainly because it is the conventional method of reporting graft survival in the 
transplantation literature currently. The technique was originally used by actuaries in 
the 19th century and modified by Greenwood in 1926 (Greenwood, 1926), Berkson 
and Gage in 1950 (Berkson et al., 1950), Wood and Boag also in 1950 (Wood et 
al., 1950), Merrell and Shulman in 1955 (Merrell et al., 1955), Kaplan and Meier in 
1958 (Kaplan et al., 1958) and finally by Ederer (Ederer,1961) in 1961. The 
technique is also called the actuarial method and product-limit method. Prior to the 
introduction of the technique patients who were lost to follow were assumed to either 
have all been alive or died. Neither of these assumptions was correct and the result 
was that this led to the over- or underestimation of the survival rate respectively. In 
the Kaplan-Meier method the individual survival times are used and there is no 
withdrawal group. Patients who fail to reach the endpoint (graft failure in the case of 
our patients) were censored. Censored data implies that the endpoint has not been 
reached as would be the case in patients whose grafts are still functioning at the end 
of the observation period. The main disadvantage of the method is that if there are 
too many withdrawals of alive patients or too many patients lost to follow-up, the 
results can be affected by the poor quality of data (Mould, 1998c).
Life table method
An alternative method of calculating the survival of patients is to use the life table 
method for grouped data where for a large series of patient data the survival times 
can be grouped and the calculations thus made easier. The assumption made by 
this method is that patients withdrawn (alive or lost to follow-up) in a time interval are 
alive on average for half the interval. The question of which of the above two tests to 
choose, is not entirely clear. The factors to be taken into consideration are the 
length of follow-up available, on how many grafts have already failed, and also on 
the pattern of graft loss that are grouped together in the early months following 
transplantation. With small samples the Kaplan-Meier is the better test while with 
large numbers grouping can take place. In practice the two tests often yield results
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that differ very little from each other. For the purposes of this study the Kaplan-Meier 
method was used but the life table method for grouped data has also been 
calculated and, as expected, shows curves which are virtually identical (Appendix 
Fig. 4-13b) (Mould,1998c).
Comparisons of survival curves
The tests that are most commonly used for the comparison of survival curves are the 
logrank and Mantel-Haenszel tests. The logrank method is capable of comparing 
two or more curves while the Mantel-Haenszel method is restricted to two. The two 
tests are in fact related and both are approximated by the x2 -statistic. It has been 
shown that significance by the logrank will always be confirmed by the more exact 
but also more complicated Mantel-Haenszel method. It is therefore unnecessary to 
use the Mantel-Haenszel method unless the logrank is on the borderline. For the 
purposes of this study, the logrank test was used (Schwartz et a/., 1980).
Cox proportional hazards method
The logrank test performs a univariate analysis. In practice the results of renal 
allograft survival is influenced by a number of prognostic variables and therefore a 
multiple regression model such as the Cox proportional hazards method is more 
appropriate (Cox, 1972). Multivariate analysis gives a series of hazard ratios each 
one of which indicates the magnitude of the effect on outcome of that particular 
variable, if all the other variables are assumed to held constant. However, the Cox 
regression model requires care in its application and may not be appropriate in all 
circumstances. The underlying assumption of the model is that the ratio of the risks 
of graft loss in two subgroups is constant over time (hence proportional hazards) 
(Mould, 1998a). This is certainly not true for the graft loss following transplantation 
where the loss of graft occurs initially and there are a number of long term survivors 
(Appendix Fig. 3-12). It is in fact not reasonable to assume that the hazard ratio is 
independent of time. This problem with the Cox regression model has been 
experienced previously and commented upon (Langlands et al., 1979). In the case of 
our patients, the logrank test was used initially and any results that were significant 
were then subjected to multivariate analysis as well. Both results are reported.
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In the second and subsequent parts of the study dealing with the malignancies, all 
patients were included and considered at risk from the date of the first transplant to 
the patient's death or March 31, 1999. This approach has been adopted by several 
authors (Blohme et a/.,1985;Hoshida et al., 1997). The variables that we considered 
were the age of the patients at the time of the diagnosis of malignancy was made, 
race, sex, immunosuppressive therapy and number of transplants. In addition the 
interval between the first transplant and the diagnosis of the first malignancy (called 
the latent period) was documented. The incidence rate of malignancies in the 
transplanted cohort was over the study period of 23 years was calculated. The 
definition of incidence rate:
No. o f new cases of malignancy arising in a defined population over a given time
period
Total person-time at risk during that period
The measure of disease frequency also called the incidence density (dos Santos 
Silva, 1999) that in the case of this study was expressed as the number of lesions per 
1000 patient-years of follow-up. By this method the time that each individual is at 
risk is taken into account and the denominator is the sum of each individual's time at 
risk. This approach is known as the subject-years or person-years method and it is 
widely used in epidemiology especially in the analysis of incidence and mortality of 
cancer (Armitage et al., 1987). The shortcomings of this method have been 
highlighted by Windeler and Lange (1995) who have suggested alternatives. 
However, their main criticism was directed at the use of the concept in the 
osteoporosis literature although some of the comments would be relevant to our data 
as well (Windeler et al., 1995). Care has been taken in the interpretation of our data 
to avoid the limitations of the technique.
Multivariate analyses using the multiple linear regression model included the 
following variables: age (below and above 40 years), race, sex, immunosuppressive 
treatment and number of grafts. The latent periods were compared using the 
Student's t-test (see comments above). The study group was compared with the 
general population (South African National Cancer Registry) by using the expected
Stellenbosch University http://scholar.sun.ac.za/
Aims and Methods 3-12
numbers of cancers obtained by applying the age, sex and race specific incidence 
experienced by the general population. The expected numbers of cases were then 
summed to obtain the total number of expected, of the various forms of cancer. 
These values were compared with the observed number of cases by means of the 
risk ratio (observed/expected). The test of significance is the usual one of 
comparing an observed random variable with its expectation under the Poisson 
assumption. The expected number of malignancies in this population was calculated 
from the 1985-1995 South African National Cancer Registry incidence rates. The 
relative risk is the ratio between the number of cancer cases in the transplanted 
population to the number of cases expected in the general population. The relative 
risk was calculated because the absolute incidence of the malignancies was not 
known with certainty. The relative risk or odds ratio (odds of developing a disease 
among transplanted and non-transplanted patients) are commonly employed when 
the denominator is not known in population studies of cancer risks (Mould,1998b). 
The relative risk was used as a measure of the magnitude of the risk of Kaposi’s 
sarcoma and other malignancies compared to the general population with a 95% 
confidence interval. Significance was set at the 5% level and all tests were two- 
tailed.
DETAILS OF SURGICAL TECHNIQUE USED
The surgical team was responsible for the harvesting of donor organs from heart- 
beating donors after in-situ cooling through a catheter placed in the common iliac 
artery. Renal preservation was by means of flushing and simple cold storage in ice 
slush for periods generally not exceeding 24 hours. The kidney was implanted extra- 
peritoneally with the renal artery anatomised end-to-side with a cuff of aorta to the 
external or common iliac artery in most cadaveric donor transplants. 
Ureteroneocystostomy to a submucous tunnel in the bladder dome was the preferred 
technique in the majority of cases. In living donor transplants a similar technique 
was used except that no aortic cuff was taken.
DETAILS OF PREPARATION OF PATHOLOGICAL SPECIMENS
All tissues were fixed in 10% formaldehyde in phosphate buffered saline (PBS) pH
7.4 for 6-12 hours and processed overnight, through ascending concentrations of
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ethyl alcohol (70%, 2x 96% and 3x 100%) (Merck, Darmstadt, Germany), xylene 
(Merck, Darmstadt, Germany) and molten paraffin wax (Histowax, Leica, Nussloch, 
Germany). Sections of 5-7 jam were cut from wax-embedded tissue. Sections were 
mounted on Silane coated glass slides (Fluka, Buchs, Switzerland). Haematoxylin 
and eosin staining was performed on dewaxed and rehydrated sections by staining 
with Mayer’s haematoxylin for 10 minutes and counterstaining with 1% eosin for 1 
minute. Sections were then rinsed in running tap water, dehydrated through 
ascending concentrations of ethyl alcohol (70%, 96% and 2x 100%), cleared in xylol 
and coverslipped with DPX mountant.
Immunocytochemistry was performed on hydrated formaldehyde fixed paraffin 
sections. Endogenous peroxidase was blocked with 3% hydrogen peroxide in 
methanol for 10 minutes. Sections were then washed in PBS pH 7.6 at room 
temperature. Non-specific binding was blocked with normal goat serum (DAKO, 
Glostrup, Denmark, cat. no. X0907) diluted 1:10 with PBS. Excess normal serum 
was drained from the slides and the primary antibodies applied which included, Von 
Willebrand factor (DAKO code A0082, Denmark, Glostrup) diluted 1:200, CD31 
(DAKO code 0823, Glostrup, Denmark) diluted 1:500 and CD34 (DAKO code 
M7168, Glostrup, Denmark) diluted 1:500 in PBS pH 7.6. The sections were 
incubated with the relevant primary antibodies for 60 minutes. Following incubation 
slides were washed in three changes of PBS of 5 minutes each. The excess buffer 
was drained and the biotinylated goat anti-mouse and rabbit immunoglobulin LSAB2 
kit link-antibody (DAKO, Glostrup, Denmark, cat. no. K0609) applied and incubated 
for 30 minutes. Thereafter, the sections were washed as previously described and 
incubated with horseradish peroxidase conjugated streptavidin-biotin complex (ABC) 
LSAB2 kit (DAKO, Glostrup, Denmark cat. no K0609), and allowed to incubate for 30 
minutes. Sections were washed as before. Positive labelling was demonstrated by
0.05% 3,3-diaminobenzidine tetrachloride (DAB) in PBS, pH 7.6, to which hydrogen 
peroxide was added immediately prior to incubation in the substrate for 3-5 minutes. 
After washing in running tap water, sections were counterstained with Mayer’s 
Haematoxylin, dehydrated, cleared and mounted in DPX.
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Appendix
Table 3-2 Conditions to be met for the appropriate use of the t-test.
1. The observations must be independent in order to avoid bias.
2. The observations must be drawn from normal populations.
3. These normal populations must have the same variance.
4. The variables involved must have been measured in an interval scale, so 
that it is possible to use arithmetic operations.
From Mould, R. F. (1998b).
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Chapter 4
RESULTS
(1) A ll Pa tie n ts  Un d er g o in g  R e n a l  T r a n s p la n ta tio n  
DEMOGRAPHIC DETAILS
S
ince the commencement of the renal transplant program in April 1976 at the 
Tygerberg Hospital, 542 patients had received 623 renal allografts by the end 
of March 1999. The demographic details of the patients are shown (Table 4- 
1). Fewer females than males were transplanted, but this reflects the slightly greater 
proportion of males on dialysis in our renal replacement program.
Table 4-1 Demographic details o f renal allograft recipients
Black Coloured White
Male 44 154 96 294
Female 12 147 89 248
Total 56 301 185 542
Mean Age (yrs) 38.9 36.6 37.1 37.0
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Fig. 4-1 Age of Patients at Primary Transplantation
Age (Years)
Age distribution (Fig. 4-1)
The mean age of the patients at the time of transplant was 37.0 years, with no 
significant difference in the age of males and females or between the race groups 
(Student's t-test). The youngest patient transplanted was 8 years old and the oldest 
64 years. The accompanying figure indicates the number of transplants done in the 
various age groups.
Race (Fig. 4-2)
The racial distribution of the patients who received renal allografts corresponded with 
that of the population of the Western Cape Province. There was a slight relative 
predominance of white patients transplanted but this difference was starting to even 
out as the racial laws were repealed allowing more blacks into the Western Cape 
Province. The lower numbers of black patients was the result of bias against blacks 
by virtue of their poorer social circumstances that resulted in their exclusion from the 
renal replacement program. In addition, blacks were largely confined to the 
"homelands" and freer population movement only occurred after 1985.
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Immunosuppression
Conventional The standard immunosuppression until October 1983 was 
azathioprine at 1-2 mg/kg per day and methylprednisolone at doses varying 1-2 
mg/kg per day over the years. A total of 123 patients received conventional 
treatment over the 7-year period.
Cyclosporine From October 1983, cyclosporine was included as part of triple 
therapy and was administered to 419 patients. Patients were maintained on 
cyclosporine for the life of the graft. The dose of cyclosporine was regularly 
monitored and the dose adjusted to maintain whole blood trough levels between 
250-350 ng/l. The dose of cyclosporine was reduced at 3-6 months and whole blood 
trough levels were maintained between 150-250 ng/l. Cytochrome P450 inhibitors 
such as ketoconazole and diltiazem were not used routinely to allow the reduction in 
the dose of cyclosporine. Under the triple immunosuppressive regimen oral 
methylprednisolone dose was reduced at 3-6 months to maintenance of 8 mg per 
day. Azathioprine was administered at doses of 50-100 mg per day with the majority 
receiving the lower dose.
Acute rejection This was treated with intravenous pulses of methylprednisolone 250- 
500 mg per day for 3 consecutive days. Polyvalent anti-thymocyte globulin or anti­
lymphocyte globulin as well as OKT3 monoclonal antibodies were used individually 
(and occasionally sequentially) to treat steroid-resistant rejection as part of rescue 
therapy.
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Fig. 4-2 Comparison of the population of the Western Cape and the racial profile of 
the transplant patients at the Tygerberg Renal Unit.
Population of the Western Cape 
Census 1996
Black
22%
White
21%
Coloured
56%
Racial Distribution of Renal Transplant Recipients
1976-1999
Black
10%
White
34%
Coloured
56%
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Table 4-2 Number o f renal grafts transplanted 
in this cohort until March 31st 1999.
No. of patients transplanted 542
No. of kidneys transplanted 623
No. of patients with single grafts 470
No. of patients with two grafts 64
No. of patients with three grafts 7
No. of patients with four grafts 1
Multiple Grafts (Table 4-2)
Multiple grafting was performed in 72 patients who between them received 153 renal 
allografts. The immunosuppressive treatment was not increased for subsequent 
grafts and patients received the treatment in use at the time of their subsequent 
transplants. Induction therapy using polyvalent serum or monoclonal antibodies for 
highly sensitised patients was not routinely used. On occasion, plasmapharesis was 
used in this situation for the first week following the transplant.
Primary Renal Disease (Fig. 4-3):
The most common disease leading to end-stage renal failure in our cohort of patients 
was chronic glomerulonephritis, which accounted for 42% of all the causes of chronic 
renal failure. The diagnosis of chronic renal failure was confirmed histologically in 
36% of these cases while in the rest the diagnosis was made clinically.
Racial differences Hypertension was the second most common cause of renal 
failure especially in the non-white patients. In the latter it accounted for 27% of all­
cause end-stage renal failure compared with only 5.4% of the white patients. 
Autosomal dominant polycystic kidney disease, by contrast, was more common in 
the white patients in whom it accounted for 19% of all-cause end-stage renal disease 
compared with 4.7% in the non-white patients.
Diabetes In our experience diabetes was an uncommon cause of primary renal 
disease in our cohort because the majority of patients with diabetic nephropathy and
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□  Unknown 
BCGN
□  CPN
□  AN
■  Cystic
□  Hereditary
■  Hypertension
□  Diabetes
■  SLE
■  Miscellaneous
White (n = 185)
3% 3% 5%
Fig. 4-3 Racial differences in primary renal diseases resulting in end-stage renal failure.
□  Unknown 
BCGN
□  CPN
□  AN
■  Cystic
□  Hereditary
■  Hypertension
□  Diabetes
■  SLE
■  Miscellaneous
Non-white (n = 357)
2% 1 % 30/0
AN = analgesic nephropathy; CGN is chronic glomerulonephritis; CPN is chronic pyelonephritis; 
Cystic is autosomal dominant and other hereditary forms of cystic kidney disease; Hereditary is other 
hereditary forms of kidney disease; SLE is systemic lupus erythematosis.
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Fig. 4-4a Renal Allograft Recipients
Factors Influencing Patient Survival
Overall Patient Survival - 1976 to 1999 Influence of Graft Failure in First Year
S u rv iva l (Years) Survival (Years)
Influence of Age Influence of Donor Source
S u rv iva l (Years) S u rv iva l (Years)
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end-stage renal disease were not offered renal replacement treatment, usually 
because of associated co-morbid factors. Less than 4% of all patients transplanted 
were diabetics.
Other causes Analgesic nephropathy was seen in both white and non-white 
patients but is now uncommon with the last case being diagnosed in 1985. Of the 10 
cases that were transplanted, 8 were female patients. Although the Western Cape 
has a high incidence of systemic lupus erythematosis (SLE) less than 2% of patients 
transplanted had end-stage lupus nephritis and all, except one, were female.
PATIENT AND RENAL ALLOGRAFT SURVIVAL
Patient Survival (Fig. 4-4a and Appendix Fig. 4-12b)
Over the study period 542 patients received first grafts. The actuarial one-year 
patient survival was 81% with the highest mortality occurring in the first year. 
Univariate and multivariate analyses revealed that patient survival was related to 
patient age, with patients older than 40 years having a much worse outcome; 
patients who received cadaveric kidneys and patients whose grafts failed within the 
first year did much worse. Patient survival was not significantly influenced by the 
race, gender or duration of dialysis prior to transplantation. The most common 
cause of death was sepsis, which accounted for 38% of all patient deaths; acute 
myocardial ischaemia resulted in 6.7% of deaths. Of the patients who died in the 
first year 43% succumbed to infective complications and 6.7% to acute myocardial 
ischaemia. In subsequent years infections continued to be the main cause of 
mortality with cardiovascular disease remaining an important second cause. 
Malignancies accounted for 8 (2.5%) of all deaths. One-half of all cancer deaths 
were due to disseminated Kaposi's sarcoma with all 4 deaths occurring within the 
first year and either within days of the diagnosis or with the confirmation at 
postmortem examination. Two patients succumbed to lung cancer long after their 
grafts had failed, while there was one case each of malignant lymphoma and 
hepatocellular carcinoma. All the non-Kaposi's sarcoma malignancies occurred after 
one year. Of the 8 cancer patients who died 5 were male and 3 female. Neither 
patient survival nor graft survival correlated with the duration of pre-transplant 
dialysis. Lack of data did not allow us to determine the effect of other factors such
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Fig. 4-4b Survival o f Primary Renal Allografts (n =  542)
April 1976 - March 31,1999
Survival
(Years)
Note: The numbers within the graph represent the number of surviving patients who were still at risk 
for the development of malignancies. See Appendix Table 4-12a for the linear hazard model. For a 
life-table analysis of the same data see Appendix Fig. 4-13a.
as type of dialysis, donor gender, cold ischaemia time, and tissue matching on 
patient or graft survival.
Graft Survival (Fig. 4-4b)
The overall one-year graft survival rate was 62% while just over one third of grafts 
survived 5 years. Patient death was also considered graft failure for the purposes of 
this study. Of the 542 patients transplanted until March 31 1999, 321 had died. Of 
these 180 (56%) died with functioning grafts. There were 200 patients whose grafts 
failed before they died. Patient death therefore accounted for 47.3% of all grafts lost. 
The remaining patients lost renal function progressively over months to years with 
chronic allograft nephropathy being the most likely cause. Acute rejection due to 
lack of compliance and chronic cyclosporine nephrotoxicity may have contributed but 
these were not objectively documented. Some 27 patients survived for more than 20
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Fig. 4-5 Factors Influencing Primary Renal Allograft Survival
Influence o f Age Azathioprine vs Cyclosporine
Survival
(Years)
Survival
(Years)
Males vs. Females Comparison by Race Groups
Survival
(Years)
Survival
(Time)
Note: All comparisons were done using the logrank test. All significant results were repeated using Cox proportional hazards model.
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Fig. 4~6b Primary Renal Allograft Survival
Source of Donor Kidney Primary Renal Disease
Survival (Years) Survival (Years)
years with functioning grafts, all under azathioprine. The number of patients at risk 
of malignancies is indicated on the survival curve. The number represents the 
patients with functioning grafts on immunosuppressive therapy as well as patients 
who were previously exposed to immunosuppression for more than 28 days and 
continued receiving dialysis therapy. For the purposes of this study these patients 
were considered permanently at risk for the development of malignancies.
Factors influencing primary renal allograft survival (Figs. 4-5 and 4-6)
The factors that could have an impact on graft survival were evaluated. These 
included the type of immunosuppressive therapy (azathioprine compared to 
cyclosporine), the patient's race, sex and age. Our data supports the benefit of 
cyclosporine on graft survival with over 20% improvement in graft survival compared 
to azathioprine at one year. Patients aged 40 years or less at the time of 
transplantation had a significantly better outcome compared to older recipients. 
However, when death with a functioning graft was corrected for, graft survival in the 
older patient was as good as, if not better than in the younger patient. There was no
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Fig. 4-6b Graft Survival
Censored for Patient Death with Functioning Grafts
Survival (Years)
difference in graft survival among the 3 race groups studied nor was there a gender 
difference in graft survival. An unexpected finding was the importance of the 
underlying disease in the outcome of the grafts. Patients with undiagnosed primary 
renal disease or diseases that could not be placed in one of the other specified 
categories fared the best. The diabetic group did surprisingly well but the careful 
selection of patients with uncomplicated disease for the renal replacement program 
undoubtedly accounts for the good initial results. The patients with systemic lupus 
erythematosis (SLE) and hypertension fared the worse of all the patients although 
the number of SLE patients was very small.
Graft survival with regrafting
The outcome of re-grafting in 72 patients is shown (Appendix Fig. 4-13b). The 
overall one year graft survival of second and subsequent transplants was 58% and 
31% at 5 years compared to the 65% and 35% in the primary graft survival of this 
cohort.
Stellenbosch University http://scholar.sun.ac.za/
Results 4-13
(2) Patients W ho Developed  Malignancies 
OCCURRENCE OF MALIGNANCIES
Incidence of malignancies (Fig. 4-7)
In 542 patients receiving renal allografts over the 23-year study period, 44 (8.1%) 
malignancies developed in 41 patients. The mean follow-up period was 6.3 years 
(95% confidence interval: 5.8 - 6.7) with the longest being 22 years. However, if only 
the patients who were exposed to immunosuppressive agents for a period exceeding 
28 days are taken into consideration then the number of patients at risk decreases to 
460 (Fig. 4-4b) and the incidence of malignancies rises to 9.6%. The mean follow-up 
period of this group was 6.4 years (95% confidence interval: 5.9 - 6.9). For the 
purposes of this study, however all calculations requiring estimations of relative 
incidence were done using the entire cohort of patients.
O fiL f-7  Cumulative No. o f Post-Renal 
Transplant Malignancies
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All malignancies that manifested within 28 days of transplantation were considered 
to have developed before the transplant and were therefore excluded. Only one 
case of transitional cell carcinoma of the bladder was thus excluded when the 
diagnosis was made on cystoscopy done at two weeks because of persistent post­
operative haematuria. The majority (61%) of patients developed their first 
malignancies within the first five years following renal transplantation. Only one 
patient developed a malignancy after 15 years (Fig. 4-7). A major reason for this is 
the progressive decrease in the number of surviving patients at risk for the 
development of malignancies (Fig. 4-4a).
Incidence rate
Another method of representing the incidence of malignancies in this cohort of 
patients who have been followed up for varying periods of time is the incidence per 
number of patient-years (also called the incidence density) that takes into 
consideration the period that the patients survived. The total patient-years at risk in 
this cohort were 3450.28. The incidence rate of malignancies in this cohort was 
12.8 per 1000 patient-years.
Lesions (Table 4-3)
Kaposi's sarcoma was by far the most common malignancy that developed and 
accounted for 47.7% of all lesions followed by non-melanoma skin malignancies. 
However there were marked racial differences in the pattern of the malignant lesions 
(see below). Of the tumours commonly seen in the general population, only lung and 
breast malignancies were represented.
Comparative demography (Table 4-4)
The mean age of the patients at the time of renal transplantation was 42 years 
compared to 45 years at the time of the diagnosis of the first malignancy. The 
incidence of malignancies was comparable in the patients who were transplanted 
after the age of 40 years to younger patients. In patients aged over 40 years the rate 
of malignancies was 20.9 per 1000 patient-years and 9.6 in the younger patient. 
The differences were not significant. The male to female ratio of the patients with 
malignancies (1:0.84) corresponds with that of the transplant population (1:0.78).
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Table 4-3. Type and frequency of posttransplant malignancies (n = 44).
Lesion No. (%)
Kaposi's sarcoma 21 (47.7%)
Non-melanoma skin 12 (27.2%)
Lung 3 (6.8%)
Breast 2 (4.5%)
Malignant lymphoma 2 (4.5%)
Liver 1 (2.2%)
Thyroid 1 (2.2%)
Renal Cell 1 (2.2%)
Malignant melanoma 1 (2.2%)
The 19 malignancies occurring in the 248 female patients represents a 7.6% 
incidence of malignancies which was not significantly different from the 25 (8.5%) 
that was detected in the 294 male patients (x2 - test). The number of malignancies in 
male patients was 11.1 per 1000 patient - years and comparable to the 13.1 per 
1000 patient - years in female patients.
Table 4-4. Incidence and demographic details o f patients who developed 
malignancies
Black 
(n = 56)
Coloured 
(n = 301)
White 
(n = 185)
Total 
(n = 542)
No. of malignancies (%) 4(7.1) 21(7.0) 19 (10.3) 44 (8.1)
Incidence (per 1000 pat-yrs) 12.1 12.1 13.6 12.8
Male 3 9 11 23
Female 1 11 6 18
Total no. of patients (%) 4 (7.7) 20 (6.6) 17 (9.1) 41 (7.5)
Mean age1 (yrs)
1 . .. . . . .
50 43 42 45
Age at the diagnosis of the first malignancy
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Table 4-5. Racial1 differences in the number o f patients who developed
malignancies.
White 
(n = 17)
Non-white 
(n = 24)
P- value^
Kaposi's sarcoma 2 19 0.03
Skin 13 0 0.0000
Squamous cell 5 0
Basal cell 7 0
Malignant melanoma 1 0
Lung 0 3 0.21
Breast 1 1 0.64
Malignant lymphoma 1 1 0.64
Liver 1 0 0.16
Thyroid 1 0 0.16
Renal Cell 0 1 0.47
The total number of non-white patients was 357 and the number of white patients 185.
2
Multiple linear regression analysis. The same results were obtained with ANOVA.
Table 4-6. Comparative incidence of malignancies in different groups o f renal
allograft recipients.
Group No. of malignancies 
diagnosed (%)
Group No. of malignancies 
diagnosed (%)
P-value1
Males 
(n = 294)
25 (8.5%) Females 
(n = 248)
19 (7.7%) 0.79
Black 
(n = 357)
25 (7.0%) White 
(n = 185)
19(10.2%) 0.56
Age < 40-years 
(n = 329)
24 (7.3%) Age > 40-years 
(n = 213)
20 (9.4%) 0.59
Conventional 
(n =123)
9 (7.3%) Cyclosporine 
(n = 419)
35 (8.4%) 0.33
Single graft 
(n = 470)
1 .. ... _ '
39 (8.3%) Multiple grafts 
(n = 72)
5 (6.9%) 0.49
Multiple linear regression analysis. The same results were obtained with ANOVA.
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Racial differences
The incidence of malignancies was not significantly different in the white and non­
white patients (Table 4-4). The number of black patients was too small to allow 
meaningful analysis, and they were therefore included with the coloured patients as 
the non-white group for purposes of statistical analysis. The number of lesions per 
1000 patient-years was 13.6 in both the white patients and 12.1 in the non-white 
patients. The pattern of malignancies between the races (Table 4-5) was however 
strikingly different but there were differences in other comparative groups (Table 4- 
6).
Main differences Of note in the racial differences in the pattern of posttransplant 
malignancies was the absence of any primary skin malignancies (excluding Kaposi’s 
sarcoma) in the non-white patients and the significantly higher incidence of Kaposi’s 
sarcoma in the non-white patients. There was no difference in the incidence of the 
other malignant lesions. Using multivariate analyses there was no difference in the 
incidence of malignancies between the race groups, the gender groups or patients
Fig. 4-8 Latency Period
Imuran vs. Cyclosporine
Mann-Whitney U test: P = 0.09
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who had received multiple compared to single grafts. Of note was that there was no 
significant increase in malignancies under cyclosporine (Table 4-6).
Immunosuppression
Under azathioprine the number of malignancies was 7.4 per 1000 patient-years 
compared with 13.9 under cyclosporine (also see Table 4-6). The difference was not 
statistically different. However, when the latent period between renal transplantation 
and development of the first malignancy was established, there was a significant 
difference in the intervals under cyclosporine as compared to conventional 
immunosuppressive treatment using azathioprine (P = 0.017, Student’s T-test). The 
mean interval under azathioprine was 86.9 months (95% confidence intervals: 34.1 - 
140.5) compared to 41.3 months cyclosporine (95% confidence interval: 27.9 - 54.7) 
(Fig. 4-8). The shortest interval to the development of a malignancy was 2.8 months 
to the diagnosis of Kaposi's sarcoma in a patient under cyclosporine. The shortest 
interval under azathioprine was 8.4 months also for the development of Kaposi’s 
sarcoma although the lesion was disseminated in this patient. Patients who received 
multiple renal allografts and were thus exposed to multiple courses of 
immunosuppressive therapy did not have an increased propensity to develop 
malignancies (Table 4-6).
Stellenbosch University http://scholar.sun.ac.za/
Results 4-19
(3) T he m a lig n a n c ies  in th e  tr a n s p l a n t e d  p a t ie n t s : 
Ka p o s i's S a r c o m a
DEMOGRAPHY AND CLINICAL ASPECTS (Table 4-7)
Incidence and racial distribution
Kaposi's sarcoma was the single most common malignancy and accounted for 21/44 
(47.7%) of all malignancies. Of the 41 patients who developed a tumour 21 (51.2%) 
developed Kaposi's sarcoma. Kaposi's sarcoma occurred in 21/542 (3.9%) of all 
patients receiving renal allografts. Kaposi's sarcoma was significantly more common 
in non-white patients accounting for 19/357 (5.32%) of all malignant lesions in this 
group. In contrast, only 2 (1.08%) of 185 white transplant patients developed 
Kaposi's sarcoma (p = 0.032, multiple linear regression analysis). Of the 17 white 
patients who developed a malignancy 2 (11.7%) developed Kaposi's sarcoma but 
among the 24 non-white patients with malignancies 19 (79.2%) developed Kaposi's 
sarcoma (p = 0.0000, Fisher's exact). The number of Kaposi’s sarcoma lesions was
1.4 per 1000 patient - years in the white patients and 9.2 per 1000 patient - years in 
the non-white patients. None of the patients were of Jewish or Mediterranean origin.
Age
The mean age of patients at the time of diagnosis of Kaposi's sarcoma was 42 years 
(range: 27-54 years). The mean age of patients at the time of the primary transplant 
was 39 years (range: 24-50 years) compared to the mean of 37 years (range: 8-64) 
for the transplant cohort. Patients who were aged over 40-years also did not have a 
higher incidence of Kaposi's sarcoma compared to the younger patients [10/213 
(4.7%) vs. 11/329 (3.3%), P = 0.78, multiple linear regression analysis].
Relative risk of Kaposi's sarcoma (Table 4-8)
The risk of developing Kaposi’s sarcoma in our cohort of patients was increased by a 
factor of 235 when compared to the lesions expected in the non-transplant 
population.
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Table 4-7 Demographic and clinical data on the cohort of patients with Kaposi's sarcoma
Patient Age Sex Race Treatment Distribution 
of lesions
Latency
(mo.)
Treatment
Discontinued
Outcome
Patient/Lesions
Outcome
Renal
AL 38 Male Caucasian Azathioprine Visceral 8.4 All Died of disseminated 
disease
-
JM 45 Male Coloured Azathioprine Cutaneous 228.3 Cyclosporine Lesions improved Maintained
JA 53 Male Coloured Azathioprine Cutaneous 24.0 All Lesions improved Graft loss
KM 49 Male Coloured Cyclosporine Cutaneous 21.2 All + DXR + Chemo 
(M)
All
Lesions improved Graft loss
JW1 39 Male Coloured Cyclosporine Visceral 11.2 Died of disseminated 
disease
-
MO 29 Female Coloured Cyclosporine Cutaneous 2.9 All Lesions improved Graft loss
IM 54 Male Black Cyclosporine Mucocutaneous 56.3 Cyclosporine Lesions improved Maintained
LF 49 Male Black Cyclosporine Cutaneous 26.8 Cyclosporine + DXR 
(M)
Lesions improved after 
DXR
Maintained
LC 44 Female Coloured Cyclosporine Cutaneous 64.1 Cyclosporine Lesions improved Maintained
RT 31 Male Coloured Cyclosporine Cutaneous 34.4 Cyclosporine + 
DXRxl
Lesions improved Maintained
GN 35 Female Coloured Cyclosporine Mucocutaneous 22.2 Cyclosporine Lesions improved Maintained
WB 27 Male Coloured Cyclosporine Cutaneous 4.1 Cyclosporine Lesions improved Maintained
GO 41 Male Coloured Cyclosporine Cutaneous 17.5 Cyclosporine Lesions improved Maintained
MB 43 Female Caucasian Cyclosporine Visceral 4.1 Cyclosporine + 
Chemo (S)
Died of disseminated 
disease
-
CM 50 Female Black Cyclosporine Cutaneous 8.9 Cyclosporine Lesions improved Graft loss 
(advanced 
renal failure)
SG 53 Female Coloured Cyclosporine Cutaneous 61.4 Cyclosporine Lesions improved Maintained
RJ 40 Female Coloured Cyclosporine Visceral 8.3 Nil Died of disseminated 
disease
-
LJ 48 Female Coloured Cyclosporine Cutaneous 13.9 Cyclosporine Lesions improved Graft loss 
(advance 
renal failure)
RB 36 Female Coloured Cyclosporine Visceral 13.3 Cyclosporine + DXR 
(M) (after 3mo.)
Lesions improved, 
relapse after 2 years
Maintain­
ed
ML 44 Female Coloured Cyclosporine Cutaneous 31.5 Cyclosporine Lesions improved Maintained
Dl 37 Male Coloured Cyclosporine Visceral 10.6 Mycophenolate Lesions improved Maintained
Patient with clinical visceral Kaposi’s sarcoma organ involvement. Postmortem examination not obtained. DXR is radiotherapy; Chemo is chemotherapy
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Table 4-8 Relative risk for the development o f Kaposi’s sarcoma in various groups
Group Relative risk 95% CL1
Overall 235.1 146.0 359.4
Sex
Male 540.5 279.3 944.2
Female 118.3 54.0 224.5
Age
< 45 yrs 510.9 279.0 857.2
> 45 yrs 113.0 102.8 526.3
Race
White 174.4 36.0 420.1
Coloured 308.4 168.6 517.4
Black 149.8 4.8 383.6
'Confidence limits
The risks were calculated for the different race, gender and age groups (Table 4-8) 
(also see Appendix Table 4-16). Males, those below the age of 45 and coloured 
patients had the greatest relative risk of developing Kaposi’s sarcoma.
Gender
There was no significant male predominance in the incidence of Kaposi's sarcoma. 
The number of male patients who developed Kaposi's sarcoma was 11/294 (3.7%), 
not significantly from the 10/248 (4.0%) of females who acquired the lesion (x2 - test). 
The male to female ratio was 11:10 (1:1), which was the same as the gender ratio of 
the renal transplant population. Kaposi's sarcoma was therefore equally common in 
the 2 sexes.
Immunosuppression
Of 419 patients under cyclosporine, 18 developed Kaposi's sarcoma, compared with
3 of the 123 patients receiving azathioprine. The difference was however not 
statistically significant (P = 0.37, multiple linear regression analysis). Patient JM 
developed Kaposi's sarcoma 10 months after commencement of cyclosporine, 
having previously received azathioprine and methylprednisolone for 18 years after
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transplantation. The azathioprine was being replaced by cyclosporine to allow the 
introduction of allopurinol to control severe gout. The skin lesions of Kaposi's 
sarcoma regressed when cyclosporine was discontinued.
Cutaneous involvement
The skin was involved in all patients diagnosed with Kaposi’s sarcoma. Details of 
the skin lesions were not available for two patients (JA, AL). In the remaining 19 
patients the lower limbs were involved in 16 (84.2%) of cases. No particular area of 
the leg was favoured with lesions being reported from the buttock to the sole of the 
foot. The upper limbs were affected in 6 (32.6%) of the patients. The torso was 
involved in 5 (26.3%) patients and the hard palate in only 2 (10.6%) patients (these 
patients are identified as having mucocutaneous involvement in Table 4-7).
Extra-cutaneous involvement
Lymph node and/or visceral organ involvement by Kaposi’s sarcoma was present at 
initial presentation in 6 (28.6%) patients. Bilateral inguinal lymph node disease 
occurred in two patients (RB, Dl) and was associated with skin involvement. Three 
patients with visceral organ involvement also had deep lymph node disease (AL, MB, 
RJ). Four patients had extensive visceral organ disease (AL, JW, MB, RJ) at the 
time of the initial diagnosis of Kaposi’s sarcoma. One patient (RB) who did not 
have visceral organ involvement was found to have disease of her bronchial tree 
when Kaposi’s sarcoma relapsed almost two years after the initial presentation (see 
page 4-26 for further details).
Latent period
The mean interval between renal transplantation and the diagnosis of Kaposi’s 
sarcoma was 32.0 months (95% confidence intervals: 9.96 - 54.16). If patient JM 
who developed Kaposi’s sarcoma only after the secondary introduction of 
cyclosporine is excluded from the analysis, the mean interval is 22.25 months (95% 
confidence intervals: 13.44 - 31.05). The shortest interval was 2.9 months (patient 
MO) and the longest (excluding patient JM) was 64.1 months (patient LC). The 
mean interval to the diagnosis of Kaposi’s sarcoma under azathioprine was 86.9 
months (95% confidence intervals: 2178 - 391.6) compared with 22.9 months (95% 
confidence intervals: 22.9 - 13.2) under cyclosporine (P = 0.03, Student's t-test).
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The data must however be interpreted with caution because of the small number of 
patients in the azathioprine group and the very wide standard deviation. If patient 
JM is excluded from the analysis then there is no difference in the latent intervals in 
the two treatment groups. There was no difference in the mean latent intervals of 
males and females (23.0 months compared to 21.4 months). However, there was a 
significant difference in the time interval between the diagnosis of local disease 
compared to disease with lymph node and/or visceral organ involvement with the 
latter occurring 16.5 months earlier (Fig. 4-9).
Fig. 4-9 Latency Period
Kaposi's Sarcoma: Visceral vs Cutaneous disease
Mann-Whitney U test: p = 0.014 
Management
Treatment of the patients who developed Kaposi’s sarcoma was primarily either 
withdrawal or reduction of immunosuppression. The policy in our Renal Transplant 
Unit until 1989 was the complete withdrawal of immunosuppression. From 1989, the 
immunosuppression was reduced by the withdrawal of cyclosporine and the 
maintenance of the patient on azathioprine and methylprednisolone. The 
cyclosporine was selected for withdrawal because it was considered to be the most
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potent immunosuppressive agent. In the majority of cases the cyclosporine dose 
was tapered over several weeks rather than abruptly discontinued. The exceptions 
were patient MB who had visceral organ involvement and in whom the cyclosporine 
was abruptly stopped when it became apparent that the patient had extensive 
disease; the other exception was patient RJ who died before the diagnosis of 
Kaposi’s sarcoma could be confirmed. Patient Dl received mycophenolate mofetil as 
part of a phase 2 clinical drug trial. With the development of the Kaposi’s sarcoma, 
the trial drug was withdrawn as required by trial protocol but the cyclosporine was 
maintained at standard doses.
Adjunctive radiotherapy
Four patients (GO, LF, RB, JM) with localised disease underwent either single or 
multiple courses of radiotherapy in an effort to control certain aspects of the disease. 
Whereas 3 patients received treatment for focal skin disease, patient RB received 
radiotherapy for a non-cutaneous lesion. This patient had very painful bilateral 
inguinal lymphadenopathy and required irradiation when the pain became 
unbearable despite the withdrawal of cyclosporine and attempts at pain control 
failed. A single patient (KM) with isolated skin involvement received chemotherapy 
as well. Patient MB who had very aggressive and extensive visceral disease also 
received chemotherapy pre-terminally but with little benefit.
Prognosis
Visceral organ involvement at presentation was an important determinant of patient 
outcome. All four patients presenting with visceral organ involvement died within 
days of the diagnosis being made or the diagnosis was confirmed at postmortem 
examination (RJ). The 2 patients (RB, Dl) with bilateral inguinal lymphadenopathy 
but no apparent visceral organ involvement responded well to reduction in 
immunosuppression although the former required local irradiation after 3 months to 
control pain over the enlarged lymph nodes on one side as mentioned earlier.
Skin lesions generally responded to the reduction or withdrawal of 
immunosuppressive therapy. Occasionally some lesions required local irradiation
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Fig. 4-10 Renat function following reduction of immunosuppression
Serum creatinine at initial diagnosis of KS and one year later
Time
(see above). The lesions healed over several months often leaving behind 
pigmented or hyperkeratotic lesions.
The renal prognosis of patients who did not succumb to disseminated disease was 
directly related to the strategy employed with regard to the immunosuppressive 
treatment. All three patients in whom the immunosuppression was withdrawn had 
functioning grafts at the time when Kaposi’s sarcoma was diagnosed but all grafts 
were lost to acute rejection. Dialysis had to be re-instituted in these patients at a 
mean of 5 weeks after withdrawal of the immunosuppressive agents. In contrast, the 
only patients to lose their grafts with the elimination of cyclosporine from their 
immunosuppressive regimen were two patients (CM, LJ) who already had advanced 
renal failure (plasma creatinine values > 800 ^mol/l) when Kaposi’s sarcoma was 
diagnosed. The difference in the outcomes of these two management strategies was 
highly significant (P = 0.014, Fisher's exact, two-tailed). In the treatment reduction
group, the 12 patients had reasonably well preserved renal function when treatmenti
was reduced. None developed acute rejection.
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At one year 11 of the 12 patients in whom immunosuppression had been reduced 
and who had plasma creatinine values below 500 fj.mol/1 had survived and all had 
functioning allografts. The mean plasma creatinine was 165.2 jamol/l (95% 
confidence intervals: 80.7 - 249.7) at the time of the diagnosis of the Kaposi’s 
sarcoma. One year after the diagnosis and discontinuation of cyclosporine 
(mycophenolate mofetil in the case of patient Dl) the mean plasma creatinine value 
was 142.2 jj.mol/1 (95% confidence intervals: 84.8 - 199.6). The difference was not 
significant (Student's paired t-test, P = 0.248) (Fig. 4-10). Patient JM died of 
septicaemia 9 months after the diagnosis of Kaposi's sarcoma. He had a functional 
graft at the time of his demise. Patients GN and LF died of septicaemia and heart 
failure respectively both with functioning grafts 5 years after the diagnosis of 
Kaposi’s sarcoma. In both Kaposi’s sarcoma was in remission at the time of their 
final illnesses.
Relapse (See Fig. 9-5)
A single patient (RB) experienced relapse of Kaposi’s sarcoma. This occurred 22 
months after the initial diagnosis and after the original lesions had resolved. The 
relapse involved lesions on both legs but with no involvement of the inguinal lymph 
nodes as had been the case with her original disease. Her relapse was, interestingly 
enough, preceded by repeated episodes of cellulitis affecting both legs over a period 
of 3 months. At the time of her presentation with relapse of Kaposi’s sarcoma she 
had severe ulcerating infections involving both legs. She was only on azathioprine 
50 mg and methylprednisolone 8 mg daily. An endoscopic examination of the 
stomach and duodenum was normal but bronchoscopic examination revealed a 
lesion very suspicious of Kaposi’s sarcoma. A biopsy was not considered to be safe. 
The lesion was still present when the bronchoscopic examination was repeated 2 
months later but no new lesions were seen. The patient was treated for her septic 
lesions on her legs with antibiotics and local dressings. The dose of the azathioprine 
was further reduced to 25 mg per day. Her renal function deteriorated by 30% 
before the reduction in the azathioprine dose but remained stable thereafter. 
Withdrawal of immunosuppression was not an option in this patient because she was 
not considered to be a suitable candidate for the local renal replacement program.
Stellenbosch University http://scholar.sun.ac.za/
Results 4-27
Other investigations
Patients Dl, RB, ML and SG all underwent routine gastroscopy to establish the 
presence of upper gastrointestinal disease. All the patients had normal 
examinations. Routine chest X-rays were also available on most of the patients. 
Two patients (MB, RB) had abnormal findings and both were subjected to 
bronchoscopic examination. In all the other patients with focal skin disease no 
suspicious abnormalities were found. The X-rays of patients AL, JW and JA had 
were not available for review.
Human immunodeficiency virus (HIV) test
All the patients tested negative for the human immunodeficiency virus (HIV) with two 
exceptions. One patient (JA), a coloured male tested positive for the human T- 
lymphotrophic virus III (HTLV III) in 1985 before routine testing for HIV became 
available. Another patient (AL), a white male was diagnosed with Kaposi's sarcoma 
in 1978 before the HIV had been described.
HLA profiles
The HLA antigen frequencies in renal transplant patients with and without Kaposi’s 
sarcoma were compared. Partial antigen profiling was available for 518 (98.9%) of 
the patients and full profiling (including DR antigens) was available in 457 (84.3%) of 
all the patients. The HLA antigen profile was available in 19 (90.5%) of the 21 
Kaposi’s sarcoma patients. No single HLA antigen occurred with significantly 
increased frequency in Kaposi’s sarcoma patients compared to the Kaposi’s 
sarcoma negative patients. The HLA-A2 antigen was the one most commonly 
encountered in the Kaposi’s sarcoma patients occurring in 5 (26%) of 19 patients but 
it also occurred in 144 (28.9%) of the 499 non-Kaposi’s sarcoma patients. The 
HLA-A2 antigen was the most frequently encountered class I antigen in this cohort 
occurring in 149 (28.8%) of the patients. HLA-DR2 was the most frequent class II 
antigen and occurred in 121 (28.9%) of the patients. HLA-DR2 also occurred in 4 
(26.6%) of the 15 Kaposi’s sarcoma patients who had full HLA-antigen typing 
available.
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PATHOLOGY OF THE KAPOSI’S SARCOMA LESIONS
The original pathological material was reviewed in all except two patients. The 
tissue of patients AL and JA was no longer available for examination. The tissue of 
the remaining 19 patients was re-examined and the diagnosis of Kaposi’s sarcoma 
confirmed. Postmortem examinations were performed on 3 of the 4 patients (AL, 
MB, RJ) who succumbed to the disease. In patient RJ the diagnosis of Kaposi’s 
sarcoma was only confirmed at postmortem examination.
Skin disease (Table 4-9)
Cutaneous Kaposi’s sarcoma was present in all 19 patients. The skin lesions were 
classified morphologically into macules-patches, papules-plaques and nodules- 
tumours according to Safai (1981). Seventeen (71%) of the 24 skin lesions biopsied 
fell into the second category, 5 (21%) were nodules and only 2 (8.3%) in the 
macule-patch category. Fifteen of the patients had multiple cutaneous lesions of 
which the most advanced were selected for biopsy. The 21 skin biopsy specimens 
that were available for examination were histopathologically classified according to 
Harawi et al. (1989): 3 (14.2%) were early type; 11 (52.3%) were mixed type lesions,
6 (25.5%) were spindle type lesions and only 1 (4.8%) lymphangiomatous type 
lesion. There were no angiomatous, inflammatory or pleomorphic type lesions 
present in this cohort.
In the two patients with disseminated disease in whom tissue was available for 
examination it was found that patient MB had the mixed variant of Kaposi’s sarcoma 
in the skin but spindle type lesions in the visceral tissue. Patient RJ had the spindle 
variant of Kaposi’s sarcoma in the skin as well as all involved tissue examined at 
postmortem examination. Patient RB who had sequential skin biopsies showed 
progressively early, spindle and mixed lesions. Patient Dl had mixed type lesions in 
both the skin and the lymph node, which were biopsied contemporaneously. All 4 
solitary lesions were of the mixed type. There was a comparable distribution of the 
lesion types between males and females. There were no discernible differences in 
the pattern of the histological type of lesions that occurred on the legs compared with 
those lesions elsewhere.
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Table 4-9 Distribution and pathological aspects o f Kaposi’s sarcoma lesions
Patient A ge Sex Race Tissue Distribution N um ber M orphology H isto logy
WB 30 Male Coloured Skin Face, arms Multiple Nodules Spindle
LC 44 Female Coloured Skin Arms Multiple Macules, papules Early
LF 53 Male Black Skin Leg, arm, trunk Multiple Papules, plaques Early
LJ 48 Female Coloured Skin Shoulder Solitary Nodule Mixed
IM 56 Male Black Skin Legs, palate, nose Multiple Papules, nodules Lymphangiomatous
CM 51 Female Black Skin Leg Multiple Papules, plaques Spindle
KM 60 Male Coloured Skin Leg Multiple Plaque, papules Mixed
GN 38 Female Coloured Skin Leg, palate Solitary Plaque Mixed
MO 39 Female Coloured Skin Leg, arm Multiple Papules Mixed
GO 42 Male Coloured Skin Leg Multiple Plaques, papules Mixed
RT 43 Male Coloured Skin Leg Multiple Patches, plaques Mixed
JW 49 Male Coloured Skin Leg, trunk Multiple Papules, nodules Spindle
MB 46 Female Caucasian Skin
Liver
Lung
Trunk, abdomen Multiple Papules, nodules Mixed
Spindle
Spindle
RJ 41 Female Coloured Skin
Lymph
-node
Lung
Stomach
Kidney
Trunk, legs 
Mesenteric, 
mediastinal
Multiple Papules Spindle
Spindle
Spindle
Spindle
Spindle
RB 36 Female Coloured Skin
Skin
Skin
Lymph-
node
Lung
Legs 5/97 
Legs 10/97 
Legs 7/00 
Inguinal
Multiple
Multiple
Multiple
Plaque
Papules, plaques 
Nodules
Early
Spindle
Mixed
Spindle
SG 53 Female Coloured Skin Legs Multiple Plaques, papules Mixed
Dl 38 Male Coloured Skin
Lymph-
node
Abdomen
Inguinal
Solitary Plaque Mixed
?
ML 45 Female Coloured Skin Buttock Solitary Nodule Mixed
JM 45 Male Coloured Skin Legs, arms Multiple Macules, papules Spindle
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Table 4-10. Postmortem findings in 3 patients with disseminated Kaposi’s sarcoma. 
Patient Visceral Organs I Lymph nodes Involved
Stomach Liver Spleen Lung Renal
Allograft
Bone
Marrow
Lymph
Nodes
AL Yes Yes No Yes No No Mesenteric
RJ Yes Yes Yes Yes Yes Yes Mesenteric,
mediastinal
MB No Yes No Yes No No Hilar
Postmortem findings
The range of organ involvement in the 3 patients who underwent postmortem 
examination is shown (Table 4-10). Of note is the observation that Kaposi’s 
sarcoma affected the lungs and deep lymph nodes in all three patients. One patient 
(RJ) had extensive disease including renal allograft and bone involvement. In the 
two patients (MB, RJ) in whom Kaposi’s sarcoma tissue was available for review, the 
histolological features indicated the spindle variety of Kaposi’s sarcoma according to 
Harawi et al. (1989).
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(4) T he m a lig n a n c ie s  in the  tr a n s p l a n t e d  p a t ie n t s : 
No n -Ka p o s i's s a r c o m a  m a l ig n a n c ie s
SKIN MALIGNANCIES AND PRE-MALIGNANT LESIONS (TABLE 4- 
11)
Incidence
Malignant skin lesions exclusively affected white patients. In no instance did a single 
black or coloured patient developed a skin malignancy despite the fact that non­
white patients formed the bulk of the transplant population and despite the prolonged 
follow-up period. All 13 (7.0%) skin malignancies occurred among the 185 white 
patients. Of the 20 malignancies detected in the white group 13 (65%) were skin 
malignancies. Basal cell carcinoma occurred in 7 patients and squamous cell 
carcinoma in 5 patients. Two male patients had both basal cell carcinoma and 
squamous cell carcinoma. Both these patients had pre-malignant lesions as well: 
one had solar keratosis, Bowen's disease and in situ squamous cell carcinoma 
lesions of the skin; the other patient had multiple solar keratosis lesions. In addition, 
one patient with basal cell carcinoma had multiple in situ squamous cell carcinoma 
lesions. All non-melanoma skin lesions with the exception of one squamous cell 
malignancy, occurred in male patients. The incidence of non-melanoma skin 
malignancies was significantly greater in white males developing in 11/96 (11.4%) 
compared to white females 1/88 (1.1%), (p = 0.0046, x2 - test). The mean age of 
patients at the time of diagnosis of the first non-melanoma skin malignancy was 41 
years (range: 34-60). A single case of malignant melanoma was recorded and this 
in a white female patient under azathioprine.
Of 101 skin biopsies for suspected skin tumours, 98 lesions were either malignant or 
pre-malignant (Table 4-11). Of the total number of skin biopsies, 83 (83%) were 
from 2 patients (LM and NvdW). Squamous cell carcinoma was the most frequently 
encountered lesion accounting for 59% of the 63 malignancies and 38% of all 
suspicious skin lesions. The number of squamous cell carcinoma lesions exceeded 
the basal cell carcinoma lesions by a factor of 1.7. Solar keratosis
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Table 4-11 Details o f the discrete malignant and premalignant skin lesions in white 
renal transplant patients.
Age No. of 
biopsies
SQ CA BCCA Carcinoma-
in-situ
SK Other lesions
LM 43 65 27 16 6 12 Metatypic carcinoma 
Basosquamous (X2) 
Keratoacanthoma 
Verruca vulgaris (X2)
NvdW 50 18 7 1 4 6 Bowen's disease 
Verruca vulgaris
JB 60 9 - 1 4 - Anaplastic carcinoma
MG 53 2 1 - - 1
AM1 31 1 - - - - Malignant melanoma
MN1 41 1 - 1 - - -
Kaposi’s
sarcoma
34 1 1 “ - • -
DL 55 1 - 1 - - -
CV 36 1 - 1 - - -
FvdW 40 1 1 - - - -
FIR
Total
39 1
101 37
1
22 14 19 '
Female patients. SQ CA is squamous cell carcinoma; BCCA is basal cell carcinoma; SK is solar 
keratosis
was the most common pre-malignant condition followed closely by in-situ carcinoma. 
Single cases of Bowen's disease of the leg, anaplastic carcinoma most probably of 
sweat gland origin and a metatypic carcinoma involving a nasal ala, were diagnosed. 
The two patients (LM and NvdW) with the most abundant skin lesions also had 
verruca vulgaris on the penis and shoulder respectively. For the purposes of this 
study, different types of lesions were only counted once, irrespective of the number 
of lesions that appeared.
Latent period The mean time interval to the development of the first basal cell 
carcinoma lesion was 63.4 months (95% confidence interval: 27.2 - 99.5) compared 
to the 82.1 months (95% confidence interval: 2.4 - 166.6) to the first squamous cell 
carcinoma (data not shown). The difference was not statistically significant (p = 0.6; 
Student’s t-test).
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Influence of sun-exposure (Fig. 4-11) Of the 104 cancerous and pre-cancerous 
lesions 87 (83.7%) occurred in sun-exposed areas of the body which included the 
face, the head, the neck and the dorsum of the hands. Each of the more common 
type of lesion also occurred predominantly in sun-exposed areas. Whereas invasive 
squamous carcinoma of the skin occurred almost exclusively in sun-exposed skin, in 
the case of in situ squamous carcinoma the proportion of lesions in the two areas 
approached unity: this difference in the number of lesions in the two areas was 
significant (p = 0.0006; x2 - test,). No lesions were described in the groin or in the 
axillae.
Influence of immunosuppression In the 69 white patients transplanted under 
azathioprine, 4 (5.8%) non-melanoma skin malignancies and 1 (1.4%) malignant
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Table 4-12 Comparison of types of malignant skin lesions in white renal transplant 
patients under two immunosuppressive treatment regimens.
Azathioprine Cyclosporine
No. of patients at risk 69 116
No. of lesions 5 10
Incidence1 5.8% 8.6%
• Squamous cell carcinoma1 3 2
• Basal cell carcinoma1 1 6
• Malignant melanoma1 1 0
• Anaplastic carcinoma1 0 1
• Metatypic carcinoma1 0 1
Mean latent period in mo. (95% C L)1 
-n ;—  ' • . ' 7." :"T. ,—:------
95.1 (3 .4- 186.8) 55.7 (18.35-93.0)
P = NS, comparing malignant skin lesions in patients under azathioprine and cyclosporine.
melanoma were detected. The incidence of non-melanoma skin malignancies under 
cyclosporine was not statistically different in the 116 white patients with 8 (6.9%) 
malignancies in this group (p = 0.83, x2 - test). No malignant melanomas occurred 
in the cyclosporine group. The latent period to the development of the first skin 
malignancy was not significantly different under cyclosporine compared to 
azathioprine (Table 4-12). All the skin tumours were adequately treated with 
excision biopsies. None of the patients developed metastatic lesions or died as a 
direct result of the skin malignancy.
Carcinoma of the bronchus (Table 4-13)
Carcinoma of the bronchus was diagnosed in 3 patients. The details of the patients 
are shown. All three patients were cigarette smokers and had received triple 
immunosuppressive therapy including cyclosporine. Both male patients had failed 
grafts and had received haemodialysis treatment for approximately 10 years after 
failure of the renal allograft, before developing the bronchial lesion. Neither of these 
two patients was therefore on immunosuppressive therapy at the time of the 
diagnosis of the lung. Both patients presented with advanced lesions which
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Table 4-13. Details o f renal transplant patients diagnosed with carcinoma of the 
lung.
Patient PT Patient JM Patient DJ
Race Coloured Black Coloured
Sex Male Male Female
Age at transplant (yrs) 30.6 36.7 44.5
Age at malignancy (yrs) 42.0 46.2 51.4
Haemodialysis recommenced 5-Aug-87 12-Oct-89 -
Duration of immunosuppression (mo.) 17.4 6.67 71.82
Cigarette use (pack yrs) 27 18 26
Latency period (mo.) 139.2 119.4 83.3
Histology of carcinoma - Undifferentiated Adenocarcinoma
Treatment Radiotherapy Radiotherapy Surgery
Outcome/survival (mo.) Mortality (3) Mortality (4) Alive (March 00)
were considered inoperable and both underwent palliative radiotherapy. In patient 
JM, the diagnosis of malignancy was made on cytological examination of the sputum 
which showed poorly differentiated malignant cells. A formal biopsy was not 
undertaken. In patient PT, cytological examination of the sputum was unhelpful and 
a histological diagnosis of a malignancy could not be confirmed because material 
obtained was inadequate. However, the clinical and radiological evidence was 
sufficiently strong to warrant radiotherapeutic intervention. Tests for tuberculosis 
and fungal infections were repeatedly negative. Patients PT and JM survived 3 and
4 months respectively following the diagnosis with both succumbing to complications 
arising from the primary malignancy.
Patient DJ developed her lesion while on immunosuppressive treatment. She 
presented with a discrete lesion in the upper lobe of the right lung and the malignant 
nature of the lesion was proven on fine needle aspiration. In the absence of any 
metastases the lesion was considered curable and she underwent surgical resection. 
Post-operative sputum examination also revealed the presence of acid-alcohol fast
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bacilli; the patient was commenced on a course of anti-tuberculous treatment and is 
doing well 6 months after surgery.
The relative risk of the development of lung cancer was compared to the incidence in 
age- race- and sex-matched subjects in the general South African population. The 
risk of lung cancer among renal allograft recipients was not increased in the white 
patients but was doubled in coloured patients and increased 2.4 fold in black patients 
(see Appendix Table 4-17).
Breast carcinoma
Two female patients, both under cyclosporine, developed carcinoma of the breast. 
The first patient, who was coloured and aged 51 years, was diagnosed with 
infiltrating ductular adenocarcinoma of the right breast at a peripheral hospital 16 
months after renal transplantation. She underwent radical mastectomy and died 2 
years following the surgery of an unrelated cerebrovascular accident.
The second patient, a white recipient aged 53 years was also diagnosed with an 
infiltrating duct carcinoma 53 months after renal transplantation. She was treated 
with radical mastectomy and tamoxifen. Fifty-seven months later she presented with 
relapse of the malignancy in regional lymph nodes. The patient was referred for 
local irradiation. The patient continues to do well one year after the treatment with a 
well-functioning graft.
The risk for the development of breast cancer was compared to age- race- and sex- 
matched South African controls (see Appendix Table 4-18). The risk of this lesion 
was reduced in all race groups.
Malignant lymphoma
Two patients, both receiving cyclosporine-based triple therapy, developed malignant 
lymphomas. The first patient was a white female who was 16 years old at the time of 
her primary renal transplant. This graft never functioned and was lost as the result of 
acute rejection and rupture. The second transplant was performed 20 months later. 
The patient again suffered acute rejection that was treated with conventional pulses 
of methylprednisolone and the graft maintained some function. Two months after the
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second transplant the patient presented with biopsy-proven acute cellular rejection 
and this time the patient received a 7-day course of OKT3 monoclonal antibodies. 
The patient died 18 days after this admission with the cause of death at postmortem 
examination being established as disseminated mucormycosis. An unexpected 
finding at postmortem examination was that of a large cell lymphoma with 
involvement of lymph nodes, the spleen, tonsils, gastric mucosa and the renal 
allograft. Both native kidneys had been removed before the first transplant because 
the patient had had severe ureteric reflux with ongoing sepsis. The patient was also 
found to have cytomegalovirus pneumonitis. Another incidental finding in this patient 
at postmortem examination was the presence of papillary carcinoma of the thyroid 
gland, which manifested as a solitary nodule that had not been clinically detectable.
The second patient was a coloured female aged 44 years at the time of renal 
transplantation. The patient had an uneventful course following the transplant. She 
was never treated for acute rejection and never received OKT3 monoclonal 
antibodies. She presented 8 years after transplantation with a 9-month history of a 
painless annular ulcer on the left lower leg measuring 30 mm in diameter associated 
with dermal nodules. Biopsy of the lesion showed infiltration by malignant lymphoma 
cells that predominantly had the B-cell phenotype. The diagnosis of a diffuse large 
B-cell lymphoma (REAL classification)1 was made. The patient did not have 
cytomegalovirus infection. The only therapeutic intervention undertaken was the 
reduction of the patient's immunosuppression by withdrawing azathioprine. She 
was maintained on conventional doses of cyclosporine and methylprednisolone. A 
repeat skin biopsy done 4 months later showed features of a chronic ulcer but no 
evidence of the lymphoma. The patient's renal function remained stable and the 
azathioprine was permanently withheld. However, the patient subsequently had to 
have a below-knee amputation because of uncontrollable sepsis of the left leg.
No other renal transplant patient exposed to OKT3, used to treat steroid-resistant 
acute renal allograft rejection, developed malignant lymphoma. The relative risk for 
the development of non-Hodgkin's lymphoma (NHL) is increased in the white and 
coloured patients by 2.9 and 1.5 respectively while black patients had no increased
1 Revised European-American classification of lymphoid neoplasms
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risk of developing NHL (Appendix Table 4-19). Initially, patients were treated with 
OKT3 for 7-10 days but over the years the duration of therapy was reduced to 5 days 
and on occasion 3-day courses were given. On no occasion was treatment 
continued for longer than 14 days. No patient received more than one course of 
OKT3 for fear of the reaction to anti-murine antibodies.
Hepatocellular carcinoma.
A single patient developed hepatocellular carcinoma. The patient was a white male, 
aged 22 years at the time of renal transplantation. The patient was initially hepatitis 
B-virus negative but seroconverted 4 months following the transplant. The graft 
functioned for 4 years before dialysis was re-initiated. The patient developed 
intractable ascites 3 years after the transplant. Extensive investigations were 
undertaken. Two years later a visceral angiogram showed a large vascular lesion in 
the liver in keeping with hepatocellular carcinoma. No biopsy was undertaken 
because of the vascularity of the lesion and the serum a-foetoprotein levels 
remained normal. He succumbed to complications related to the hepatocellular 
carcinoma 2 months later. A postmortem examination was not performed.
Renal cell carcinoma
The diagnosis of renal cell carcinoma was suspected in one coloured male patient. 
He was 58 years old when he received his renal allograft. Investigations undertaken 
30 months after the transplantation to diagnose the renal lesions included ultrasound 
and computerised axial tomography. These showed large cystic lesions related to 
the kidney. Surgical intervention was planned to confirm the diagnosis but the 
patient died unexpectedly soon afterward of unrelated causes. At postmortem 
examination the macroscopic appearance of the lesion was in keeping with renal cell 
carcinoma but the tissue was too autolytic to allow an histological diagnosis to be 
made.
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(5) P r e -existin g  Ma lig n a n c ie s  in R e n a l  T r a n s p la n t
Pa tien ts
Introduction
Malignancies were documented in 6 patients prior to renal transplantation. The 
details of these patients and their lesions are shown in Table 4-14. In 4 patients the 
diagnosis was made before they received their grafts. In the other two cases the 
diagnosis was made within two weeks of the transplant suggesting that the lesions 
must have been present before the transplant. In the first group of patients, single 
cases of a seminoma, skin carcinoma, breast carcinoma and renal cell carcinoma 
were diagnosed.
Case studies
Seminoma The patient (MM) who was diagnosed with this lesion was a phenotypic 
female who had been on dialysis for 49 months. The patient was a true 
hermaphrodite who presented with ascites and an abdominal mass. At surgery the 
uterus and an adnexal seminoma were removed. No further treatment was given for 
the malignancy. The patient was transplanted and received triple
Table 4-14 Details o f patients with malignancies preceding renal transplantation
Patient Age
(yrs)
Sex Race Site Histological Type Treatment Interval
(mo)2
MM 25 Female Black Gonad Seminoma Surgery 73
BC3 44 Male White Skin Squamous cell CA Excision 15
LC4 36 Female Coloured Breast Intraducal CA Surgery and 
Iridium rods
33
JA3 37 Male Coloured Kidney Renal cell CA Surgery 90
JC 46 Male Coloured Thyroid Papillary CA - 0
CvdH5 37 Male White Bladder Transitional cell CA Fulguration 0
This is age at the diagnosis of the malignancy
2 This refers to the time from the initial diagnosis of the malignancy to the primary renal transplant.
3 These patients received multiple grafts
4 This patient subsequently developed Kaposi’s sarcoma
5 This patient was under azathioprine. The rest were transplanted under cyclosporine 
CA is carcinoma
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immunosuppressive therapy. At 8 years follow-up the patient remains free of 
disease with a well-functioning graft.
Squamous cell carcinoma of the skin Only one white male patient (BC) had 
evidence of a malignant skin lesion before transplantation. The dermis surrounding 
the lesion exhibited features of severe solar keratosis. The patient had been on 
dialysis for less than 1 month when the lesion was detected. The lesion was excised 
and the patient subsequently transplanted under triple therapy including 
cyclosporine. The patient received his first graft 16 months after the initiation of 
dialysis. The first graft was lost after only 4 days and a second graft was 
transplanted 8 months later, which functioned for 2 years before it was lost to chronic 
rejection. Of note is that when the patient died 15 months later of cardiovascular 
disease, he had developed no new malignant skin lesions.
Breast carcinoma One female patient (LC) underwent a mastectomy with clearance 
of the regional lymph nodes for breast carcinoma. She also had adjunctive 
radiotherapy to the lesion. At the time of the surgery the patient already had 
moderately impaired renal function and was commenced on dialysis 32 months after 
the diagnosis of the malignancy. She was transplanted one month later under triple 
immunosuppressive therapy including cyclosporine. She had no further recurrence 
at 94 months follow-up. She did however develop Kaposi’s sarcoma at 64 months 
after the transplant (see above for further details).
Renal cell carcinoma A nephrectomy was performed in a male patient (JA) for a 
renal cell carcinoma 8 years before he was commenced on dialysis. The disease 
had not infiltrated the inferior vena cava or the regional lymph nodes. He had no 
further treatment for the lesion. He received a renal allograft 8 weeks after the 
initiation of dialysis and was maintained on triple immunosuppressive treatment. The 
first graft failed after 39 months but the patient received a second allograft 6 months 
later. At the time of his demise 10 months later the patient had no evidence of 
recurrence of the renal cell carcinoma.
Other lesions One patient (JC) was found to have an incidental papillary cell 
carcinoma of the thyroid at postmortem examination. The patient had died within 24
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hours of complications arising from the transplant surgery. One other patient (CvdH) 
was found to have a transitional cell bladder carcinoma at cystoscopy done 2 weeks 
after the transplant for persistent haematuria. The patient required repeated 
treatments to fulgurate the lesion. This patient was the only one to receive 
azathioprine treatment. The patient died 14 years later of causes unrelated to the 
malignancy.
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Fig. 4-12a Graft Loss over time expressed as Probability Density 
Model: Linear Hazard
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Fig. 4-12b Renal Allograft Recipients 
Factors influencing Survival
Patient Survival 
Influence o f  Immunosuppressive therapy
Patient Survival 
influence o f Primary Renal Disease
------ MIS (n = 59)
------CPN (n = 82)
------CGN (n =  220)
—  PKD (n = 49)
—  HTN (n =  100
—  DM (n =  22) 
SLE ( n *  10)
Duration of Dialysis Prior to Transplantation Influence o f Race
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Fig. 4-13a Survival of Primary Renal Allografts 
Life Table Model: Linear Hazard
Interval (Years)
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Fig. 4-13b Graft Survival
Multiple Transplants (n = 72)
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Survival (Years)
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Table 4-16 Relative risk o f the development o f Kaposi’s sarcoma in the race groups
Observed Expected Relative Risk
Age Total No. of Sum of 0 Proportion of total No. of Sum of E (O/E) 95% CL
group cancers1 cases cancers cases
% Proportion
White Males 15-44 2 1 3 0.72 0.0072 0.0144 0.0172 174.4 36.0 420.1
45-64 1 1 0.1 0.001 0.001
Females 15-44 4 1 0.04 0.0004 0.0016
45-64 1 0 0.02 0.0002 0.0002
Coloured Males 15-44 6 6 14 0.53 0.0053 0.0318 0.0454 308.4 168.6 517.4
45-64 2 1 0.17 0.0017 0.0034
Females 15-44 4 5 0.18 0.0018 0.0072
45-64 3 2 0.1 0.001 0.003
Black Males 15-44 1 1 4 1.08 0.0108 0.0108 0.0255 149.8 40.8 383.6
45-64 3 2 0.49 0.0049 0.0147
Females 15-44 0 0 0.19 0.0019 0
45-64 1 1 0.12 0.0012 0.0012
Excludes non-melanoma skin malignancies.
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Table 4-17 The relative risk for the development o f lung cancer in renal allograft recipients.
Observed Expected Relative Risk
Age Total No. of cases Sum of 0  Proportion of total No of cases Sum of E (O/E) 95%
group cancers cancers CL
% Proportion
White males 15-44 2 0 0 4.24 0.0424 0.0848 0.3249 0.0 0.00 11.35
45-64 1 0 10.52 0.1052 0.1052
females 15-44 4 0 2.21 0.0221 0.0884
45-64 1 0 4.65 0.0465 0.0465
Coloured males 15-44 6 1 2 7.76 0.0776 0.4656 1.0035 2.0 0.03 5.55
45-64 2 0 14.29 0.1429 0.2858
females 15-44 4 0 2.65 0.0265 0.106
45-64 3 1 4.87 0.0487 0.1461
Black males 15-44 1 0 1 6.83 0.0683 0.0683 0.418 2.4 0.06 13.33
45-64 3 1 10.89 0.1089 0.3267
females 15-44 0 0 1.45 0.0145 0
45-64 1 0 2.30 0.023 0.023
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Table 4-18 Relative risk for the development o f breast cancer in renal allograft recipients.
Observed Expected Relative Risk
Age Total No. of Sum of O Proportion of total cancers No. of Sum of E (O/E) 95% CL
group cancers cases cases
% Proportion
White males 15-44 2 0 1 0.66 0.0066 0.0132 1.5751 0.6 0.02 3.54
45-64 1 0 0.76 0.0076 0.0076
females 15-44 4 0 30.58 0.3058 1.2232
45-64 1 1 33.11 0.3311 0.3311
Coloured males 15-44 6 0 1 0.35 0.0035 0.021 1.4775 0.7 0.02 3.77
45-64 2 0 0.45 0.0045 0.009
females 15-44 4 0 19.23 0.1923 0.7692
45-64 3 1 22.61 0.2261 0.6783
Black males 15-44 1 0 0 0.52 0.0052 0.0052 0.158 0.0 0.00 23.35
45-64 3 0 0.85 0.0085 0.0255
females 15-44 0 0 12.72 0.1272 0
45-64 1 0 12.73 0.1273 0.1273
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Table 4-19 Relative risk for the development o f non-Hodgkin's lymphoma (NHL) in renal transplant patients.
Observed Expected Relative Risk
Age Total No. of Sum of 0 Proportion of total cancers No. of Sum of E (O/E) 95%
group cancers cases cases CL
% Proportion
White males 15-44 2 0 1 6.84 0.0684 0.1368 0.3446 2.9 0.08 16.17
45-64 1 0 4.14 0.0414 0.0414
females 15-44 4 1 3.21 0.0321 0.1284
45-64 1 0 3.8 0.038 0.038
Coloured males 15-44 6 0 1 7.12 0.0712 0.4272 0.6483 1.5 0.04 8.59
45-64 2 0 2.29 0.0229 0.0458
females 15-44 4 0 2.65 0.0265 0.106
45-64 3 1 2.31 0.0231 0.0693
Black males 15-44 1 0 0 4.91 0.0491 0.0491 0.1196 0.0 0.00 30.84
45-64 3 0 1.95 0.0195 0.0585
females 15-44 0 0 1.59 0.0159 0
45-64 1 0 1.20 0.012 0.012
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Chapter 5
THE OUTCOME OF
RENAL
TRANSPLANTATION
The results of kidney transplantation have improved remarkably during the past 25 years (Cecka,1998). Some of the developments that have influenced improvements are indicated in Fig. 5-1. The paradoxical benefit of pre-transplant blood transfusions was recognised in 1973 (Opelz et al., 1973) and during the subsequent years the majority of patients were given blood transfusions 
as an extension of the immunosuppressive regimen. The use of deliberate blood 
transfusions was discontinued in the late 1980s because the survival rates for 
patients not transfused had improved to the point that little advantage was gained by 
continuing this practice (Opelz, 1987). Patient survival rates also improved between 
1975 and 1986 with better patient selection and the development of better treatment 
modalities (Cecka,1998). The introduction of OKT3, a monoclonal antibody capable
Stellenbosch University http://scholar.sun.ac.za/
Outcome o f  Transplantation 5-2
f5>
£3
CO
ro
2ioc
o
100
90+ Patient
80
TO
60+ Graft 
50
<10 
30 
20 
10 
0
(1981)
f ife *(1984)
, Transfusions . .  > 
(1975-1985)
UCLA Registry > <
75
-t-
80
Center MMF 
Specific Nears!
Data (1996) 
Release 
(1991)
UNOS — >
_ _ 4 — i----- - | . ■
85
Year
90 95
Fla- 5-1 Factors impacting on patient and graft survival in the United States 
(Cecka,1998).
of inhibiting T-cell activity added a powerful tool for the treatment of acute rejection 
when it was introduced for clinical use in the early 1980's (Cecka,1998). However, it 
was the introduction of cyclosporine into routine clinical practice in late 1983 that 
changed the field of organ transplantation forever. Graft survival rates improved on 
average by 15% over the subsequent 2 years in the USA (Cecka, 1998). The recent 
introduction of a new generation of drugs may lead to further improvements in graft 
survival.
THE RENAL REPLACEMENT PROGRAM
The Tygerberg Unit
The renal transplant program was established at our institution in 1976 as the prime 
modality of treatment for end-stage renal failure. This was preceded by the initiation 
of a dialysis program and the two have from the outset remained complementary and 
non-competitive modalities of therapy in this unit. A multidisciplinary team is 
responsible for the renal transplants. The surgical team is responsible for the 
implantation of the graft and attends to all surgical problems. The medical team is 
responsible for the manipulation of the immunosuppressive protocol and long-term 
follow-up of these patients. Efficient radio-isotope radiology, biochemistry and 
anatomical pathology services have contributed to the success of the program.
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Single centre study: Advantages
This institution has been submitting its statistics to the South African Dialysis and 
Transplant Registry (SADTR) since the inception of this body in 1984 and all our 
data were reported as part of the national registry. While this method of study clearly 
has statistical advantages, results differ widely in individual units and the pooling of 
data obscures the variations in a single unit. This study is therefore a single centre 
cohort study with the advantage of having complete data on the majority of patients.
Rates
The number of transplants performed in our unit and in the centres in South Africa is 
woefully inadequate to meet the needs of a growing nation. It has been estimated 
that the annual incidence of end-stage renal failure in South Africa is 250 patients 
per million population (pmp) (Meyers, 1995). In 1994 the number of new patients 
entering renal replacement therapy was 17 patients pmp, and even this figure is an 
overestimation because no allowance for the increase in the population since 1991 
was made (SADTR, 1994). In this respect the number of patients receiving treatment 
lags far behind the figures for new patients not only in Europe and the United States 
of America but also developing countries with similar gross national products (GNP) 
as South Africa (Moosa et al.,2001). The number of renal transplants performed in 
South Africa is 8.7 patients pmp (SADTR,1994), which is in the same range as 
countries with a similar GNP (Moosa et al.,2001).
The influence of events that occur early following renal transplantation such as 
delayed graft function/acute rejection on long-term graft survival, has been widely 
reported, but its association with patient survival has received less attention 
especially in developing countries. We evaluated the factors that influenced patient 
and graft survival and found, among other factors, that age was an important 
determinant of outcome and that the graft survival in the first year had a major 
impact on patient survival.
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(1) PATIENT SURVIVAL
Rates
Present study
In the present study, actuarial patient survival was 81% at one year, 58% at five 
years and 36% at 10 years. This is somewhat poorer than that reported by Washer 
et al. (1983) who found 85% and 72% 1-year and 5-year patient survival rates and 
more recently by Troppman et al. (1995) 93% and 79% at the same time intervals, 
while Gorlen et al. (1992) reported 48% and 45%, 5-year and 10-year patient 
survival rates. More recently excellent patient survival rates exceeding 95% at 1 
year and approaching 85% at 5 years have been reported (Arend et al., 1997). The 
present study was not designed to compare patient survival between the different 
forms of renal replacement treatment, but recent evidence suggests that although 
initial mortality may be higher after transplantation, long-term patient survival was 
clearly superior compared to dialysis (Fig. 5-2)(Wheeler, et al., 2000).
Other developing countries
Comparison with other developing countries is more difficult because the majority 
perform living-related donor renal transplantation whereas all but 13 of our cases 
were cadaveric donor transplants. Our results are comparable to those few 
countries that have a cadaveric donor transplant program (vide infra). The higher 
mortality in our patients compared with those in developed countries is almost 
certainly related to the very high infective complication rate that we continue to 
experience. Whereas in developed countries infections remain the main cause of 
mortality in the first year, cardiovascular deaths become more important thereafter 
(vide infra). In our experience infections remains the main cause of patient mortality 
throughout.
Causes of patient mortality
Infections
The mortality rate was highest in the first year, with sepsis being the main cause of 
patient death. Septicaemia and pulmonary infections together accounted for almost 
70% of all infections. After the first year sepsis remained the major cause of death 
followed by myocardial ischaemia. This is in agreement with many studies,
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Fip. 5-2 Adjusted relative risk o f death among 23 275 recipients of a first cadaveric 
transplant, in comparison to the mortality in all patients on dialysis awaiting 
transplantation. From Wheeler et al. (2000).
consisting of earlier series, which have reported infection as the leading cause of 
death in a mix of patients with and without graft function (Hill et al., 1991 ;Karakayali 
et al., 1995;Kim et al., 1994;Kirkman et a/.,1982;Najarian et al., 1979;Salvatierra et 
a/.,1976;Sato et a/.,1994;Scroggs et a/.,1987;Tilney et a/.,1978;Washer et al., 1983). 
In more recent reports (Dlugosz et al., 1989;Gorlen et a/.,1992;Hiesse et 
a/.,1997;Matas et al., 1993) including a series by Lindholm et al. (1995) ischaemic 
heart disease was the overwhelming cause of death accounting for 53% of deaths 
with graft function (vide infra). The discrepancy in the leading cause of death 
among studies can be explained by several differences including the transplant era 
(pre- vs. cyclosporine), patient selection, posttransplant interval under observation, 
nosological definition of terms and the source of mortality statistics (Ojo et al.,2000).
High patient mortality
In our population almost 60% of the patients died within 10 years of receiving their 
first renal transplant. This surprisingly high figure is explained by the high
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prevalence of sepsis and cardiovascular disease in this population and by the 
inclusion of patients who died after their grafts had failed, this group accounting for a 
large proportion of the deaths. Previous reports have excluded or censored this 
group of patients in their analyses (Arend et a/., 1997) which may have been 
misleading because our study demonstrates that graft loss correlates with an 
increased risk of death. A Turkish report on 1021 patients transplanted between 
1975 and 1994, found that 48% of patients who died within 4 years succumbed to 
infections, with the pulmonary infections being the most prevalent, followed by 
septicaemia complicated by multi-organ failure (Karakayali et a/.,1995). A similar 
finding was made by Sato et al. (1994) who report that infections accounted for 51% 
of deaths in their cohort of 316 patients transplanted between 1972 and 1990. 
Pulmonary infections and septicaemia were again the most common types of 
infection.
Dutch experience
Arend et al. report on 1002 Dutch recipients of first renal transplants treated between 
1966 and 1994, and established that in the first year infection was the most frequent 
cause of death (34%) but after the first year cardiovascular death was most common 
(44%) (Arend et al., 1997). Compared with the general population the all-cause 
standardised mortality ratio (SMR) was 12.1 in the first year and fell to 4.4 in the 
subsequent years. The largest contribution to the all cause SMR in the first year was 
non-cardiovascular and non-malignant causes of death, which included sepsis 
(sepsis was not recorded separately because the Dutch population death rates for 
infectious causes of death were not available) (Arend et al., 1997). Sepsis continues 
to be a risk for death even for transplant patients who have survived for more than 5 
years.
Other issues
Kirkman et al. (1982) report that sepsis was the cause of death in 18% of recipients 
of renal allografts who had survived more than 5 years. Despite improved 
experience with the use of immunosuppressive drugs and decreased risk of sepsis 
this group of patients remains at high risk of early death (Woo et al., 1999). Although 
it is beyond the scope of this study to identify the possible mechanisms, it is likely the 
result of multiple factors including the effect of early return to dialysis, the physical
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trauma of major surgery and the increased exposure to immunosuppressive agents
in those cases where acute rejection was considered to play a role. Cardiovascular 
i
disease remains a very important cause of death in renal transplant recipients in the 
present study and in most reported series. According to Levey et al. (1998) risk 
factors for cardiovascular disease in transplant recipients include hypertension, 
hyperlipidaemia, diabetes mellitus, smoking, menopause, hyperhomocystinaemia, 
and physical inactivity. These risk factors are based largely on those established for 
cardiovascular disease in the general population. Exposure to these risk factors may 
account at least in part for the development of de novo cardiovascular disease in 
renal transplant patients (Kasiske et al., 1996).
Malignancies as a cause of mortality
Uncommon
In most reports, including ours, infections and cardiovascular deaths dominate 
posttransplant mortality (Frisk et a/.,1987;McGeown et a/.,1988;Murray et a/.,1976), 
while malignancies are an uncommon cause of death. In our cohort only 8 (2.5%) 
deaths could be ascribed to an underlying malignancy. This contrasts with the 
findings of Kirkman et al. (Kirkman et al., 1982) who report that malignancies 
occurred in 14% of 217 long-term renal allograft recipients who had grafts 
functioning for more than 5 years. Skin tumours were most common with metastatic 
squamous cell carcinoma caused two deaths, while adenocarcinoma of the 
oesophagus caused one death. Malignancies accounted for 9% of all patient 
deaths. None of the patients had lymphomas. Similarly, a Turkish report found that 
malignancies caused 8.6% of patient deaths in a cohort of 1021 patients followed-up 
over 19 years. The fatal malignancies were 2 lymphomas, and one case each of a 
brain tumour, Kaposi's sarcoma and gastric carcinoma (Karakayali et al., 1995). In 
an early report from the pre-cyclosporine period on 299 patients, only two patients 
succumbed to malignancies accounting for a mere 4% of patient deaths. The 
malignant lesions were an undifferentiated sarcoma and malignant lymphoma 
(Washer et al., 1983).
Late complication
Gorlen et al. (1992) found that malignancies were an important cause of patient 
mortality in the second decade after transplantation, responsible for 20% of all
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patient deaths. Arend et al. (1997) report an overall patient mortality rate of 12% but 
found that malignancies were an uncommon cause of patient mortality in the first 
year accounting for 2% of deaths. However, malignancies accounted for 18% of 
deaths after 1 year (Arend et al., 1997). Another important finding was that death 
due to malignancy was relatively less frequent in men (11%) compared to females 
(22%) (Arend et al., 1997). The number of cancer deaths in our own cohort was too 
small to allow a valid conclusion with regards to the gender of patients who 
succumbed to malignancies (3 females and 5 males). A Japanese study reported a 
4.2% mortality in 316 renal allograft recipients transplanted over a 22 year period, 
with both cancer deaths being due to gastric lesions, a common cause of 
malignancies in that part of the world (Sato et al., 1994). In Korea, sepsis is the most 
common cause of mortality as elsewhere in the world, with malignancies only an 
infrequent cause of death (Kim efa/.,1994).
Long-term survivors
Long-term survivors who die with functioning grafts most commonly succumb to 
cardiovascular disease but malignancies were the third most common cause of 
death in a recent multi-centre American study. Malignancies were responsible for 
9% of deaths (Ojo et al.,2000). A similar mortality rate due to cancer was reported 
recently from a single centre study in the United Kingdom of 589 patients over 9 
years (Woo et a/., 1999).
Factors influencing patient survival (Fig. 4-4a)
Age
One of the most significant factors determining the mortality of patients is patient 
age. In the present study patients aged more than 40 years at the time of the 
primary transplant, had a mortality rate that was significantly greater than that of 
younger patients, with the discrepancy increasing with time. At 5 years, only 40% of 
the older group have survived compared to 62% of the younger group and at 10 
years the figures are 18% and 48% respectively. This is in agreement with previous 
studies that reported increased risk in the older patient throughout the transplant 
period (Meyer et al., 1996;Perez et al., 1990) and in partial agreement with others. 
Arend et al. (1997) report that the crude first year mortality rates were roughly the 
same for all age categories in the first year but increased significantly for patients
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aged over 40-years but only after the first year. Hirata et al. (1996) analysed the 
data reported to the United Network for Organ Sharing (UNOS) Scientific Renal 
Transplant Registry by participating centres between 1987 and 1995. In the cohort 
of 46 971 first cadaveric renal transplant recipients there were 5 036 deaths. The 
relative risk of dying for a patient aged 45 years was double that for a patient age 31- 
45 years and almost 4-fold greater than patients aged 2-15. Unlike the experience in 
our group however, the risk remained relatively constant over time (Hirata et 
al., 1996).
In a single centre study from the United Kingdom of 589 primary renal transplant 
patients the risk of patient death progressively increased as the age of patients at 
transplantation increased. The risk of death at 50-59 years was almost double that 
of patients aged 40-49 and triple that of patients aged 30-40 (Woo et a/., 1999). A 
study of the clinical outcome in elderly patients revealed that the 10-year patient 
survival was 45% in patients aged > 60 years compared to 68% in patients aged 18 
to 59 years (Doyle et a/.,2000). The main explanation for the excess mortality in 
older patients in the present study may be the development or acceleration of co- 
morbid diseases that resulted in the 3.5 fold greater incidence of ischaemic 
myocardial events. Ojo et al. (2000) also support a direct mechanistic relationship 
with premature cardiovascular death in the elderly renal allograft recipient. In the 
present study there was also more sepsis than in younger patients which may have 
contributed to the excess mortality (Hirata et al., 1996). The susceptibility to infection 
may be attributed to the decline in immunocompetence with age, as has been 
reported (Hirokawa,1992).
Gender
No difference in patient survival was found in the present study with regard to race or 
gender. This contrasts with the findings of Arend et al. who report a lower mortality 
in women both in the first year posttransplant and during long-term follow-up (Arend 
et al., 1997). In an earlier, smaller study done over a mean observation period of 9.5 
years the mortality was higher in female patients than males: 60% vs. 39%, although 
the difference was not statistically different (Gorlen et al., 1992). Similarly, Troppman 
et al. (1995) found that the relative risk of mortality was higher in females (1.25) but
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the difference was not significant. Woo et al. (1999), reporting on patients treated 
entirely in the cyclosporine era found that patient survival was much better in women 
than in men (hazards ratio: 0.66). In another study male patients had a 1.16 greater 
risk of dying with graft function relative to female patients (Ojo et al. ,2000).
Race
In the same study African American and other race group recipients had a lower risk 
of death with graft function, after controlling for other factors, compared with whites 
(relative risk = 0.92) (Ojo et al., 2000). According to the USRDS 1999 Annual Report 
patient survival was virtually identical in white and black. The patient survival at one 
year was 97.9 and 98.0 for living donor transplants in black and white patients 
respectively. Among recipients of cadaveric donor allografts the 1-year survival was 
96.5 and 95.7 respectively. In the present study we were also unable to find any 
significant racial differences in patient survival after first renal transplantation, which 
confirms our earlier report of this observation (Moosa et al., 1992).
Death with functioning grafts
Of note is that over the 23-year period of the present study death with functioning 
grafts accounted for 44% of grafts lost in patients aged over 40 years. For patients 
aged less than 40 years 26% of grafts were lost due to death. In a similar analysis 
done in California over 5 years, death with functioning grafts occurred in 6% of 
patients aged 30 to 45 years. For patients aged over 45, 13% of grafts were lost as 
a result of death over the 5 year time period (Hirata et al., 1996). Ojo et al. (2000) 
have also confirmed the importance of death with functioning graft as a very 
important cause of graft loss. In their experience almost one-half of all graft-loss was 
due to death with function (Ojo et a/.,2000) making this and chronic rejection the 
most important causes of graft-loss in developed countries (Morris,1997). Besides 
age, the other important determinant of death with function has been found to be 
end-stage renal failure caused by diabetes. The excess risk of death in these 
patients can be explained primarily by significantly higher rates from both 
cardiovascular disease and stroke in the diabetics (Ojo et al.,2000). Because of the 
small number of diabetics in our cohort we were unable to confirm these findings.
Stellenbosch University http://scholar.sun.ac.za/
Outcome o f  Transplantation 5-11
Dialysis prior to transplantation
Controversy surrounds the role of dialysis prior to transplantation in subsequent 
patient survival. In two recent studies patient survival was significantly worse the 
longer the period of dialysis prior to transplantation. Cosio et al. (1998a) evaluated 
523 patients transplanted at a single centre followed up for a mean of 7 years. The 
patients who had been transplanted pre-emptively had a mortality of 7% compared 
with 23% who were dialysed for 1-2 years and 44% of patients dialysed for more 
than 3 years. The type of dialysis i.e. continuous ambulatory peritoneal dailysis 
(CAPD) vs. haemodialysis, did not correlate with patient survival. However, graft 
survival when censored for patient death, was not significantly influenced by the 
duration of dialysis prior to transplantation. In pre-emptive transplantation of kidneys 
from living donors, however, graft survival is better if patients receive their grafts 
before the initiation of dialysis (Mange et al.,2001). Ojo et al. (2000) analysed 
registry data and studied the causes of death in 18 482 patients among 86 502 
recipients. They also found that a history and duration of pre-transplant dialysis 
treatment (> 6 months) to be associated with an increased risk of death with function. 
They concluded that the longer exposure to the immunosuppressive effect of both 
renal failure and dialysis, as well as the greater likelihood of malnutrition contributed 
to the adverse patient survival posttransplant.
Our own findings indicate that duration of dialysis does not significantly impact on 
patient survival following renal transplantation. This is in accordance with the results 
of a study of paediatric patients (Nevins et a/.,1991), and another of adult diabetic 
patients (Ekstrand,1993). Woo et al. (1999) after controlling for the effect of early 
graft function, age, gender, and primary renal disease found that the influence of 
time on renal replacement therapy prior to transplantation was not significant. In a 
cohort of 1002 Dutch recipients of first renal transplants there was no effect of the 
type or duration of pre-transplant dialysis on posttransplant patient mortality (Arend 
et al., 1997). O'Donoghue et al. (1992) similarly found no effect of the dialysis 
modality on patient survival after 10 years follow-up. Arend et al. (1997) have 
suggested that these findings could be explained by selection bias, because death 
rates of patients on dialysis are high (Anonymous,1991) and survival of a long period 
of haemodialysis can be expected ". . . to select patients with the strongest 
constitution". The pre-emptive transplantation of kidneys from living donors without
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dialysis being initiated is associated with better renal allograft survival. The 
reduction in the rate of acute allograft rejection suggests that pre-emptive 
transplantation may modulate immune mechanisms that shorten allograft survival 
(Donnelly et a/.,1996;Mange et a/.,2001;Schurman et a/.,1997). Patient survival 
rates were not studied in the latter reports.
Early graft loss
Graft loss within the first year was another important determinant of patient mortality 
in the present study. Graft loss was used as a surrogate for delayed graft function 
and acute rejection in the first year. Five years after the primary renal transplant only 
30% of patients who lost their grafts within the first year survived as compared to 
70% of those recipients whose grafts were retained. Most of the deaths in the 
former occurred within the first year (see Fig. 4-4a, Chapter 4). The excess patient 
mortality rate almost certainly reflects the complications of the use of additional 
immunosuppression to salvage a failing kidney. In addition, the immunosuppressive 
effects of both renal failure and dialysis treatment, and the greater likelihood of 
malnutrition may have adversely affected posttransplant patient survival (Cosio et 
al.,1998a). The majority of the patients died of septic complications, cardiovascular 
disease and gastrointestinal haemorrhage. Clearly, the price of trying to salvage a 
failing graft at all costs is very high. The fact that patients with primary non-function 
or later graft loss have an increased mortality when they return to dialysis is not 
unexpected, but it is of considerable clinical importance.
Our findings concur with those of Woo et al. (1999) who demonstrated that the 
mortality of patients whose grafts failed to function was 44% compared with 29% in 
patients with delayed graft function. They also found a correlation between the 
serum creatinine levels at 3 months and patient survival. Data from the Canadian 
Organ Replacement Registry 1990 Report have previously also documented poorer 
survival in patients following a failed first transplant (Cattran et al., 1993). The 
highest mortality was in those who lost their grafts within 90 days compared with 
graft loss after 90 days followed by those who maintained good function. The 4-year 
patient survival rates were 59% vs. 72% vs. 85% respectively. The most common 
cause of death (22%) in these patients was sepsis as was the case in our study. In 
a recent study the combination of delayed graft function and early acute rejection
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were associated with an increased relative risk of patient mortality (Troppmann et 
al., 1995), confirming the findings of other studies (Gorlen et a/.,1992;Hirata et 
a/.,1996;Lindholm et al., 1995;Ojo eta l.,2000).
Source o f kidney
In the present study it was determined that patients who received their grafts from 
living related donors, also had a better survival than patients whose kidneys are 
derived from cadaveric donors. The superior tissue matching, fewer rejection 
episodes and optimal timing of the transplant no doubt contributed to the improved 
outcome. Myburgh et al. (1983) have made similar observations with regard to 
patient survival in patients receiving cadaver as opposed to grafts from a related 
donor. In their experience the main difference was the higher mortality in the first 
year (78% vs. 93%), which is followed by a steady and parallel attrition thereafter. 
By far the major cause of mortality in the present study as well as the one reported 
by Myburgh et al. (1983) is sepsis. They relate this complication to the intensity of 
immunosuppression during the initial period and were therefore not surprised to find 
the excess patient and graft mortality. The maintenance immunosuppressive 
regimen in the two groups is similar after the first year. The South African findings 
concur with those of other centres confirming the superiority of patient and graft 
survival of living donor transplants over cadaver donor transplants (Arend et 
al., 1997;Gorlen et al., 1992;Karakayali et al., 1995;Sato et a/.,1994;Tilney et 
a/.,1978;Washer et al., 1983). However, Kirkman et al. (1982) report that there were 
no differences apparent in survival after 5 years between recipients of living related 
and cadaver donor allografts nor was graft survival dependent upon donor source 
during this late follow-up period.
Primary renal disease (Appendix Fig. 4-12b)
Hirata et al. (1996) found that after the age of the patient, the primary renal disease 
leading to end-stage renal failure was the most important factor influencing the 
mortality rate, with diabetes mellitus carrying the greatest risk. In our cohort we 
demonstrated that patients with hypertension fared the worst. The main reason for 
the failure to confirm the widely held observation of poorer outcome is the small 
number of diabetics that were transplanted (less than 4%) leading to a type II error.
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In addition, the diabetic patients that we selected for transplantation were generally 
young and had minimal co-morbid disease.
Immunosuppressive treatment (Appendix Fig. 4-12b)
The survival of patients receiving azathioprine and cyclosporine was comparable in 
the first 6 years, but thereafter the mortality rate of patients under cyclosporine was 
much worse than patients receiving conventional therapy. This is almost certainly 
related to the cumulative cyclosporine toxicity resulting in hypertension, diabetes 
mellitus and possibly malignancies. At 10 years, 44% of patients on conventional 
therapy were still alive compared to 30% of patients on triple therapy. This 
observation brings into question the long-term safety of cyclosporine. This 
observation is even more pertinent if one considers that the dose of steroids used in 
the conventional treatment were generally much greater than is the current practice 
under cyclosporine. Our observation therefore seems to suggest that it may be 
worthwhile discontinuing the use of cyclosporine when the risk of graft failure is at its 
lowest. Randomised conversion from cyclosporine to azathioprine at 3 months was 
associated with comparable 3-year and improved long-term patient survival 
(Hollander et a/.,1995a;Kootte et al., 1988b). The need for immunosuppression is 
greatest soonest after renal transplantation and it is generally accepted that it can be 
cautiously reduced from one year onward. A recent study of randomised conversion 
at one year was not associated with significant adverse effects on long-term patient 
or graft mortality. Both blood pressure control and renal function showed 
improvement (MacPhee et al., 1998). Most studies have compared graft survival 
under the two treatment regimes and few have compared patient survival as has 
been done here. In these reports conflicting results have been published with 
respect to the effect of cyclosporine on long-term patient survival (Hollander et 
al., 1995a; Kootte et al., 1988b; Kootte et al., 1988a; Paul et al., 1992; Sato et al., 1994; 
Stiller et al., 1991). The distribution of the causes of death is similar under 
cyclosporine and conventional treatment with cardiovascular disease being the most 
common cause of death (Penn,1993). Hollander et al. (1995b) report a higher 
incidence of cardiovascular death in patients maintained on cyclosporine. 
Cyclosporine is known to have an effect on a number of cardiovascular risk factors 
including the blood pressure (Porter et al., 1990), lipid profile and glucose tolerance 
(Harris et al., 1986), which all improve if patients are converted to azathioprine.
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OTHER CONSIDERATIONS
Previous malignancy
An important observation made by Doyle et al. (2000) who were trying to predict the 
clinical outcome in the elderly renal allograft recipient was that a history of non-skin 
malignancy was associated with poor graft and patient survival. Several of their 
patients aged over 60 years (a group that we would not transplant) died of metastatic 
disease despite extensive screening to rule out residual or recurrent tumour prior to 
transplant, and an average disease-free interval of 2.6 years for these patients 
compared with 10.9 years in patients without recurrent malignancy, suggesting that 
the elderly patients may require a longer period disease-free interval prior to 
transplant. The poor survival of the remaining patients suggests that a history of 
malignancy may predispose to death in other ways such as an increased 
susceptibility to infection related to prior chemotherapy or radiation treatment (Doyle 
et a/.,2000). In the present study the impact of prior malignancies on patient and 
graft survival could not be evaluated because the number of patients with cured 
lesions (6), who were grafted was too small to allow statistical evaluation.
Limitations
One of the limitations of our analyses is that we did not compare the survival rates of 
our patients with those of patients on the transplant waiting list treated with 
haemodialysis. Such an study was done by Port et al. (Port et al., 1993) who 
observed that an initial excess risk of mortality in the posttransplant period but a 
subsequent decline with the equal cumulative mortality rate being achieved on day 
325. A survival advantage brought about by the renal transplant therefore seems to 
commence 1 year after transplantation. In the analysis by Schaubel et al. (1995) the 
risk of mortality in patients aged 60 years and over on haemodialysis was 
approximately double the risk of transplanted patients.
(2) GRAFT SURVIVAL
Rates
The overall actuarial graft survival in the present study was 64% at one year 
decreasing to 36% at 5 years and 21% at 10 years. A comparative analysis is made
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in Table 5-1 (page 5-25) with other developing countries. The fact that our 
observations are made almost entirely on cadaveric donor transplants and include 
patients both under azathioprine and triple therapy need to be taken into 
consideration to explain the apparently poorer results obtained in the present study. 
In some of the latest reports from developed countries: 1-year and 5-year graft 
survival rates of 87% and 67%, respectively, are being achieved (Troppmann et 
a/., 1995), and 84% at one year, 68% at 5 years and 55% at 10 years (Woo et 
a/., 1999). By multivariate analysis, the main factors that influenced the outcome of 
the grafts in the present study were: the age of the patient (less or greater than 40 
years), the type of immunosuppression (azathioprine or cyclosporine), the underlying 
renal disease that led to the renal failure as well as the source of the donor kidney 
(living related or cadaver).
Factors influencing graft survival (see Fig. 4-5)
Age
In the present study graft survival was significantly better in patients aged <40 years 
compared to older patients and this difference increased the longer the follow-up. 
Patient survival stratified for age reveals a curve that closely follows that of graft 
survival. Patient death with functioning grafts therefore may explain the discrepancy 
in the survival of grafts in the 2 age groups. In the older age group 42% died with 
functioning grafts compared to 27% of the younger age group. This accounted for 
47% of grafts lost. In a recent large survey Ojo et al. (2000) report that 38% of their 
over 18 000 deaths were deaths with graft function and this accounted for 43% of 
graft loss (Ojo et a/.,2000). Most of the patients were over 40 years and sepsis was 
the commonest cause of death even after the first year. Several factors were 
identified as predictors of reduced graft survival in the elderly patient: increasing 
patient age, a pre-transplant history of non-skin malignancy, time on the waiting list 
of less than 1 year and recurrent tobacco use (Doyle et a/.,2000). When graft failure 
in the elderly was censored for loss due to patient death, there was a decrease in 
graft failures with increasing age (Doyle et a/.,2000). The decrease in graft failures 
can be attributed to declining immunocompetence with age as has been previously 
suggested (Hirokawa,1992).
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Immunosuppressive regimens
Cyclosporine had a dramatic impact on 1-year allograft survival and rekindled world 
interest in organ transplant in the early 1980’s. In the United States the approval of 
cyclosporine in November 1983 resulted in an improvement in graft survival of 15% 
in the subsequent 2 years (Cecka,1998). One-year graft survival in our cohort 
dramatically improved by over 20%, a difference that was maintained for 
approximately 8 years. After that period more patients on conventional therapy had 
functioning grafts. This observation has been confirmed by others who found that 
despite its initial impact on graft survival cyclosporine, disappointingly has had little 
beneficial effect on long-term graft survival when compared with conventional 
immunosuppressive regimen of azathioprine and steroids (The Canadian Multicentre 
Transplant Study Group,1986;Calne,1987;Fischel et a/.,1991;MacPhee et 
a/., 1998;Morris et a/., 1987). Cyclosporine therefore appears to reduce early graft 
loss compared to azathioprine. However, as indicated above, cyclosporine is 
associated with a greater late patient mortality rate. The initial improvement in graft 
survival in our patients could not be explained by an improvement in patient survival, 
which was the same under conventional treatment and was almost certainly related 
to the reduction in acute allograft rejection rates affected by the use of cyclosporine.
Race
Contrary to reports both from this country (Modiba et al., 1989) and elsewhere non­
white patients had the same graft survival rates as white patients in the present 
study. Black patients specifically had the same graft survival rates as the other 
groups. This confirms an earlier report in which we found that white and non-white 
patients had the same one-year graft survival (Moosa et al., 1992). The long-term 
survival of renal allografts in black patients has been reported to lag behind those of 
all other races (Koyama et al., 1994). The 1- and projected 10-year survival of first 
cadaver donor transplants were 84% and 47%, respectively, in white recipients 
compared to 81% and 23% in a similar sized cohort of black recipients in the same 
age range. After the first year, the rate of graft-loss was more than twice that of 
white patients (half-life of 10.8 years vs. 4.9 years). Important determinants of 
outcome may be socio-economic and histocompatibility differences (Butkus et 
al., 1992), and possibly poorer blood pressure control. However, our previous study 
has refuted the socio-economic aspect of this argument (Moosa et al., 1992). Also,
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Asian patients who have similar difficulties finding histocompatible donors 
experience graft survival rates superior to those of white patients (Cecka et 
a/., 1992b). Most of the current studies concur that black patients have comparable 
1-year survival rates but that the problem seems to be with long-term graft retention 
(Butkus et a/.,1992;Koyama et al., 1994). A higher incidence of late graft rejection 
among black recipients (Tesi et al., 1997) may be an indication of greater difficulty in 
maintaining adequate immunosuppression for these patients.
Gender
There is no gender difference in the survival rate of renal allografts in the present 
study. This contrasts with the findings of others who report better graft survival in 
women (Perez et al., 1990) but confirms the findings of the majority of others who 
also found no relationship between graft survival and gender (among other factors) 
(Cecka et al., 1992a;Cole et al., 1995;Gulanikar et a/.,1992;Troppmann et 
a/.,1995;Troppmann etal., 1996). Troppman et al. (1995) using multivariate analysis 
could not demonstrate a difference in graft survival. Ojo et al. (2000) found that 
males patients had a 1.16 greater relative risk of death with graft function compared 
to females (Ojo et al.,2000). Veller et al. (1987) report that with renal 
retransplantation female patients fared less well than their male counterparts. It has 
been suggested that this could be due to the female patients having higher levels of 
pre-formed lymphocytotoxic antibodies (Koka et al., 1989), but in the study by Veller 
et al. (1987) the proportion of males and females with levels of pre-formed antibodies 
was comparable. The effect of parity on graft survival does not appear to have been 
investigated yet (Veller et al., 1987). However, the degree of pre-sensitisation was 
not specifically looked at in the present study.
Primary disease
It is recognised that the primary disease leading to end-stage renal failure can have 
an influence on graft survival (Levey et al., 1966). Hirata et al. (1996) established 
that patients with hypertension had the highest graft failure rate and of even greater 
concern was that it was associated with a relatively higher patient mortality. 
Hypertension was the second most common cause of end-stage renal failure in our 
patients after chronic glomerulonephritis. Patients who had diabetes did surprisingly 
well in the short term, but there were few long-term survivors. The diabetic patients
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in our cohort were very carefully screened before admission to the replacement 
program and are not representative of the average patient with diabetic nephropathy. 
The poor outcome in hypertensive patients almost certainly reflects the damage 
caused by the disease that affects the patient and the new graft. Hirata et al. (1996) 
ascribed the poor outcome among hypertensive patients to the fact that more than 
half the patients transplanted for hypertension were black (Katznelson et al., 1995).
Donor kidney
The source of the donor kidney also plays an important role. The number of living- 
related transplants performed was only 14. Despite this small number, the graft 
survival was significantly better both by univariate and multivariate analysis. This 
result is very encouraging and has influenced us to pursue this source of organs 
more vigorously. Koo et al. (1999) recently investigated the reason for the superior 
graft survival following living donor kidney transplant. They postulated that part of 
this result was due to the kidney being obtained under optimal conditions from 
healthy donors whereas cadaveric kidneys may have been exposed to inflammatory 
events around the time of brain death. They were able to prove their hypothesis by 
comparing the expression of inflammatory antigens in biopsy specimens from 
cadaveric kidneys vs. living related donor kidneys.
Multiple Grafts
Despite major advances in immunosuppressive therapy a significant number of renal 
allografts are lost mainly from rejection, either acute or chronic (Sumrani et al., 1993). 
The result is that the pool of patients with failed grafts continues to grow and in our 
population represents a significant source of patients entering the renal replacement 
program. Retransplantation presents many challenges including recipient 
sensitisation from the initial graft (Cecka et al., 1988), technical aspects of 
engraftment (Koyle et al., 1988) and a higher risk of immunologic graft loss (Iwaki et 
al.,1987b). Kidney retransplantation was performed in 72 of our patients who 
between them received additional 81 kidneys following the primary grafts. In our 
study population the retransplant rate of 13.0% is comparable with the values of 11.8 
- 15.9% reported in the literature (Fasola et al., 1989;Howard et al., 1984;Jackson et 
a/.,1989;Salmela et a/.,1990;Stratta et al., 1988). One year graft survival in patients
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undergoing retransplantation has consistently been 10 - 15% lower than those 
primary transplantation, both before (Howard et a/.,1984) and after (Iwaki et 
a/., 1987a) the introduction of cyclosporine. In the present study the overall 1- year 
graft survival was 7% less than that of primary grafts and at 5 years there was only a 
3% difference in graft survival compared to the primary grafts. Veller et al. (1987) 
reported on a South African experience with 108 renal retransplantation procedures. 
The actuarial graft survival at 1 and 5 years were 53% and 41% respectively 
compared to those of our patients in the present study of 58% and 30%. They found 
that factors that influenced subsequent renal allograft survival included the level of 
pre-formed antibodies, the use of cyclosporine and the duration of function of the 
primary graft. Age >40 years was not associated with a detrimental outcome unlike 
the experience in other centres (Caine et a/.,1968;Peters,1982). Other major 
determinants of graft survival in renal retransplants are early function among cadaver 
donor recipients, donor source and the absence of rejection within the first year after 
engraftment (Sumrani et al., 1993). Controversy still surrounds the influence of race, 
pre-formed antibody levels and the presence of diabetes on the outcome of 
retransplants (Stratta et a/.,1988;Sumrani et al., 1993). Veller et al. (1987) 
recommend, and we concur, that regrafting should be considered after failure of the 
primary transplant, especially if the graft was lost to chronic rejection. Recent 
studies confirm that kidney retransplantation is associated with diminished overall 
graft survival (Kountz et a/.,1972;Opelz et a/.,1976;Schulak et a/.,1984;Spees et 
al., 1983;Stratta et al., 1988) but the discrepancy between primary and second 
cadaver-donor 1-year graft survival has improved from 8% in 1988 to 2% in 1991 
(Kerman et al., 1997). Graft nephrectomy contributes to poorer graft survival and is 
not recommended (Abouljoud et al., 1995).
Stellenbosch University http://scholar.sun.ac.za/
Outcome o f  Transplantation 5-21
(3) PATIENT AND GRAFT SURVIVAL IN SOUTH 
AFRICA
GAUTENG PROVINCE EXPERIENCE
The very first renal transplant was performed in South Africa soon after it became a 
recognised form of treatment for end-stage renal failure (vide supra). The first report 
of the South African experience was on 159 consecutive first cadaver renal 
transplants recipients who received renal allografts over an 8-year period in 
Johannesburg. The actuarial graft survival was 69% at one year and 59% at 5 
years. This included 16 patients who received grafts from living related relatives and 
5 retransplants (Myburgh et al.,1976). Myburgh et al. (1983) detailed the 17-year 
experience of the Johannesburg group starting in 1966. At the time of their analysis 
they had transplanted 525 kidneys into 468 patients. They used conventional 
therapy and for the first half of the period under review used prophylactic graft 
irradiation. Prednisone in varying doses was used over the years. One-year patient 
survival was 78% while graft survival was 52%. Better results were obtained with 
living related transplants (Myburgh et al., 1983). The patients transplanted in 
Johannesburg were predominantly white patients.
Black patients
Two centres treating exclusively black patients reported results in 1989. Bauling et 
al. (1989) reporting from Medunsa, Pretoria found the actual 4-year patient survival 
to be 78% and graft survival 70% in a group of 59 patients, half of who received 
cyclosporine. All the organs, bar one, were from cadaveric donors. At the (Chris 
Hani) Baragwanath Hospital, Johannesburg, 51 patients received renal allografts, of 
which 88% were from cadaveric donors. Of the cadaver donors 30% were black. 
Actuarial 1- and 5-year patient survival rates were 52% and 27% for cadaveric donor 
transplants. The corresponding graft survival rates were 38% and 28% (Modiba et 
al., 1989). The majority of the patients received conventional therapy and only 4 
were under cyclosporine. According to Meyers et al. (1988), reporting from the 
General Hospital, Johannesburg, graft survival in 60 black renal allograft recipients 
was comparable to that of white patients provided the former were maintained on
Stellenbosch University http://scholar.sun.ac.za/
Outcome o f  Transplantation 5-22
cyclosporine. Actuarial graft survival increased from 30% to 72% when cyclosporine 
was not discontinued (Meyers et al., 1988).
WESTERN CAPE PROVINCE EXPERIENCE
Tygerberg hospital experience
A report from our unit established an overall 1-year graft survival rate of 70% under 
cyclosporine but found no racial difference (Moosa et al., 1992). The introduction of 
cyclosporine improved graft survival rate by 23% at 1-year compared with 
conventional therapy.
Groote Schuur hospital experience
The group from Cape Town also reported the results of the introduction of 
cyclosporine and found that the 1-year patient and graft survival rates in 50 
recipients were 94% and 88% respectively. The mean follow-up period was only 8 
months however, ranging from 1 to 15 months. The complication rate was low 
probably because cyclosporine was discontinued at 3 months and substituted with 
azathioprine (Jacobson et al., 1985). This group discontinued cyclosporine at 3 
months in order to minimise the long-term toxic effects of the drug (Cassidy et 
al., 1986). The same group recently reported the results of renal transplants from 
living-related donors (Kahn et al., 1994). The 1- and 5-year survival rates of HLA- 
identical donor renal transplantation were 95% and 81% compared to 79% and 64%, 
respectively, for one-haplotype-matched donors. Donor specific blood transfusions 
(DST) significantly improved graft survival in patients with only one-haplotype match 
but the data are difficult to interpret because DST and cyclosporine were introduced 
simultaneously. In a follow-up report on their policy of discontinuing cyclosporine at 
3 months, Cassidy et al (1986) found that in the 26 patients under review, 35% had 
acute rejection episodes. The acute rejection episodes were reversed after 
treatment with methylprednisolone in all patients except one. The practice of 
discontinuing cyclosporine at varying periods after transplantation still remains 
controversial but is practised in many developing countries for reasons of economic 
necessity (Table 5-1, page 5-25). However, it is not widely practised in South 
Africa.
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Centre effect
The marked discrepancy between the results reported by the Cape Town group and 
our own is cause for great concern. Although the "centre-effect" is well recognised 
(Benlahrache et a/.,1987;Cho et a/.,1996;Evans et a/.,1991;Gjertson,1993;Ogura et 
a/.,1991;Shabtai et a/.,1991) it is important to try to establish why two centres 
operating in the same region and serving the same population have such discrepant 
results (88% vs. 70% 1-year graft survival rate under cyclosporine). One of the main 
differences between the two units is the policy toward cyclosporine, with the Cape 
Town group discontinuing the agent at 3-months to 1-year. The greater 
immunosuppression used in our Unit may result in more graft losses to cyclosporine 
nephrotoxicity or infective complications. According to South African Registry data 
the 1-year and 5-year patient survival rates from 1984 to 1994 were 84% and 64% 
respectively. The corresponding graft survival rates were 70% and 60% respectively 
(SADTR, 1994).
Malignancies as a cause of mortality
The only other South African single centre (Johannesburg) to determine causes of 
mortality in renal transplant patients established that 5% of all deaths among 525 
patients were due to malignancies and that all the deaths occurred more than one 
year after transplantation. The fatal malignancies were liver and skin lesions (two 
cases each), and one case each of lung, rectum and kidney cancer, and malignant 
melanoma (Myburgh et a/.,1983). The SADTR reports that malignant disease 
caused 3% of all patient deaths in 1994, compared with 4% in 1984 (SADTR, 1994). 
In the present study 50% of the cancer deaths occurred in the first year. The high 
mortality rate in our patients in the first year compared to the other reports is due to 
the nature of the malignant lesion that our patients develop. Kaposi's sarcoma is 
much more prevalent in our cohort than in any of the other centres that have 
reported the results of patient survival and it is a malignancy that occurs earlier than 
the other common forms. Our cohort is relatively younger than the patients treated 
in the developed countries: the mean age of our patients is 37 years while that of 
other centres is much higher (Arend et a/.,1997;Gorlen et a/.,1992;Ojo et 
al.,2000;Rao et al., 1983;Woo et a/., 1999). Our patients would therefore perhaps be 
less vulnerable to the cancers that afflict recipients in the developed countries.
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(4) PATIENT AND GRAFT SURVIVAL: COMPARISON 
WITH OTHER DEVELOPING COUNTRIES
Comparison with other developing countries is more difficult because in most 
developing countries living donors form the basis of the renal transplant programs. 
However, several countries do have cadaver donor programs. The results of our 
predominantly cadaveric donor-based renal transplant program compares favourably 
with those recently reported from other developing countries (Table 5-1).
While renal transplantation is the treatment of choice for end-stage renal failure in 
developed countries, in many developing countries it remains the only viable long­
term therapeutic modality. The high cost of setting up and maintaining chronic 
dialysis programs, the lack of technical expertise and the rural location of the 
majority of the population places maintenance haemodialysis and continuous 
ambulatory peritoneal dialysis (CAPD) outside the economic capacity of many 
developing countries (Arije et a/.,1995;Chugh et a/.,1995;McLigeyo et a/., 1988). This 
is particularly true of sub-Saharan Africa (excluding South Africa) where very few 
centres exist which are able to provide any form of renal replacement treatment 
(Assounga,1999;Swanepoel,1999;Were,1999). Dialysis activity in a developing 
country is generally related to the gross national product (GNP) per capita. 
However, South Africa is treating many fewer patients on maintenance 
haemodialysis compared to countries such as Brazil, Mexico and Argentina that 
have GNP per capita very similar to our own (Fig. 5-3). Transplant activity is also 
related to GNP per capita and here South Africa compares very favourable with 
other developing countries at the same level of economic development (Fig. 5-4). 
Since the commencement of our Transplant program in 1976, a detailed analysis of 
outcome has never been undertaken. A report in 1992 compared graft survival in 
white and non-white groups, but no further analyses have been attempted since.
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TABLE 5-1. Immunosuppressive regimens used in selected developing countries and outcomes
Country
(Period)
No. Donor Type 
Transplants
Immuno
suppression1
% Survival (at year indicated) 
Patient Graft
Reference
Australian
Aboriaines
48 CD NS . " . 79(1)+ 53(3) Kirubakaran 
and Pugsley, 1992
(1971 - 1990)
Banaladesh 
(1982- 1992)
68
26
LRD
LURD
Aza
CsA2 '
96(1)+ 81(3) Rashid etal., 1992
Brazil
(1970- 1989) 
(1987- 1989)
687
60
239
1051
467
45
LRD
LURD
CD
LD
CD
?
NS
CsA (42%) 
CsA (75%)
89(2)
80(2)
70(1)+ 49(5)
76(2)
61(2)
Goldani et al., 1991 
Sesso et a/. ,1990
Eqypt 
( -  1994)
( -  1992)
45
130
15
30
124
LRD
LURD(C)
CD
LRD
LURD(C)
Aza (Good
matches)
CsA
CsA
CsA
CsA
92(1)+ 86(5) 
88(1)+ 80(4)
89(1) + 73(5) 
86(1)+ 58(4)
Barsoum,1994 
Barsoum, 1992b
India
(1985- 1988)
153
303
LRD
LURD(C)
Aza
CsA (low dose) -
83(1)
83(1)
Thiagarajan et 
a/., 1990
Iran
(1989-1994) 
(1984- 1992)
16
180
220
241
LRD
LURD
LRD
LURD(C)
CsA
CsA
CsA
CsA
91(5) 88(5)
83(1)+ 69(3) 
76(1)+ 70(3)
Reissi et al., 1995
Simforoosh et 
al., 1992
Kuwait 53 LURD (C) NS 90(2) 90(2) Johny et al.,1990
(1985-1990)
Mexico 
(1967- 1991)
282
10
46
LRD
LURD
CD
CsA21984 
(Aza in HLA 
identical LRD)
86(1)+ 68(5) 77(1)+ 60(5) Bordes-Aznar et 
a/., 1992
Pakistan 500 LRD CsA1990 93(1)+ 83(5) 90(1)+ 78(5) Rizvi etal., 1998
(1975-1996) 
(1985- 1994) 300 LRD NS 90(1)+ 74(5) 87(1)+ 70(5) Naqvi and Rizvi,1995
PhiliDDines 
(1969- 1992)
1024 LRD
CAD
CsA2 (1983) 
CsA2
90(1)
75(1)+ 71(3)
90(1)
62(1)+ 56(3)
Liquete and 
Ona,1992
Saudi Arabia 
(- 1999)
( -  1995)
-2500
910
46
60
44
LRD
CD
LRD
CD
LURD (C)
CsA
CsA
NS
96(1) + 95(1)
100(1)
95(1)
86(1)
90(1)+ 78(1)
90(1)
78(1)
72(1)
Al-Khader,1999 
Chaballout et al., 1995
SinaaDore 
(1985- 1992)
47
157
LRD
CD
CsA
CsA
95(1)+ 88(7) 86(1)+ 77(7) 
98(1)+ 92(6)
Vathsala et al. ,1992
Slovenia
(1986-1991)
83
65
CD
LRD
CsA
CsA
91(1)+ 88(3) 
95(1)+ 93(5)
73(1)+ 73(3) 
90(1)+ 90(3)
Kandus et al., 1992
South Africa 241 CD CsA 75(3) 60(3) Naicker,1996
(1993)
Sri Lanka 
(1985-1992)
105 LRD CsA2 71(1)+ 47(4) 71(1) + 47(4) Sheriff etal., 1992
Taiwan 
(1968- 1992)
-1000 LRD
CD NS
92(1) 82(1) Lee, 1992
Turkey 80 LURD NS 95(1-3) 80(1-3) Daar,1991
(1985-1989) 
(1975- 1993)
(1985- 1992)
766
230
391
LRD
CD
LRD
CsA (1985) 
CsA
DST+ Aza 
or +CsA
Aza: 60(10) 
CsA: 87(1) + 
72(5)
DST 98(1) 
-DST 94(1)
Aza: 42(10) 
CsA: 66(1) + 
37(5)
92(1)
72(1)
Haberal etal.,1995a 
Hamaloglu et al., 1992
U.A.E.
(-1991)
89 LURD (C) CsA 94(1)+ 84(3) 92(1)+ 83(3) Masri et al., 1993
U.A.E./Oman 
(1984- 1988)
130 LURD (C) CsA 82(1) + 
81(3.75)
77(1) + 
75(3.75)
Salahudeen et 
a/., 1990
1. Regimen predominantly used.
2. Cyclosporine discontinued at 3 to 12 months.
CD = cadaveric donor; L(R)D = living (related) donor; LURD = living unrelated donor; LURD (C) = commercial living unrelated 
donor; Aza = azathioprine; CsA = cyclosporin as part of triple or dual therapy; NS = not specified; DST = donor specific blood 
transfusion.
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FIG. 5-3. Dialysis in Selected Developing Countries (1994, vs. United States)
Patients per million population
Modified from Moosa etal. (2001).
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Modified from Moosa et al. (2001).
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Table 5-2. Demography of renal replacement therapy in developing countries 
compared with the registry data from the United States and Australia/New Zealand.
Country No. of 
Patients
Mean Age 
(years)
Males (%) Reference
Brazil 1563 38 (CAD)1 
33 (LRD)
63 Sesso et a/., 1990
India (1) 265 36 80 Kathuria et al. ,1995
India (2)
■
310 - 93 Chugh et a/., 1993
Kenya 77 30 64 McLigeyo et al., 1988
Malaysia 37 37 64 Lei et al., 1992
Morocco 2000 51 59 Bourquia,1999
Nigeria 368 <40 73 Mabayoje et al., 1992
Oman/UAE 130 38 62 Salahudeen et al., 1990
Pakistan (1) 500 32 78 Rizvi et al., 1998
Pakistan (2) 79 43 61 Kumar et al., 1992
Qatar 187 41 55 Rashid et al., 1998
Reunion 767 52 41 Albitar et al.,1998
South Africa 7331 40-592 59 SADTR,1994
Slovenia 151 35 70 Kandus et al., 1992
Turkey (1) 520 35 77 Yildiz et al., 1998b
Turkey (2) 562 32 80 Kekec et a/., 1992
US 79 102 61 53 US Renal Data System, 1999
Australasia 1708 58 58 ANZ Data Report, 1999
'CAD = cadaveric and LRD = living related donor transplant, 2peak ages
Demographics (Table 5-2)
In line with the experience in other developing countries, the mean age of patients 
commencing renal replacement treatment in our unit is considerably younger than in 
developed countries. In the United States the mean age of patients commencing 
dialysis is 61 years (US Renal Data System,1999), while the mean age of our 
patients who received primary renal allografts was 37 years. The main reason for 
the relative youth in our population is the deliberate exclusion of older patients from 
the program purely for reasons of economy.
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There was a slight male predominance in the number of patients who were 
transplanted in our unit. Males constituted 54% of the transplant population, 
compared to 53% in the United States. In other developing countries the proportion 
of males varied from 41% (Reunion) to 93% (India), with the average being 68%. 
The SADTR (1994) reported that 59% of the patients in South Africa who were 
transplanted, were males. It is likely that the overall bias against females reflects 
social and cultural factors that favour males (Table 5-2).
CAUSES OF CHRONIC RENAL FAILURE
Chronic glomerulonephritis
Chronic glomerulonephritis was the most common cause of end-stage renal failure in 
our patients. The diagnosis was presumptive in the majority of cases although it was 
confirmed histologically in 36%. The nature of the underlying glomerulonephritis that 
leads to renal failure is uncertain. In a large clinicopathological study of 2827 Indian 
patients with renal disease reported by Date et al. (1987) nephrotic syndrome was 
found to be the most common clinical presentation, and membranous nephropathy 
the commonest cause of nephrotic syndrome in adults over the age of 40 years 
(Date et al., 1987). Renal disease may also present with the nephritic syndrome. 
Diffuse proliferative glomerulonephritis, crescentic nephritis and mesangial 
proliferative glomerulonephritis accounted for almost 90% of all cases. In the study 
by Date et al. (1987) as in our practice, patients with small kidneys and those with 
classic diabetic nephropathy did not undergo pathological examination. Anti- 
streptococcal antibodies were elevated in 50% of the patients with nephritis 
confirming the predisposition of individuals in the topics to infections (Date et 
al., 1987). The much higher incidence of chronic glomerulonephritis in non-white 
patients (48%) compared to the white patients in the present study suggests that the 
poor socio-economic conditions prevailing among the latter may have contributed to 
increased infections and the higher incidence of acute nephritis.
Zimbabwean experience
Seggie et al (1984) reviewed the Zimbabwean experience and reported that 
infections with p-haemolytic streptococcal, hepatitis B and syphilitic infections 
contributed to the development of glomerulonephritis in 46% of patients who
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underwent renal biopsies. In this series, 41% of the post-streptococcal infections 
were complications of scabies infections (Seggie et al., 1984). Glomerulonephritis in 
Africa is characterised by the high prevalence of proliferative glomerulonephritis in 
older adults, both idiopathic and postinfectious (Brown et al., 1977;Kung'u et 
a/.,1980;Seedat,1979). IgA nephropathy, which is estimated to be the most common 
glomerulonephritis in the world (D'Amico,1987), is relatively uncommon in black 
patients in South Africa (Swanepoel e£a/.,1989).
Hypertension
In sub-Saharan Africa, hypertension is the most common cause of end-stage renal 
disease in black individuals (Seedat et al., 1984). In South Africa it accounts for 37% 
of black, compared to 8% of white, end-stage renal disease patients (Seedat, 1999). 
In the present cohort, 27% of non-white patients and 5% of white patients who were 
transplanted, had hypertension as the primary cause for their end-stage renal 
disease, confirming the local and international experience of the high incidence and 
severity of hypertension in the black population (US Renal Data System,1999). 
Hypertension also develops at an earlier age in the black patients than in white 
patients in South Africa (Seedat,1999), as is the case in the United States (Weiss et 
al., 1938). Black females aged 35-40 years have a higher prevalence of 
hypertension than males in the same age range (Seedat,1983). Urbanised blacks 
also have a much higher prevalence of hypertension (Akinkugbe,1985), possibly 
related to dietary changes (Seedat,1999). Another important consideration is that 
only 10% of black hypertensive patients in South Africa have effective control of 
blood pressure; blood pressure control is much better in white (22%) and Asian 
hypertensive (40%) patients (Seedat, 1983), in part perhaps to the better health care 
available to these racial groups (Seedat, 1999).
Diabetic Nephropathy
Diabetic nephropathy is the single most common cause of end-stage renal disease 
in United States (Ismail et a/.,1999), Japan and industrialised Europe (Raine,1993). 
In the United States over 40% of patients receiving treatment for end-stage renal 
failure have diabetic nephropathy and the number is steadily increasing (US Renal 
Data System,1999), as is the experience in Europe (Pirson,1996;Rodriguez et 
al., 1997). By contrast it accounts for between <1% - 14% of patients receiving
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treatment for end-stage renal disease in developing countries (Albitar et 
a/.,1998;Alzaid et al.,1994). In our cohort less than 4% of patients who received 
grafts, were diabetics. The sharp contrast between developing and industrialised 
(Ritz et a/., 1999) countries may be due to bias against the selection of these patients 
for renal replacement therapy rather than the rarity of diabetic nephropathy. In our 
cohort, diabetics who were aged 50 years or more, who had evidence of either 
cardiac or vascular disease, were excluded from the program.
Ethnic groups
A marked ethnic predisposition to end-stage renal disease and diabetes in some 
non-white populations has been noted (Ritz et a/.,1999). In Australasia diabetic 
nephropathy was the primary cause of end-stage renal failure in 42% of the 
Australian Aborigines, 61% of the New Zealand Maories and 49% of the Pacific 
Islanders (Disney et al., 1998). This is very similar to differences seen between 
mainland France and the overseas territories (Albitar et a/.,1998;Cordonnier et 
al., 1993). This pattern is confirmed by the USRDS data that show that that diabetes 
accounts for a larger proportion of incident cases among the non-white races 
particularly blacks, Asians, and Native Americans (US Renal Data System, 1999). 
Irrespective of ethnicity, Western lifestyle is also associated with an increase in end- 
stage renal disease from diabetic nephropathy (Ritz et al., 1999). As our local 
population becomes increasingly urbanised, we can expect to see an increase in 
end-stage renal disease due to this disease. If the experience in the United States 
and Japan are indicative of future trends, then this “silent epidemic” of diabetes 
mellitus can be expected to wreak havoc among the population and present new 
challenges for nephrologists in future (Ritz et a/., 1999).
Silent epidemic
The reasons for the increase in the incidence of type II diabetes in the Western 
population is the advancing age of the society and it is known that the prevalence of 
type II diabetes increases with advancing age (Ritz et al., 1999). More importantly, 
however is the fact that survival of patients with diabetes has continuously improved 
over the past few decades mainly as a result of improvements in the general care of 
these patients with anti-hypertensive therapy and treatment of coronary heart 
disease (Ritz et al., 1996). End-stage renal failure due to diabetic nephropathy is, in
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a sense, a disease of medical progress. This can be compared to the situation in 
1922 when insulin therapy became available. Whereas before this date most 
patients succumbed to infections or ketoacidosis, atherosclerosis became the main 
cause of death 10 years after the introduction of insulin. Similarly today, as patients 
with diabetes have a greater chance of surviving the cardiovascular complications, 
they live long enough to develop end-stage renal failure (Ritz et a/.,1999).
Treatment o f end-stage diabetic nephropathy
The renal replacement treatment of choice for patients with end-stage renal failure is 
renal transplantation, (preferably with a kidney from an HLA-matched sibling), with 
the other treatment options being haemodialysis and continuous ambulatory 
peritoneal dialysis. However, the survival of diabetic patients is still very poor on 
dialysis. In an early series mean patient survival was 11 months and the authors 
concluded that "dialysis for such patients...carried little likelihood of long-term 
survival or improvement in quality of life" (Ghavamian et al., 1972). Survival has 
improved greatly with mortality decreasing from 46% in 1982 to 29% in 1993 in the 
United States (Friedlander et al., 1997) . However, the diabetic patient continues to 
fare worse than the non-diabetic patient (Anonymous,1997;Disney et 
a/.,1998;Port,1993). The Catalonia registry illustrates the differences: 5-year survival 
is 30% on haemodialysis for diabetics compared to 60% for non-diabetic renal failure 
patients (Rodriguez et al.,1997). In a recent study it was found that 32% of diabetic 
patients died after a mean follow-up of 211 days, mostly from cardiovascular disease 
(Chantrel et a/., 1999). The coronary death rate was estimated to be 10 fold greater 
in diabetics on renal replacement therapy as compared to their non-diabetic 
counterparts. Other cardiovascular as well as infectious causes were recorded in a 
similar proportion of deaths in diabetics as in non-diabetics (Brunner et al., 1988) The 
poor prognosis of patients referred late and the contribution of iatrogenic, therefore 
reversible, factors to deterioration in renal function has also been emphasised 
(Chantrel et a/., 1999).
Graft survival
Recent studies have found comparable graft survival rates between diabetic 
recipients and matched controls as was our own experience (McMillan et al., 1990). 
Indeed, in the first 5 years after transplantation, renal allograft survival is similar in
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diabetic and non-diabetic recipients (Cecka,1996) but overall mortality in diabetic 
patients is three times that in non-diabetic group (Hirata et al.,1996). In contrast, 
other authors have experienced much worse transplant survival in recipients in 
whom the primary cause of renal failure was diabetes (both type 1 and type) (Morris 
et a/.,1999). The main reason is the greater likelihood of death with a functioning 
graft as a result of comorbid cardiovascular disease resulting from accelerated 
atherosclerosis, sudden death related to autonomic neuropathy and infections 
(Fischel et al., 1991;Morris et a/., 1999)
Simultaneous pancreas-kidney transplantation
The long-term prognosis of patients with diabetes and end-stage renal failure 
appears to be better after renal transplantation compared with dialysis. The results of 
renal transplantation in diabetic patients are acceptable provided macrovascular 
disease has been excluded (Hirschl,1995). What has remained controversial is the 
additional benefit to be gained by a simultaneously transplanted pancreatic graft. 
Recent studies have however proven that simultaneous pancreas-kidney 
transplantation prolongs the survival of diabetic patients with renal failure (Smets et 
a/.,1999). In the United States simultaneous pancreas-kidney transplantation is now 
regarded by many clinicians as the treatment of choice for uraemic diabetic patients 
(Kumar et al., 1999) in the absence of advanced coexisting vascular disease or after 
its correction (Pirsch et a/.,1996;Schweitzer et al., 1997). However, in other parts of 
the world including South Africa, pancreatic transplantation has been viewed more 
critically. Reasons for the controversy are multiple but centre around the following 
observations: (1) Simultaneous pancreas-kidney transplantation is associated with a 
higher incidence of surgical complications than kidney transplantation alone (Bruce 
et a/.,1996;Pirsch et al., 1996;Stratta et a/.,1993;Sutherland et 
a/.,1997;Sutherland,1997); (2) although simultaneous pancreas-kidney 
transplantation improves the patient's quality of the life (Adang et a/.,1996;Bruce et 
al., 1996;Cosio et a/.,1998b;Kiebert et al., 1994) its effect on established diabetic 
complications is controversial (Pirsch et a/.,1996;Remuzzi et al., 1994;Stratta et 
a/.,1993;Sutherland et a/.,1997;Sutherland,1997); (3) it has been suggested that 
simultaneous pancreas-kidney transplantation increase mortality compared with 
kidney transplantation alone (Manske et al., 1995); (4) the perceived risk associated
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with the requirement for greater immunosuppression to prevent acute rejection 
(Remuzzi et a/.,1994).
Advantages Strong arguments are made in support of pancreatic transplantation at 
the time of renal transplantation to establish a return to normal carbohydrate 
metabolism (Pirsch et a/.,1996;Schweitzer et al., 1997). Quality of life is improved 
through the abolition of dietary restrictions, freedom of exogenous insulin 
administration and constant blood glucose monitoring, and the removal of the fear of 
hypoglycaemia (Kumar et a/.,1999). The results of simultaneous pancreas-kidney 
transplantation are very encouraging. Patient and pancreatic graft 1-year survival 
rates of 92% and 79%, and 5-year rates of 81% and 67% have been achieved - 
results which are comparable to cadaveric renal transplantation in non-diabetic 
uraemic patients (Cecka,1996;Hirata et a/.,1996;Pirsch et a/.,1996;Schweitzer et 
al., 1997). More importantly, when diabetic patients receive renal allografts, changes 
of diabetic nephropathy recur within 2 years (Najarian et al., 1989), progressing to 
end-stage disease in 10 years. Successful pancreatic transplantation prevents the 
recurrence of diabetic nephropathy in the renal allograft (Kumar et al., 1999).
Selection Critical to the success of simultaneous pancreas-kidney transplantation is 
the careful selection of patients. Diabetic patients have to be free of ischaemic heart 
disease, cerebrovascular disease and major peripheral vascular disease to be 
considered candidates for simultaneous pancreas-kidney transplantation. Advances 
in surgical practice and the introduction of newer immunosuppressive agents have 
contributed substantially to the success of the procedure (Bartlett et 
al., 1996;Pearson et al., 1997). The outcome of simultaneous pancreas-kidney 
transplantation has been found to be comparable to patient and graft survival 
following living-related kidney transplantation, and considerably better than that 
following cadaveric transplantation (Rayhill et a/.,2000). Simultaneous pancreas- 
kidney transplantation thus improves the ability of the diabetic patients to live more of 
their expected lifespan. This suggests that glycaemic control even as a late 
intervention in a diabetic's lifetime may beneficially affect survival (Becker et 
al.,2000). Kumar et al. (1999) argue that these developments warrant a reappraisal 
of the cautious approach taken by centres outside of the United States toward 
simultaneous pancreas-kidney transplantation.
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SUMMARY
Our data has shown that both overall patient and graft survival are better in younger 
patients, patients under cyclosporine and when a relative donated the kidney. 
Patient survival in addition is adversely affected by the failure of the graft to remain 
functional for the first year. Neither gender nor race has any major influence on 
either patient or graft survival. Diabetic patients fared as well initially but most grafts 
were eventually lost by 5 years after transplantation from patients dying of 
cardiovascular disease. Long-term survival of grafts under cyclosporine is less than 
in patients under azathioprine. Hypertensive patients suffered a poorer outcome 
compared to patients with other primary renal diseases. In non-diabetic patients 
death with functioning graft is also a major cause of graft loss.
Recommendations that arise from this survey are that while every attempt should be 
made to maintain a functioning graft especially in the first year, meticulous care 
should be taken to avoid sepsis, using less aggressive immunosuppressive 
strategies as well as adequate chemotherapeutic prophylaxis. In patients with 
severe rejection that fails to respond to treatment attempts to salvage the graft at all 
costs should be avoided in order to reduce patient mortality. Also important is that 
chronic renal failure should be prevented from developing in diabetic patients by 
good glycaemic control as proven by the Diabetes Control and Complications Trial 
(1993).
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Chapter 6
THE FREQUENCY OF 
CANCERS FOLLOWING 
RENAL TRANSPLANTION
R
enal transplantation is accepted as the definitive treatment for end-stage 
renal failure. A successful renal transplant affords the physician a form of 
treatment which is superior in terms of patient survival (Port et 
a/.,1993;Schnuelle et al., 1998), the recipient a superior quality of life (Bremer et 
al., 1989; Evans et al., 1985; Simmons et al., 1984) and the society great savings in 
the total cost of treatment (Kyllonen et al., 1994; Laupacis et al., 1996; Russell et 
al., 1992). With improvements in clinical care and advancements in 
immunosuppressive regimens, patients and grafts are surviving for longer periods of 
time. Graft survival has increased to 80 - 90%, 1 year and 55 - 70%, 5 years after 
renal transplantation respectively (Agodoa et al., 1995; Disney, 1995; Mallick et 
al., 1995; Opelz,1992; Teraoka et al., 1995). Epidemiological studies that were 
performed before the availability of cyclosporine failed to demonstrate a substantial 
survival advantage of transplant recipients over dialysis patients on a waiting list 
(Burton et a/.,1987;Garcia-Garcia et a/.,1985;Hutchinson et a/.,1984;Vollmer et
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al.,1983). However, more recent data from diverse sources have clearly indicated 
that renal transplantation reduces patient mortality (Agodoa et al., 1995; Disney,1995; 
Mallick et al., 1995; Teraoka et al., 1995). As a result of the prolonged survival of 
grafts and patients, other problems associated with sustained immunosuppression 
are now becoming evident. A significant cause of morbidity in patients who are 
recipients of renal allografts is the development of neoplasms, a well recognised, but 
poorly studied, problem (London et al., 1995).
The increased incidence of malignancies with the prolonged use of 
immunosuppressive agents was predicted as long ago as 1967 (Swanson et 
al., 1967) and the first documentation of the occurrence of de novo malignancies in 
renal allograft recipients was made in 1968 (Doak et a/.,1968;Editorial,1968;Zukoski 
et al., 1968). It was subsequently realised that these patients are indeed at 
considerable risk of neoplasia (Penn et al., 1969). Solid organ transplantation is 
associated with more than a 20-fold increase in the incidence of carcinoma and a 40- 
fold increase in the incidence of non-Hodgkin’s lymphoma (Gupta et al., 1986a;Kinlen 
et a/.,1979;Kinlen,1982;Penn,1989). The difficulty in assessing small numbers of 
patients in specific centres prompted the creation of multicentre registries. Penn 
(1987) initiated the Cincinnati Transplant Tumor Registry (CTTR) in the USA and 
Sheil (1977) started the Australian and New Zealand Dialysis and Transplant 
Registry that covered the pan-Pacific region. Both multicentre registries act as 
repositories for data on this important subject. These registries have confirmed the 
persistent increase in the incidence of malignancies in renal allograft recipients and 
have also revealed the different patterns of malignancies in these patients compared 
to the general population (Sheil,1977; Wehrli et al., 1998).
SINGLE CENTRE vs. MULTICENTRE REPORTS: STRENGTH AND 
WEAKNESSES
Single Centre Reports
The incidence of malignancies varies in different geographical regions from 0.75% in 
India to 27% in Australia (Table 6-1, page 6-9). However, the data need to be 
interpreted with caution. Periods of follow-up that are reported vary widely and some 
centres report only the most serious lesions while less serious ones such as skin
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cancers and carcinomas-in-situ may not be reported. Also, many centres excluded 
from the denominator the patients who failed to maintain their grafts for minimum 
periods ranging from 1 to 4 months (Herr et a/., 1979; Starzl et al., 1970). Many 
studies from single centres (Birkeland,1983b; Gruber et al., 1994) included patients 
treated in the early era of transplantation when graft survival and patient follow-up 
was short. Comparing the results of single centres therefore also has to take these 
limitations into consideration. In Table 6-1, the raw data were used to calculate the 
incidence of malignancies, in order to allow meaningful comparisons. The total 
number of patients transplanted irrespective of the outcome of the graft or the patient 
was used as the denominator. This method underestimates the true incidence of 
malignancies because patients whose grafts fail or who die are not at risk of 
developing malignancies. Starzl et al. (1970) illustrated that by excluding the 
patients who died or whose grafts failed within the first 4 months the incidence of 
malignancies increased from 5.3% to 7%. In the present study the incidence of skin 
cancers increased from 8% to 9.5% if the patients who were exposed to 
immunosuppressive agents for less than one month were excluded.
Renal transplant recipients are at considerable risk of tumours but the difficulty of 
assessing small groups of patients (Gruber et a/.,1991 ;London et al., 1995;Tokoro et 
al.,1992) in a specific centre prompted the creation of multicentre registries. The 
Cincinnati Transplant Tumor Registry (CTTR) and the Australian and New Zealand 
Dialysis and Transplant Registry have produced ongoing reports on particular 
tumours associated with transplantation (see Table 6-1 for relevant references).
REGISTRY DATA
The Cincinnati Transplant Tumor Registry (CTTR), currently known as the Israel 
Penn World Transplant Tumor Registry (IPWTTR) started as the Denver Transplant 
Tumor Registry and collects data voluntarily submitted by physicians from transplant 
centres around the world. Credit is due to the late Dr Israel Penn who launched the 
project in 1968 and regularly reported back to the international community on his 
findings. Table 6-1 illustrates some of the changes in the pattern of malignancies in 
the decades since the birth of the Registry. The main observation with regard to the 
CTTR is the progressive decline in the relative number of patients suffering from 
lymphomas. In the early period lymphomas accounted for more than one third of all
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F/£L 6-1 The exponential increase in the number of posttransplant malignancies.
malignancies. Since then the relative incidence of lymphomas has progressively 
declined and currently accounts for just over 10% of all malignancies reported to the 
registry. This decline in the relative incidence of lymphomas is also reflected in the 
Australian and New Zealand experience.
The CTTR records an exponential increase in the number of malignancies from its 
inception in 1968 to 2000 as more patients received organs and as patients and 
grafts survive for longer periods of time (Fig. 6-1).
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Although registry and other multicentre studies have contributed greatly to our
understanding of the epidemiology of posttransplant malignancies, there are several
drawbacks in the analysis and interpretation of such data. These potentially
confounding variables include (Gruber et a/., 1994):
1. One of the major problems of registry data is that although the number of patients 
with malignancies is known, the number of patients who received transplants is 
not. The database also does not include information on the length of follow-up 
for the patient groups. These limitations preclude the determination of the true 
incidence of malignancies (Mihalov et a/.,1996).
2. Another difficulty in analysing the CTTR data derives from the fact that the large 
series based on national transplant registries report data referred from centres 
using different and often non-comparable immunosuppressive regimens 
(Montagnino et a/.,1996).
3. Variation in the intensity and type of immunosuppressive therapy employed by 
the different transplant centres and within transplant centres depending on 
transplant source; also certain centres in developing countries withdraw 
cyclosporine at varying times following transplantation (Montagnino et a/.,1996).
4. Variation in the completeness of reporting: certain centres would report all 
malignancies whereas others only the more lethal or morbid types (Starzl et 
a/., 1970).
5. The grouped data is the analysis of all organ and tissue transplants recipients 
(Gruber et al.,1994).
6. The difficulty in using actuarial life-table analyses when comparing cancer 
incidence between conventionally treated patients and cyclosporine treated 
patients to account for different follow-up periods (Gruber et al., 1994).
7. The difficulty in controlling or analysing for relevant risk factors such as transplant 
number, donor source, diabetic status and recipient age (Gruber et al., 1994).
8. The CTTR provides a comprehensive description of different type of tumours but 
fails to give information on the risk of developing these tumours (Gaya et 
al., 1995).
9. The Australia and New Zealand Transplant Registry does give the relative risk of 
de novo malignancy but does not indicate if there is a relationship between the 
relative risks and the duration of immunosuppression (Gaya et al., 1995).
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Despite universal recognition of malignancy as an important complication following 
organ transplantation, there are discrepant views on the importance of the lesion in 
different parts of the world. In the USA the incidence of lymphoproliferative 
syndrome is disturbingly high but little recognition is given to squamous cell 
carcinoma of the skin as a cause of significant morbidity. Greater attention has been 
paid to Kaposi's sarcoma which remains rare even in the transplant patient (London 
et a/., 1995). In reality, cutaneous squamous cell carcinoma affects many more 
renal transplant patients than lymphoproliferative disease especially in countries with 
sunny climates such as Australia and is becoming a significant cause of mortality 
(Sheil et al., 1993).
Most studies on posttransplant malignancies have originated from developed 
countries that have predominantly Anglo-Saxon populations. Reports from Japan 
(Hoshida et a/.,1997;Kishikawa et a/.,1998;Yasumura et al., 1997) and from 
developing countries, excluding South Africa, have indicated that the incidence of 
malignancies ranges from 0.75% in India (Thiagarajan et al., 1998) to 6.15% in 
Taiwan (Yang et al., 1998). If allowance is made for the shorter follow-up in these 
countries then the incidence is comparable to that of countries with a predominantly 
Anglo-Saxon population. What does differ remarkably between the two groups of 
countries (Anglo-Saxon vs. non-Anglo-Saxon) is the difference in the type of tumours 
that occur after organ transplantation.
CLASSIFICATION OF MALIGNANCIES
Following successful renal allografting patients can develop malignancies from 3 
potential sources. De novo malignancies are the most common and accounted for 
all the malignancies in our cohort of patients. Tumors may also be transmitted to the 
patient with the graft if the donor had an undetected malignancy at the time of the 
transplant. Indeed, the first indication that immunosuppressed patients were 
susceptible to malignancies came when apparently normal kidneys were 
transplanted from donors dying with cancer. It was soon recognised that such 
organs harbour malignant cells that could proliferate in the recipient with fatal 
consequences (Martin et al., 1965; McPhaul et al., 1965). Our policy is not to use 
organs from donors with malignancies except if the lesion is a primary brain tumour,
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although there are some centres that even avoid these donors. There are several 
reports of these types of malignancies and the patients have generally done poorly 
unless the graft was removed as soon as possible. Finally, malignancies in renal 
transplant recipients may be recurrences of tumours that were treated in the 
recipient before the transplant. The policy in our Renal Unit is to wait at least 2 years 
following treatment of cancers before transplanting patients with previous cancers 
(Matos et a/.,1977; Penn,1983), and thus far none has developed a relapse of the 
original tumour.
GEOGRAPHIC VARIATIONS IN THE INCIDENCE AND 
DISTRIBUTION OF MALIGNANCIES
In the present study based on a cohort in the Western Cape Province of South 
Africa, 7.6% of all the patients who received renal allografts developed at least one 
malignancy. The incidence of malignancies in this study is distressingly high but 
comparable with the experience of other centres around the world (Table 6-1, page 
6-9). The incidence of posttransplant malignancies varies, depending on geographic 
location, environmental factors and ethnic/racial makeup of the population - 
indicating a possible genetic basis for the predisposition toward posttransplant 
malignancies.
Skin cancers
The importance of environmental factors is emphasised by the observation that the 
incidence of skin cancer among renal allograft recipients varies with the amount of 
solar exposure. In areas with limited amounts of sunlight there is a 4- to 7-fold 
increased incidence but in areas with copious sunlight there is a 21-fold increase 
over the already high incidence experienced in the local population (Bouwes et 
a/.,1991). In an Australian series the incidence of posttransplant malignancies 
reported was 24% of which 75% were skin malignancies (Sheil et a/., 1991). 
Similarly, in South Africa, 7.3% of renal transplant patients developed malignancies 
of which 59% were primarily of skin (Disler et a/.,1981).
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Countries with moderate climate
However, exposure to sunlight is not the only factor because a surprisingly high 
incidence of posttransplant skin tumours was reported from countries with a 
moderate climate. In a series of 523 transplant recipients from Toronto, Canada 
there was an 18.5-fold increase in squamous cell carcinoma of the skin (Gupta et 
a/., 1986b). Similarly, a study of 934 renal transplant patients from a Swedish centre 
found a 29-fold increase in incidence in comparison to controls (Blohme et a/.,1985). 
A similar increase was reported from Finland where investigators found a 20.1 fold 
increase in the risk for skin cancer (Kyllonen et a/.,1994). Interestingly, and contrary 
to findings in other countries with moderate climates, Hartevelt et al. (1990) reported 
that in the Netherlands the incidence of squamous cell carcinoma was increased by 
a factor of 250, basal cell carcinoma 10 fold, and was therefore on a level with the 
studies reported from Australia and New Zealand (Hardie et al., 1980; Sheil et 
al., 1979).
Ethnic/Racial factors
The fact that sun-exposure is not the only factor in the development of skin 
malignancies is aptly demonstrated by the observation that countries with abundant 
sunlight but a predominantly non-Caucasian population do not experience a similar 
increase in skin cancers (Table 6-1). This is further corroborated by the observation 
in the present study that there is an absence of skin cancers in non-Caucasian 
patients from the same geographical area as the Caucasian patients. This supports 
the observations by Disler et al. (1981) who also found that skin cancers occurred in 
white patients but not the black renal transplant patients; patients from the Middle 
East are also exposed to an abundance of sunlight but rarely have skin malignancies 
(Al-Sulaiman MH et al., 1994); among Japanese, Korean and Taiwanese patients 
skin cancers also occur uncommonly (Hoshida et a/.,1997;Kim et a/.,1998;Yang et 
al., 1998). These extensive observations sen/e to illustrate that beside environmental 
factors, genetic factors may play a role in the predilection for skin malignancies. The 
relevance of ethnicity/race/genetics following renal transplantation is further 
demonstrated by variation in the pattern of malignancies in different race groups in 
this study as well as that seen in different regions of the world as will become 
apparent later.
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TABLE 6-1. Crude incidence of the commonest posttransplant malignancies in 
countries with predominantly Anglo-Saxon populations compared to other regions in 
the world.
Country Year No. of No. of Incidence Treatment Skin Lymphoma Kaposi's Reference 
____________________ Patients Malignancies________  _______________ (%) (%) (%)_________________________
Western Countries
Australia 1996 6993 1915
Australia 1991 5879 1379
Australia 1987 4241 794
Australia 1980 735 23
Denmark 1982 2339 72
Finland 1994 2090 94
France 1997 1710 133
Germany 1994 590 30
Italy 1996 854 76
Spain 1992 2222 66
Sweden 1985 934 32
UK 1995 542 54
UK 1995 918 70
UK 1994 492 27
USA (AL) 1995 3359 137
USA (MN) 1994 1887 158
USA (MN) 1991 2030 144
USA(IL) 1996 305 28
USA(OH) 1993 876 76
Non-Western Countries
Cape Town 1982 209 7
Egypt 1997 950 22
Iran 2000 1216 21
India 1998 1862 14
Japan 1994 755 21
Japan 1997 1744 46
Japan 1992 257 6
Jo'burg 1996 1374 106
Jo’burg 1993 989 75
Jo'burg 1981 193 14
Korea 1998 1600 32
Kuwait 1999 785 33
Mexico 1992 318 16
Pakistan 1999 630 12
Saudi 1993 630 37
Saudi 1994 730 35
Stellenbosch 2001 542 41
Taiwan 1992 193 8
Taiwan 1998 390 24
Turkey 1998 557 25
Turkey 1999 1167 33
27.38 Both 75.1 3
23.46 Both 18 2.3
18.72 Both 77 2.8
14.30 Imuran 77 9
3.08 Imuran 18 16.6
4.50 Both 10.6 7.4
7.78 Both 39 15
5.08 Both 53 0
8.90 Both 46 4
2.97 Both 53 7.6
3.43 Imuran Excl. 9
9.96 Both 63 18.5
7.63 Both 53 9
5.49 Both 51.8 14.9
4.08 Both 41 8.8
8.37 Both 57 10.7
7.09 Both 53 13
9.18 Csa 71 7.1
8.68 Both 57.9 2.6
3.35 Imuran 42.8 0
2.32 Both 4.5 13.6
1.73 Csa 14.2 33.3
0.75 Both 7.1 21.4
2.78 Both 0 0
2.64 Both 0 10.9
2.33 Both 16 0
7.71 Both 61 3
7.58 Both NS NS
7.25 Imuran 59 0
2.00 Csa NS NS
4.20 Both 6 24.2
5.03 Both 37.5 18.8
1.90 Csa 0 50
5.87 Both 0 10.8
4.79 Both 0 8.6
7.56 Both 31.7 4.9
4.15 Both 0 37.5
6.15 NS NS NS
4.49 Csa 4 4
2.83 Both NS NS
0.73 Sheil.1996
0.8 Sheil et a/.,1991
0.9 Sheil et a/.,1987
0 Sheil et al., 1980
2.7 Birkeland, 1983a
2.1 Kyllonen ef a/.,1994
6.8 Hiesse et a/.,1997
6.6 Ritters et al., 1994
17 Montagnino et al. , 1996
7.6 Vilardell ef a/., 1992 
0 Blohme et a/., 1985
1.9 Gaya et al., 1995
0 London et al., 1995
3.7 Kehinde ef a/. ,1994 
0 Diethelm ef a/., 1995 
0 Gruber ef al. ,1994 
NS Gruber ef al., 1991
3.6 Mihalov ef a/.,1996 
1.3 Barrett ef al., 1993
28.6 Cassidy ef a/., 1982 
50 Bakref a/., 1997
23.8 Ghods etal.,2000
0 Thiagarajan ef al. , 1998
0 Yokota ef a/.,1994
0 Hoshida ef a/., 1997
0 Tokoro ef a/., 1992
6.6 Margolius,1996
6 Margolius ef a/.,1994
7.1 Disler ef a/., 1981
15.6 Kim ef a/.,1998
24.2 Samhan ef a/.,1999
6.2 Bordes-Aznar ef a/.,1992
33.3 Askari ef a/., 1999 
68 Qunibi ef a/., 1993
76 Al-Sulaiman ef a/.,1994
53.6 Present series 
12.5 W uefa/,,1992
8.3 Yang ef al., 1998 
68 Ecderef a/., 1998
25.8 Karakayali ef a/.,1999
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COMPARISONS WITH OTHER COUNTRIES
The present study has highlighted the disturbingly high risk of malignancies following 
renal transplantation. The overall risk of 7.6% is quite misleading. If the number of 
patients who did not receive immunosuppression for more than 28 days are 
excluded because either the patient or the graft failed to survive, then the incidence 
rises to 8.9%. Also patients who have been transplanted most recently have not 
been followed up for a period of time exceeding one year. By 5 years 68% and by 
10 years 93% of the malignant lesions had developed in our patients. Of the 
patients who had survived for more than 15 years with a functioning graft 2 (8.3%) 
developed malignancies. This is considerably less than the 20% reported from 
Australia (London et a/.,1995) and undoubtedly reflects the differing patterns of 
malignancies seen in developed countries. The distribution of malignancies that 
occurs in our population differs very markedly on racial/ethnic grounds. The patients 
of Anglo-Saxon origin, had patterns of malignancies which closely resemble that 
reported by developed countries whereas the pattern followed by the non-Caucasian 
group of our patients reflected that reported by other African and Central Asian 
centres (Bakr et a/.,1997;Qunibi et a/.,1988).
Australian and New Zealand experience
Sheil et al. (1991) report from Australasia, which has a sunny climate similar to ours, 
that skin cancer is the most prevalent malignant lesion in their population of renal 
transplant patients. It occurred in 18% of posttransplant patients with a mean follow 
up 6.4 years. Skin cancer was responsible for 74% of all malignancies. Squamous 
cell carcinoma was the most common form and occurred in almost 75% of those with 
skin cancer (Sheil et a/.,1991). In our patients, who had a mean follow-up period of 
6.4 years, the incidence of skin cancer in the white patients was 7.0%, much lower 
than in their Australasian counterparts, but skin cancer did account for 65% of all 
malignancies in white patients. Not a single non-white patient in our study 
developed a primary skin malignancy. Sheil and his colleagues make no mention of 
the problem of malignancies in Aboriginal Australians (Sheil,1994a;Sheil et 
a/.,1997;Sheil,1999). In agreement with the Australian experience (Sheil et 
a/.,1980;Sheil et a/.,1987;Sheil et a/.,1991;Sheil,1996) as well as that elsewhere 
(Cassidy et a/.,1982;Gaya et a/.,1995;Hiesse et a/.,1997;Kyllonen et a/.,1994;Mihalov
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et a/.,1996;Montagnino et a/.,1996;Ritters et a/.,1994;Vilardell et al., 1992) squamous 
cell carcinoma was the most common skin lesion accounting for 59% of the skin 
malignancies in our patients. This is a reversal of the usual pattern where basal cell 
carcinoma predominates. None of our patients had metastatic lesions but 
metastases occurred in up to 16% of the patients with cutaneous malignancies 
reported by Sheil et al. (1980; 1994b). While they also experienced a mortality of 
3% among patients with skin cancers (Sheil et al.,1987), none of our patients died as 
a direct result of their skin lesions. A very important observation also made by Sheil 
et al. (1980, 1991) was that in their population risk of cancer is increasing 
exponentially with time and they have extrapolated that any of their patients surviving 
33 years after renal transplantation must expect to develop some form of cancer
100 % ,
80  %
60  %  -
40  %  -
20 %
Patients at Risk (7255) Australia and NZ
 —   Any Cancer
Skin 
~ X ~  Non Skin
- - Age-Matched Gen. Popn.
o %
p < .001
k  , I  1, I. A U ,  k ,  ■ 1 , i— i  - I — i .  ,.,-A
r 100 %
80  %
■ 60  %
-  40  %
20 %
0 %
10 15 20
Years PostTransplant
25
F/q. 6-2. The risk o f developing a malignancy is indicated as the percentage 
probability each year after renal transplantation. The plots include all cancers, all 
skin cancers and all non-skin cancers. Modified from Sheil et al. (2001).
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Table 6-2. The relative risk o f posttransplant malignancies in Japanese patients 
compared with non-skin tumours in Australian patients and patients in the present 
study.
Stomach Liver Skin Breast Lymphoma Kidney
Tokoro et al., 1992 13.04 14.3 100 25 NS1 NS
Hoshida et al., 1997 1.4 1.36 79 1.53 11.1 80
Sheil, 1994 2.82 - 1.3 8.8 4.3
Present study 0 1.7 - 0.6 1.8 4.8
’NS is not specified
2This is the risk for all alimentary tract tumours
(Fig. 6-2). Most malignancies are skin cancers and we can perhaps expect a similar 
pattern in our white patients.
Japan
In Japan, the incidence of posttransplant malignancies is among the lowest in the 
world ranging between 2.3% and 2.8% (Hoshida et a/.,1997;Tokoro et 
a/.,1992;Yokota et al., 1994) compared with 7.6% in the present study and 6-8% 
reported by Penn (1994). However, more importantly is the tumour types seen 
compared with that in Western countries. The most common posttransplant 
malignancy is carcinoma of the stomach (Gunji et al., 1990), while skin carcinoma 
and lymphomas, the most common lesions in the Western countries are very rare 
(Hoshida et a/.,1997;Tokoro et a/.,1992;Yokota et al., 1994). These studies have 
shown that the pattern of cancer development in renal allograft recipients is similar to 
that occurring in the general Japanese population. This contrasts with our own 
experience and that of other developing countries (vide supra), as well as the 
experience in Western countries where the malignancies common in the general 
population are not the lesions that occur following organ transplantation 
(Penn,1989). Epidemiological studies have suggested that the Japanese population 
is predisposed to gastric carcinoma due to its dietary habits and hereditary 
background (Inoue et al., 1994).
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Hepatoma is the second most common tumour posttransplant (Tokoro et a/., 1992) 
and this is related to the high prevalence of hepatitis B and C infections (Arita et 
al., 1992; Tanaka et al., 1991; Yu et al., 1990). Malignancies of the alimentary tract 
account for almost 60% of all posttransplant malignancies in Japanese patients 
(Yokota et al., 1994) compared with 20% of all non-skin malignancies in the 
Australian experience (Sheil,1994b) and 11% of those reported by the CTTR 
(Penn,1993). Several authors (Table 6-2) have reported the relative risk of the 
various malignancies in transplanted patients compared to the general Japanese 
population. The other malignancy that has been detected with increased frequency 
in the Japanese transplant patients is carcinoma of the bladder (Hoshida et al., 1997; 
Ishikawa et al., 1998). Of all malignancies that occur in Japanese patients following 
renal transplantation renal cell carcinoma carries the highest relative risk (Table 6-2) 
(Hoshida et al., 1997). Under cyclosporine the relative risk was 122 compared with 
33 under non-cyclosporine immunosuppressive regimens (Hoshida et al., 1997). All 
but one patient with bladder cancer reported by Ishikawa et al. were receiving 
cyclosporine (Ishikawa et al., 1998). The Japanese patients who developed 
malignancies following renal transplantation are much younger than the patients in 
the general population and were, on average, 40 years old (Hoshida et 
a/., 1997;Yokota et al., 1994), much like their Western counterparts in whom 
malignant lesions were detected. The median age at diagnosis of malignancy in the 
general Japanese population is 64 years and fewer than 5% of cancer patients are 
diagnosed below 40 years of age as having the same type of malignancy as 
observed in the transplant patients (Hoshida et al., 1997).
Not surprisingly, considering the type of the lesions that these patients were 
susceptible to, the period between the transplant and the detection of the tumour 
was relatively long and averaged over 6 years (Table 6-1). In at least 2 reports the 
latent period to tumor appearance was significantly shorter under cyclosporine 
compared with azathioprine (Hoshida et al., 1997;Yokota et al., 1994). The prognosis 
of the patients with posttransplant malignancies was poor with only 43% surviving 
after follow-up periods ranging from 1 month to 8 years in one study. Most of the 
deaths were related directly to the underlying malignancy (Yokota et al., 1994).
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Table 6-3. Site o f the most common malignant lesions in the Western Cape 
population in order o f frequency (from the National Cancer Registry, 1998).
White Coloured Black
Male Female Male Female Male Female
Prostate Breast Stomach Cervix Stomach Cervix
Colorectal Colorectal Prostate Breast PSU1 Stomach
Stomach PSU Lung Stomach Lung Breast
Lung Cervix PSU PSU Prostate PSU
PSU Melanoma Colorectal Colorectal Liver Lung
'PSU is site of primary tumour unknown
The reason for the great interest in the Japanese experience is the predisposition of 
the local community of the Western Cape, in common with the former, to carcinoma 
of the stomach. It is the most common malignancy in the non-white males and after 
carcinoma of the cervix the most common lesion in the females (Table 6-3). Despite 
sharing with the Japanese the risk of stomach carcinoma, in contrast to the 
Japanese renal transplant population, carcinoma of the stomach did not occur in any 
of our renal transplant recipients. Hepatitis B virus (HBV) infection is a risk factor for 
hepatocellular carcinoma. In our patients the chronic carrier rate of HBV is 5-10%, 
comparable to the rate in Far Eastern countries (Robson et al., 1994). Hepotocellular 
carcinoma is therefore not uncommon in black rural patients who have the highest 
HBV carriage rate. However, the only renal transplant patient to develop 
hepatocellular carcinoma was a white patient who had seroconverted soon after 
renal transplantation. Of note is that no cases of posttransplant Kaposi's sarcoma 
have been reported in any of the studies from Japan that are available to date 
(Hoshida et al., 1997;Tokoro et al., 1992;Yokota et al., 1994). This suggests that the 
correct environmental or genetic factors for Kaposi's sarcoma formation are absent 
in this ethnic group. This is in stark contrast to the experience in the present series 
and that of other developing countries (vide infra). The absence of Kaposi's sarcoma 
in the Japanese patients was noted even in long-term survivors who had functioning 
grafts for more than 10 years. In a group of 267 patients, 26 (9.7%) developed 
malignancies but none had Kaposi’s sarcoma nor were there any cases of lymphoma 
noted in these long-term survivors. Interestingly, the most common malignancies in
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these patients were of the skin (mostly squamous cell carcinoma). Hepatoma was 
the next most common lesion with the disease proving universally fatal (Yasumura et 
al. ,1997).
Other Far East countries
There are very few reports from other countries in the Far East on their experience 
with posttransplant malignancies. Kim et al. (1998) documented a 2% incidence of 
malignancies in 1600 Korean kidney transplant patients. There were 5 cases of 
Kaposi's sarcoma, which accounted for 15.6% of total malignancies and occurred in 
0.3% of all recipients. Yang et al. (1998) reported an incidence of posttransplant 
malignancies of 6.2% in 390 Taiwanese renal transplant patients. The most 
common malignancies were transitional cell carcinoma of the bladder and carcinoma 
of the liver which each accounted for 8/25 (32%) malignancies. Kaposi's sarcoma 
occurred in 2/25 (8%) patients with tumours (Yang et al., 1998). The high incidence 
of hepatoma and bladder carcinoma was ascribed to the high incidence of infection. 
No cases of skin cancer were diagnosed. In an earlier report the incidence of 
posttransplant malignancies was 8 (4.1%) among 193 Taiwanese renal allograft 
recipients. The most common lesions were hepatocellular carcinoma and 
lymphoma, each accounting for 37.5% of all lesions. Kaposi's sarcoma was present 
in 1 patient thus accounting for 12.5% of all lesions. No skin or bladder cancers 
were found either (Wu et al., 1992). The absence of any skin malignancies is in 
keeping with the trend demonstrated by countries that do not have a predominantly 
Caucasian population. What is surprising is the absence of genito-urinary cancers, 
which has been commonly reported by other countries in the Far East region and 
was by far the most common type of malignancy in the later report from Taiwan (vide 
supra). One explanation for this discrepancy is that the size of their cohort is very 
small and their observation period was only 10 years.
Africa and the Central Asian
The incidence of malignancies in this region (excluding South Africa) is reported to 
be between 0.75% and 5.87%, which is somewhat lower than that reported by the 
Western countries. However, if skin malignancies are excluded then the cancer 
incidence of 4.7% is very comparable (Penn, 1991). In many of these countries 
renal transplantation is still in its infancy. The patients are comparatively young and
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the follow-up period short. Another explanation for the lower incidence is that most 
transplants in these countries are from living-related donors and consequently 
patients received less immunosuppressive treatment (Bakr et al.,1997). However, 
most striking is the distribution of types of reported posttransplant malignancies. 
With a single exception, one of the most common malignancies in all of these 
countries is Kaposi's sarcoma, which accounted for 24% to 76% of all malignancies 
(Table 6-1). The single exception was an Indian report that failed to detect a single 
case of Kaposi's sarcoma (Thiagarajan et al., 1998). The other observation is the 
relatively higher incidence of lymphomas in this group of countries. In the most 
recent CTTR report lymphomas comprise 11% of all reported malignancies 
(Penn,2000). In developing countries, the incidence ranges from 8.6% in Saudi (Al- 
Sulaiman MH et al., 1994) to 50% in Pakistan (Askari et a/., 1999). However, the 
incidence of lymphomas in the West also used to be very high when transplant 
programs were launched but decreased over time as experience was gained with the 
use of immunosuppressive drugs (Rao,1998). This may well be the case in the 
developing countries, many of which have transplant programs that are in their 
infancy. In the present study lymphomas comprised 4.9% of all the malignancies 
that we detected.
Skin cancers were very uncommon in these countries and in several reports none 
were documented. The lower incidence of skin cancers partially explains the lower 
overall incidence of cancers in these countries. The only African country outside 
South Africa to report its experience with posttransplant malignancies in detail is 
Egypt (Bakr et a/.,1997). In agreement with other developing countries in the region, 
Kaposi's sarcoma accounted for 50% of all malignancies. Bladder carcinoma, not 
surprisingly for an area in which schistosomiasis is endemic, constituted 14% of all 
malignancies and was as common as lymphomas. All the patients who had 
carcinomas of the bladder following renal transplantation had a history of urinary and 
intestinal schistosomiasis and bilharzial hepatic fibrosis.
Saudi Arabia
In contrast to the Australian experience, Qunibi and his colleagues (1988; 1993) 
report that Kaposi's sarcoma is the most common malignancy to occur in renal 
transplant patients in Saudi Arabia. In 630 renal allograft recipients transplanted
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over a 17-year period, 26 cases of Kaposi's sarcoma were identified, an incidence of 
4.1% compared with the reported incidence of 0.4% among recipients from 
developed countries (Penn, 1979). Kaposi's sarcoma represented 68% of tumours 
in their renal transplant population. In our non-white population of renal transplant 
recipients the risk of developing Kaposi's sarcoma was 5.32% and accounted for 
almost 80% of all malignancies. By contrast, Kaposi's sarcoma although 
considerably more common in renal transplant patients still accounted for only 4.3% 
of all malignancies in the latest reports by Penn (2000) and 0.73% in the reports by 
Sheil (1996)! The shorter follow-up period may well account for the Saudi patients 
having a lower incidence of other malignancies compared to our own group. In a 
larger cohort of 950 patients from neighbouring Egypt transplanted over an 18-year 
interval, Bakr et al. (1997) report a 2.3% incidence of posttransplant malignancies. 
Kaposi's sarcoma accounted for 50% of the lesions. None of the de novo malignant 
lesions described by either Qunibi et al. (1988; 1993) or Bakr et al. (1997) were 
primary skin cancers.
Other countries
Ecder et al. (1998) report that 68% of the posttransplant malignancies among the 
557 Turkish patients followed over 14 years was Kaposi's sarcoma. They report 
only a single case of skin cancer in their cohort and 2 cases of lymphoma. In 
contrast, Mexico that is situated on a similar latitude as South Africa but has a 
predominantly Anglo-Saxon population, the most common posttransplant malignancy 
in 318 patients followed for 24 years was carcinoma of the skin and it was 
responsible for 63% of all lesions while lymphomas accounted for 9%. No cases of 
Kaposi's sarcoma were diagnosed (Bordes-Aznar et al., 1992).
SOUTH AFRICAN EXPERIENCE
Johannesburg
The very first South African reports of posttransplant malignancies originated from 
Johannesburg in 1981. Disler and colleagues reported 14 (7.2%) malignancies in 
193 patients transplanted since 1966. The most common malignancies were those 
of the skin, which occurred in 9 patients. The predominant lesion was squamous cell
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carcinoma, which occurred in 8 patients and basal cell carcinoma in 2 patients with 
one patient having both types of lesions. They observed that 63% of patients with 
squamous cell carcinoma of the skin originally had analgesic nephropathy and 
postulated a causal relationship. They noted a single case of Kaposi's sarcoma and 
2 cases of in-situ carcinoma of the cervix. They also reported the first case of 
Philadelphia chromosome positive chronic myeloid leukaemia in a transplant patient. 
The mean interval between transplantation and the diagnosis of malignancy was 
32.6 months with the earliest lesion being diagnosed at 4 months. No cases of 
lymphomas were diagnosed. The race of the patients was not specified in this 
report. However, from other reports originating from the same group at that time, it is 
known that the majority of the patients were white with very few non-white patients 
receiving grafts at this time despite the latter forming the bulk of the population of the 
region (Myburgh et a/.,1983). This explains the high incidence of skin cancer in the 
renal transplant population and essentially confirms the findings of the current study 
that Anglo-Saxon patients in South Africa, like their counterparts in other parts of the 
world (Liddington et a/., 1989) are predisposed to skin cancers following renal 
transplantation.
The race of the patient who had Kaposi's sarcoma was also not specified. The 
patient was treated with radiotherapy but died later of septicaemia, with no evidence 
of Kaposi's sarcoma at the post-mortem examination. The dose of 
immunosuppression was not reduced in this patient. Another important observation 
made by Disler et al. (1981) and one that confirms those of this study was that the 
patients who developed neoplasms had better graft survival and are less likely to 
have acute rejection than the other patients. They suggested that these patients had 
a ". . . generally poor immunosurveillance mechanism allowing them to better 
tolerate the foreign antigens of the allograft and the altered antigens of the neoplastic 
cells." (Disler et al., 1981).
Johannesburg update
Margolius et al. (1996) updated the Johannesburg experience of posttransplant 
malignancies recently. Of 1374 patients receiving renal allografts over a 30-year 
period 106 (7.7%) patients developed 134 malignancies. The transplanted recipients
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Table 6-4. Kaposi's sarcoma at two South African centres
Incidence Mean Sex Race Latency Treatment Outcome
Age (yrs) M:F W:NW (mo.) (see text)
Jo’burg1 0.5 46 6:1 2:5 19 Withdrawal Poor
Stellenbosch2 
i___
3.9 42 11:10 2:19 22 Reduction Fair
'Margolius (1996) 
2Present study
were overwhelmingly white and therefore, not surprisingly, the most common 
malignancy was that of skin, which accounted for 61 % of the malignancies. Kaposi's 
sarcoma comprised 7% of all patients with posttransplant malignancies. Five of 7 
patients with Kaposi's sarcoma were non-white (Margolius et al., 1994; 
Margolius, 1996) while both white patients to develop Kaposi's sarcoma were of 
Mediterranean origin.
Margolius et al. (1996) observed as we did that Kaposi's sarcoma occurred 
predominantly in non-Caucasians: of 297 non-white renal recipients 1% developed 
Kaposi's sarcoma compared with 0.19% of the white patients. The incidence of 
Kaposi's sarcoma was higher by a factor of over 5 in our patients with 5.32% of the 
non-Caucasian patients and 1.08% of our Caucasian patients developing the 
malignancy following renal transplantation. The reasons for the marked 
geographical difference in the incidence are not immediately apparent (Table 6-4). 
One reason for the difference may that our region (the Western Cape) has a 
predominantly coloured population that may be at greater risk compared to all the 
other race groups. Genetic factors and/or the higher prevalence of certain viral 
infections such as HHV-8, may be responsible. Table 6-4 summarises the main 
features of Kaposi's sarcoma in the two South African centres. Other major 
differences are evident in data from the two regions. Kaposi's sarcoma in its 
classical form is considerably more common in males than in females. This male 
predominance is lost in other forms of the disease as aptly demonstrated by our own 
data and confirmed by other centres around the world. In our cohort, slightly more 
males received renal allografts than females and once this was corrected for there 
was no gender difference in the incidence of Kaposi's sarcoma. Since Margolius et
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al. (1996) do not specify the number of females who received renal allografts, it is 
not possible to exclude the fact the many more males may have been grafted than 
females. Also the number of cases is very small and it is possible that as more 
cases are diagnosed the discrepancy may become less pronounced.
Although no cases of malignant lymphoma were identified in the early reports from 
South Africa, Margolius et al. (1996) reported 4 cases (3% of all non-cutaneous 
malignancies) compared to 2 cases (6.4%) in the present series. The Tumour 
Registries reported that malignant lymphomas (Penn et a/.,1988;Sheil et a/.,1991) 
constituted 12% of all non-cutaneous malignancies (Sheil,1994b). The relative 
incidence of malignant lymphomas, for reasons that are unclear, therefore is 
considerably less in South Africa than reported elsewhere, especially other 
developing countries where lymphomas constitute up to one in three posttransplant 
neoplasms (Askari et al., 1999) (Table 6-1).
Because Margolius et al. (1996) did not report the differential incidence of 
malignancies under azathioprine and cyclosporine, or the effect of race on the 
incidence of malignancies in their cohort further comparisons between their study 
and ours is not possible. Of note in our study is the observation that unlike other 
studies (Mihalov et al., 1996) patients aged more than 40 years at transplantation, 
and male sex were not associated with an increased incidence of malignancies. 
Cyclosporine was not associated with a greater incidence of malignancies compared 
to conventional therapy and this finding has been widely confirmed by others 
(Montagnino et al., 1996) although the time to the first neoplasm was reduced by 
more than one-half in agreement with Mihalov et al. (1996). Importantly, patients 
under cyclosporine were not more prone to develop Kaposi’s sarcoma, although 
others have suggested that there is an increased risk of Kaposi's sarcoma due to the 
increased degree of immunosuppression (Montagnino et al., 1996).
Cape Town
Cassidy et al. (1982) reported the first Cape Town experience with de novo post- 
renal transplant malignancies. Of 209 patients transplanted between 1967 and 
1979, 8 (3.8%) developed malignant tumours. This is almost one-half the incidence 
reported from Johannesburg by Disler and his colleagues one year earlier (Disler et
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al., 1981). In the Cape Town series skin malignancies occurred in 3 patients, all of 
who were white renal allograft recipients. Kaposi's sarcoma was diagnosed in 2 
patients. The race of patients with Kaposi's sarcoma was not specified in the report 
but in comparing the difference in the incidence of malignancies with the 
Johannesburg group the authors do emphasise that over 50% of their patients were 
non-white. Cassidy and his colleagues also state that unlike the Johannesburg 
experience less than 3% of their patients suffered from analgesic nephropathy, a 
disease known to be prevalent among white females (Cassidy et al., 1982). The 
mean duration of immunosuppressive treatment was 35 months with the shortest 
intervals being in two patients who had developed Kaposi's sarcoma at 16 and 18 
months respectively. In contrast to Disler et al. (1981), Cassidy et al. (1982) 
withdrew all immunosuppressive treatment in the two patients with Kaposi's 
sarcoma. One patient died of disseminated disease 19 months later while the 
disease was cured in the second patient although she lost her graft to acute rejection 
when the immunosuppressive treatment was withdrawn. Neither centre reported any 
cases of lymphomas. Cassidy et al. (1982) in agreement with Disler et al. (1981) 
and the current series report the incidental finding of carcinoma of the thyroid. 
Cassidy et al. (1982) report a single case of sclerosing undifferentiated carcinoma of 
the thyroid diagnosed at autopsy in a patient dying of septicaemia 44 months after 
transplantation. The case of papillary carcinoma of the thyroid reported by Disler et 
al. (1981) was discovered when the patient underwent a parathyoidectomy 2 months 
posttransplant. Our own case has been described in detail above (see Results). 
Cassidy et al. (1982) observed that 80% of the patients in whom malignancies were 
diagnosed and in whom tissue typing was available had the HLA-A28 antigen in 
common, compared to 9% and 7% in the general population and transplanted 
patients.
The present study is unique in the South African setting in reporting in detail the 
various factors that influence the development of malignancies in renal allograft 
recipients over a prolonged period of time. It has identified the importance of race in 
determining the distribution of the type of malignancies and highlighted the risk of 
Kaposi's sarcoma in the non-Caucasian population. This is also the first study in 
South Africa to determine the relative risks of the various malignancies.
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OTHER MEASURES OF THE FREQUENCY OF CANCERS
Relative Risks
The relative risks in the current study were determined using the expected number of 
tumours based on the National Cancer Registry statistics and the actual numbers of 
cases observed in the study. The national statistics relate to the general population 
although it would be more appropriate to compare renal transplant recipients and 
non-transplanted dialysis patients with each other. However, no registry of cancers 
in dialysis patients exists. There are some reports of an increased incidence of 
malignancies in uraemic patients (Matas et al., 1975) but these have found an 
excess of non-Hodgkin's lymphoma (Kantor et al., 1987) and renal tumours (Port et 
al., 1989). The racial mix of our population also differs somewhat from that of the 
National Cancer Registry. There is a greater proportion of coloured patients in our 
series because our patient profile is that of the Western Cape in which this race 
group predominates (Fig. 4-2.) More importantly however is that the Western Cape 
has a relatively greater proportion of white patients, which should increase the 
overall risk of skin cancers. However, although these factors could alter the overall
Table 6-5 Relative risk o f various malignancies reported
Country All Skin KS Lymphoma Reference
ANZ1(non-skin) 3.4 - >1000 8.8 Sheil,1994b
ANZ - - - 300 Sheil et al., 1980
ANZ - - >1000 9.9 Sheil et al., 1987
Finland 2.7 20.1 - 5.82 Kyllonen et al., 1994
Germany 4.9 - - - Ritters et al., 1994
Italy - 6.2 224.7 7.4 Montagnino et al., 1996
Japan 7.4 100 - - Tokoro et al., 1992
Japan 2.8 - - 12.4 Hoshida et al., 1997
Stellenbosch 3.3 - 204.3 1.8 Current study
Sweden - 29(lip) - 22 Blohme et al., 1985
Taiwan 13.8 - - - Yang et a/., 1998
UK 5.3 162 - - London et al., 1995
USA(ML)
i _______
2.5(males) 4.2 - 33 Hoover et al., 1973
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calculated relative risk, they would not affect the subgroup comparisons made within 
the current series. No detailed risk ratios are available for comparison with other 
South African transplant units. Disler et al. (1981) report that the incidence of skin 
cancer was 41.5 cases per 1000 transplanted patients, which was a 16-fold increase 
over the predicted number for the general population. In view of the unreliability of 
the reported data on skin cancer, the National Cancer Registry of South Africa, like 
many other tumour registries, excludes skin cancers from its tumour statistics. The 
relative risk of skin cancers therefore could not be calculated for the present cohort 
of transplant recipients. The calculation of relative risks requires access to national 
or regional tumour registries that are seldom available in developing countries. 
Comparison with other developing countries was not possible because of the lack of 
this information. Data were available from some Western countries and is shown in 
Table 6-5.
The overall risk of cancer in transplanted patients is increased by between 2.5- to 
27-fold in various populations. The excess risk was greatest in the case of Kaposi's 
sarcoma, which is extremely rare in the general population in developed countries 
(Sheil et al., 1987; 1994b). In some of the early reports, the risk of lymphomas was 
30 to 40 times that expected with certain subtypes being 350 times more common 
(Hoover et a/.,1973;Sheil et al., 1980). In an early multicentre report the risk of 
lymphoma was increased early after transplantation and the risk remained uniform at 
various times after transplantation. The risk ratio (observed/expected) of lymphoma 
was 33 within the first year, the same in the next four years and 40 for patients 
transplanted for longer than 5 years (Hoover et al., 1973). In contrast, the risk of 
other cancers increased with longer follow-up. The risk ratio of skin cancers 
increased from 1.8 within the first year, to 2.8 within the first 5 years posttransplant, 
to 4.3 beyond 5 years (Hoover et al., 1973). The same report was one of few to 
compare the risk ratio of the genders. The relative risk of lymphomas was 
comparable with the risk ratio being 32.1 in males and 38.1 in females. The risk of 
cancers other than lymphomas was 2.5 greater than expected in males but in 
females the risk of other cancers was not increased. Subsequent studies have failed 
to make the same comparisons as this early study (Hoover et al., 1973).
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The current report is unique in comparing the relative risk of various malignancies on 
the basis of age, sex and race. Although there are some reports of comparisons 
between the genders (Gaya et a/.,1995;Hoshida et a/.,1997;Tokoro et al., 1992) there 
are a few age-matched (Hoshida et a/.,1997;Montagnino et al., 1996) and no race- 
matched comparative studies that could be found in the English literature. The risk 
of non-skin malignancies was increased by a factor of 3.8 in our patients followed up 
for a maximum of 23 years or a total of 3450 patient-years of observation. This 
compares with a relative risk of 3.4 for non-cutaneous tumours from New Zealand 
and Australia (Sheil, 1994b) and 6.2 reported from the United Kingdom, with the latter 
having accumulated 2622 patient-years of follow-up (Gaya et al., 1995). The only 
country with a predominantly non-Caucasian population to report its results was 
Japan. In the first report of a small number of patients the overall relative risk was 
7.41 (Tokoro et al., 1992). The 257 patients were followed up over 24 years. In a 
second, much larger study, the reported relative risk was 2.78. A total of 12 982 
patient-years of observation had been accumulated. The 1744 patients had been 
followed up over 29 years (Hoshida et al., 1997).
In studies that have compared posttransplant malignancies between the genders, 
the excess risk is greater in men than in women. In an early report from the USA, 
the relative risk of malignant lymphomas was 38.1 in females compared with 32.1 in 
males. However, the other non-cutaneous malignancies were 2.5 times more 
common than expected in men only. In females the risk of other cancers was not 
increased (Hoover et al., 1973). In a report from the United Kingdom the relative risk 
of all malignancies was 7.3 in males (n = 165) and 4.9 in females (n = 109) (Gaya et 
al., 1995). However, if only non-cutaneous lesions were considered the excess risk 
was 4.9 in males and 4.5 in females (Gaya et al., 1995). In the two Japanese studies 
the relative risks were 2.91 (males: n = 1155) and 2.46 (females: 589) (Hoshida et 
al., 1997), and 7.94 (males: 205) and 5.56 (females: 52) (Tokoro et al., 1992) 
respectively. In the current study the excess risk of non-cutaneous malignancies 
was 4.3 in the 294 males and 3.4 in the 248 females. The reasons for the lower 
excess risk of malignancies could include the smaller number of females receiving 
grafts, the smaller cumulative doses of immunosuppressive administered to females 
by virtue of their lower body mass. Hormonal and genetic factors may also play a 
role. In the current study the most striking difference was in the relative risk of
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Kaposi's sarcoma, which was more than 5-fold greater in females than in males. 
This contrasts with the reports by Montagnino et al. (1996) who found the excess risk 
was similar in men and women.
The current study is unique in its ability to compare the risk of cancer in different 
populations in the same geographical area. The non-white patients had a much 
greater risk of non-skin cancer than the white patients. This excess was largely due 
to the increased incidence of Kaposi's sarcoma in the former. White patients have 
double the risk of malignant lymphomas while the risk of breast carcinoma was 
reduced in all race groups. The non-white patients were also at increased risk of 
developing lung cancer but other malignancies that occur commonly in the non-white 
population, such as stomach and liver carcinomas, were not seen. The relative 
youth of the transplant recipients may be one explanation for the rarity of these 
common tumours. Hepatitis B infected patients are seldom accepted for renal 
replacement treatment, providing a possible explanation for the rarity of 
hepatocellular carcinoma. Changes in the patients' life-style habits and diet following 
the onset of chronic renal failure and the institution of renal replacement therapy may 
also play a possible role in the reducing the risk of malignancies of the stomach 
among the current cohort. Among the Japanese who also have a high incidence of 
gastric carcinoma in their general population the excess risk of this lesion in the 
transplant recipients is 1.4 while that of liver carcinoma is 1.36 (Hoshida et al., 1997).
Incidence density of posttransplant malignancies
The incidence density is another tool for looking at the incidence of malignancies 
which corrects for varying periods of follow-up. It is therefore perhaps more accurate 
than the raw incidences which are commonly quoted. It is also more accurate than 
the risk ratios because these require an accurate knowledge of the incidence of 
malignancies in the underlying general population. With very few tumour registries in 
developing countries, risk ratio is unlikely to be a useful comparative measure. In 
addition, the relative risk does not give the absolute incidence and the frequency of 
individual lesions will influence the value of others even if the absolute incidence of 
the other lesions remains constant (dos Santos Silva, 1999; Rosner,2001).
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TABLE 6-6. Incidence density o f posttransplant malignancies in various countries.
Country No. of 
Patients
Cumulative
Patient-years
Overall
(pyr)1
KS
(pyr)
Lymphoma
(pyr)
Skin
(pyr)
Reference
Finland 2090 12055 7.8 0.17 0.6 1.0 (Kyllonen et al., 1994)
Italy 854 5874 12.9 2.2 0.5 3.4 (Montagnino et al., 1996)
Japan 1744 12982 3.5 0 0.38 0 (Hoshida et al., 1997)
S'Bosch 542 3450 12.7 6.1 0.6 3.4(8.5)2 Current study
Sweden 934 4547 7.2 0 2.0 Excl. (Blohme et al., 1985)
Taiwan 390 1659 15.0 1.2 0.6 0 (Yang et al., 1998)
UK 274 2622 27.0 0.38 3.8 7.2 (Gaya et al., 1995)
USA 
1 .
6297 11224 5.3 NS 2.2 1.9 (Hoover et al., 1973)
pyr is per 1000 patient-years at risk.
2The incidence of skin cancer in white patients
Many studies have corrected for varying periods of follow-up in patients by using the 
cumulative number of years since the patients were transplanted and estimating the 
number of malignancies in terms of patient-years (Birkeland,1983b;Blohme et 
al., 1985;Gaya et a/.,1995;Hoover et a/.,1973;Kyllonen et a/.,1994;Montagnino et 
al., 1996). However none have used this figure to estimate the number of 
malignancies. Using the data supplied by Blohme (1985), we calculated that the 
incidence of malignancies was 7.2 per 1000 patient-years in the Swedish cohort 
compared to that of the current study of 12.8. They however excluded all skin 
cancers from their estimates and the comparable value of the current study is 9.3 
non-cutaneous malignancies per 1000 patient years. In an earlier study from 
Maryland, USA the total patient-years of observation were 11 224 and the incidence 
of all malignancies following renal transplantation was 5.3 per 1000 patient-years. 
When skin cancers were excluded, the incidence was 3.4 per 1000 patient-years. 
The study was one of few to look at gender differences. Using the data supplied the 
incidence of malignancies could be calculated and were 4.4 and 3.0 per 1000 
patient-years in male and female recipients respectively (Hoover et al., 1973).
In a recent study from the United Kingdom (UK), the cumulative follow-up was 2 622 
patient-years. Using the data supplied, the incidence of all cancers was 27.0 per 
1000 patient-years but was only 14.1 per 1000 patient-years if skin malignancies 
were excluded (Gaya et al., 1995). In a recent Japanese report the incidence
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densities of all posttransplant was the lowest reported with both skin and malignant 
lymphomas being very uncommon (Hoshida et al., 1997). The incidence densities of 
cancers from various countries and periods are summarised in Table 6-6 for 
comparison with that of the current study. Skin cancer among white patients in the 
present series is the highest in terms of incidence density. What is surprising is the 
very high incidence density of skin cancers in the UK patients. In the Nordic 
countries the incidence densities of skin cancers is lower but it still remains the most 
common posttransplant malignancy in these patients (Blohme et a/.,1985;Kyllonen et 
al., 1994). Patients from the Mediterranean region are recognised to have a higher 
incidence of posttransplant Kaposi's sarcoma (Penn, 1997) and therefore the high 
incidence density of the lesion in Italy is not unexpected.
SUMMARY
The frequency with which malignancies occur following renal transplantation has 
been investigated using several techniques. What is clear is that there is a marked 
increase in these lesions in our patients as well as in most units that have reported 
their data. The risk of these tumours was recognised soon after the establishment of 
renal transplantation as a clinical option for the treatment of end-stage chronic renal 
failure (Penn et al., 1969).
The pattern of malignancies has changed. In the initial period, lymphomas were the 
most commonly encountered lesions to be replaced by skin lesions. Whether this 
represented a true decrease or was a function of the relative increase in the number 
of skin cancers is difficult to be certain because most of the available registry data, 
the only source of continuous data over the years, fails to record the number of 
patients at risk. The Australian and New Zealand registry also records a decrease in 
the proportion of lymphomas as the number of skin malignancies rapidly escalated 
but it remains uncertain whether the absolute incidence has changed over the years 
(Sheil, 1994b). What has been observed is that the relative risk of lymphomas 
increases to a maximum within a few months of transplantation but remains constant 
thereafter (Hoover et al., 1973). In contrast, the relative risk of skin cancer increased 
with time (Gaya et al., 1995). It is unclear why there should be an increase in skin
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cancer but not other tumours the longer a patient receives immunosuppressive 
treatment, although some hypotheses have been offered (Gaya et a/., 1995).
What should be noted is the difference in the type of cancers in cancers in the 
Western countries compared to the rest. In all countries with a predominantly Anglo- 
Saxon population even those with temperate climates skin cancers are the most 
common malignant lesions to occur following renal transplantation. This is in stark 
contrast to countries in Africa and the Middle-East where Kaposi's sarcoma is the 
predominant lesion. Among the Japanese neither skin cancers nor Kaposi's 
sarcoma occur and the malignant lesions that occur in the general population occur 
most frequently in the transplant patients as well. This contrasts with the experience 
in all areas including our own, where the most prevalent malignancies in the general 
population occur with similar or lower frequency in the renal transplant recipients 
(Yang et a/.,1998).
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Chapter 7
A BRIEF HISTORY OF 
KAPOSI: THE MAN AND 
THE DISEASE
M
oriz (Moritz) Kaposi first described the disease that today bears his 
name in 1872. Before embarking on the historical aspects of the 
disease, it is appropriate to sketch briefly the biography of the man 
himself who made such a major contribution to the field of dermatology. He was one 
of the few who experienced the Golden Age of the Viennese School and transmitted 
its essence to succeeding generations.
HIS LIFE
Dr Moriz Kaposi (Fig. 7-1) was born Moritz Kohn on October 23, 1837 (Fig. 7-2) in 
Kaposvar, a small town with a population of 20 000 situated on the river Kapos 
(Safai,1984) in Southern Hungary, to an orthodox Jewish family of limited material 
means (Holubar et a/.,1981). The family did not have any intellectual pretensions or 
any outstanding achievements. The young Kohn was a bright student who excelled
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Fig. 7-1 A photographic portrait of Professor Moriz Kaposi (1837 -1902).
at the local Gymnasium, and moved on to Pressburg (now known as Bratislavia) 
where he completed the last four years of his secondary schooling in the German 
Gymnasium (Frankl,1971 ;Frankl,1975). He matriculated at the University of Vienna 
in 1856. He qualified cum laude from the University earning the degree of Doctor of 
Medicine in 1861, a Doctor of Surgery in 1862, and a Master of Obstetrics in 1866. 
His main interest however was in dermatology, which was stimulated by his 2-year 
stint in Sigmund's Department of Syphilology at the Allgemeines Krankenhaus 
around 1864. He successfully applied for the post of Privatdozent (Associate
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Fig. 7-2 The entry recording the birth o f Moritz Kohn in the Mosaic birth registry. 
Interestingly the birth record on page 62, number 43, contains a postscript in 
Hungarian by Rabbi Emanuel Herzog in 1902 that reads: "meghalt mint Professor 
Kaposi Becsben 1902 marc 6" (died as Professor Kaposi in Vienna (on) March 6, 
1902). Adapted from Holubaret al. (1981.)
Professor) in 1866 and was subsequently transferred to Ferdinand von Hebra's 
department of dermatology (Weidenfeld, 1981).
Ferdinand von Hebra was the founder of dermatology in Vienna. Von Hebra had 
worked as an assistant to Skoda and had been strongly influenced by Rokitansky's 
ideas of pathology. He achieved international recognition with his publication
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Versuch einer auf pathologische Anatomie gegrundeten Eintheilung der 
Hautkrankheiten (Attempt at a Classification of Skin Diseases on Basis of 
Pathological Anatomy), which appeared in 1845. Following this, von Hebra's clinic 
achieved great popularity .as a training centre of excellence in dermatology 
(Holubar,1981). Professionally, Kohn and von Hebra complemented each other very 
well. Von Hebra was a skilled observer and experienced diagnostician but had 
limited skills at microscopy. Kohn on the other hand, trained in the post-Virchow era, 
had the skills that his mentor lacked. Together, they undertook the revision of von 
Herbra's opus Hautkrankheiten that appeared in 1860.
They collaborated well together and undoubtedly also socialised together because 
Moritz met and fell in love with von Hebra's daughter, Martha. There was however a 
major obstacle to their engagement: the difference in their religious beliefs. The von 
Hebra's were Roman Catholics while Kohn was Jewish. The problem was solved 
when Kohn embraced Roman Catholicism in 1869. The couple were married on 
February 6, 1869. The union was a satisfactory one with Kohn and Martha von 
Hebra having 5 children, 3 sons and 2 daughters (Holubar et al., 1981). By all 
accounts Kohn (Kaposi) was a devoted husband and loving father. In 1871 he 
applied for and was granted the legal right to change his name to Kaposi, after the 
river Kapos of his birthplace in Hungary (Fig. 7-3). The reason he offered for 
changing his name was that he wished to avoid confusion with other members of the 
teaching faculty who were also named Kohn. Whether this was the only reason or 
whether it had anything to do with his recent conversion to Catholicism has been 
questioned (Dirckx,1988). The Jewish community of Vienna probably held him in 
disdain for his action but did not ostracise him professionally, continuing to refer 
patients to him because of his competence as a dermatologist.
Kaposi worked as his father-in-law's faithful and accomplished associate until von 
Hebra's death in 1880. Kaposi was unanimously chosen as his successor, 
bypassing the standard procedure that required the submission of 3 names (Fig. 7- 
4). For Kaposi this was a major achievement because, in Vienna, at the time, Jews 
were barred from professional preferment, suggesting that his religious conversion 
and thoughtful choice of bride had paid professional dividends. Hans von Hebra, 
Kaposi's brother-in-law, was also a dermatologist working as a lecturer in the same
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Fig. 7- 3. The river Kapos from which Moriz Kaposi derived his name. From 
www.kaposvar.hu/varos/fldrize.html (downloaded April 4, 2001).
department but there seems to have been little love between them as Hans was 
passed over for promotion for 20 years (Ober, 1988). Kaposi headed the 
department for 20 years and made enormous contributions to the literature. He was 
a prolific writer and published on a range of subjects: erythema multiforme, 
rhinoscleroma, dermatitides in diabetics, lichen rubra moniliformis, impetigo 
herpetiformis, scleroderma, the pathogenesis of pigmentations and depigmentations, 
acne, sarcomatosis cutis and totaled 115 publications (Spiegler,1902). He also 
published the famous "Textbook of Skin Diseases" that first appeared in 1880. Its 
worldwide popularity is reflected by the fact that it reached its fifth edition and was 
translated into several languages (Weidenfeld,1981). In 1872, the same year that he 
described his Pigmentsarkom, he also published a detailed treatise on lupus 
erythematosis "New Contributions to the Knowledge of Lupus Erythematosis", one of 
his first works under the name Kaposi (Breimer,1994;Weidenfeld,1981). Well known 
was Kaposi's unique position on lupus which, unlike his contemporaries who 
considered it a special form of skin tuberculosis, he considered as a clinical condition
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Flg . 7 ±  The letter of appointment (in German Gothic) o f Professor Moriz Kaposi to 
the chair o f the Department of Dermatology founded by his father-in-law Ferdinand 
von Hebra by imperial resolution dated February 8, 1881. The right column relates 
to the pertinent report to the emperor by the minister o f "Cultus and Unterricht". The 
details o f the appointment are spelt out in the left column and the document is signed 
by Emperor Franz Joseph I (1830 -1916). Adapted from Holubar et al. (1981).
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F/'q. 7-5. Kaposi's tomb in Vienna. The figure on the tomb was created by Kundman 
who used Kaposi's wife Martha as a model. Adapted from Holubaret al. (1981).
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sui generis because he had found a unique form to be a true form of tuberculosis 
which he characterised as tuberculosis cutis propria (Weidenfeld,1981). He was 
internationally respected as a dermatologist, recognised for his astute observations 
and respected as a gifted albeit dogmatic teacher (Breimer,1994). Together with 
Unna in Hamburg and Hutchinson in London, Kaposi is considered one of the 
leading dermatologists of his era. Beside his description of Kaposi’s sarcoma, he is 
also credited with the first description of xeroderma pigmentosum (Kaposi, 1882).
On October 24, 1900 one day after celebrating 25 years as the head of one of the 
leading Dermatology Institutes in Europe, he suffered a minor stroke from which he 
made a full recovery (Weidenfeld,1981). He was to suffer another stroke one year 
later, but this time his recovery was incomplete. Despite his handicap, he continued 
with his professional activities and lectures refusing to be parted from what was the 
essence of his life. Even in the hours before his death he stubbornly refused to take 
to bed. He died quickly and painlessly on March 8, 1902, "after a life replete with 
fruitful activity enriched by success, as proved by the all the honours which can be 
bestowed on an academic teacher. .  . .With him died a great spirit, a restless worker 
and a good human being" (Weidenfeld,1981) (Fig. 7-5).
HIS WORK
In 1872 Kaposi published an account (Fig. 7-6) of 5 cases of a lesion which he 
labeled Idiopathisches multiples Pigmentsarkom der Haut (Idiopathic multiple- 
pigmented sarcoma) (Kaposi,1872). He described 5 patients, all men over 40 years 
of age from all corners of the Habsburg empire (Breimer,1994), who had multiple 
cutaneous red-blue nodules, mainly on the extremities. One patient died and 
underwent a postmortem examination while a second patient had a biopsy. Follow- 
up data is unfortunately not given for this patient or the others. Kaposi shared his 
experience with Virchow who informed him of a case of a ten-year old boy who had 
presented to him with similar nodular lesions on the leg that had proliferated and 
proved fatal within a year. The histopathological appearance of Virchow's case 
resembled that of Kaposi's cases. From these limited observations Kaposi made 
some generalisations and summarised the nature of the problem as follows:
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IdiopatMsclies multiples Pigmentsarkom der Haut,
V*0
Dr. K a p o s i ,
liitcciit itn >l«r Univernititt in W»n.
Mit Recht hebt K o b n e r  in einera liber Sarkome der H a u t. 
handelnden Aufsatze*) hervor, dass diese Neubildung auf der 
Haut an und fur sich selten vorkommt, und bisher mehr Object 'i 
anatomischer als klinischer Aufmerksamkeit gewesen ist. Daselbst 
werden zwei Krankheitsfiille raitgetheilt, in deren erstem Haut%
* sarkome in grosser Anzahl als metastatiiche Bildungen, w ahr-^  
f scheinlich yon den Lymphdriisen der Leistengegend her, ent- %
• standen waren, wtthrend im zweiten Falle die allgemeine Sarko;
‘ matosis von einem seit Kindheit bestandenen Naevus des linken^l 
Zeigefingers ausgegangen war, der primar in ein pigm entirtesS; 
y SpindeJzellensarkom sich umgewandelt hatte. Beide Falle en-. J 
digten innerhalb drei Jahren todtlich. Die Section war in einera ^  
derselben gestattet worden. •>>'
Ich glaube eine Form des Pigmeutearkoms der Haut als :
i - •..'•w j‘ eine typisch-Tclinische von denjenigen absondem zu konnen, welche ^
unter alien Unistanden als consecutive (m etastatische) Eruptioneri
und demnach von den verschiedensten Primarherden ausgejien .
t  konnen, und deren Beispiele in den Fallen von K o b n e r  ge-X ,
geben sind.
k Ich will die hier zu beschreibende Form deshalb als idio- 
V pafhischts multiples PigmeiitsarJcom der Haut bezeichnen.
Als Grundlage ftir die Aufstellung dieser Form dienen mir * 1 
fiinf einschlagige Beobachtungen; dieselben sollen hier specielll 
mitgetheilt werden, nicht nur weil der Gegenstand neu, undl
i. Form und Verlauf der Krankheit von der grosst^n Wichtigkeit;
if-
*) Dieses Archir 1869, 3. Heft, pag. 369.
L _ .  '
Fig. 7-6 Copy o f Kaposi’s first article describing the disease that bears his name.
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"Nodules ranging from the size of a peppercorn to that of a pea or a hazelnut . . . 
brown-red to blue-red in colour develop in the skin without a known . . .  cause. Their 
surface is smooth, their consistency elastic; they sometimes swell like an angioma. 
They are either isolated and then protrude, after growing larger, in a peripheral 
shape, or else they form clusters and remain fla tte r. . . .They usually appear first on 
the sole of the foot and the instep, . . . also on the hands . . . where they are 
accompanied by diffuse thickening of the skin and deformity of the feet and the 
hands.
During the further progress . . . isolated nodules and groups of nodules also 
appear on the arms, legs, face, and trunk . . . .  Some of the nodules may atrophy 
and regress. . . . They ulcerate later on . . .  . The lymph nodes do not enlarge 
significantly . . . .  Finally, identical nodules appear in the larynx, trachea, stomach, 
intestines, and other nodules form in the liver." His description of the disease is 
remarkably accurate and can hardly be improved upon. Even his histological 
observations were remarkably accurate: "The histological structures consists of foci 
of fusiform spindle cells and a rich network of capillaries".
However, contrary to our current understanding of the prognosis of classical Kaposi's 
sarcoma, he wrote "Die Krankheit fuhrt zum Tode und zwar innerhalb einer kurzen 
Frist von 2-3 Jahren. . . . Die Krankheit muss nach den vorliegend Ehrfahrungen von 
vornherein nicht als unheiibar, sonderen auch als lethal gelten." (The disease leads 
to death and it does so within the short span of two to three years. . . .The disease 
must, according to our existing experiences, be considered a priori not only incurable 
but also lethal). Indeed, three of his 5 patients were dead within 12-16 months after 
the initial diagnosis. On the basis of postmortem findings of characteristic lesions 
everywhere, not only on the limbs, trunk and face but also in the gastrointestinal tract 
and the liver, Kaposi suggested that the disease was disseminated from the start 
rather than a local tumour that later metastasised:"muss fur dieses Ubel eine bereits 
von Anfang her vorhandene allgemeine Erkrangkung (Dyskrasie) angenommen 
werden" [(one) must postulate, for this scourge, that there is a generalised disease 
(dyscrasia) pre-existing from the beginning] (Breimer,1994). This controversy 
remains unresolved to this day.
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Fig. 7-7 Earliest chromolithographs of Kaposi's Idiopathisches multiples 
Pigmentsarkom. The top frame depicts lesions on the right foot and the lower frame 
lesions on the hands. From Hebra et al. (1856).
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Table 7-1 Some names applied to the tumour since its initial description.
Year Author Name
1872 Kaposi Idiopathic multiple pigmented sarcomas of the skin
1878 Tanturri Sarcoma idiopathicum telangiectoides
1883 Hardaway Sarcoma cutis
1884 Babes Angiosarcoma peritheliale fusocellulare
1889 Funk Sarcomatous gummatoides
1894 Kaposi Sarcoma idiopathicum multiplex haemorrhagicum
1894 Unna Acrosarcoma multiplex cutaneum telangiectoides
1898 Tommasoli Primitives hemorrhagisches acrosarcoid
1899 Bernhardt Sarcomata idiopathica multiplica pigmentosa cutis
1899 Gilchrist Angiosarcoma
1899 Pospelow Acroangioma hemorrhagicum
1901 Radaeli Angioendothelioma cutaneum
1902 Pelagatti Acrosarcoma
1910 Sequeira Granuloma angiomatoides
1912 Sternberg Kaposi's sarcoma
Adapted from Ober, (1988)
There were other criticisms of his otherwise brilliant description. Despite his 
reputation as a keen clinical observer and an astute histopathologist of cutaneous 
diseases, Kaposi failed to illustrate his article with chromolithographs of either the 
gross appearance of the lesions or drawings of the histopathologic sections. 
Fortunately, a chromolithograph of outstanding quality appeared contemporaneously 
in the publication Atlas der Hautkrankenheiten edited by Hebra, Elfinger and 
Heitzman (1856) (Fig. 7-7). Kaposi remained silent on the subject until 1894 when 
he proposed that name of the condition be changed to Sarcoma Idiopathicum 
Multiplex Haemorrhagicum because the word pigmentsarkom had created confusion 
with melanoma (Kaposi,1894). Kaposi later embellished his original description of 
the disease and finally had 16 patients, all men, who he noted still had an 
unfavourable prognosis (Kaposi, 1895).
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What's in a name (and the contribution of others) (Table 7-1)
The name change made by Kaposi (1894) was to be one of many name changes 
that the condition was to undergo over the following decades. Following Kaposi's 
original description, other observers added their anecdotal experiences and many 
tried to develop more precise vocabulary that would take account of the feature that 
they felt was most distinctive. There was general consensus that the condition was 
a sarcoma as illustrated by the list of names ascribed to the lesion over the years 
and most authors added Kaposi's name in parenthesis or quotation marks to the 
tumour. Sternberg's eponymous label largely settled the issue in 1912 but this did 
not prevent subsequent authors like Hamdi and Halil from suggesting the unwieldy 
lable of "perithelioma mutiplex nodulosum cavernosum lymphangiectoides 
cutaneum" in 1927. When this title did not find favour with the scientific community, 
Hamdi and Resat proposed the equally unwieldy "acroepithelioma idiopathicum 
multiplex cavernosum lymphangiectoides cutaneum" in 1932.
Cell of origin
The multiplicity of names (there have been over 40) given to this disorder highlights 
one of the enigmas of this disease faced by the early authors - and that still remains 
a challenge for modern investigators, namely, the cell of origin of the tumour 
(Hutt,1984). Most investigators favoured (as do most current researchers) vascular 
endothelium, either dermal capillaries or perivascular lymphatics but a minority 
believed that the tumour arose from the adventitia. Sternberg (1912) felt that the 
lesion arose from smooth muscle cells in the adventitia. Pautrier and Diss (1929) 
developed the idea that the tumour arose from vascular neuromuscular annexes and 
schwannian elements, and presented the concept of a pseudosarcoma arising in 
neurovascular dysgenesis. Involvement of the reticuloendothelial system was 
invoked by Dorffel (1932) who suggested some relation to the lymphoblastic 
tumours, an opinion shared by many others (Lane et a/.,1953; Nicholas et al., 1928; 
Puhr,1931). Lane and Greenwood (1953) reported the first case of Kaposi's 
sarcoma to be associated with a confirmed lymphoproliferative disease, mycosis 
fungoides.
In an exceptional review of the subject by Becker and Thatcher in 1938, 
observations from tissue culture were added that showed that the spindle cells did
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not have the cytological features of either fibroblasts or smooth muscle cells. They 
discounted the reticuloendothelial hypothesis but failed to commit themselves to a 
position with regard to the cell of origin. Despite this groundbreaking work, only 3 
years later, Symmers, in a detailed clinicopathological study, asserted that the 
tumour unequivocally arose from fibroblasts (Symmers, 1941). The nature of the 
cell of origin continued to be debated even into the era of the electron microscope. 
In 1962 Pepler and Theron published a series of electron photomicrographs that 
fairly convincingly showed that the tumour arose from Schwann cells. However, the 
later arrival of immunoperoxidase techniques have demonstrated that factor VIII is 
present in many of the proliferating cells, with the result that current opinion favours 
the simple endothelial cell as the origin of the tumour as initially proposed by Gilcrest 
and Ketron in 1916.
Other Reports of the Tumour
It was the accumulation of anecdotal cases that was to outline the nature of the 
disease. The most important one was that of Tomasso De Amicis, a Neapolitan 
dermatologist whose 1882 monograph was rediscovered by Francesco Ronchese, a 
Providence, Rhode Island dermatologist in 1958. In his monograph entitled Dermo- 
polimelano-sarcoma Idiopatico, De Amicis describes 12 cases seen in Northern Italy. 
All his patients were male, including a 5-year old boy who presented with a lesion on 
the nose. The adult patients presented with the conventional nodules on the limbs, 
with later development of lesions on the penis, palate, chin, and elsewhere. Biopsies 
were obtained in 4 cases and 3 patients were followed up until their demise only 
months later. There is no follow-up information given on the remainder implying a 
more indolent course. In one of his patients the pigmented nodules on the foot 
spontaneously regressed after 4 years (Ronchese, 1958). De Amici subscribed to 
the then popular theory expounded by Cohnheim that the tumour arose from 
embryonal cells that had lain dormant until an as yet unspecified stimulus triggered 
their malignant transformation (Ronchese, 1958). De Amici's detailed drawings of the 
histology of the lesions depict the main features of the tumour (Fig. 7-8).
Many other clinical accounts of the disease appeared during the late 19th century 
and early 20th century. Some of these reports were accompanied by 
histopathological observations while others were not. A summary of these reports by
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Dorfell allowed certain misconceptions to be cleared up, including the one that the 
disease occurred almost exclusively in Italian and Eastern European males. It was 
also widely recognised that the tumour was rare in childhood and adolescence and 
that although the cases generally progressed slowly, a number proved rapidly fatal 
with widely disseminated lesions (Ober,1988). An early, purely dermatological 
study by Funk (1889) noted that the early form of the tumour was either a macula, "a 
blotch having a yellowish-red, red, brownish, or bluish-red colour, and the size of a 
pea" or a flat papule, "the size of a millet seed which may shoot up from the border 
of the macula". Funk suggested that from the early macules and papules sarcomas 
later developed as "a nodule . . .  a soft spongy tumour . . .  a diffuse infiltration of the
Fig. 7-8 Drawing o f a vascular space surrounded by spindle cells: a, enlarged blood 
vessels; c, fusiform cells; d, pigment granules; f, highly pigmented sarcoma cells; g, 
pigmented coil cells. From De Amicis (1882) in Ronchese (1958).
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skin . . . (or) subcutaneous nodules" (Funk,1889). Kaposi's sarcoma begins as a 
macule and then progresses to tumour stages of plaque, papule-plaque, or nodule- 
ulcerating tumour.
The accumulation of case reports also allowed the discovery that the classical form 
of the disease had two different types of natural history very much like that described 
in the present report of post-renal transplant Kaposi's sarcoma. There was an 
indolent form that remained confined to the limbs, face and occasionally other parts 
of the integument, even involving mucous membranes; and a more aggressive form 
with visceral involvement. Postmortem reports showed involvement of lymph nodes, 
lungs and liver but particularly of the gastrointestinal tract. Another important 
observation that was evident from these studies was that the disease was 
multicentric in origin and that the "secondary" lesions were not true metastases. 
This prompted Lang and Haslhofer (1935) to suggest that the disease should 
perhaps be considered a systemic angiomatosis.
Many reports on Kaposi's sarcoma appeared in the 1950's. It is stated that no 
disease comes of age until it is the subject of a monograph. For Kaposi's sarcoma 
this was to be in 1957, 87 years after the original description and was undertaken by 
Bluefarb (1957). It neatly condensed the knowledge of Kaposi's sarcoma available 
up to that time and was well illustrated. Just prior to the appearance of the 
monograph, the report of McCarthy and Pack (1950) from the United States 
epitomised the clinical experience of Kaposi's sarcoma. They contrasted 36 cases of 
Kaposi's sarcoma with 20 cases of angiosarcoma. They noted that the male to 
female ratio was 92:8, that 78% of their patients were aged over 40 years, that the 
presenting lesions affected the extremities with 73% on the feet and 14% on the 
hands, that 83% of their patients were Jewish (44%) or Italians (39%), that the mean 
survival was 8 years and that 19% were free of the disease 5 years after the initial 
diagnosis of the disease. Three (8%) of their patients developed lymphoproliferative 
disease. Treatment of their patients consisted of wide surgical excision of the 
solitary lesion and radiotherapy if the disease was more extensive.
Cox and Helwig (1959) reported an even larger cohort in that decade. They had 50 
patients with Kaposi's sarcoma, 44 of whom had the benefit of longterm follow-up. In
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contrast to the earlier report from the United States by McCarthy and Pack (1950), 
there were no Jews in the cohort reported by Cox and Helwig (1959), but 11 of the 
50 patients were black (it had previously been thought that Kaposi's sarcoma was 
rare in this race group). These authors confirmed that Kaposi's sarcoma was similar 
in all the racial groups. Although 25 of the patients died, death was directly 
attributable to the sarcoma in only 11 (22%) of the cases. At the time of their report
19 (38%) patients were still alive, 9 (18%) with residual disease and 10 (20%) were 
disease-free 8 years after the initial diagnosis. Two of their patients developed a 
lymphoproliferative disease. They noted that the association with these diseases but 
concluded " . . .  neither the clinical nor the pathological features justify the 
classification of Kaposi's sarcoma as a malignant lymphoma or a reticuloendothelial 
disease" (Cox et a/., 1959).
African Kaposi's sarcoma
Hallenberger described the first case of Kaposi's sarcoma involving an African 
patient in 1914. However, the prevalence of the disease was not appreciated until
20 years later when Smith and Elmes (1934) reviewed a series of 500 tumours in 
African patients and discovered that 10 (2%) were Kaposi's sarcoma. In 1950 
Kaminer and Murray (1950) drew attention to fact that the disease was common in 
"Bantu" men in South Africa. It subsequently became apparent that the disease is 
endemic on the African continent particularly in the sub-Saharan region, in countries 
such as Uganda, Tanzania and Congo. Over the subsequent years, several reviews 
of Kaposi's sarcoma in Africa appeared culminating in a conference that was held in 
Kampala, Uganda in 1961 and that led to the publication of the monograph by 
Ackerman and Murray (Ackerman et a/., 1963). In the same year Oettle (1962) also 
observed that Kaposi's sarcoma accounted for 12% of all malignancies in Zaire (now 
known as the Democratic Republic of Congo). He noted that the disease behaved 
differently compared to the classical form that was known in Europeans. A second 
report on Kaposi's sarcoma in South Africa also appeared in the same year 
(Keen, 1962). At about that time Lothe (1963) published the largest series ever 
reported consisting, of 211 cases of Kaposi's sarcoma in Ugandan Africans.
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Posttransplant Kaposi's sarcoma
It had first been recognised that Kaposi's sarcoma was associated with a breakdown 
of immune surveillance because of the number of cases described where second 
malignancies were present. The commonest lesions were malignant lymphomas. 
In a report of 83 cases of Kaposi's sarcoma, O'Brien and Brasfield (1966) found that 
18 (14%) developed a second malignancy, all of which were lymphomas. The 
association of Kaposi's sarcoma with the use of immunosuppressive agents has also 
been recognised for some time. Zemek et al. (1964) described Kaposi's sarcoma in 
a patient with autoimmune haemolytic anaemia treated with steroids, while Mazzaferi 
et al. (1968) had a patient with multiple myeloma who developed Kaposi's sarcoma 
after treatment with an alkylating agent.
The very first case of Kaposi's sarcoma following a renal transplant was reported in 
1969, a mere 3 years after the first successful renal allograft was performed (Siegel 
et al., 1969). Subsequent to this, a spate of reports appeared confirming the 
association between immunosuppression, renal transplantation and Kaposi's 
sarcoma (Haim et al., 1972; Hardy et al., 1976; Klepp et al., 1978; Meyers et al., 1976; 
Myers et al., 1974; Stribling et al., 1978). Kaposi's sarcoma has come to be 
recognised as one of the most common malignancies to occur following solid organ 
transplantation. Penn (1979) published the first series of cases to occur in allograft 
recipients, immunosuppressed with azathioprine and prednisone. Kaposi's sarcoma 
carries the highest relative rate of occurrence of all posttransplant tumours (Harwood 
et al., 1979) (see Chapter 6).
AIDS-Associated Kaposi's sarcoma
The description of Kaposi's sarcoma in young homosexual males in 1981, heralded 
the onset of the acquired immunodeficiency syndrome (AIDS) epidemic and drew 
attention to this uncommon malignancy once again (Borkovic et a/.,1981;Gottlieb et 
a/.,1981;Hymes et al., 1981). The role of immunosuppression in the development of 
Kaposi's sarcoma was highlighted by this epidemic but the exact mechanism 
whereby the immunosuppression leads to the multicentric proliferation of vascular 
endothelium remains to be clarified. At one point a third of patients who had AIDS 
had Kaposi's sarcoma but the incidence has fallen subsequently (Jacobson et 
al., 1995).
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Chapter 8
KAPOSI'S SARCOMA
E p id e m io l o g y
Classic Kaposi's sarcoma described by Moriz Kaposi in 1872 remained the only clinical form of Kaposi's sarcoma to be recognised until the 1960s when the African form of the disease, also known as endemic Kaposi’s 
sarcoma was recognised as an unique entity (Ackerman , et a/.,1963;Oettle,1962). 
Soon thereafter, the first cases of Kaposi's sarcoma related to immunosuppressed 
patients appeared in the literature (Mazzaferri, ef a/.,1968;Zemek,1964) and the first 
series of cases related to renal transplant recipients soon confirmed the association 
between Kaposi's sarcoma and immunosuppressed patients (Penn,1979b). This 
iatrogenic form of Kaposi's sarcoma is now associated with all forms of solid organ 
transplants but especially with renal transplantation. The most recent form of 
Kaposi's sarcoma heralded the onset of the worldwide acquired immunodeficiency 
syndrome (AIDS) epidemic in 1981 (Borkovic, ef a/.,1981 ;Gottlieb.,1981 ;Hymes et 
al. ,1981) and is the most common form of malignancy in these patients.
All forms of Kaposi's sarcoma share the same histological appearances (Ackerman et 
al., 1988) but there are marked differences in the clinical behaviour of the disease 
among the different epidemiological forms, with marked variations in the prognosis
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between the forms as well (Harawi, 1989). This chapter will compare and contrast the 
iatrogenic form of the disease with the classical, endemic (African) Kaposi's sarcoma 
and AIDS-related Kaposi's sarcoma. Subsequent chapters will highlight the clinical 
features, the pathological appearances and management of Kaposi's sarcoma. 
Before embarking on the epidemiological description of the disease it is perhaps 
appropriate to highlight certain problems inherent in this exercise. Research design 
depends on existing conditions and trends prevailing in populations. As an example, 
researchers in Africa rely on relative frequency of cancers (as we did) because in 
most populations the denominator is unknown (Wahman et a/.,1991). Clearly, the 
relative frequency is important in this situation but does not allow for meaningful 
comparisons with other regions. In addition, rates may be biased by over- or 
underreporting. Individual risk factors, which will be discussed below, also need to be 
evaluated with caution because factors may exert an influence on others, and may 
change over time; ethnicity and geography are closely associated, and different forms 
of Kaposi's sarcoma may be difficult to distinguish from each other (Wahman et 
a/., 1991).
EPIDEMIOLOGICAL TYPES (Table 8-1)
Classic (Sporadic) Kaposi's sarcoma
Incidence
This type of Kaposi's sarcoma accounts for only a fraction of malignancies among 
Europeans and North Americans. In the United States of America (USA) the 
incidence is well below 1%. The estimated annual rate of Kaposi's sarcoma in the 
USA before the outbreak of AIDS, from 1973 to 1979 was 0.29 cases per 100 000 
population of men and 0.07 cases per 100 000 population of women (Biggar et 
a/., 1984a). The Mayo Clinic experience was reviewed by Reynolds et al. (1965) who 
reported only 70 cases over a 38-year period and these accounted for 0,06% of 
malignancies diagnosed at that institution. Others have suggested an even lower 
incidence of 0.02% in the USA (Oettle,1962). Before 1980 the prevalence of classic 
Kaposi's sarcoma was highest in the countries bordering the Mediterranean, with the 
rate being 1.8 per 100 000 person-years. These rates are high compared with the 
rates of less than 0.5 per 100 000 person-years observed in the USA, Northern 
Europe, Asia, Australia and South America (Biggar et a/.,1984a;Dictor et
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a/.,1988a;Harnly et a/.,1988;Oettle,1962). Although rare in Northern Europe, the 
incidence of classic Kaposi's sarcoma was increasing among young men in the two 
decades before the onset of the AIDS epidemic, suggesting an infective aetiology for 
the disease (Dictor et al., 1988a). Classic Kaposi's sarcoma usually affects 
Caucasian men, with 75% of cases occurring in patients aged 60 years or older. 
Although the disease has been described in a variety of countries and ethnic groups, 
classical Kaposi's sarcoma has a predilection for persons of Mediterranean origin, 
especially Italians, and Ashkenazic Jews who originate from Eastern Europe 
(Beral, 1991; Dorffel, 1932;Oettle, 1962).
Clinical features
The classic disease is nodular in 85-90% of the cases and the aggressive clinical 
pattern is unusual. In a comprehensive study at the Mayo clinic in 1965, only 7 of 
the cohort of 70 (10%) patients had the aggressive pattern of Kaposi's sarcoma and 
of these 5 required amputations of the affected limb (Reynolds et al., 1965). 
However, in a more recent series, of the 41 patients with classic Kaposi's sarcoma
10 (24%) had an aggressive, rapidly progressive course (Friedman-Birnbaum et 
al., 1993). The patches, plaques and nodules are deep-red to violaceous. The feet 
and ankles are the most common sites of involvement for the initial lesion and in the 
series from the Mayo Clinic, the lower limbs were ultimately always involved 
(Reynolds et al., 1965). The lesions tend to occur first on the one foot and then 
become bilateral and spread upward (Harawi,1989). The distal parts of the arms are 
the next most common site of involvement giving the descriptive "glove-and- 
stocking" distribution of the lesions (Harawi,1989). Involvement of the skin of the 
head and neck occurs in 14% of cases and generally only occurs when there is 
widespread cutaneous involvement by the Kaposi's sarcoma (Cox et 
al., 1959;Reynolds e ta i, 1965).
Prognosis
Although the majority of patients with the classic form have a lifespan that is close to 
normal (Friedman et al., 1990), there are marked variations in the reported prognosis 
of patients with the disease and this is vividly illustrated in two series from the USA 
(Table 8-2). In the Armed Forces Institute of Pathology (AFIP) series, the Kaposi's 
sarcoma had a more rapid and progressive course than is generally accepted.
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Table 8-1. Characteristics of the various epidemiological types of Kaposi's sarcoma.
Type Predominant Mucocutaneous Mucocutaneous Population at Risk Age at M:F Clinical Course
Lesions Distribution Onset (yrs) Ratio
Classic Some patches, mostly plaques Usually confined to lower Eastern European, Jewish, 50-80 10- Indolent, gradual increase in number
and nodules, usually rounded extremities; disseminated lesions 
late in course of disease
and Mediterranean 
backgrounds
15:1 of lesions often associated with 
lymphoedema; visceral lesions occur 
late, often discovered at postmortem; 
survival 10-15 years
Endemic African
1. Benign nodular Papules and nodules Multiple localised tumours, most 
commonly seen on the legs
Black African adults 25-40 17:1 Indolent, resembles classical type 
disease; survival 8-10 years
2. Aggressive Large exophytic nodules and 
fungating tumour
Most often located on the 
extremities
Black African adults 25-40 Progressive development of multiple 
lesions, with invasion and destruction 
of underlying subcutaneous tissues 
and bone, survival 5-8 years
3. Florid Nodules Widely disseminated Black African adults 25-40 Rapidly progressive, locally invasive, 
early visceral involvement; survival 3-5 
years
4. Lymphadenopathic Rarely manifests lesions Minimal Black African children 2-15
(mean 3)
3:1 Rapidly progressive; survival 2-3 years
Iatrogenic Patches, plaques and nodules Usually localised to the Patients on 30-60 2.3:1 Indolent; occassionally tumour
Immunosuppression extremities; rarely disseminated immunosuppression 
including renal transplant 
recipients
(mean 42) regression after immunosuppression is 
discontinued
Epidemic (HIV- Patches, plaques, nodules often Multifocal, widely disseminated, Homosexual men (95%) 18-65 106:1 Rapidly progressive; survival 2 mo. to
associated) fusiform and irregular often symmetric; frequent oral 
lesions
5 years
Modified from Drotman et a/.( 1995) and Tappero et al. (1993).
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Table 8-2. Clinical course of classical Kaposi's sarcoma in two centres in the USA 
(AFIP and Mayo Clinic).
Cox et al., 1959 Reynolds et al., 1965
No. of cases 44 53
Dead 25 (57%) 29 (55%)
Death due to Kaposi's sarcoma 11(44%) 29(55%)
Duration of disease (yrs)
Long 38 13-32
Short 2 <3
Alive with Kaposi's sarcoma 9 24
Mean duration (yrs) 5.5 13
Longest duration (yrs) - 50
Alive without Kaposi's sarcoma 10 0
Mean duration (yrs) 8 -
Modified from Harawi (1989).
Unfavourable prognostic features included the occurrence of multiple and rapidly 
developing lesions, lymph node involvement and visceral involvement, and the 
young age of the patient (under 45 years) (Cox et al., 1959). In some cases death is 
associated with the occurrence of a second malignancy that develops in 35% of 
these patients (Reynolds et al., 1965;Safai et al., 1980;Safai et al., 1981).
Endemic Kaposi's sarcoma of Africa
As an entity endemic Kaposi's sarcoma was born at a symposium held at Makerere 
Medical College in Kampala, Uganda in May 1961 under the auspices of the African 
Committee of the International Union Against Cancer. Most of the participants were 
workers from Africa with vast personal experiences and the meeting culminated in 
the publication of a collection of 23 papers (Ackerman et al., 1963).
Incidence (1)
The greatest concentration of Kaposi's sarcoma in the world occurs in eastern 
equatorial Africa where Kaposi's sarcoma accounted for, on average between 4 and
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10%, of all malignancies before the onset of the AIDS epidemic 
(Harawi, 1989;Oettle, 1962). However, individual reports from various African 
countries show the percentage to range from less than 1% to more than 90%!, 
depending on the area (Hutt,1984a; Lothe,1963; Oettle, 1962; Slavin et al., 1969; 
Templeton et al., 1973). In some countries Kaposi's sarcoma is the fourth or fifth 
commonest tumour in men (Hutt, 1984b). The areas that are affected are 
predominantly hill and open savannah bush country at an altitude of 1200 to 1500 
metres in Zaire, Kenya and Tanzania (Safai,1984), Uganda, Rwanda, Burundi, 
Malawi, Zambia and Zimbabwe (Desmond et a/.,1991). In the AIDS era, the data 
from central African countries have shown significant alterations in the incidence of 
Kaposi's sarcoma. In Uganda Kaposi's sarcoma has caused 49% of all 
malignancies in men and 18% of cancers in women. This incidence in men (30.1 per 
100 000 population) represents an increase of more than 10-fold since the 1950s 
and is about 3 times that in women (11 per 100 000) (Thijs,1957;Wabinga et 
al., 1993). Interestingly the countries previously known to have the highest rates of 
endemic Kaposi's sarcoma are now the African countries reporting the largest 
number of cases of AIDS to the World Health Organisation (Anonymous, 1990).
Incidence (2)
The areas particularly endemic for Kaposi’s sarcoma are northeast Zaire (now called 
the Democratic Republic of Congo) and northwest Uganda (west Nile district) (Fig. 8- 
1). From this epicentre the incidence of Kaposi's sarcoma falls radially, gradually to 
the south, and more precipitously to the north and the western horn of Africa 
(Templeton, 1981). The tumour is endemic in southern Sudan but not in Khartoum 
or other parts of North Africa (Hutt, 1984b). Asian and European residents do not 
share the increased rate that is evident in the native population (Taylor et al., 1972). 
Another observation made in South Africa was that the incidence of Kaposi's 
sarcoma was 10 times greater in the black population than among whites of the 
same region (Oettle, 1962). Several large series of endemic Kaposi's sarcoma have 
been reported. The most notable among these include those from Zaire, 230 cases 
(Thijs, 1957) and 299 cases (Kalengayi et al., 1984), Uganda, 339 clinical cases 
(Taylor et al., 1972) and 37 post-mortems (Templeton,1972), Tanzania, 117 cases 
(Slavin et al., 1969), and 220 cases (Schmid,1973). In all these series the disease
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Fip. 8-1 The proportional frequency (male and female combined) of endemic 
Kaposi's sarcoma in the African continent. Modified from Hutt (1984).
exhibits the same basic clinical patterns outlined in Table 8-1. The peak age of 
afflicted males is one or two decades younger than in patients with classic Kaposi's 
sarcoma.
Classification of Endemic Kaposi's sarcoma
Taylor and his colleagues (1971b) described a clinical classification system for 
patients with endemic Kaposi's sarcoma based on their experience in Uganda. The
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disease occurs as benign nodular, florid, locally aggressive or disseminated forms 
(Table 8-1).
Benign nodular
The clinical features and prognosis of localised endemic Kaposi's sarcoma are 
similar to those of classic Kaposi's sarcoma. Like the classic form, endemic Kaposi's 
sarcoma is predominantly nodular, involves primarily the distal extremities, especially 
the legs, and is usually associated with lymphoedema (Slavin et al., 1969;Thijs, 1957).
The skin of the head and neck seem to be spared when the cutaneous disease is 
localised (Thijs,1957). Skin lesions may occur singly or in crops and occasionally 
lesions regress spontaneously. The prognosis of this form of Kaposi's sarcoma is 
generally good with patients surviving for over 10 years after diagnosis 
(Armes, 1989). Lymph node or bone involvement is rare (Taylor et al., 1971 b).
Locally invasive forms
Florid Kaposi's sarcoma is also frequently seen in adults who present with fleshy, 
friable, exophytic masses that often extend through tissue planes to involve 
periosteum and underlying bone. The closely related locally aggressive Kaposi's 
sarcoma is less common and presents with swelling and marked induration of the 
hand or foot, commonly with adjacent bony involvement (Taylor et al., 1971b). 
Survival in these two forms of Kaposi's sarcoma can be prolonged with 
chemotherapy, although the prognosis is worse than the local form. Untreated the 
lesions are locally destructive and may lead to death within a year (Armes,1989).
Disseminated Kaposi's sarcoma
In the pre-AIDS era, disseminated or generalised Kaposi's sarcoma was very rare 
and occurred most commonly in younger adult and female patients (Kyalwazi,1981). 
It is now the form described most commonly in patients with HIV infection. In 
disseminated endemic Kaposi's sarcoma skin lesions accompany widespread 
visceral involvement. However, in contrast to patients with AIDS, internal organ 
involvement (most commonly the liver, lungs, adrenals, and small intestine) in 
patients with endemic Kaposi's sarcoma was usually silent and discovered only at
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postmortem examination (Desmond et al.,1991). The prognosis of this form of 
endemic Kaposi's sarcoma is poor.
Endemic Kaposi's sarcoma in childhood
The lymphadenopathic form of endemic Kaposi's sarcoma is a variant that occurs in 
African children. Skin lesions are either absent or sparse and then atypical in site 
and form. The lymph nodes are however characteristically infiltrated by massive, 
symmetrical tumour deposits. These children usually succumb to the disease within 
one year of the diagnosis (Armes,1989). Kaposi's sarcoma in children therefore has 
several distinctive features: (1) occurrence of lymph nodes in the absence of skin 
involvement; (2) predilection for eyelids, lacrimal glands, jaw, parotid, and other 
salivary glands; (3) poor patient survival; (4) and a lower male-to-female ratio than 
seen in adult Kaposi's sarcoma (Olweny et al., 1976).
Prognosis
It has been reported that the prognosis in endemic Kaposi's sarcoma depends on the 
clinical pattern at presentation (Templeton et al., 1975). The age and sex of patients 
influence the pattern of disease likely to be found but the prognosis for a given 
clinical pattern was the same in both sexes and at different ages 
(Harawi,1989;Templeton et al., 1975). The only deaths among the patients with the 
nodular form of the disease were due to intercurrent sepsis. The mean 3-year 
survival of patients with locally aggressive disease was 64%. All patients with 
generalised Kaposi's sarcoma died of their disease after a mean period of 2 years 
(Templeton ef a/.,1975).
Epidemiology of Kaposi's sarcoma in Africa in the AIDS era
The onset of the HIV epidemic has had a profound impact on the epidemiology of 
Kaposi's sarcoma in Africa. The first cases of Kaposi's sarcoma in black African 
patients were reported from Belgium. Clumeck et al. (1984) described 3 cases of 
Kaposi's sarcoma in 22 Zairean patients with AIDS. Another report from Zambia 
described a group of patients younger than those with endemic Kaposi's sarcoma 
with atypical lesions such as generalised symmetrical lymphadenopathy, 
oropharyngeal and gastrointestinal tract lesions, respiratory distress and gross
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weight loss. Skin lesions were seen in unusual sites such as the face, trunk and 
genitalia (Bayley et al., 1985). This group of atypical Kaposi's sarcoma patients 
compared to those with endemic Kaposi's sarcoma are younger (Armes,1989), 
usually are of a higher socioeconomic class, and include a relatively higher number 
of female patients (Coker et al., 1986). It is also characterised by a poor response to 
conventional therapy and early deaths (Bayley et al., 1985). Subsequent reports 
originating from other parts of Africa confirmed that Kaposi's sarcoma was part of the 
clinical spectrum of HIV-related diseases in Africa and current data suggested that 
approximately 5-15% of African AIDS patients present with Kaposi's sarcoma 
(Desmond et a/.,1991; Piot et al., 1984; Van de Perre et al., 1984).
Serology in the two forms of Kaposi's sarcoma
Serologic studies have made it apparent that two populations of Kaposi's sarcoma 
patients now exist in Africa: "atypical" or epidemic Kaposi's sarcoma associated with 
HIV-1 infection and endemic Kaposi's sarcoma which is not associated with retroviral 
infection. In the serologic study reported by Bayley et al. (1985), the enzyme-linked 
immunosorbent assays (ELISA) for HIV were positive in 95% of African patients with 
epidemic Kaposi's sarcoma. In contrast only 16% of patients with endemic Kaposi's 
sarcoma were HIV-positive. In other endemic areas serology for HIV-1 was 
consistently negative (Biggar et a/.,1984c;Otu,1988). As indicated earlier, patients 
with "atypical" Kaposi's sarcoma had lesions in unusual sites such as lymph nodes, 
liver, spleen, lungs, and gastrointestinal tract. Kaposi's sarcoma has also been 
described in HIV-2 infection. In a recent report 4 of 17 (24%) AIDS patients had 
Kaposi's sarcoma (Clavel et al., 1987). Kaposi's sarcoma in African patients can 
therefore occur in patients without HIV or in patients with either HIV-1 or HIV-2 
infection.
Changes in the epidemiology
In areas with a high prevalence HIV-1 infection, there are now more cases of 
epidemic than endemic Kaposi's sarcoma and this has been associated with a 
marked change in the age and sex distribution of Kaposi's sarcoma in these 
countries. Wabinga (1993) compared Kaposi's sarcoma patients diagnosed by
Stellenbosch University http://scholar.sun.ac.za/
Epidemiology o f KS 8-11
Table 8-3. Changing demography of Kaposi's sarcoma in Uganda
Period 1964-1968 1983-1987 1988-1990
Patients (no.) 314 407 362
Peak age (yrs) 40-49 20-29 20-29
Male:Female 14:1 5:1 4:1
Disseminated disease (%) 5 47 77
Adapted from Desmond et al. (1991).
pathology in Uganda from 1964 to 1968 with those from 1984 to 1987 and found that 
Kaposi's sarcoma patients in the post-AIDS era were younger and more likely to be 
women. Interestingly, in 1964-1968 patients who developed generalised disease 
were more likely to be women but by 1983-1987, men were more prone this form of 
the disease. Some of the demographic changes in Kaposi's sarcoma in Uganda are 
shown in Table 8-3. The demographic changes in Kaposi's sarcoma have been 
noted in other African countries. In Malawi a six-fold increase in Kaposi's sarcoma
Table 8-4. Endemic vs. Epidemic Kaposi's sarcoma in Zambia
Endemic Epidemic
Peak age 5th decade 3rd decade
Females (%) 5-12 25
Pattern Nodular, Aggressive Disseminated
Constitutional symptoms Absent Weight loss
Response to treatment Excellent Poor
Course Indolent Fatal
HIV + (%) 25 90
Relative incidence (%)
1975-1982 80 20
1983 50 50
1984 40 60
1985 25 75
Adapted from Bayley (1991), Downing et al. (1984)
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among women has been noted from 1983 to 1988 and the male to female ratio 
declined from 10:1 to 3:1 (Liomba et al., 1989). In Zimbabwe, the male to female 
ratio was 4.6:1 with the mean age 34 years in men and 31 years in women (Latif et 
al., 1989). In Uganda the comparative gender ratio is 2:1 and the peak ages 35-39 
years in males and 25-29 years in females (Wabinga et al., 1993). The Zambian 
experience with Kaposi's sarcoma is shown in Table 8-4.
Epidemic (AIDS-associated) Kaposi's sarcoma
Since its initial description in July 1981 in association with Pneumocystis carinii 
pneumonia in homosexual men, Kaposi's sarcoma has remained one of the major 
hallmarks of AIDS (Friedman-Kien et al., 1981). In 1985 and 1986 Kaposi's sarcoma 
occurred in 28-33% of patients with AIDS in the USA (Centers for Disease 
Control, 1986;Haverkos et al., 1985a). Kaposi's sarcoma was the primary disease in 
25% of the AIDS cases and in 15% it was the only manifestation of the illness 
(Centers for Disease Control, 1986). On the basis of Kaposi's sarcoma incidence 
rates in the USA from 1973 to 1979, the overall risk of Kaposi's sarcoma in AIDS 
patients is more than 20 000 times that of the general population and 300 times that 
of other immunosuppressed patients (Beral et al., 1990). The clinical patterns of 
epidemic Kaposi's sarcoma are a combination of noninvasive mucocutaneous 
lesions and of disseminated disease.
At risk groups
Early reports
Kaposi's sarcoma varies markedly in incidence in the different groups at risk for 
AIDS. Early data from the Centers for Disease Control (CDC) in Atlanta, Georgia in 
the USA showed that Kaposi's sarcoma occurred in 36% of homosexual men 
compared to 10% of Haitians, 4.3% of intravenous drug abusers and 1.4% of 
haemophiliacs (Haverkos et al., 1985a). Kaposi's sarcoma occurred in 12.5% of 
female drug abusers while ethnicity did not alter the incidence of the disease in the 
various risk groups (De Jarlais et al., 1984). The majority (95%) of Kaposi's sarcoma 
cases occur in HIV-infected homosexual men. Other important observations are that 
the infants of mothers with Kaposi's sarcoma and perinatally acquired HIV have in no 
instance developed Kaposi's sarcoma (Gutierrez-Ortega et al., 1989). There are
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some reports, however, of heterosexual couples in which both partners had AIDS 
and developed Kaposi's sarcoma (Bary et a/.,1991 ;Janier et al., 1990).
Later reports
More recent data, however, show a lower incidence of Kaposi's sarcoma in 
homosexual males but it remains the group at greatest risk for Kaposi's sarcoma 
(Table 8-5). Male patients account for 98.3% of all HIV-related Kaposi's sarcoma 
(Drotman et al., 1995). This unequal distribution of Kaposi's sarcoma among persons 
with AIDS provides an important clue to the aetiology of Kaposi's sarcoma. 
Remarkably similar distributions of Kaposi's sarcoma have been reported from the 
United Kingdom, Italy, Spain, and Australia (Beral,1991;Serraino et al., 1992).
Table 8-5. Number of adult patients with AIDS who develop Kaposi's sarcoma, by 
risk group and gender in the USA until 1994.
HIV Risk Group Gender % with KS
Homosexual/Bisexual Male 19.1
Homosexual/Bisexual and Male 15.7
intravenous drug abuser
Born in Caribbean/Africa Male 5.4
Female 4.2
Heterosexual partner of person Male 6.4
born in Caribbean/Africa
Female 2.5
Blood transfusion Male 3.9
Female 1.6
Haemophilia Male 1.2
Female 0
Total Male 14.1
Female 1.6
Adapted from Drotman et al. (1995).
Stellenbosch University http://scholar.sun.ac.za/
Epidemiology o f  KS 8-14
Kaposi's sarcoma in homosexual men
Declining proportion of Kaposi's sarcoma
The proportion of homosexual men who develop Kaposi’s sarcoma has been 
decreasing, possibly as the result of practice of safer sex procedures (Roth, 1991). 
In 1981 63% of homosexual men with AIDS in San Francisco had Kaposi's sarcoma 
while in 1985 this incidence was 24% (Drew et al., 1988). The relative incidence of 
AIDS-associated Kaposi's sarcoma has been decreasing in all patients at risk: 
Kaposi's sarcoma was the initial diagnosis in 33% of the first 1000 Centers for 
Disease Control (CDC) reported cases compared to only 10% of 1100 cases 
reported to the CDC between January and August 1987 (Des Jarlais et al., 1987). At
Homosexual or 
bisenuel mala
Homosexual nr 
b isexual mats 
and intravenous 
drug usar
Heterosexual, born 
inC arlbbean /A lrica
Transfusion 
'“ 7" .re c ip ie n t, mals
Intravenous 
drug user, mal b 
< /  Transfusion
recip ient, female" 
Intravenous 
drug user female
i ^ ' O l h e r ’hetafosexuai, 
1988 female
Fip. 8-2 Percentage of AIDS patients with Kaposi's sarcoma by year of diagnosis of 
AIDS and risk group for period 1983-1988. Modified from Beral et al. (1990).
the onset of the epidemic Kaposi's sarcoma occurred in 40% of patients with AIDS 
(all risk groups) but this was down to 28% by 1985 (Haverkos et al., 1985a). The 
relative decline using a logistic model has been 26% per year in homosexual men 
and 20% per year in the other AIDS risk groups (Beral et al., 1990) (Fig. 8-2). 
However, as more HIV-infected patients are diagnosed with AIDS the actual number 
of cases and hence the incidence of Kaposi's sarcoma has continued to increase 
because the latter is calculated from prospectively collected data from cohort
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populations followed up over time with known infection rates (Chow et 
al., 1989;Jacobson efa/.,1990).
Problems with the interpretation of the perceived declining incidence 
The variations in the occurrence of Kaposi's sarcoma in AIDS patients may be 
artifactual due to different analytical approaches, or may be a real reflection of 
differences in exposure or host susceptibility (Jacobson et al., 1995). A problem in 
reviewing population rates is that the size of the populations at risk are generally 
unknown. In addition, inferences based on using the proportion of Kaposi's sarcoma 
among AIDS cases need to account for the relative increases of other AIDS 
diagnoses. If, for example the number of other opportunistic AIDS infections 
increases each year, the relative number of Kaposi's sarcoma among all cases 
would decrease (Jacobson et al., 1995). Plausible explanations for the observed 
temporal differences in the occurrence of Kaposi's sarcoma exist. Attenuation of 
exposure to the aetiological agent may have occurred in specific populations. This 
together with a fixed latency between agent and disease would result ultimately in a 
decrease in the number of cases (Jacobson et al., 1995). Also, given the high 
mortality of Kaposi's sarcoma with more than 50% of patients dying within two years 
of presenting with an AIDS-defining illness (Bacchetti et a/.,1988;Bindels et 
a/.,1991 ;Friedland et al., 1991;Jacobson et a/.,1993;Lemp et a/.,1990;Rothenberg et 
al., 1987), HIV-1 infected individuals presenting with another illness may die prior to 
developing Kaposi's sarcoma (Jacobson et al., 1995).
Early in the epidemic, AIDS reporting was more comprehensive in that surveillance 
data were updated with each illness that an AIDS patient developed. Subsequently, 
for the most part, the only illnesses reported to the public health authorities are those 
apparent when AIDS is diagnosed. Although underreporting could play a role in the 
decrease in the reported cases of Kaposi's sarcoma, a study in San Francisco that 
did extensive follow-up of all AIDS patients failed to confirm underreporting of 
Kaposi's sarcoma (Rutherford et al., 1989). In the Multicenter AIDS Cohort Study, 
the decline in the percentage of patients with Kaposi's sarcoma was minimal 
(Jacobson et al., 1990). Some authors have attributed part of the decline to the 
shorter incubation period for AIDS when the manifestation is Kaposi's sarcoma
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rather than Pneumocystis carinii pneumonia (Lifson et al., 1990a). The first patients 
to be diagnosed in the AIDS epidemic would be the ones with the shortest incubation 
periods and the ones most likely to have Kaposi's sarcoma. This phenomenon 
explains that as persons with the longer incubation periods are diagnosed the 
percentage with Kaposi's sarcoma would seem to decrease (Drotman et al.,1995). 
Other authors have suggested additional hypotheses to explain the phenomenon of 
apparent decline in the proportion of patients with AIDS who develop Kaposi's 
sarcoma (Beral et a/.,1990;Centers for Disease Control,1987;Haverkos et 
a/.,1985b;Haverkos,1990;Lifson et a/.,1990b;Reynolds et al., 1990;Rutherford et 
a/.,1990;Winkelstein, Jr. et al., 1988). Large decreases in the incidence of Kaposi's 
sarcoma in AIDS patients have also been reported from other countries such as Italy 
(Serraino et al., 1992).
Geographic variation in incidence: Homo- and bisexual males 
An important observation is that the risk of Kaposi's sarcoma is not geographically 
uniform in homosexual men with AIDS. Therefore, in the USA and UK, homosexual 
and bisexual men with AIDS are more likely to have Kaposi's sarcoma if they live in 
foci of the AIDS epidemic. In the USA, the incidence ranges from 3% in Kansas and 
6% in Iowa, to 30% in California and 31% in New York (Beral et al., 1990). It has 
also been found that homosexual men who resided in either California or New York 
are at greater risk for the development of Kaposi’s sarcoma than are homosexuals 
residing in other areas (Schechter et a/., 1991). Moreover, it was found in Vancouver 
that men were more likely to have Kaposi's sarcoma if they had had sexual relations 
with a man from San Francisco, Los Angeles or New York (Archibald et al., 1992). 
Homosexual men from Baltimore, Pittsburg and Chicago were also more likely to 
have Kaposi's sarcoma if their partners were from San Francisco (Drotman et 
al., 1995). In the United Kingdom, homosexual and bisexual men from London are 
twice as likely to have Kaposi's sarcoma as are men from other areas (Beral et 
al., 1991). Also in the United Kingdom, homosexual men were also more likely to 
have Kaposi's sarcoma if their partners were from the USA or Africa (Beral et 
al., 1991). A similar pattern of Kaposi's sarcoma is also seen in among persons who 
acquired HIV infection through other routes, such as sharing needles or heterosexual 
contact, but the relative risks are not as high (Drotman et al., 1995). Geographical
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clustering has also been observed in other countries (Pedersen et a/.,1990;Selik et 
al., 1987). Women with AIDS were four times more likely to have Kaposi's sarcoma if 
their partners were bisexual males rather than intravenous drug abusers (Beral et 
al., 1990;Biggar et a/.,1985;Biggar et al., 1989).
Geographic variation in incidence: Heterosexual persons
The risk of Kaposi's sarcoma is especially high in HIV-positive subjects who originate 
in Africa or the Caribbean countries (Table 8-6). The proportion of heterosexual 
AIDS patients who are reported to have Kaposi's sarcoma ranges from 8-18% in 
Africa and 6-9% in the Caribbean (Beral,1991). This contrasts with the rates in AIDS 
patients born in the USA or UK, in whom the incidence Kaposi's sarcoma is less than 
1% (Beral,1991). The incidence of Kaposi's sarcoma was high in Africa before the 
onset of the AIDS epidemic. It may be that African subjects are asymptomatic 
carriers of the agent that causes Kaposi's sarcoma. The incidence of Kaposi's
Table 8-6. Kaposi's sarcoma in heterosexual AIDS patients by country of origin
Country of origin Incidence 
of KS (%)
Reference
Africa
Rwanda 18 Van de Perre et
al., 1984
Zaire 16 Piot et a/. ,1984
Zaire (Resident in UK) 14 Clumeck et al., 1984
Africa (Resident in 13 Beral et al., 1991
Belgium)
Africa (Resident in USA) 8 Beral et al., 1990
Caribbean
Haiti 9 Beral et al. ,1990
Excluding Haiti 6 Beral et al., 1990
USA/Europe
USA 1 Beral et al., 1990
UK 0 Beral et a/., 1991
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sarcoma in the Caribbean before the onset of the AIDS epidemic is largely unknown. 
In Puerto Rico the incidence of Kaposi's sarcoma was higher than in the rest of the 
USA (Biggar et al.,1984a) and it may well be that the asymptomatic carrier rate is 
also higher than in the US population accounting for the high risk in this group 
(Beral,1991).
Risk factors for Kaposi's sarcoma in male homosexuals
Kaposi's sarcoma is rarely diagnosed among those who acquired the disease 
parenterally, haemophiliacs and intravenous drug abusers (Table 8-5) (De Jarlais et 
a/.,1984;Haverkos et a/.,1990;Jaffe, 1990;Selik et al., 1987). Concomitant with the 
AIDS epidemic, Kaposi's sarcoma has been reported in young male homosexuals 
not infected with HIV-1 (Friedman-Kien et al., 1990). Results from case-control and 
cohort studies among homosexual men infected with the HIV-1 have provided 
evidence for behavioural risk factors for the disease (Archibald et al., 1992;Goedert et 
a/.,1987;Haverkos et al., 1985b;Jacobson et al., 1990;Jaffe et a/.,1983;Marmor et 
al., 1982). In the earliest studies there were significant but nonspecific, associations 
of Kaposi's sarcoma with sexual behaviour including the number of sexual partners, 
history of sexually transmitted diseases and number of partners from bathhouses. In 
addition there was an association with the use of recreational drugs (Haverkos et 
al., 1985b;Jaffe et al., 1983;Klepp et al., 1978). The postulation of nitrite inhalant 
abuse predisposing to Kaposi's sarcoma arose from its use as a sexual stimulant by 
homosexual men (Haverkos et al., 1990). Although some investigators have 
demonstrated an association between nitrite inhalant use and Kaposi's sarcoma 
(Haverkos et al., 1985b;Marmor et al., 1982), this finding has not been confirmed by 
subsequent studies of larger well-defined populations (Armenian et a/.,1993;Goedert 
et a/.,1987;Jacobson et a/.,1990;Lifson et a/.,1990a;Polk et al., 1987). Similar 
associations of Kaposi's sarcoma with other types of recreational drugs such as 
marijuana and hashish, make this causal hypothesis less plausible (Archibald et 
al., 1992). It has been suggested, that nitrites, which are vasodilators, may facilitate 
the transmission of an infectious agent during sexual intercourse (Archibald et 
al., 1992). Although, the association between Kaposi's sarcoma and increased 
sexual activity has been demonstrated in most studies, specific risk behaviour has 
not been consistently identified (Jacobson et al., 1995). Several reports have
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demonstrated an association with sexual activity in which exposure to faeces was 
likely (Beral et al., 1990;Jacobson et al., 1990) but this observation was not 
consistently corroborated (Archibald et al., 1992;Elford et a/.,1992;Lifson et 
a/.,1990a;Matondo,1992). As an indicator of sexual activity, history of prior sexually 
transmitted infections was most consistently associated with Kaposi's sarcoma 
(Haverkos et al., 1985b). In a recent study the risk of Kaposi's sarcoma was shown 
to be additive with the number of sexually transmitted infections (Armenian et 
al., 1993). In the same study it was found that any partner from the West Coast of 
America, use of inhaled nitrites, and the number of male sexual partners in the 
preceding two years also increased the risk of Kaposi's sarcoma in HIV-1 infected 
homosexual men (Armenian et al., 1993). These associations with sexual activity 
and infections are consistent with a putative infective cofactor that is sexually 
transmitted. In addition to the sexual aspects of Kaposi's sarcoma transmission, 
Kaposi's sarcoma is more frequent in among whites than among black AIDS 
sufferers (Centres for Disease Control, 1982; Haverkos et al., 1982).
Incubation period of Kaposi's sarcoma
Kaposi's sarcoma is usually not a late complication of the immunocompromised 
state. In 80% of cases in which Kaposi's sarcoma occurs, it is the presenting 
symptom (Lifson et al., 1990a). Studies of transfusion recipients (Beral et al., 1990) 
and homosexual men (Lifson et al., 1990a) indicate that the time between HIV 
infection and the onset of AIDS is shorter for those with Kaposi's sarcoma than those 
with other manifestations of AIDS. When the time between transfusion and the 
onset of AIDS was compared between those who had Kaposi's sarcoma and 
Pneumocystis carinii pneumonia, the incubation period was consistently found to be 
6.6 month longer in the latter (Beral et a/., 1990).
The initial lesions of AIDS-associated Kaposi's sarcoma occur in many different sites 
and systemic spread is common (Hutt,1984b). The earliest skin lesions are often 
difficult to diagnose both clinically and histopathologically (Gottlieb et al., 1982).
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Iatrogenic Kaposi's sarcoma
The first cases of Kaposi's sarcoma related to the use of immunosuppressive agents 
were reported soon after renal transplantation became clinically accepted as a form 
of renal replacement treatment (Hardy et a/.,1976;Siegel et al., 1969). 
Approximately 15% of cases of Kaposi's sarcoma seen in Europe and North America 
prior to the onset of the AIDS epidemic were due to immunosuppressive treatment 
(Harwood et al., 1979a;Klepp et al., 1978). The very first case of Kaposi's sarcoma in 
a renal transplant recipient provides some clues as to the epidemiological nature of 
the disease that was to unfold subsequently.
The first case
The first case of Kaposi's sarcoma to occur following renal transplantation was a 35- 
year old black female patient suffering from chronic renal failure due to chronic 
pyelonephritis (Siegel et al., 1969). The patient received a renal allograft that 
functioned well initially but was complicated by the development of mild acute 
rejection, which responded to local irradiation and high-dose steroids. She had a 
second rejection episode 4 months after the transplant. This proved to be more 
resistant to treatment requiring 3 successive doses of cactinomycin, and two courses 
of local irradiation before the renal function stabilised at a creatinine clearance of 35 
ml/min. The patient had several infective complications and pre-terminally she 
developed a serious Pseudomonas and Aerobacter sinus infection that induced her 
physicians to withdraw all immunosuppression and resume haemodialysis. She 
developed acute and severe respiratory distress eight months after the transplant 
and died despite aggressive attempts at resuscitation. At postmortem examination 
she was found to have extensive visceral Kaposi's sarcoma involving the lungs, 
oesophagus, bladder, stomach, mediastinal and retroperitoneal lymph nodes. 
Unusually, no skin lesions were note either ante- or postmortem (Siegel et al., 1969).
Siegel and his colleagues (1969) recognised the uniqueness of their case because 
they knew Kaposi's sarcoma to be a disease of elderly men of Caucasian origin with 
a benign course in general. In this instance, the patient was young, female and 
black while the disease followed a very aggressive course. The authors made the 
astute suggestion that the tumour was related " . . .  to the alterations in the immune
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status of the host". They observed that Kaposi's sarcoma not uncommonly occurred 
with other malignancies (Bluefarb,1957) that were associated with ". . . reduced or 
abnormal immune response, similar in many ways to that produced by the use 
immunosuppressants . . ." (Smith,1968). Another important association that they 
made was that between viral infection and certain tumours. Siegel et al. (1969) 
stated ". . .virus-like particles have been reported in the plasma of patients with 
reticulum cell sarcoma, Hodgkin's disease, lymphomas, and a variety of leukaemias,
. . ." (Newell et al., 1968). In addition they noted that Henle et al. (1968) had 
demonstrated the presence of high titres of anti-Epstein Barr Virus (EBV) in 100% of 
Burkitt's lymphoma patients. They predicted, "If there are oncogenic viruses with 
pathogenicity in man, it seems very likely that we will see an increasing incidence of 
neoplasia associated with homograft rejection in patients undergoing 
immunosuppressive therapy" (Janier et al., 1990). And how correct they were in their 
predictions!
Two other early reports
Other cases of Kaposi's sarcoma were described in the early and mid-1970's. In the 
earlier report 2 cases were described (Myers et al., 1974), both patients were young 
and had Kaposi's sarcoma soon after transplantation (the 36-year old female patient 
developed the disease at 9 months after transplant and the 27-year old male at 7 
months); the race/ethnicity of the patients was not mentioned. The female patient 
had non-Hodgkin's lymphoma of the brain but was free of Kaposi's sarcoma when 
she died of Pseudomonas aeruginosa septicaemia 31 months after transplantation. 
Azathioprine was discontinued but she maintained renal function albeit impaired until 
her death. In the male patient, the skin lesions of Kaposi's sarcoma eventually 
disappeared but only after all immunosuppressive treatment was discontinued. 
Hardy et al. (1976) described a 48-year old Puerto Rican patient who developed 
Kaposi's sarcoma 9 months after renal transplant. Azathioprine was discontinued 
which led to complete regression of the lesions.
First series
Penn compiled the first series of cases of de novo Kaposi's sarcoma to occur 
following organ transplantation in the late 1970s. This series highlighted the high
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incidence of Kaposi's sarcoma in organ transplant recipients in whom it comprised 
3% of all de novo malignancies (Penn,1979a), giving rise to the description of this 
epidemiological type of Kaposi's sarcoma. The Denver Transplant Tumor Registry 
that was initiated by the late Dr Israel Penn collected information on malignancies in 
organ transplant recipients from transplant centres around the world. By 1978 the 
Registry had collected details on 630 de novo malignancies that had occurred in 604 
organ transplant recipients, most of whom had received renal allografts. Of these, 
20 (3.2%) were Kaposi's sarcoma. In comparison the incidence of Kaposi's 
sarcoma in the general population in the USA was less than 0.6% of all cancers 
(Caro, 1975). It was also noted that the average age of 42 years (range: 23 to 59) in 
these patients was considerably less than that of patients who had classic Kaposi's 
sarcoma in whom the peak incidence was in the seventh decade but comparable to 
those patients who had African (endemic) Kaposi's sarcoma in whom the disease 
peaked in the fourth decade (vide supra) (Caro,1975). Penn (1979) also noted that 
the male preponderance of iatrogenic Kaposi's sarcoma (with a ratio of 2.3:1) was 
considerably less than that of the classic type (with a ratio of 15:1) 
(Templeton,1981). In this initial report a spectrum of ethnic and racial groups, 
including black patients, were found to be affected. However, of the 20 cases in this 
report, 2 were white South Africans of Portuguese descent. Also noted, were 
concomitant malignancies in two patients with non-Hodgkin's lymphoma and colonic 
cancer, respectively. The patients were all heavily immunosuppressed.
Steroids and Kaposi's sarcoma
Although Kaposi's sarcoma has been associated with a spectrum of patients 
receiving chronic immunosuppressive therapy, beside that for organ transplantation 
(Gange et a/.,1978;Kapadia et a/.,1977;Klein et a/.,1974;Leung et al., 1981), the 
number of cases of steroid-induced Kaposi's sarcoma reported in the literature only 
totaled 18 by 1987 (Schulhafer et al., 1987). The male to female ratio in the latter 
report was 4:1 and all the patients, but 2, were aged more than 60 years. The 
majority of these patients presented with lesions on the legs typical of sporadic 
Kaposi's sarcoma. The course of the disease was benign with only 2 deaths directly 
due to the Kaposi's sarcoma. A study from Israel of patients on steroids 
demonstrated a genetic susceptibility in persons of Italian and Mediterranean
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descent (Trattner et al., 1993). The number of patients on steroid 
immunosuppression who have Kaposi's sarcoma is very small if the extent of the use 
of steroids for a variety of medical conditions is taken into consideration.
Organ transplant recipients
Most of the patients on prolonged immunosuppressive therapy at present are 
recipients of organ transplants (Harwood et al., 1979a;Myers ef a/.,1974). It has been 
estimated that approximately 16% of these patients develop de novo malignancies at 
an average of 37 months after transplantation. If non-melanoma skin malignancies 
and in-situ carcinoma of the cervix are excluded, then malignant lymphoma accounts 
for 25% of these cancers and Kaposi's sarcoma some 5%. Kaposi's sarcoma is the 
first malignancy to appear, presenting, on average, 16 months after transplantation. 
Malignant lymphomas are the next neoplasms to appear, presenting at a mean of 32 
months (Harawi,1989). Considering the number of patients receiving 
immunosuppressive therapy, the overall risk of developing iatrogenic Kaposi's 
sarcoma is very small (Klepp ef al., 1978). Other factors, including genetic 
susceptibility and the prevalence of human herpesvirus 8 (HHV-8) in the community, 
are likely to potentiate the effect of the immunomodulating drugs (Harawi,1989). The 
genetic susceptibility is supported by the data of Harwood ef al. (1979b) who report 
7 cases of iatrogenic Kaposi's sarcoma among 44 cases of Kaposi's sarcoma. All 7 
patients with iatrogenic Kaposi's sarcoma were either Jewish or of Mediterranean 
ancestry, as were 40 of the 44 patients with all types of Kaposi's sarcoma. There 
were four patients with Kaposi's sarcoma following renal transplantation in a cohort 
of 100 recipients of similar ethnic background i.e. Jewish or Mediterranean ancestry. 
This represented a 400- to 500-fold increase in the incidence of Kaposi's sarcoma in 
renal allograft recipients compared with a control population of the same ethnicity 
(Harwood ef al., 1979b).
Highest incidence
Saudi Arabia currently has the highest incidence of iatrogenic Kaposi's sarcoma ever 
reported (Akhtar ef a/.,1984;Qunibi ef al.,1993). The incidence of Kaposi's sarcoma 
in renal allograft recipients was 5.3% of 263 patients transplanted over 11 years 
(Qunibi ef al., 1993). This is much higher than the 0.18% - 0.3% in recipients in the
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USA (Penn,1986) or the 1.6% in a recent Italian study (Montagnino et al., 1994). In 
the series of renal transplant recipients from Saudi Arabia, Kaposi's sarcoma 
accounted for 87.5% of all malignancies! (Qunibi et al., 1993). In Britain, the USA 
and Australasia Kaposi's sarcoma is far less common than transplant-associated 
lymphoma (Kinlen et a/.,1981;Penn,1988). If the crudely calculated incidence of 28 
per 100 000 population of Kaposi's sarcoma in the Saudi population is correct, 
Kaposi's sarcoma may be more common in this population than in other 
Mediterranean people. The male to female ratio was 1.5:1, which was similar to the 
ratio of patients receiving renal allografts (Qunibi et al., 1993). The mean interval after 
transplantation to the occurrence of the Kaposi's sarcoma was 15.6 months.
Epidemiological variables
The mean age of patients with iatrogenic Kaposi's sarcoma is 42 years and the male 
to female ratio 2:1. This ratio is similar to the gender ratio of the patients undergoing 
renal transplantation. Unlike the endemic or classic Kaposi's sarcoma there is no 
marked male excess of iatrogenic Kaposi's sarcoma. Lesions tend to occur soon 
after transplantation and the disease process can be reversed or at least halted by 
the withdrawal of the immunosuppressive therapy (Penn,1988). This suggests that 
there may be symptom-free carriers of the causal agent and that 
immunosuppression results in clinical expression of the disease in carriers. Thus, an 
individual's immunological status probably determines whether Kaposi's sarcoma is 
expressed clinically and also the severity of the disease as well as the anatomical 
distribution of the associated lesions (Beral,1991). Of the 68 cases of post-organ 
transplantation Kaposi's sarcoma recently reported, 72% had involvement limited to 
the skin and mucosa, while the remaining had visceral organ involvement. The 
outcome of the two groups was also markedly different with 51 % of the former going 
into remission on therapy, compared to only 16% of those with visceral organ 
involvement (Penn,1986). The mean duration of the therapy was 61 months if the 
patients received combination therapy (Gange et al., 1978). This is almost double 
compared to the 32 months in the present study.
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Table 8-7 A comparison of the largest series of posttransplant Kaposi's sarcoma
reported with the experience in the present study.
Year
Reported
No. of 
Patients
Incidence Latency
(Range)
mo
KS in 
1 year
M:F
Ratio
Mean Age 
(Range) 
yrs
Mucocut­
aneous
disease
Benign
Disease1
(%)
% of all 
Cancer2
Reference
Saudi
1987 12 3.4% 13.6
4-48)
NS3 2:1 36.9
(16-23)
91% 42 NS Al Sulaiman et 
a/., 1987
1988 14 5.30% 12.5
(1-37)
67% 1.8:1 38.6
(25-55)
93% 64 87.5 Qunibi ef a/., 1988
1993 25 4% 15.6
(1-63)
62% 1.5:1 39
(18-56)
92% 77 70 Szende et al., 1997
1994 35 4.7% 15.9
(3-89)
NS 2:1* 40
(11-63)
86% 71 76 Al Sulaiman MH et 
al., 1994
1997 39 4.8% 15.9
(3-89)
NS 2.5:1 40
(11-63)
87% 76 Shaheen et a/., 1997
CTTR
1979 20 - 16
(4-53)
NS 2.3:1 42 90% 55 4.9 Penn,1979b
1997 356 
Stellenbosch
21
(1-225.5)
46% 3:1 43 (4.5-67) 84% 60 5.7 Penn,1997
2001 21 3.9 32
(2.9-228)
38% 1:14 42 (27-54) 100% 71 65.6 Present Study
1 Benign disease is limited to the skin and/or lymph nodes
2 Excludes non-melanoma skin malignancies and in-situ carcinoma of the cervix.
3 NS is not specified
4 Corrected for the number of females transplanted 
5Age at transplantation
COMPARATIVE EPIDEMIOLOGY
The largest series of cases of Kaposi's sarcoma in organ transplant recipients are 
compared to the present study (Table 8-7). The Saudi's have the largest single 
centre experience while Dr Penn has accumulated the largest collection of cases 
from around the world.
Saudi experience.
Contributions to the Saudi experience have been made by several authors. Al- 
Sulaiman et al. (1987) were the first to report the unusually high incidence of 
Kaposi's sarcoma in the native Arab population treated at the Armed Forces Hospital 
in Riyadh. Among 350 renal transplant patients, 12 (3.4%) developed Kaposi's 
sarcoma. The mean age of patients who had Kaposi's sarcoma was 36.9 years and 
of the 12 patients, 4 were females giving a gender ratio of 2:1. In the following year, 
Qunibi et al. (1988) of the King Faisal Specialist Hospital also in Riyadh, reported on
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their experience. Among 263 renal transplant patients treated over 11 years, 14 
cases of Kaposi's sarcoma were identified, an incidence of 5.3% with the lesion 
accounting for 87.5% of all tumours in this cohort. On the other hand the overall 
incidence Kaposi's sarcoma in renal transplant recipients in Western countries has 
been reported to be 0.4% (Odajnyk et al., 1985). In a subsequent report, 5 years 
later, Qunibi et al. (1993), confirmed the exceptionally high incidence of Kaposi's 
sarcoma in his patients. In the updated report, there were 25 (4%) patients who had 
Kaposi's sarcoma after renal transplantation in a cohort of 630 recipients. Both 
cadaveric and living donor renal allograft recipients were affected. Triple therapy 
and azathioprine were used as immunosuppression.
In a follow-up report from the Riyadh Armed Forces Hospital, Al-Sulaiman and Al- 
Khader (1994), found that the incidence of Kaposi's sarcoma among their renal 
transplant patients was 4.7% (35 cases out of 750 renal transplant recipients). In 
their patients the tumour accounted for 76% of all malignancies. A further update by 
the same group reported 4 additional cases giving an incidence of 4.8% among 800 
recipients (Shaheen et al., 1997). Saudi patients who had Kaposi's sarcoma included 
both living donor and cadaver donor organ recipients. Beside the high incidence, the 
other epidemiological features of the Saudi experience are comparable to that 
reported by Penn.
Our own data compare well with that of the Saudis. The proportion of our renal 
transplant patients who have Kaposi's sarcoma appears to be lower than that 
reported by the Saudis, in whom almost all the patients were of Arab origin. Our 
cohort of patients is not as homogenous as the Arab population. If only the non­
white patients in our cohort are considered then of the 357 transplanted over 23 
years, 19 had Kaposi's sarcoma, giving an incidence of 5.32%! one of the highest in 
the world. Kaposi's sarcoma accounted for 79.1% of malignancies in the non-white 
patients. Among the 185 white recipients of renal allografts Kaposi's sarcoma 
occurred in 2 patients, an incidence of 1.08%, which is significantly less than that of 
the non-white group. Kaposi's sarcoma comprised only 11.8% of all malignancies in 
the white patients. Further demographic data are given in Table 8-7. The marked 
difference in the incidence of Kaposi's sarcoma in the two racial groups in the same
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geographical area is emphasised by the present study. The racial difference in the 
incidence of Kaposi's sarcoma in persons residing in the same geographical region 
has been appreciated for African Kaposi's sarcoma. Interestingly, these 
observations were made in South Africa where it was established that the incidence 
of Kaposi's sarcoma was ten-fold greater in blacks than white in the same region 
(Oettle, 1962). However, our study is the first, we believe, to demonstrate this 
discrepancy in iatrogenic Kaposi's sarcoma.
The minor differences in the gender ratios between our report and that of the Saudis 
is almost certainly related to the differences in the relative number of males and 
females transplanted. Our male-to-female ratio of 1:1 has been corrected for the 
slightly greater number of males transplanted.
Penn Reports
Penn (1997) updated the original experience with Kaposi's sarcoma almost 2 
decades after his first report (vide supra) (Penn, 1979b). The average ages (Table 8- 
7) at which patients developed Kaposi's sarcoma remained unchanged despite the 
progressive increase in the age of the patients receiving dialysis. The only 
differences that were noticeable in the two reports were that Kaposi's sarcoma 
accounted for more posttransplant malignancies in the latter period (4.9% vs. 5.7%) 
and that the disease was followed a more malignant course in the earlier period 
(Table 8-7). The main criticism against the Penn reports is the failure to establish an 
incidence of Kaposi's sarcoma in organ transplantation. The reports can only allow 
comparisons with other forms of cancers. Compared to both the Saudi experience 
and our own, Kaposi's sarcoma rarely accounted for more than 5% of all 
malignancies in developed countries (Table 8-7, and Chapter 6); the latter also 
contains further discussion on the topic. It is interesting to note that the incidence of 
Kaposi's sarcoma among the white patients in our cohort was comparable to that of 
the transplant patients from developing countries, whereas the non-white patients 
suffered the same risk for Kaposi's sarcoma as their counterparts in developing 
countries.
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Explanation of differences
Since it has been established that the putative cause of Kaposi's sarcoma is the 
HHV-8 (Martin et al., 1998), it may be that the virus is considerably more prevalent 
among the poor, as many infections are. It could also be that the immunity of the 
less privileged allows the greater expression of the virus. The other possibilities are 
that there are genetic/ethnic differences that predispose to either the viral infection 
and/or the occurrence of Kaposi's sarcoma. However, although there have been 
some suggestions that certain HLA antigens may occur more frequently than others 
in Kaposi's sarcoma (Alamartine et a/.,1995;Hutt,1984b;Myskowski et 
a/.,1997;Shepherd et a/.,1997;Strathdee et al., 1996), no consistent relation to an 
HLA antigen has been demonstrated so far (Krown,1997;Sheil et al., 1997).
EPIDEMIOLOGICAL VARIABLES: THE HOST AND THE 
ENVIRONMENT
Age Distribution
Classic Kaposi's sarcoma
The incidence of Kaposi's sarcoma varies with age, depending on the type of 
disease. The mean age of the five adult patients described by Kaposi (1872), was 
54 years, and since then the age of onset of classic Kaposi's sarcoma has changed 
very little. Classic Kaposi's sarcoma occurs in the elderly patient, the average age 
being 63 years with the highest incidence being in the sixth through to eighth decade 
of life (Safai,1984). However, although the mean age remains high, review of the 
descriptive studies (Table 8-8) reveals that the classic form can occur in children 
much younger, as noted by Kaposi himself in his initial report.
Epidemic Kaposi's sarcoma
The epidemic form of Kaposi's sarcoma is seen in younger patients with the mean 
age of 39 years (Haverkos et al., 1982). Among homosexual men with AIDS in the 
USA, the percentage with Kaposi's sarcoma is higher among 25- to 44-year-old men 
than among those who were older or younger (Beral et al., 1990). The risk of 
Kaposi's sarcoma among homosexual and bisexual men with AIDS decreases 
rapidly with age to levels one third of those seen among 25- to 44-year-old men
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Table 8-8. Age at presentation of classic Kaposi's sarcoma
Country Period of No. of Age (yrs) Reference
study cases Mean Range
Germany/USA 1920's 15 54 22-83 Dorffel.1932
USA 1965 70 50-59 10-89 Reynolds et a/., 1965
USA 1954-1975 90 64 26-90 DiGiovanna et al., 1981
Norway 1970-1975 49 74 28-92 Klepp et al., 1978)
Greece 1984 10 >60 Papaevangelou et al., 1984
Sardinia 1984 12 69 57-78 Contu et al., 1984
Sweden 1958-1982 529 74 9-101 Dictor et al. ,1988a
Modified from Wahman et al. (1991).
(Beral et al.,1990). The typical finding for classical Kaposi's sarcoma of an increase 
risk with age is therefore not evident in men with AIDS - indeed the reverse is true 
with the risk being lowest of all in men with AIDS who are over 55 years of age. The 
age pattern has changed over time in the USA with the younger men showing the 
greater proportionate decline in risk of Kaposi's sarcoma than older men 
(Beral,1991). Some of the recent generation of young men would not have been 
sexually active until after the onset of the AIDS epidemic, and their relatively lower 
risk of Kaposi's sarcoma may reflect the declining incidence of venereal diseases 
and hence the likelihood of exposure to the causative agent (Beral, 1991).
Endemic African Kaposi's sarcoma
The African form of the disease as analysed by Davies and Lothe (1934) has a peak 
incidence in the first decade, rare cases in the second decade and then a 
progressive increase in incidence throughout adult life (Davies et al., 1934) (Fig. 8-3). 
Subsequently, endemic Kaposi's sarcoma was classified into 4 categories (Taylor et 
al., 1971b) (vide supra). Kaposi's sarcoma was recognised in two distinct age groups: 
young adults, with a mean age 35 years who generally had benign nodular disease, 
but occasionally aggressive or florid disease that was fatal within 5 to 8 years; and 
young children with a mean age of 3 years with fulminant lymphadenopathic disease, 
fatal within 2 to 3 years (Olweny,1984).
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Fia. 8-3 Age of Occurrence of all forms of African Kaposi's Sarcoma
(n = 990)
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This figure was drawn using data obtained from Biggar et a/.,1984b;Keen,1962;Kungu et 
a/.,1981;McHardy et a/.,1984;Oettle>1962;Phillips et a/.,1987;Schmid,1973;Slavin et a/.,1969;Taylor et 
al., 1971b
Iatrogenic Kaposi's sarcoma
Among iatrogenically immunocompromised patients with Kaposi's sarcoma, age is 
less strongly correlated with onset of the disease than is duration from initiation of 
immunosuppression (Penn,1979b;Stribling et al., 1978). The disease like the 
epidemic form tends to occur in younger patients with the mean age of around 40 
years. The mean age of 42 years in our own group of Kaposi's sarcoma patients is 
in line with the experience elsewhere (see Table 8-7). The forms of Kaposi's 
sarcoma therefore associated with severe degrees of immunosuppression appear to 
behave in a similar fashion. Classic Kaposi's sarcoma is therefore the only form of 
Kaposi's sarcoma that has a predilection for the elderly.
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Table 8-8. Variation in the gender ratio of classic Kaposi's sarcoma.
Year Reported Male: Female Reference
1872-1895 15:1 Kaposi,1895
1932 13:1 Dorffel,1932
1965 11:1 Reynolds et al., 1965
1968-1972 3:1 Dictor et al., 1988a
1970-1975 2:1 Klepp et a/.,1978
1981 3:1 DiGiovanna et al., 1981
1984 4:1 Papaevangelou et al., 1984
1985 3:1 Ross et al., 1985
Gender Distribution
All the patients described by Kaposi in his initial report were males and the early 
male-to-female ratio was reported to be 15:1 (Hutt, 1984a). Over the years there has 
been decrease in the ratio as indicated in Table 8-8. The decrease may be the 
result of an increasing prevalence of an agent cofactor in women or in heterosexual 
populations in general. If a sexually transmitted agent is indeed responsible, the 
sexual revolution of the 1960s may have contributed to the decrease in the sex ratio 
of Kaposi's sarcoma (Wahman et a/., 1991). The number of women with classic 
Kaposi's sarcoma remains small and most of the observations of the gender 
differences in the behaviour of the disease have been made in women with endemic 
African Kaposi's sarcoma.
Differences and possible explanations
African Kaposi's sarcoma is ten times or more common in men as in women (Table 
8-9); what is also striking here is the lack of significant variation of the sex ratio over 
the years. In a study of 34 women with Kaposi's sarcoma in Uganda, the mean age 
was 36.6 compared to 48 years in men (Templeton,1972). Among African women, 
the disease shows a different distribution of types with an increase in the generalised 
pattern, which behaves more aggressively. In all endemic areas the tumour occurs 
mainly in men, but the male-to-female ratio increases with age from 1.7:1 in the first
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Table 8-9. Occurrence of African Kaposi's sarcoma by gender.
Country No. of cases % Males Reference
Uganda 12 96 Hardy et al., 1976
Uganda 624 95 Hoxtell et al., 1977
Uganda 37 94 Holecek et al., 1978
Uganda 339 93 Herr et al., 1979
Tanzania 117 92 Sheil et al., 1980
South Africa 11 100 Birkeland,1983a
Tanzania 200 80 Birkeland,1983b
Zaire 14 93 Huang et al., 1995
South Africa 18 83 Lebbe et al., 1995
South Africa 117 90 Mihalov et al., 1996
Kenya 425 88 Buccianti et al., 1996
Nigeria 27 100 Foreman et al., 1997
decade to 15:1 or more in those over 60 years (Kalengayi et al., 1984). These 
observations suggest that some modifying factor, probably hormonal rather than 
chromosomal in nature, protect women (Templeton,1981). The X-chromosome is 
unlikely to bear a protective gene because it should also protect female children. 
Oestrogens have been used to treat males with Kaposi's sarcoma (Hurlbut et 
al., 1949), but with no success in patients with established disease (Templeton, 1981). 
Relatively few cases of Kaposi's sarcoma have been observed in pregnancy and 
during oral oestrogen therapy, but there does appear to be an acceleration of tumour 
nodule formation (Taylor et a/.,1971a). This may be due to the immunosuppression 
that occurs at this time, that abrogates any hormonal influences. Only scanty 
information is available on the relative frequency of the disease before and after the 
onset of the menopause. Available data do not give an indication whether resistance 
to disease was afforded by the hormonal milieu of an active menstrual cycle or by 
some other aspect of female physiology (Templeton,1981). Trauma has been 
suggested as playing a possible role in the aetiology of Kaposi's sarcoma. Blue- 
collar workers are more prone to the disease than office workers. Barefoot
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Fig. 8-4 The prevalence of Kaposi's sarcoma in the different AIDS risk groups by 
sex. Modified from Beral et al.(1990).
populations are more prone to the disease than those who wear shoes. It has been 
suggested that men are more likely to sustain repeated trauma to the extremities 
than women. While this is probably true for Europeans and Americans, this is not 
the case in many African tribes where women do the bulk of the manual labour. In 
these areas men are still much more prone to the disease at an age when life is 
sedentary and rather protected (Templeton,1981). In Africa, Kaposi's sarcoma in the 
AIDS era is a disease of heterosexual males. Kaposi's sarcoma occurs in only 3-8% 
of women with AIDS compared to 35% of men with the syndrome (Harawi,1989). No 
studies have compared the natural history of Kaposi's sarcoma in males and females 
but anecdotal evidence reports suggest that the clinical course of the disease may 
be worse in women than in men (Myburgh et al.,1987; Templeton et al., 1975; 
Templeton,1981).
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Epidemic Kaposi's sarcoma in developed countries (Fig. 8-4)
In contrast to the African experience, 95% of all cases of Kaposi's sarcoma in 
patients with AIDS in Europe and North America are homosexual men (Harawi, 
1989). Gender differences in the risk of epidemic Kaposi's sarcoma are more 
difficult to determine because of the confounding by route of transmission. The 
groups with the highest risk (homosexual men) and the lowest risk (persons with 
haemophilia) are essentially men (Drotman et al., 1995). The risks among 
transfusion recipients or intravenous drug abusers can be compared but the higher 
risk among men may be caused by misclassification of men who deny homosexual 
contact. If heterosexual men and women are compared, there would appear to be 
no major differences in risk of Kaposi's sarcoma by age or sex: among Caribbean- 
born people with AIDS living in the USA, 7% of males and 5% of females were 
reported to have Kaposi's sarcoma, while among African heterosexuals with AIDS 
14% of both men and women had Kaposi's sarcoma (Beral et al., 1990;Beral et 
al., 1991). However, in a study from Puerto Rico, it was reported Kaposi's sarcoma 
occurred in 4.5% of heterosexual females and 14% of heterosexual males, 
compared to 18% of homosexual males (Beral et al., 1990). Women exposed to 
different risks for AIDS, have varying risks of developing Kaposi's sarcoma as 
discussed above.
Iatrogenic Kaposi's sarcoma
The male-to-female ratio is the least in patients with iatrogenic Kaposi's sarcoma 
(Table 8-7). In all the larger series the ratio is < 3:1, and in our experience the 
incidence in males and females is the same once the correction is made for the 
number of patients who were transplanted. The reason for the almost equal sex 
distribution in the iatrogenic form of the disease is difficult to explain. The influence 
of the hormones that have been postulated to play a role (Templeton,1972), may be 
lost when patients become uraemic. Since the majority of patients who are reported 
with iatrogenic Kaposi's sarcoma are from developing countries, it may be that the 
agent responsible for Kaposi's sarcoma is more prevalent in these populations and 
that the infection is equally common in women and men. Although other forms of 
Kaposi's sarcoma are more common in men, females tend to have more severe 
disease (Wahman et al., 1991); however, none of the reports including the present
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study corroborate this observation for the posttransplant form of the disease. Since 
most of the observations are in African women with Kaposi's sarcoma it may be that 
they present later because of poorer access to health care facilities.
Geographical Variation
Classic Kaposi's sarcoma is found primarily in people of Mediterranean and 
Southern European countries and in people with ancestors from these regions. 
Reports from Greece and Italy have indicated the high prevalence of the disease in 
these regions (Contu et a/.,1984;Papaevangelou et a/.,1984;Papasteriades et 
a/.,1984;Robbins et al., 1986). Sardinia in Southern Europe has a prevalence of 1.8 
cases per 100 000 persons per year (Contu efa/.,1984), compared to 0.27 cases per 
100 000 persons per year in Sweden (Blohme et al., 1984) and 0.32 cases per 100 
000 persons per year in the USA (Ross et al., 1985).
Kaposi's sarcoma appears to be more common in sub-Saharan Africa than in the 
rest of the world (Fig. 8-1). The incidence peaks in central Africa and diminishing 
from there. Eastern Congo-Kinshasa (formerly Zaire) is the epicentre of high 
frequency of Kaposi's sarcoma where the tumour accounts for over 10% of all 
malignancies (before the onset of the AIDS epidemic) (Hutt,1984b). From there the 
proportional frequency declines to the west and the south. In most countries in the 
equatorial belt of Africa the tumour accounted for 3% of all malignancies and in some 
it is the fourth or fifth most common tumour in men (Hutt, 1984b). In South Africa, 
Kaposi's sarcoma accounts for ~1% of all malignancies among blacks 
(Hutt,1984a;Hutt,1984b). Within the geographic areas there are further 
regional/ethnic differences. In Asia and the Far East Kaposi's sarcoma occurs only 
sporadically and in most areas is extremely rare even in countries ecologically 
similar to sub-Saharan Africa (Hutt,1984b). Less than 3 cases had reported each 
from South America, Australia, and Asia by 1962 (Oettle, 1962).
Although techniques for the collection of data, accessibility to medical care and the 
completeness of reporting undoubtedly vary between countries, the differences in 
rates between the regions are believed to be true (Collier et al., 1988). Speculations 
to explain these differences have emphasised variations in climate (Taylor et
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al., 1972), altitude (McHardy et al., 1984), and exposure to insects or parasites 
(McHardy et a/.,1984;Williams et al., 1966) as risk factors for the disease. There are 
interesting similarities in the geographic distribution of endemic Kaposi's sarcoma 
and the African form of Burkitt’s lymphoma. However, despite the high concordance 
between the two diseases in regions, there are many epidemiological differences in 
patterns of disease (Hutt, 1981 ;McHardy et a/.,1984;Templeton,1981), and the 
parallels frequently drawn between these entities may be misleading.
Epidemic Kaposi's sarcoma
Geographic variations in the frequency of Kaposi's sarcoma among homo- and 
heterosexual men with AIDS have been discussed in detail above. Fig. 8-5 serves to 
emphasise the geographic variability of the disease in the USA with the highest rates 
occurring on the East coast and New York, both areas with very high rates of HIV 
infection.
c~i <ia%
I I Less Than 
100 AIDS
________ Cases_______________________________________________________ ______ ___________ ______
F/'q. 8-5 Geographic variation in the prevalence of Kaposi's sarcoma in white 
homosexual and bisexual men in the USA. Note the very high rates on the western 
seaboard and the New York region. Modified from Beral, (1991).
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Table 8-10. Frequency of Kaposi's sarcoma in renal transplant recipients
Country and Patients No. of renal Reference
city/region with KS (%) recipients
Australia: Sydney 0.17 4241 Sheil et al., 1987
Canada: Toronto 0.54 1300 Shepherd et al., 1997
England: London 0.31 1304 Webb et al., 1997
France:lle de France 0.45 6229 Farge,1993)
Lyon 0.48 2500 Touraine et al., 1996)
Germany: Hanover 0.06 1497 Behrend et al., 1997
Italy: Milan 1.5 854 Montagnino et al., 1996
Rome 3.3 302 Lesnoni La Parola et al., 1997
Egypt: Cairo 1.2 950 Bakr et al., 1997
Israel: Petah Tiqva 2.4 330 Shmueli et al., 1989
Saudi: Riyadh 4.1 630 Qunibi et al., 1993
South Africa: Jo'Burg 0.5 989 Margolius et al., 1994
S'bosch 3.9 542 Present study
Spain: Madrid 0.5 609 Gomez dos Santos et al., 1997
Santander 0.23 431 Portillo Martin etal., 1992
Iatrogenic Kaposi's sarcoma
In common with the other forms of Kaposi's sarcoma, the iatrogenic form also has 
areas of geographical predilection (Table 8-10). The reports from Saudi Arabia (Al- 
Sulaiman MH et a/.,1994;al Suleiman et a/.,1987;Qunibi et a/.,1988;Shaheen et 
a/.,1997;Szende et al., 1997), Egypt (Bakr et al., 1997) and Israel (Shmueli et 
al., 1989) clearly suggest that the Middle East is an area of high risk for 
posttransplant Kaposi's sarcoma. By contrast the incidence in developed countries 
is very much lower. Even within these geographical areas, there are regional/ethnic 
variations. In Saudi Arabia, the majority of the patients who have Kaposi's sarcoma 
are from the southwestern region of the country (Al-Sulaiman et al., 1994;Qunibi et 
al., 1988). In the report by Al-Sulaiman and Al-Khader (1994), 200 (27%) of their 730 
transplant patients originated from the southern region of the Arabian Peninsula, 
whereas 22 (64%) of the 35 patients with Kaposi's sarcoma were from that area.
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The other group in Riyadh, Saudi Arabia reported an incidence of 63% in people 
from the south (Qunibi et al., 1988).
The experience in South Africa also suggests a geographical difference with a 
incidence of iatrogenic Kaposi's sarcoma higher in the south than in the north. 
Margolius et al. (1994) report that 0.5% of their renal transplant patients developed 
Kaposi's sarcoma compared to the 3.9% of the patients in the present study. 
However, there are major differences in the renal transplant populations. The 
majority of Johannesburg patients were white, whereas our patients were 
predominantly non-white. Nevertheless, the incidence of Kaposi's sarcoma was 
1.08% even in our white patients which is double the overall incidence reported by 
the Johannesburg group.
Posttransplant Kaposi's sarcoma seems to occur more frequently in less developed 
countries. A notable exception is India. The first case of Kaposi's sarcoma in India 
was reported in 1998 despite the large number of kidney transplants performed in 
the country. Both sporadic and AIDS-related Kaposi's sarcoma are very rare in India 
and by 1998 only one case of the latter had been reported (Ajithkumar et al., 1998). 
The reason for the exceptionally high incidence in our cohort and in the Saudi 
patients may be related to our use of treatment regimens that result in relative over­
immunosuppression. In general, protocols used around the world are derived from 
the West and have been tested on patients who have better states of nutrition 
(Hutt, 1984b) and who may tolerate immunomodulation much better. If the AIDS- 
related Kaposi's sarcoma is any guide, it can be predicted that when developing 
countries start transplanting on a larger scale, those who have a high background 
incidence of Kaposi's sarcoma in the population can be expected to have a higher 
incidence of posttransplant Kaposi's sarcoma (Wahman ef a/.,1991).
Ethnicity and race
Until the onset of the AIDS epidemic Kaposi's sarcoma was widely considered to be 
a disease of a specific ethnic or racial group. There is predominance of Kaposi's 
sarcoma among Ashkenazic Jews and among people of Mediterranean (especially 
Italian) heritage (Brownstein et a/.,1973;DeWys et a/.,1982;DiGiovanna et
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a/.,1981;Feuerman et a/.,1973;0'Brien et a/.,1966;Reynolds et al., 1965) and among 
African blacks (Wahman et al., 1991). The disease appears to be rare in Asians and 
people from South America (Hutt, 1984b). In a large survey of cancers in Los 
Angeles, it was found that based on all-site distribution of cancer cases with both 
religion and birthplace known, the number of Jewish males born in eastern Europe 
with classic Kaposi's sarcoma was six times the number expected (Ross et al., 1985).
Endemic Kaposi's sarcoma
Among black African people there are regional differences in the incidence of 
Kaposi's sarcoma. In Kenya, the tribes that live in the high cool areas with moderate 
rainfall have the highest incidence of Kaposi's sarcoma (Laor et al., 1979). In 
Tanzania, there is considerable variation in Kaposi's sarcoma incidence rates in 
different districts and analysis of incidence shows that geographic rather than ethnic 
or sociocultural factors accounted for these differences (Rothman,1962). In Uganda, 
the disease is more common in the west than other regions of the country 
(Tedeschi,1958). These observations would suggest that environmental factors 
might be playing a role (Beral, 1991). In South Africa, the overall incidence of cancer 
between 1949 and 1953 was approximately equal in whites and blacks, but the 
crude rate of endemic Kaposi's sarcoma was ten-fold higher among blacks than 
among whites (Oettle,1962). Possible explanations for this discrepancy included 
genetic predisposition, an inherent metabolic defect, contact of certain ethnic groups 
with a limited environmental factor or spread of an agent within a relatively closed 
intermixing population (Hutt,1984b).
Epidemic Kaposi's sarcoma
In epidemic Kaposi's sarcoma it has been found that Haitian-born heterosexual AIDS 
cases had Kaposi's sarcoma more commonly than did heterosexual patients of other 
ethnic origins (Selik et al., 1987). Based on the study of the race, drug use, and 
sexual preference it was concluded that race or ethnic group influences the 
frequency of Kaposi's sarcoma independently of homosexuality (Selik et al., 1987). 
In an analysis of all the cases reported to the Centers for Disease Control by 1989, 
Kaposi's sarcoma was in fact not found to be consistently related to race (Beral et 
al., 1990); rather risk was correlated with being located in the initial foci of the AIDS
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epidemic. Other studies corroborated that ethnicity did not alter the incidence of 
Kaposi's sarcoma in the various risk groups (De Jarlais et al.,1984). The controversy 
regarding the influence of race may be explained by other intervening factors that 
work differently in different populations (Wahman et al., 1991).
Postrenal transplantation
In a study of renal transplant patients reported from Toronto, Canada, Harwood et al. 
reported that of 44 patients with Kaposi's sarcoma 40 (91%) were of Jewish or 
Mediterranean heritage (Harwood et al., 1979b). The present study is 
epidemiologically unique in demonstrating conclusively that the incidence of Kaposi's 
sarcoma in two populations of renal transplant patients, one Caucasian and the 
other, non-Caucasian (but predominantly Coloured) residing in the same geographic 
area can differ markedly. This observation has never been made before although 
Margolius alluded to it in his report on Kaposi's sarcoma in renal transplant patients 
at the Johannesburg Hospital. In the latter series 4 (66%) of 6 patients in whom 
Kaposi's sarcoma occurred were non-Caucasian, an unusually high frequency 
considering that non-white patients constituted only 30% of the renal transplant 
recipients (Margolius, 1996). As mentioned earlier, George Oettle was the first to 
note the profound racial differences in the susceptibility to the disease: blacks were 
considerably more prone to Kaposi's sarcoma than the whites, Coloureds and Indian 
living alongside them (Oettle, 1962). Oettle (1962), very pertinently, found no cases 
of Kaposi’s sarcoma in Coloured or Indians in his study confirming observations 
made in Cape Town and Durban that indicated that the disease was rare in these 
race groups in South Africa. Parenthetically, the first case of Kaposi's sarcoma in 
Cape Town was described by Uys and Bennett (1959). Oettle (1962), with great 
foresight speculated on the role of viruses in the aetiology of the disease but 
considered the failure to transmit the disease by inoculation into humans and 
animals an obstacle to the infectious aetiology of the disease. A very interesting 
observation, is that Kaposi's sarcoma was thought to be rare in full-blooded African- 
Americans, which is in striking contrast to the experience in South Africa (Kaminer et 
al., 1950). Kaminer et al. (1950) speculated that anthropological differences 
accounted for the difference. African-Americans are descendant from West African 
blacks of unique tribal origins, while the South African blacks are mainly of Hamitic
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origin. However, in a later report of 50 patients with Kaposi's sarcoma from the USA,
11 (22%) were black and the authors confirmed that the clinical features were the 
same in all racial groups (Cox et al., 1959). This was confirmed in a recent report 
that showed that African-American did not have an increased incidence rate of 
Kaposi's sarcoma compared to whites (Biggar et a/.,1984a).
Our unique finding of the differential incidence rate in Caucasian compared to non- 
Caucasians would suggest that genetic factors rather than environmental factors 
may account for the increased risk of Kaposi's sarcoma in our non-white population. 
Early studies of histocompatibility loci in persons with the disease indicated a link 
between classic and epidemic forms Kaposi's sarcoma, and HLA-DR5 (Friedman- 
Kien et al., 1982). However, careful analysis of those reports suggests that the 
association of HLA-DR5 with Italian or Ashkenazic Jewish descent may explain the 
apparent association between Kaposi's sarcoma and HLA-DR5 (Papasteriades et 
a/.,1984;Pollack et a/.,1983a;Pollack et a/.,1983b;Pollack et al., 1985). In Caucasian 
populations in which the HLA-DR5 is less common, no association between the 
antigen and Kaposi's sarcoma is found (Dalgleish, 1991). Extensive genetic studies 
using sex- and tribe-matched controls have also been performed in patients with 
endemic Kaposi's sarcoma. As was the case in the classic form these revealed no 
definite association between any of the HLA antigens, including HLA-DR5 and HLA- 
DR3 with Kaposi's sarcoma (Melbye et al., 1987). Even in endemic areas familial 
cases of the disease are interestingly, very rare (Epstein, 1972; Lothe,1963; 
Oettle,1962; Palmer,1972) (although clustering has been observed) (Lulat, 1989). 
Between 1908 and 1955 only six instances of families with multiple cases of Kaposi's 
sarcoma had been reported (Oettle,1962) and since then only two other familial 
cases have been reported (Brownstein et a/.,1973;Epstein,1972). This argues 
against an autosomal dominant or recessive mode of inheritance unless penetrance 
is very incomplete. In postrenal transplant patients an association between Kaposi's 
sarcoma and HLA-DR2 has been suggested by Qunibi et al. (1988). However, our 
observations and those of others have failed to corroborate this association (Al- 
Sulaiman et al., 1994). Neither Qunibi et al. (1988) nor we found an increased 
frequency of HLA-DR5 in postrenal transplant Kaposi's sarcoma patients compared 
with the rest of the transplant cohort.
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THE ORGANISM: SERO-EPIDEMIOLOGY
Cytomegalovirus (CMV) Infection
Before it was recognised that the HHV-8 was the aetiological agent responsible for 
Kaposi's sarcoma, the cytomegalovirus (CMV) was causally linked to the disease. 
Sero-epidemiological studies had shown higher prevalences and antibody titres to 
CMV in Europeans and American patients with the Kaposi’s sarcoma than in 
appropriate controls (Giraldo et a/.,1975;Giraldo et al., 1978). No association has 
been found for antibody to other herpesviruses, including Epstein-Barr virus or 
herpes simplex-1 or -2. After renal transplantation, as well as in other conditions 
which require iatrogenic immunosuppression, infection with CMV occurs almost 
universally (Fiala et al., 1975;Neiman et al., 1977). Similarly, the prevalence of 
antibody to CMV is virtually 100% in all areas of Africa with a high incidence of 
Kaposi's sarcoma (Giraldo et al., 1975;Giraldo et al., 1978). These observations, by 
their very nature, preclude the demonstration of an association between the two 
phenomena. Although CMV antibody titres were not formally tested in this study our 
experience is that more than 80% of dialysis patients have antibodies to CMV 
(unpublished data). Most researchers have now concluded that CMV is not directly 
involved in Kaposi's sarcoma tumour onset or maintenance (Ambinder et 
al., 1987;Dictor etal., 1988b;Roth et al., 1988;Selik et al., 1987).
Human herpesvirus 8 (HHV-8) infection
HHV-8 was initially detected in AIDS-associated Kaposi's sarcoma but was 
subsequently demonstrated to be present in all epidemiological forms of Kaposi's 
sarcoma (Chang et al., 1994). Epidemiological data suggest that a high prevalence 
of HHV-8 in the general population is correlated with a high frequency of Kaposi's 
sarcoma after renal transplantation. Seroprevalence is high in some African 
countries (>50%), moderate in Italy and lower in other Western countries (Gao et 
al., 1996). Most transplant patients have anti-HHV-8 antibodies before 
immunosuppression is started, suggesting that the subsequent Kaposi's sarcoma 
results from reactivation of the virus (Parravicini et al., 1997). HHV-8 may be 
sexually transmitted but there is evidence that the virus can be transmitted from the 
donor graft to the recipient (Parravicini et al.,1997). This could explain the rare 
occurrence of Kaposi's sarcoma simultaneously in two recipients of grafts from the
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same donor (Bottalico et al., 1997). Viral, bacterial, parasitic, and fungal infections 
are possible factors in the aggravation of Kaposi's sarcoma. The relapse of Kaposi’s 
sarcoma in one of our own patients (RB) following the onset, of serious local sepsis 
supports this contention. Admittedly, the evidence in this regard are all from 
anecdotal reports because controlled prospective trials on the prevalence of 
infections following transplantation are not available (Siegal et al., 1990). (Further 
discussion on HHV-8 appears in Chapter 17.
SUMMARY
Epidemiology is a study of disease as it pertains to the community rather than the 
individual. A classic epidemiological approach to a disease is to look at the host, the 
environment and the agent. Four epidemiological forms of Kaposi's sarcoma are 
now recognised and each of these has been described in detail here. For each form 
the host and environment has been described. The morphology of lesions of classic 
Kaposi's sarcoma, African (endemic) Kaposi's sarcoma, epidemic (AIDS-associated) 
Kaposi's sarcoma and iatrogenic Kaposi's sarcoma are similar. However, the 
reasons for the variations in the type and severity have not been established. It is 
almost certain that all types of Kaposi's sarcoma are caused by the same 
transmissible agent (HHV-8) and that the clinical expression of the disease is 
determined by the individual’s immune state. The clustering of cases in the AIDS 
epidemic provided a very important clue that the disease was sexually transmitted; 
the strange coincidence that the HHV-8 is spread in a similar way to HIV and the 
HIV-associated immunosuppression resulting in the clinical expression of Kaposi's 
sarcoma explains why the disease is so extraordinarily common in people with AIDS. 
The importance of immunosuppression in the development of Kaposi's sarcoma was 
appreciated by the widespread use of immunosuppressive agents in organ 
transplantation. Review of the world experience with posttranspiant Kaposi's 
sarcoma suggests that non-Caucasians are particularly susceptible to the disease, 
and the current study confirms that this is the case even if the non-Caucasians 
reside in the same geographical area as Caucasians. The present study has 
demonstrated that the non-Caucasian population of the Western Cape as an ethnic 
group has the highest incidence of posttranspiant Kaposi's sarcoma in the world.
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Our data also suggests that geographic variation therefore does not seem as 
important as ethnic variation.
The very young and the very old, perhaps two age groups associated with 
immunosuppression tend to have a higher incidence of the disease. Children, AIDS 
patients and, possibly, women tend to have more virulent disease. Males tend to get 
Kaposi's sarcoma at higher rates than women. Jewish and Mediterranean men have 
the highest incidence of classic Kaposi's sarcoma and African males of endemic 
Kaposi's sarcoma. Male homosexuals have a higher incidence of Kaposi's sarcoma 
than male heterosexuals do, but since the middle 1980s its incidence has been 
decreasing dramatically. There is no unequivocal association with a particular HLA 
haplotype. In iatrogenic Kaposi's sarcoma, the male-to-female ratio is reduced to 
less than 3:1 compared to classic Kaposi's sarcoma where the ratio is 9-15:1. The 
age of onset of Kaposi's sarcoma in transplant recipients is also much younger than 
the classic form, but corresponds to certain forms of endemic Kaposi's sarcoma.
Many epidemiological questions concerning Kaposi's sarcoma remain unanswered. 
These include: the reason for the male predominance of the disease; the explanation 
for the geographic and ethnic variations (including our observation of the difference 
between white and non-white patients in the same geographic area); the route of 
transmission of the virus other than the sexual one; the prevalence of HHV-8 
infection in our community (see Chapter 17). Further investigations into the 
epidemiology of Kaposi's sarcoma as well as HHV-8 would contribute to the 
knowledge of other oncogenic viruses and in this way may have great public health 
significance.
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Chapter 9
KAPOSI'S SARCOMA 
C l i n i c a l  A s p e c t s
". . .  nodules ranging from the size o f  a peppercorn to that o f  a pea or hazelnut, and brownish 
or bluish red in colour. . . ". Moritz Kaposi
Although the histological appearance of the various forms of Kaposi's sarcoma varies little, there is a wide spectrum of clinical manifestations. Classic Kaposi's sarcoma is predominantly a disease of the legs, although involvement of the lymph nodes and viscera may also occur. It is humbling to consider that since its discovery by Moritz Kaposi over a century ago, there has yet 
to be an improvement on the clinical description of the disease (Kaposi, 1872). 
African-endemic Kaposi's sarcoma presents in one of 4 clinically distinct patterns:
1. Benign nodular cutaneous disease mimicking classic Kaposi's sarcoma
2. Aggressive localised cutaneous disease invading soft tissue and bone
3. Florid mucocutaneous and visceral disease
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4. Lymphadenopathic disease rapidly disseminating to lymph nodes and visceral 
organs, usually in the absence of cutaneous lesions.
Iatrogenic Kaposi’s sarcoma is primarily a cutaneous complication of 
immunosuppressive therapy, although lymph nodes and viscera can also be 
involved. Acquired immunodeficiency disease (AIDS) associated - Kaposi's 
sarcoma is characterised by a broad clinical spectrum of disease with overlapping 
features encompassing all varieties of non-AIDS Kaposi's sarcoma (Friedman-Kien 
et a/.,1990;Harawi,1989;Tappero et al., 1993).
CLASSIFICATION
Prior to onset of the AIDS epidemic, four clinical patterns of Kaposi's sarcoma were 
recognised (Templeton,1981). These were the nodular, aggressive cutaneous, 
lymphadenopathic and systemic generalised. With the advent of the AIDS 
epidemic, a fifth pattern, referred to as the early pattern was recognised 
(Harawi,1989). Nodular Kaposi's sarcoma is the predominant clinical pattern seen in 
all types of the disease. The aggressive variety, however, seems to be much more 
common in Africa. The generalised forms of Kaposi's sarcoma are seen mainly in
Table 9-1 Incidence of various clinical patterns in the different sub-types o f Kaposi's 
sarcoma.
Cutaneous Generalised
Early Nodular Aggressive Lymphatic Visceral
Classic + 85% 10% 4% 1%
Endemic
Adult men 60% 30-35% 3-8% 2%
Adult women 40% 35% 12% 13%
Young adults ++ +++ +++
Children ++ 25-50% +
Epidemic ++ ++ + ++
Iatrogenic1 + 89% 16% 16%
Compiled with data from Blumenfeld et al. (1985); Embrey et al. (1988); Kalengayi et al. (1984); 
Reynolds et al. (1965); Templeton (1972).
1 Stellenbosch experience
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African children and young adults. In AIDS all clinical patterns of the disease occur 
with the exception of aggressive cutaneous disease (Harawi,1989; Templeton,1981). 
Our own experience with iatrogenic Kaposi's sarcoma is also reflected in Table 9-1. 
Nodular skin involvement was the most common manifestation of cutaneous 
Kaposi's sarcoma. The early lesion occurred as the only cutaneous manifestation in 
only 1 (5%) patient in our cohort.
CLINICAL FEATURES
Mucocutaneous Disease
The skin is the organ most commonly afflicted by Kaposi's sarcoma. In our study as 
well as the report from Johannesburg (Margolius et a/., 1994), all patients with 
posttransplant Kaposi's sarcoma had skin involvement. In reports by other authors 
skin involvement also occurred in the majority of patients, ranging from 87% to 93% 
(Al-Sulaiman et a/.,1994;Qunibi et a/.,1988;Qunibi et a/.,1993;Shaheen et a/.,1997). 
Of note, is the observation by Shaheen et al. (1997) that 4 of the 5 patients in their 
study without skin involvement were children. This experience concurs with that in 
African Kaposi's sarcoma where affected children have minimal skin lesions and the 
disease is characterised by generalised lymphadenopathy associated with an 
aggressive course (Dutz et a/.,1960;0lweny et a/.,1976;Slavin et al., 1970). The 
experience reported by Cincinnati Transplant Tumor Registry (CTTR), which largely 
represents developed countries, is somewhat conflicting. In the initial report 
(Penn,1979a) 90% of the patients had skin involvement but in the later report, Penn 
(1997) found that 27% of patients with visceral involvement did not have skin 
involvement. This may reflect an underreporting of posttransplant Kaposi's sarcoma 
confined to the skin. Notwithstanding this, the occurrence of Kaposi's sarcoma in the 
absence of skin lesions is extremely rare (Penn, 1979a).
Distribution
In our experience, the most common sites of skin involvement were the lower 
extremities with 12 (63%) of our patients being affected (associated with variable 
degrees of oedema), followed by upper limb involvement in 6 (32%). Kaposi's 
sarcoma lesions occurred on the extremities of 17 (89%) of our patients. Less 
commonly affected were the trunk 5 (26%) and hard palate 2 (10%). Some reports
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of posttransplant Kaposi's sarcoma fail to mention the location of skin involvement 
(Al-Sulaiman et a/.,1994;Qunibi et a/.,1988;Qunibi et a/.,1993;Shaheen et al., 1997) 
but other reports concur with our observation of lesions being localised 
predominantly on the legs (Frances,1998;Gotti et al., 1997;Harwood et al., 1979). In 
classic Kaposi's sarcoma the lower limb is the initial site of involvement in the some 
75% of cases, with the hand or forearm as the primary site in 5% of cases, and in the 
remainder the head or trunk (Lothe,1963).
In our experience there were no unusual sites that were affected, unlike the situation 
in epidemic Kaposi's sarcoma. In AIDS patients the tip of the nose is a common site 
of occurrence (Tappero et al., 1993), possibly as the result of nitrite inhalation 
(Mirvish et al., 1987). In addition, in epidemic Kaposi's sarcoma, penile and plantar 
involvement are common while palmar lesions are rare (Safai et 
a/.,1985;Volberding,1986). However, we have noted the Koebner phenomenon, i.e. 
the appearance of the lesions in scars. In a single patient in our series it involved 
the transplant surgery scar and the laparotomy scar that resulted from the insertion 
of the Tenckhoff catheter (Fig. 9-4b). The Koebner phenomenon has been observed 
previously in iatrogenic Kaposi's sarcoma (Harwood et al., 1979;Kemeny et 
a/.,1997;Mural,2000;Seckin et al., 1998). Other features of posttransplant Kaposi's 
sarcoma in comparison with other sub-types of Kaposi's sarcoma are summarised in 
Table 9-2. Iatrogenic Kaposi's sarcoma is clinically less aggressive than epidemic 
Kaposi's sarcoma, but it has been claimed that the disease is generally more severe 
than the classic form (Gotti et al., 1997).
Skin lesions (See Figs. 9-2 to 9-5)
Kaposi's sarcoma is generally believed to be a multifocal disease and manifests 
initially with either single or more frequently macules, papules and/or nodules 
(Safai, 1984). With time there is progression from the macule and patch stage to the 
papule and plaque stage. The lesions may coalesce to form large plaques or 
tumours that may become eroded, ulcerating or fungating (Safai, 1984). Lesions 
have a dark blue or purplish colour on white skin and often appear pigmented on 
black skin (Cook,1962;Reynolds et al., 1965;Taylor et al., 1971). Aged or regressing 
lesions become brownish-blue (Gotti et al., 1997). The lesions seen in our patients
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Table 9-2 Mucocutaneous lesions in the different subtypes o f Kaposi's sarcoma .
Classic Epidemic Iatrogenic
Distribution
At onset Localised Widespread Localised
Usual sites Peripheral: Central: Peripheral:
Distal extremities Trunk, arms, neck, Distal extremities
Unique sites
head,
Tip of nose Surgical Scar
Symmetry + ++ +
Visible mucosa + +++ (palate) +
Features
Common stage Nodular Early Nodular
Usual size Up to 3 cm < 1 cm Varies
Colour Deep purple Light purple Deep purple
Shape Round Oval Various
Special features - Follows cleavage -
Associated oedema Extremities
lines
Fingers, eyelids Lower limbs
Data from our study and Cox et al. (1959); Reynolds et al. (1965); Safai et al. (1985); Volberding 
(1986).
varied in size from less than 1 cm to some that were over 5 cm (See Figs. 9-2 and 9- 
4). Macular lesions are not very common and are usually seen in the early stages of 
Kaposi's sarcoma or when the lesion is regressing (McCarthy et al.,1950). Macules 
are subsequently infiltrated and may form nodular and fungiform tumours. Leg 
oedema often precedes the development of skin lesions by months (Frances,1998). 
In our experience the lymphoedema may not resolve as the skin lesions regress 
(Fig. 9-4). In some of our patients, acral lesions had marked overlying 
hyperkeratosis, superficially resembling psoriasis (Fig. 9-3C). This has also been 
described in epidemic Kaposi's sarcoma (Tappero et al., 1993). Initially lesions in 
Kaposi's sarcoma may be unilateral but with progression bilateral disease occurs. 
Pruritus of the affected areas has been reported as a symptom by some authors 
(Ddrffel,1932;Huang,1983;Symmers,1941) but the others have considered pruritus to
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be distinctly unusual (Bluefarb,1957;Safai,1984). In none of the patients examined 
by us was pruritus a prominent feature. In epidemic Kaposi's sarcoma the lesions 
are also elongated and oval shaped following the lines of cleavage. In contrast to 
the skin lesions in classic and iatrogenic Kaposi's sarcoma, the lesions in epidemic 
Kaposi's sarcoma tend generally to be smaller than 1 cm (Harawi,1989;Tappero et 
a/., 1993), pink and located on the upper trunk, and head and neck areas.
Course o f skin lesions
In classic Kaposi's sarcoma the skin lesions have an indolent course and usually 
take years to grow. In contrast, in the epidemic form of the disease, the skin lesions 
behave aggressively, enlarge and become widely disseminated usually within a few 
weeks to a few months (Friedman-Kien,1981). In iatrogenic Kaposi's sarcoma the 
course of the disease is generally benign. In a single patient in our study, 
progressive lesions on the legs formed exophytic friable tumours that became 
secondarily infected, while lesions on the sole progressed to confluence with 
ulceration, both well recognised complications (Tappero et a/., 1993). None of our 
patients developed the aggressive form of skin involvement seen in epidemic 
Kaposi's sarcoma. However, both Al-Sulaiman et al. (1994) and Shaheen et al. 
(1997) describe this aggressive pattern in over one quarter of their renal transplant 
patients who developed Kaposi's sarcoma. With aggressive skin involvement the 
lesions have "a malignant appearance and behaviour" mimicking that seen in 
epidemic Kaposi's sarcoma, characterised by rapid growth within a few weeks and 
widespread dissemination often with visceral involvement (Al-Sulaiman et 
a/.,1994;Shaheen et al., 1997). This aggressive cutaneous form of iatrogenic 
Kaposi's sarcoma has not been reported outside of Saudi Arabia (Harwood et 
a/.,1979;Margolius et al., 1994).
Oral lesions
Two (10%) of our patients had lesions on the hard palate. These lesions are usually 
purple in colour and are asymptomatic. These lesions are also described in patients 
with AIDS, in whom they may form friable tumours resembling bacillary angiomatosis 
or pyogenic granuloma (Berger et al., 1989;Tappero et al., 1993). Gingival 
hyperplasia, although not seen in our study, is another manifestation of the disease 
and it needs to be differentiated from cyclosporine-induced hyperplasia (Qunibi et
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a/., 1988). The oral lesions are often associated with gastrointestinal disease 
(Frances, 1998). Involvement of the urogenital tract or conjunctivae is less frequent. 
In patients with AIDS-associated Kaposi's sarcoma, lesions occur on the hard palate 
of 50% of cases (Ficarra et a/., 1988) while ocular adnexal involvement occurs in up 
to 20% (Shuler et al., 1989).
Unusual forms
In AIDS patients unusual forms of Kaposi's sarcoma have been described. 
Telangiectatic Kaposi's sarcoma is a rare variant (Snyder et al., 1982), while more 
recently the disease has been seen to present as generalised lymphoedema, 
ecchymotic Kaposi's sarcoma and keloidal Kaposi's sarcoma (Frans et 
a/.,1994;Schwartz et a/.,1994;Schwartz et al., 1995). These forms have yet to be 
described in iatrogenic Kaposi's sarcoma.
EXTRACUTANEOUS KAPOSI'S SARCOMA
Kaposi's sarcoma has traditionally been considered an indolent cutaneous disease. 
However, in his original paper, Kaposi alluded to the fact that the disease does have 
the propensity to involve extracutaneous sites. Of the five cases he described, a 
postmortem examination performed on one patient showed very extensive visceral 
involvement including the lungs, gastrointestinal tract and liver, although the lymph 
nodes appeared to be spared macroscopically (Kaposi, 1872).
Extracutaneous involvement occurred in 29% of our patients. However, it is likely 
that visceral involvement is much more common but that it is asymptomatic as in 
epidemic Kaposi's sarcoma. There are no postmortem studies in iatrogenic- 
Kaposi's sarcoma patients but the experience in epidemic Kaposi's sarcoma has 
shown that the disease is limited to the skin in less than 25% of AIDS-Kaposi's 
sarcoma cases (Lemlich et al., 1987;McKenzie et a/.,1991;Welch et al., 1984). 
Visceral involvement has been reported to be present in 45% of iatrogenic-Kaposi's 
sarcoma in the CTTR (Penn,1979a;Qunibi et al., 1988). An early report of four renal 
transplant recipients found no clinical evidence of visceral Kaposi's sarcoma 
(Harwood et al., 1979) and contrasts with a study from South Africa that reported 
disseminated disease in 4 of 5 patients with posttransplant Kaposi's sarcoma
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(Margolius et al., 1994). In our series, the lymph nodes were the most common 
extracutaneous site of involvement and was present in almost one quarter of the 
patients, followed by the gastrointestinal tract and lungs, in keeping with the 
experience elsewhere (Frances,1998).
Extracutaneous involvement in other subtypes of Kaposi's sarcoma 
In a review of 356 cases of classic Kaposi's sarcoma, it was found that 10% of cases 
had associated extracutaneous disease (Dorffel, 1932). Epstein (1957b) later 
reviewed 35 cases of Kaposi's sarcoma with symptomatic extracutaneous disease. 
Between these two studies, visceral Kaposi's sarcoma involved the following organs 
in decreasing frequency: gastrointestinal tract, liver, lungs and lymph nodes. In a 
review of primary extracutaneous Kaposi's sarcoma reported in the literature, 
Anthony et al. (1960) found that organ involvement occurred in the following order of 
frequency: lymph nodes, heart, gastrointestinal tract, liver and lungs. Visceral 
involvement is common in AIDS patients with Kaposi's sarcoma. Postmortem 
studies of patients with AIDS-associated Kaposi's sarcoma suggest that less than 
25% have disease limited to the skin or mucous membranes. (Lemlich et 
a/.,1987;McKenzie et al., 1991;Welch et al., 1984). The most common sites of 
visceral involvement are the gastrointestinal tract, liver, spleen, and lungs. 
Involvement of these sites accounts for death in approximately 10% - 20% of 
patients with AIDS-Kaposi's sarcoma (McKenzie et al., 1991). AIDS-Kaposi's 
sarcoma may also affect the pharynx, bone marrow, urogenital tract, brain, kidney, 
and adrenal glands (Ahluwalia et a/.,1991;Bordelon et a/.,1990;Kaul et 
a/.,1991;Kuhlman et a/.,1991;Marcusen et al., 1985). Interestingly, in a postmortem 
study from Paris, the thymus was involved in 55% of AIDS patients with Kaposi's 
sarcoma (Harawi, 1989).
Nodal Kaposi's sarcoma
In our series of iatrogenic Kaposi's sarcoma lymphadenopathy was detected in 5 
patients clinically or at autopsy. The two patients with clinically detectable Kaposi's 
sarcoma both had inguinal lymphadenopathy, associated with skin lesions. The 
three patients on whom postmortem examinations were performed, all had deep 
lymph node involvement that was not suspected clinically. In these patients the 
disease was disseminated. The diagnosis of lymph node Kaposi's sarcoma was
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confirmed by histology in all our cases. In the series reported from Saudi Arabia (Al- 
Sulaiman et al., 1994), 13 of the 35 patients had lymph node enlargement by clinical 
examination and/or computerised axial tomography (CT) scanning of the abdomen 
and chest, although the diagnosis was not histologically confirmed. The inguinal 
lymph nodes were the only superficial lymph nodes that were involved in our 
experience. The experience of the Johannesburg group is similar to ours with 2 of 
their 5 patients having inguinal lymphadenopathy (Margolius et al., 1994). On the 
other hand, Al-Sulaiman et al. (1994) report enlargement of, mainly, the cervical and 
less commonly, the axillary lymph nodes. Whereas in our patients the deep lymph 
nodes involved were the mesenteric, mediastinal and hilar glands, in the Saudi 
series the paraaotic and peritracheal nodes were mainly affected (Al-Sulaiman et 
al., 1994).
Nodal involvement in other subtypes of Kaposi's sarcoma
Symptomatic lymphadenopathy is rare in classic Kaposi's sarcoma. In one series, 
the lesion was proven on biopsy in 11% of cases. In two cases there was regional 
lymph node involvement while the remaining had generalised lymphadenopathy 
(Cox et al., 1959). However, at postmortem examination nodal Kaposi's sarcoma 
was present in 86% of cases (Cox et al., 1959). In another study involving 47 
postmortem cases, generalised lymphadenopathy was present in 6% and localised 
disease in 38% of cases (Templeton,1972). In a study of African Kaposi's sarcoma 
involving 156 cases, 10% were found to have lymph node involvement 
(O’Connell, 1977). Another study from Africa of 48 consecutive patients from Uganda 
lymph node involvement was present in 33% of the patients. However, in the latter 
study the nodes were sectioned into 4 mm slices and examined microscopically in 
their entirety (Bhana et al., 1970). In three postmortem series in patients with AIDS, 
lymph node involvement occurred on average in 56% of patients and was usually 
generalised (Lemlich et a/.,1987;Niedt et a/.,1985;Welch et al., 1984). Kaposi's 
sarcoma with generalised lymphadenopathy is usually indicative of an aggressive 
course irrespective of the presence of skin disease (Harawi, 1989).
Outcome
In iatrogenic Kaposi's sarcoma the lymph nodes tend to regress with improvement of 
the Kaposi's sarcoma elsewhere in the body on treatment (Fig. 9-1). Since there are
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several other causes of lymphadenopathy in renal allograft patients on 
immunosuppression, it is advisable to confirm the diagnosis by biopsy of the node 
(Massarelli et a/.,1982;Rywlin et a/.,1983;Ulbright et al., 1981). In a recent series of 
356 organ recipients with Kaposi's sarcoma, it was found that 8 (1.7%) of the 
patients had associated lymphomas (Penn, 1995).
Gastrointestinal Kaposi's sarcoma
In our series 2 patients who had disseminated disease at postmortem examination 
had involvement of the stomach while 3 had liver involvement. Routine endoscopy 
was performed in only 5 patients, none of whom had upper gastrointestinal Kaposi's 
sarcoma. None of the patients with disseminated disease had endoscopic 
examination prior to death. In the Saudi series (Al-Sulaiman et al., 1994), the 
gastrointestinal tract was the second most commonly involved organ after skin. 
They, however, routinely studied patients with upper gastrointestinal endoscopy 
and/or colonoscopy. Of the 26 patients who had gastroscopy, 50% appeared to
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have Kaposi's sarcoma lesions, while 45% of the 22 patients who had colonoscopy 
were suspected of having Kaposi's sarcoma lesions (Al-Sulaiman et a/.,1994;Hanid 
et a/., 1989). However, despite several biopsies from multiple sites the histological 
diagnosis of gastrointestinal was confirmed in only one-half of the cases.
Symptoms
Gastrointestinal Kaposi's sarcoma is a well-recognised occurrence in patients with 
organ transplants (Hanid et a/.,1989;Myers et a/.,1974;Qunibi et a/.,1988;Siegel et 
a/.,1969;Stribling et a/.,1978) as well as in patients with AIDS (Gottlieb et 
a/.,1981;Gottlieb et a/.,1983;Rose et a/.,1982). In the classic form of the disease, 
gastrointestinal Kaposi's sarcoma occurred in an estimated 10% of patients 
(Tedeschi et a/., 1947), although in one review of classic Kaposi's sarcoma 
gastrointestinal disease was found to be as high as 66% (Epstein,1957a). In AIDS 
patients with Kaposi’s sarcoma about 50% have gastrointestinal involvement (Wall et 
a/., 1984). Although lesions of Kaposi's sarcoma may occur anywhere in the 
gastrointestinal tract, the most common locations are the stomach and duodenum. 
Gastrointestinal Kaposi's sarcoma rarely cause symptoms (Hanid et a/.,1989;Hanno 
et a/., 1979) and are usually detected by finding infiltrated red spots on routine 
endoscopy of an asymptomatic patient (Frances,1998). Kaposi's sarcoma may 
present with non-specific upper gastrointestinal symptoms or with gastrointestinal 
bleeding (Friedman et a/.,1985;Stribling et a/., 1978); rarely other presentations have 
been reported, including perforation (Mitchell et a/.,1949), intestinal obstruction 
(Coetzee et a/., 1967), intussusception (Houghton et a/.,1988;White et a/., 1964), 
protein losing enteropathy (Laine et a/.,1987;Novis et a/.,1974;Perrone et a/.,1981), 
or septicaemia (Bieluch et a/.,1988;Glaser et a/.,1983). None of our patients had any 
gastrointestinal symptoms, while only 3 of the 26 Saudi patients with gastrointestinal 
disease had symptoms that included nausea, vomiting, malaena and rectal bleeding 
(Al-Sulaiman et a/.,1994).
Investigations
The most effective technique for investigation of the gastrointestinal tract is 
endoscopy rather than radiological studies, which are useful for filling defects but 
may miss macular lesions (Ahmed et al., 1975). The endoscopic findings of 
gastrointestinal Kaposi's sarcoma were first described in 1968 (Rajan et al., 1969)
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and three distinct appearances were recognised: a maculopapular, a polypoid and 
an umbilicated nodular lesion (Ahmed et al., 1975). The mucosa over the lesion may 
have a strawberry appearance (Ahmed et al., 1975) or a reticulated pattern giving it 
an appearance of elephant skin (Bernal et al., 1985). The colonic lesions may have a 
similar appearance but in additional may resemble segmental colitis endoscopically 
(Bernal et al., 1985). The differential diagnosis of the gross lesions include 
haemangiomas (Shepherd,1953), nodules of metastatic melanoma (Willbanks et 
al., 1970), or endometriosis (Kinder, 1953). It is also important to take several 
biopsies of suspected Kaposi's sarcoma lesions (Hanid et al., 1989) because these 
may be submucosal and may therefore be easily missed (Bernal et al., 1985). In one 
series only 23% of endoscopic biopsies of Kaposi's sarcoma were positive 
histologically (Friedman et al., 1985).
Histology
On histological examination the findings are those expected of Kaposi's sarcoma 
(see Chapter 10). However, the early stages of Kaposi's sarcoma in the 
gastrointestinal tract are not as easily recognised as in the skin or lymph nodes. The 
submucosal vessels in the gastrointestinal tract are often dilated and have irregular 
or jagged cross-sections. Plasma cells are found normally in abundance in the 
mucosa and submucosa. These findings make an early lesion of Kaposi's sarcoma 
difficult to recognise in the gastrointestinal tract (Amazon et al., 1988).
Management
An aggressive management approach is probably not justified because Kaposi's 
sarcoma of the gut does not alter the prognosis of the patient and the lesions regress 
as the disease regresses after therapeutic intervention (Al-Sulaiman et al., 1994).
Other organs in gastrointestinal system
Liver involvement is relatively uncommon but is usually associated with lesions 
elsewhere in the gastrointestinal tract (Amazon et al., 1988). Diagnosis can be made 
by computerised tomography (CT) scan of the abdomen and biopsy of suspicious 
lesions. Whereas all our patients with liver involvement came to postmortem 
examination, Al-Sulaiman et al. (1994) report that in two of their patients who had
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confirmed liver involvement, the lesions regressed in concert with lesions elsewhere. 
The oral lesions associated with Kaposi's sarcoma have been discussed above.
Pulmonary Kaposi's sarcoma
Involvement of the respiratory tract is uncommon, but well documented in all types of 
Kaposi's sarcoma. Dorfell (1932) analysed 365 cases of classic Kaposi's sarcoma 
and found that the lungs followed the lymph nodes and the gastrointestinal tract in 
frequency of involvement of internal organs. Subsequent reports confirm the 
occurrence of lung disease in classic Kaposi's sarcoma (Hanno et a/.,1979;Loring et 
a/.,1965a), and in African Kaposi's sarcoma (Lothe et a/.,1962;Templeton,1972), but 
it is in AIDS patients that pulmonary Kaposi's sarcoma has been best studied 
(Meduri et a/.,1986;Ognibene et a/.,1985;Pitchenik et a/.,1985;Purdy et a/.,1986). 
Pulmonary involvement has also been described in iatrogenic Kaposi's sarcoma 
(Gunawardena et a/.,1988;Penn,1979b), although, as in our experience, the 
diagnosis is often made postmortem (Siegel et a/.,1969).
Distribution
Any part of the respiratory tract may be affected. Upper respiratory tract involvement 
may produce hoarseness (Al-Sulaiman et a/., 1994), or obstruction whereas 
pulmonary parenchymal involvement is associated with haemoptysis, dyspnoea, or 
exsanguinating haemorrhage. Pleural lesions cause pleuritic pain. As in other 
visceral organ involvement, pulmonary disease may, rarely, occur in the absence of 
skin disease (Dantzig et a/.,1974;Misra etal., 1982).
Diagnostic procedures
Radiological examination of the chest can range from normal to reticulonodular 
shadowing or alveolar opacities with hilar adenopathy with or without pleural 
effusions (Davis et al., 1987;Gunawardena et a/.,1988;Kramer et a/.,1987;Naidich et 
a/.,1989;Nyberg et a/.,1987;Ognibene et a/.,1988;Sivit et al., 1987). Bronchoscopy is 
the investigation of choice revealing a violaceous endobronchial Kaposi's sarcoma 
lesion; a transbronchial biopsy may also be performed (Ciment et a/.,1983;Fouret et 
a/.,1987;Gunawardena et a/.,1988;Kornfeld et al., 1983). However, these procedures 
may fail to provide the diagnosis in up to 30% of cases (Hanson et al., 1987;Lau et 
a/.,1986;Meduri et a/.,1986;Pitchenik et al., 1985;Purdy et al., 1986). It has recently
Stellenbosch University http://scholar.sun.ac.za/
Clinical Aspects o f  KS 9-14
been demonstrated that Kaposi's sarcoma lesions are thallium avid (Lee et 
a/.,1988;Lee et al., 1990). Using sequential thallium and gallium scanning in AIDS 
patients with pulmonary infiltrates, it has been shown that a positive thallium scan 
with a negative gallium scan is suggestive of Kaposi's sarcoma (Lee et a/., 1991), as 
opposed to lymphoma of the lungs where the both gallium and thallium scans are 
positive (Hamada et a/.,1988;Waxman et al., 1996); in Pneumocystis carinii 
pneumonia the thallium scan is negative while the gallium is positive(Lee et 
a/.,1991). This might be a useful non-invasive technique for the investigation of 
pulmonary infiltrates in renal transplant patients.
Clinical presentation
Among our 21 renal transplant patients with Kaposi's sarcoma, four (19%) had lung 
involvement. Of these, 3 died and the lung involvement was confirmed at 
postmortem examination. Dyspnoea was the most common presentation with 
bilateral reticulonodular pattern on radiological examination of the chest. Two of the 
deceased patients had antemortem bronchoscopic examinations that showed the 
presence of endobronchial lesions. One patient was found to have endobronchial 
Kaposi's sarcoma when she presented with a relapse of Kaposi's sarcoma several 
years after the primary disease. A similar number of Saudi renal transplant patients 
(19%) had pulmonary Kaposi's sarcoma. These patients presented with low-grade 
fevers, dyspnoea, nonspecific chest pain, and haemoptysis (Al-Sulaiman et 
al., 1994). Radiologically, the typical finding, as was our experience, was the bilateral 
reticulonodular pattern, although one patient had an haemorrhagic pleural effusion. 
All patients were hypoxaemic and had restrictive patterns on lung function testing 
(Al-Sulaiman et al., 1994). Our experience, shared by Al-Sulaiman (1994), is that 
there is little correlation between the extent of skin disease and the severity of 
pulmonary involvement. With pulmonary disease the mortality is very high, usually 
due to respiratoryfailure (Al-Sulaiman et al., 1994).
Pathology
The macroscopic appearance of pulmonary Kaposi's sarcoma varies from a single 
large mass to innumerable small nodular lesions. The lesions vary in colour from 
deep red to white depending on the degree of vascularity and sclerosis. Large 
nodules may undergo haemorrhagic necrosis (Amazon et al., 1988). Histologically,
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small lesions of the lung parenchyma are perivascular or peribronchial, and infiltrate 
the surrounding lung. Macrophages containing haemosiderin are numerous within 
the alveolar spaces adjacent to the tumour (Amazon et a/., 1988). Atypia of alveolar 
lining cells adjacent to the Kaposi's sarcoma lesion has been reported (Loring et 
a/.,1965b). Early lesions of Kaposi's sarcoma may resemble granulation tissue and 
differentiation from organising pneumonitis or fibrosing alvoelitis may be very difficult. 
Fully developed lesions may resemble fibrous mesothelioma or a variety of spindle 
cell neoplasms (Dail ef a/.,1983).
Other organ involvement
Kaposi's sarcoma may occur in any organ in the body (Amazon et a/., 1988). Indeed, 
we have now described the lesions as occurring even in the renal allograft! The 
involvement of bone marrow has also been described in other forms of Kaposi's 
sarcoma but not in iatrogenic Kaposi's sarcoma, to the best of our knowledge, 
making our case the first one to be described. Splenic involvement is also rare and 
was present in the same patient who had bone marrow and allograft disease.
Bone and bone marrow involvement
Bony disease occurs in 20% of African patients with aggressive cutaneous Kaposi's 
sarcoma (Templeton,1981). Most of the bone disease results from an extension of 
the infiltrative cutaneous Kaposi's sarcoma (Taylor et al., 1971). The disease may be 
localised to the bone in endemic Kaposi's sarcoma and occur in the absence of skin 
disease (De Jarlais et al., 1984). Bone marrow involvement is extremely rare in 
classic and even epidemic Kaposi's sarcoma (Little etal., 1986).
Heart involvement
None of our patients or those in the series reported by Al-Sulaiman et al. (1994) 
suffered cardiac Kaposi's sarcoma. Cardiac involvement usually occurs as part of 
generalised disease and occurs in 16% of the various epidemiological forms of 
Kaposi's sarcoma (Harawi, 1989). Interestingly, it appears more likely to occur in the 
absence of skin disease (Anthony et al., 1960). In classic and endemic Kaposi's 
sarcoma the pericardium is more commonly involved than the myocardium 
(Templeton,1972). In a postmortem study of nine AIDS-Kaposi's sarcoma patients, 
five were found to have cardiac involvement with the subepithelial adipose tissue
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adjacent to the coronary arteries being especially affected (Silver et al., 1984). The 
myocardium and endocardium were free of disease. The patients were all free of 
symptoms of cardiac disease. In another postmortem study of 41 AIDS patients, 21 
had Kaposi's sarcoma of whom four had epicardial and myocardial disease 
(Cammarosano et al., 1985).
Central nervous system involvement
The rarity of brain involvement is ascribed to its lack of lymphatics and its the 
immunologically privileged status (Templeton,1981). None of our patients nor those 
reported from Saudi Arabia (Shaheen et al., 1997) had any overt central nervous 
system involvement. In the few cases that have been reported in classic and 
endemic Kaposi's sarcoma (Gonzalez-Crussi et a/.,1969;Loring et al., 1965b) the 
disease occurred as part of generalised disease (Rwomushana et al., 1975). Despite 
the frequency with which the brain is involved in AIDS, very few cases of Kaposi's 
sarcoma of the brain have been reported (Gorin et al., 1985;Welch et al., 1984). Of 
note is the observation that the other immunologically privileged site, the gonads are 
also generally spared by Kaposi's sarcoma (Malliwah et al., 1985; Templeton,1972; 
Templeton,1981).
Miscellaneous
In the series reported from Saudi Arabia (Al-Sulaiman et a/.,1994;Shaheen et 
al., 1997), additional sites affected were the vocal cords, nasal mucosa and penis as 
part of generalised disease. None of the Saudi patients or ours had any eye, or 
gonadal involvement.
Laboratory findings
Abnormal laboratory findings in patients with Kaposi's sarcoma include microcytic 
anaemia from chronic disease or blood loss from ulcerated lesions (Hogeman,1953). 
Cases of both autoimmune haemolytic anaemia (Reidy et al., 1982;Zemek et 
al., 1964) and microangiopathic haemolytic anaemia (Ziegler et al., 1988) have also 
been reported. Other findings usually include monocytosis and occasionally 
eosinophilia (Gotti ef a/.,1997).
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STAGING OF POSTTRANSPLANT KAPOSI'S SARCOMA
A four-stage classification was suggested by Al-Khader et al. (1988) to assist in the 
management and prognostication of iatrogenic Kaposi's sarcoma:
Stage I - Localised skin lesions involving only one limb
Stage II - Widespread lesions involving more than one limb, but disease
confined to the skin
Stage III - Involvement of one or more viscera or lymph nodes
Stage IV - Any of the above categories plus either a life threatening infection
or another neoplasia.
In a later modification of the classification (Shaheen et al., 1997) Stage IV was 
changed to be generalised Kaposi's sarcoma involving the skin, viscera and/or lymph 
nodes and each group was further substaged into:
A - No associated malignancy or life threatening infection and,
B - Associated malignancy or life threatening infection.
Our own opinion is that this classification is of limited value in terms of management 
and prognostication. Our experience is that categorising the disease into either (a) 
cutaneous with or without lymph node involvement, or (b) visceral disease with or 
without skin disease, is far more useful, both as regards management and as well as 
prognostication, as will be shown in Chapter 11. A different staging has been 
proposed for AIDS-Kaposi's sarcoma, which has the propensity for the development 
of chronic and progressive disease (Tappero et al., 1993). For patients with AIDS- 
Kaposi's sarcoma immunologic findings were shown to be most important in 
predicting survival (Myskowski et a/.,1988;Spornraft et al., 1988). For this reason the 
newer classifications now include an appraisal of the immunologic function. The 
AIDS Clinical Trials Group (ACTG) have a developed a classification that provides a 
useful approach to the practical management of AIDS-Kaposi's sarcoma patients 
(Table 9-3) (Krown et al., 1989). It must be stated however, that this is but one of 
many staging classifications that has been suggested, alluding to the fact that a 
satisfactory one has yet to be proposed (Chachoua et al., 1989; Krigel et al., 1983).
Stellenbosch University http://scholar.sun.ac.za/
Clinical Aspects o f KS 9-18
Table 9-3. A staging classification for AIDS-Kaposi's sarcoma
Good Risk (0)
(All of the following}
Poor Risk (1)
(Any of the following)
Tumour (T) Confined to the skin and/or Tumour-associated 
lymph node and/or minimal oedema or ulceration; 
oral lesions extensive oral Kaposi's
sarcoma or Kaposi's 
sarcoma in other non-nodal 
viscera
CD4 cells > 200/jj.I CD4 cells < 200/p.l
No history of opportunistic History of opportunistic 
infection or thrush; no "B"1 infection or thrush; ”B" 
symptoms, performance symptoms, performance 
status >70 (Karnofsky) status <70 (Karnofsky);
other HIV-related illness
Modified from (Krown et al., 1989)
1 "B" symptoms: unexplained fever, night sweats, > 10% involuntary weight loss, or diarrhoea for more 
than 2 weeks.
Immune System (I) 
Systemic Illness (S)
This classification differs completely from that proposed by Al-Khader et al. (1988), 
and generally supports our view that the extent and distribution of skin involvement is 
relatively unimportant and that disease isolated to the skin and /or lymph nodes has 
a good prognosis.
Yet another clinical classification, this for classic and endemic Kaposi's sarcoma, has 
been proposed by Templeton (1981) based on the African experience (Table 9-4). 
Nodular disease is the most common and occurs in the subcutaneous tissue of the 
peripheries; the typical picture is readily recognisable by the clinician. Aggressive 
lesions are usually associated with nodular disease and in many cases appear to 
arise from preexisting nodules. The greater the duration of the nodular disease the 
greater the likelihood of aggressive behaviour (Templeton,1981). Aggressive 
disease can follow one of two patterns. It may either present as an
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Table 9-4. Clinical patterns of Kaposi's sarcoma in African (Endemic) Kaposi's 
sarcoma and classic Kaposi's sarcoma with the relative frequencies.
Endemic (%) Classic (%)
Nodular 60 85
Aggressive 35 10
Exophytic (Ulcerative) 30 -
Infiltrative 5 -
Generalised 5 5
Lymphadenopathic 3 4
Lymphadenopathic and systemic 2 1
Modified from Templeton, (1981).
exophytic ulcerating lesion that often penetrates the fascia or less commonly it may 
produce a diffuse infiltration of the subcutaneous tissue giving the affected limb a 
"woody" appearance (Templeton,1981). Generalised pattern is the least common 
variety and it also has two patterns of presentation; it may take the 
lymphadenopathic form that occurs exclusively in children and rarely involves the 
skin or viscera. It has to be distinguished from malignant lymphoma by biopsy. The 
least common pattern of the disease occurs in young adults who initially present with 
widespread cutaneous, nodal and systemic involvement. The disease runs a 
fulminant course and is rapidly fatal within a matter of weeks. Templeton (1981) 
includes transplant patients in the generalised pattern although the generally benign 
behaviour of the disease, we feel, makes it inappropriate for placement in this 
category.
CLINICO-PATHOLOGICAL CORRELATION
Our experience has revealed a major discrepancy between the clinical disease and 
the findings at postmortem, where the extent of the disease is much greater than is 
suspected clinically. This may be because the disease is indeed silent and that the 
clinical manifestations of visceral disease are unusual. This is supported by the 
observation of others that in a large number of patients with Kaposi's sarcoma who 
have routine endoscopic examinations, there are lesions in the gastrointestinal tract
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that are clinically occult (Al-Sulaiman et a/.,1994;Shaheen et al., 1997). Alternatively, 
it may be that the patients with more extensive Kaposi's sarcoma disease are the 
ones who succumb and come to postmortem examination. Our own opinion is that 
the disease is probably more extensive than suspected clinically but that certain 
areas, such as the gut, are more likely to be involved with asymptomatic disease. 
The best way to resolve the matter would be to actively search for disease 
elsewhere when the skin disease is diagnosed, and to encourage postmortem 
examinations in these patients. Other authors concur with us that the involvement of 
internal organs is more frequent than clinically appreciated with estimates ranging 
from 10 to 70% of patients showing internal organ involvement (Cox et 
a/.,1959;Ecklund et al., 1962).
ASSOCIATED MALIGNANCIES
None of our patients had second malignancies associated with the Kaposi’s sarcoma 
but it has been reported that 6% of allograft recipients who develop Kaposi's 
sarcoma have a second malignancy (Penn,1997), most commonly malignant 
lymphoma (Myers et al., 1974;Penn,1995;Touraine et al., 1989). In the CTTR series 
2% of patients with Kaposi's sarcoma had malignant lymphomas (Penn,1997). 
There is also a well-established association between classic Kaposi's sarcoma and 
the development of a second malignancy (Piette,1987). In a recent report, a second 
primary malignancy was present in 37% of patients with classic Kaposi's sarcoma 
(Safai et al.,1980b) with 58% of lesions being lymphoreticular tumours. By 
comparison, in a similar study of double primaries in the general population, 
lymphoreticular malignancies only occurred in 8% of all patients with a primary 
malignancy other than Kaposi's sarcoma (Safai et al., 1980b). Other studies have 
confirmed the association between Kaposi's sarcoma and second malignancies 
(Moertel,1966;0'Brien et a/.,1966;Reynolds et al., 1965;Safai et al., 1980a;Safai et 
al., 1980b). Malignancies associated with Kaposi’s sarcoma include malignant 
lymphomas, leukaemias, myelomas, mycosis fungoides or thymomas (Ulbright et 
al., 1981). These malignancies may precede, occur simultaneously with or follow 
Kaposi’s sarcoma (Safai et a/.,1980b;Ulbright et al., 1981). Some 42% of 
malignancies in classic Kaposi's sarcoma are of epithelial origin, which may occur in 
any organ but most commonly the skin (Safai et al., 1980b). Whether this represents
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a real association with Kaposi's sarcoma or whether it is a reflection of an 
accumulated risk of developing tumours in an elderly population, is uncertain 
(Templeton,1981). Patients with AIDS are also at risk of dual malignancies. In one 
study 26% of patients with non-Hodgkin's lymphoma also had Kaposi's sarcoma 
(Safai et a/.,1992). Interestingly, an association between Kaposi's sarcoma and 
second malignancies is not seen with endemic Kaposi's sarcoma (Slavin et a/.,1969).
REGRESSION
Kaposi's sarcoma lesions usually regress when treatment is instituted, although 
spontaneous regression may occasionally occur. With regression, the Kaposi's 
sarcoma nodule gets smaller, harder, and eventually leaves a hyperpigmented scar. 
Pathologically the scar consists of dense fibrous tissue with haemosiderin deposition 
and obliteration of the blood vessels (Templeton,1981). Regression is more evident 
in iatrogenic Kaposi's sarcoma than in the other subtypes of Kaposi's sarcoma. In a 
review of 19 studies of the iatrogenic form of this disease regression occurred in 
84% of the cases on discontinuation of the immunosuppressive therapy and in 62% 
on reduction of the doses of the drugs (Brooks, 1986). It has however also been 
reported that Kaposi's sarcoma regressed in up to one-third of the cases in whom 
the immunosuppression was maintained (Schulhafer et a/., 1987). Classic and 
endemic Kaposi's sarcoma may show partial regression while complete regression 
occurs in a mere 2% of cases (Templeton et a/.,1975;Templeton,1981). In a study 
of 159 AIDS patients with Kaposi's sarcoma regression occurred only in 6 (4%) (Real 
et a/.,1985). In addition, of the 6 patients only one had complete regression with all 
the other patients having only partial regression; most patients had active lesions 
with the regressing ones (Real et a/., 1985).
RELAPSE
There is growing evidence that iatrogenic Kaposi’s sarcoma can relapse under 
certain circumstances (Al-Sulaiman et a/.,1994;Penn,1997;Poch et a/.,1992;Qunibi et 
a/., 1993). In a report of their experience and review of the limited number of cases 
identified from the literature, Doutrelepont et al. (1996) have shown universal 
recurrence of iatrogenic Kaposi's sarcoma after renal transplantation. The 
recurrence seems to occur irrespective of the waiting period after the initial disease:
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one subject developed Kaposi's sarcoma after renal transplantation despite 19 years 
of clinical remission; Doutrelepont et al. (1996) also noted that the pattern of the 
recurrent disease was similar to the first, with no life-threatening disease. Remission 
of the recurrent disease could be induced by reduction of immunosuppression albeit 
at the cost of the graft in some cases. Al-Sulaiman et al. (1992) describe recurrence 
and remission twice in the same patient following discontinuation and reintroduction 
of cyclosporine; the Kaposi's sarcoma relapsed and remitted when azathioprine was 
introduced and withdrawn. Considering the high potential risk of relapse of Kaposi's 
sarcoma the policy in our Unit has been to avoid retransplantation in patients who 
have had the disease, irrespective of the period of remission.
The single renal transplant recipient, who experienced a relapse in our series, did so 
at the time of severe local sepsis (Fig. 9-5). The patient had developed severe 
necrotising cellulitis of both lower limbs 3 years after clinical remission of the primary 
Kaposi's sarcoma. The patient, who initially had skin and inguinal lymph node 
involvement, had a recurrence of the skin disease but not of the lymphadenopathy. 
At the time of the relapse the patient was only receiving small doses of steroids and 
azathioprine. The patient was later discovered to have pulmonary Kaposi's sarcoma 
and she eventually died. To the best of our knowledge, this is the first case of 
relapse of posttranspiant Kaposi's sarcoma associated with an intercurrent infection 
to be described. AIDS-Kaposi's sarcoma has also been described to flare after 
intercurrent illness such as Pneumocystis carinii pneumonia (Tappero et al., 1993).
DIFFERENTIAL DIAGNOSIS
The clinical diagnosis of Kaposi's sarcoma is, as a rule, not very difficult if it occurs in 
a renal allograft recipient on the distal parts of the lower limbs several months after 
the transplant. Nevertheless, in certain circumstances, it can be difficult to 
differentiate patch or plaque lesions of Kaposi's sarcoma from ecchymoses, stasis 
changes, or even inflammatory changes such as lichen planus. The papular, 
nodular stages of Kaposi's sarcoma may be clinically similar to several different 
conditions such as haemangiomas, venous lakes, glomus tumours, pyogenic 
granulomas, and malignant tumours such as squamous cell carcinomas, malignant 
lymphomas, angiosarcomas and malignant melanomas (Mooney et a/.,1995;Nielsen
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et a/.,1994;Schwartz,1996). Most of these lesions are discussed in detail in Chapter 
10. Another important clinical differential diagnosis is bacillary angiomatosis 
(Brenner et a/.,1993;Cotell et a/.,1994;Levell et a/.,1995;Raoult et a/.,1994;Schwartz 
et a/.,1997;Tompkins et al..1993), a relatively new bacterial infection caused by 
Bartonella henselae or Bartonella quintana (Brenner et a/.,1993;Raoult et al., 1994) 
that has a predilection for patients with human immunodeficiency virus infection or 
others with compromised immunity. It commonly presents with multiple red skin 
lesions and visceral involvement may occur. The dermatological lesions resemble 
those of Kaposi's sarcoma.
COLOUR PHOTOGRAPHIC IMAGES (Figs. 9-2 to 9-5)
A series of photographic images of individual patients follow that demonstrate some 
of the key features of clinical Kaposi’s sarcoma as seen in our cohort of renal 
transplant recipients.
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Fig. 9-2 Patient SG.
(A) The typical appearance of Kaposi's sarcoma lesions on the legs is shown. Some 
macules are seen but most of the deep violaceous lesions are papular. The white 
arrow shows lesions along the course of a superficial vein, a pattern well recognised 
in Kaposi's sarcoma (Safai, 1984).
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Fig. 9-2 Patient SG.
The concentration of Kaposi's sarcoma lesions on the distal part of the legs is clearly 
demonstrated in these photographs (B, C) taken at the time of diagnosis. This 
patient had no inguinal lymph node involvement or lymphoedema.
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Fia. 9-2 Patient SG.
These series of photographs show the healing of papular-plaque Kaposi’s sarcoma 
lesions over time. The images were taken at the following times: (C) At diagnosis, 
(D) at 6 months (E) at 9 months (F), and at one year following the initial diagnosis. 
Note that the active lesions are deep purple in colour and give rise to healed lesions 
that are brownish in colour.
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Fip. 9-3 Patient ML.
This series illustrates the behaviour of a large tumour on the right buttock of the 
patient situated on a large plaque with two satellite lesions. The subsequent 
photographs document the remission of the lesions. The photographs were taken at 
the specified times after diagnosis: (A) and (B) 0 months (C), 3 months, (D) 5 
months, (E), 8 months and (F) 12 months after diagnosis. Note the hyperkeratosis 
resembling psoriasis in (C).
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Fig. 9-4. Patient Dl.
This series illustrates the Koebner phenomenon quite clearly with Kaposi's sarcoma 
lesions in the region of the surgical graft implantation site as well as the site of 
surgical insertion of a Tenckhoff catheter. The associated inguinal lymphadenopathy 
is illustrated, as is the oedema of the right leg. The timing of the photographs in 
relation to the primary diagnosis of Kaposi's sarcoma is as follows: (A, B, C), 0 
months: (D,E,F,G,) 2 months; (H,I), 4 months; (J,K,L), 6 months; (M,N), 9 months. 
Note the resolution of the large patch of Kaposi's sarcoma with minimal staining and 
scarring. Note the persistence of the lymphoedema of the right leg.
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Fig. 9-5 Patient RB.
This patient suffered a relapse of Kaposi's sarcoma after the onset of severe cellulitis 
of both lower limbs. Histological proof had been obtained of the initial diagnosis of 
Kaposi's sarcoma, the resolution and the subsequent relapse. The photographs 
(A,B) illustrate the healed Kaposi's sarcoma lesions (black arrow) and the new 
lesions (white arrows). Beside the skin disease, the patient also had pulmonary 
Kaposi's sarcoma disease with the relapse but no involvement of the inguinal lymph 
nodes that were affected by the initial disease.
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SUMMARY
Postrenal transplant Kaposi's sarcoma is a disease primarily of the skin, where it 
produces lesions that are fairly easily recognisable clinically. The lower parts of the 
legs are the characteristic sites to be affected and lesions are usually violaceous 
rashes that can be macules but are more commonly papules or nodules. The 
disease may also occur in the lymph nodes with the inguinal nodes the ones that 
appear to be most commonly affected clinically. Gastrointestinal involvement is the 
visceral site most often involved by the disease followed by pulmonary Kaposi's 
sarcoma. The diagnosis of Kaposi's sarcoma in renal transplant patients should be 
confirmed by histological examination of tissue because the disease can be 
mimicked by a large number of other conditions, which clinically resemble Kaposi’s 
sarcoma.
With appropriate management the disease usually remits, although patients with 
visceral disease, especially lung involvement, are less likely to do so. The disease 
predictably relapses when immunosuppression is reintroduced, making the question 
of retransplantation of uraemic patients in Kaposi's sarcoma remission, a very vexed 
one. We also describe an unusual case of relapse of posttransplant Kaposi's 
sarcoma following severe intercurrent infection.
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